2008/09 Annual Report - Hartford Hospital!

Hartford Hospital Research Program
2008/09 Annual Report

Welcome
A Message From The Vice President For Research
The past two years have presented serious economic
challenges across many sectors of our society including
medical research. During this period some grant makers
and funders were forced to cut back or suspend their
programs in the interest of a brighter economic forecast.
At the same time, these years were characterized by
unprecedented opportunity. For example, the American
Recovery and Reinvestment Act of 2009 ear marked
billions of dollars to support advancements in biomedical
and behavioral research, research infrastructure, faculty
recruitment and academics with the primary aim of creating
and preserving U.S. jobs in these and related sectors.
In the midst of these challenges and opportunities Hartford
Hospital investigators have continued to press onward,
obtaining $11.7 million in funding for research studies
during fiscal year 2009, an amount that represents a
22.8% increase in external funding over last year. In 2009,
research was identified as a key value of our organization,
and consequently “Academic Excellence” was added as a
pillar on the Hospital’s Balanced Scorecard. This addition
acknowledges the world-class work being carried out by
our investigators and highlights the hospital’s culture of
innovation in which physicians perform research because
they are genuinely committed to asking important scientific
questions that will change the practice of medicine here and
nationally.
The Research Program is proud to recognize the
achievements of Hartford Hospital investigators in
this 2008-2009 Biennial Report. We are committed to
supporting them as they continue to meet the challenges
and opportunities that the coming decade will bring to
health care and medical research. In closing, I would also
like to take the opportunity to thank the dedicated staff
of Research Administration for their excellent support of
Research at Hartford Hospital, and a special note of thanks
to Dr. Tara McLaughlin, for her excellent work in preparing
our Biennial Report.
Sincerely,
Laurine Bow, PhD
Vice President for Research

Contents
1
Research program summary
3 Financial summary
4 External funding
5 Internal funding
6 Committees
7 Research administration
10 Clinical research center
12 Preclinical research facility
13 Genomas
18 Cardiology
35 Center for anti-infective research
43 Medicine
47 Neurology
50 Nursing
53 Oncology
64 Orthopedics
65 Pathology
69 Psychiatry
89 Radiology
91 Surgery
98 Traumatology & emergency medicine
106 Urology
107 Women’s health
115 Other departments & collaborations

Research Program Summary
At the close of 2009, over 600 active research projects were
on going Hartford Hospital
Hartford Hospital investigators initiated over 350 new
studies in FY 08 and 09 and produced over 870 scientific
publications, abstracts and presentations during this period
Research Program Initiatives
During This Period Include:
• New Research Program website (www.hartfordhealth.org/
research)
• Research Rundown newsletter distributed electronically to
over 500 recipients including Hartford Hospital investigators,
medical staff and external researchers
• Research Week 2009 featured research symposium, speakers,
poster display and information
Research Program also Supported
Several Special Awards:
• Pressure Ulcer Prevention Database awarded CQIA Silver
Innovation Prize
• Falls Prevention Program awarded 2009 CQIA Innovation
Silver Award
• Stroke Center awarded American Stroke Association’s
Get With The Guidelines Stroke (GWTG–Stroke) Silver
Performance Achievement Award
Hartford Hospital: Committed to
Research Excellence…..
Translational Research…
$1.4 Million SBIR Grant: Dr. Gualberto Ruaño, and the Genomas
team were awarded a $1.4 million, 3 year NIH SBIR grant to develop
MRI+DNA- guided biomarker system for mental illness, bringing the total
amount of NIMH funding secured by Genomas in collaboration with the
Institute of Living to nearly $4 Million.
CEHDL trial preliminary results applied in
community setting:
Results from the 5 year, NIH funded Center for Eliminating Health
Disparities in Latinos (CEHDL) peer-counseling trial suggest that peer
counseling is effective for diabetes management in Latino patients. The
knowledge gained was applied in a community-based setting by PI Jyoti
Chhabra, PhD and researchers at the University of Connecticut and the
Hispanic Health Council through support group forums that took place in
the Hospital’s Brownstone clinics.
Federal Recovery Act Funding…
Dr. Paul Thompson was awarded $865,207 Challenge Grant from the
National Institutes of Health for a two-year project “CoEnzyme Q10 in
Statin Myopathy”.
Dr. Godfrey Pearlson was awarded Recovery Act Funding to expand
studies of high-risk drinking in college students, represents $771,000 in
direct costs awarded through a Challenge Grant from the National Institutes
of Health/NIAAA for two-year project “Genetic Architecture of Alcohol
Misuse Candidate Endophenotypes.”

2008/09
New Investigator Initiated Clinical Trial Support.…
Dr. Paul Tulikangas awarded grant from Astellas Pharma Inc:
The new $214,238 study will evaluate use of vaginal pessaries in the
treatment of overactive bladder symptoms in women with pelvic
organ prolapse.
Other New Funding…
Dr. Godfrey Pearlson: BARCS (Brain and Alcohol Research with
College Students) study awarded $1.5 million NIAAA genetics grant
to continue to study drinking and brain function in college students
and to identify markers for vulnerability to dysfunctional drinking
and alcohol toxicity.
Evidence Based Practice Center: The EPC received awards
through the University of Connecticut for over $600,000 for
AHRQ-sponsored projects on the use of antiepileptics and human
growth hormone.
Beth Parker PhD and Cardiology Department Research Team:
Awarded Biomedical Research Grant through State of Connecticut
Tobacco Settlement Funds to study impact of smoking cessation
on vascular function in chronic smokers- Represents a total of
$267,187 in new funding.
Hartford Hospital selected by Lance Armstrong
Foundation to develop breast cancer
survivorship program:
Hartford Hospital was awarded one of only eight national
community grants to develop a unique resource program for breast
cancer survivors, was the only site in New England to be selected
for this three-year grant representing $150,000. The evaluation
component will involve Research Program Senior Scientists.
2.

External
Research Funding Received
The external funds received are derived from the September accounting statement.
All calculations are based on the fiscal cycle of October 1 - September 30.
2008 2009
Psychiatry $3,856,000 $4,038,000
Cardiology $1,423,000 $2,782,000
Oncology $808,000 $1,608,000
CAIRD* $1,691,000 $1,418,000
Experimental Research $310,000 $413,000
Medicine $197,000 $311,000
Neurology/Neurosurgery $309,000 $147,000
Emergency Medicine/
Traumatology $15,000 $141,000
Orthopedics $77,000 $119,000
Radiology $74,000 $60,000
2008 2009
Pharmacy/EPC** $129,000 $45,000
Women’s Health $29,000 $37,000
Gastroenterology $5,000 $30,000
Surgery $69,000 $24,000
Anesthesia $3,000
Miscellaneous Support
(Research Admin) $538,000 $527,000
TOTAL $9,530,000 $11,703,000
$11,703,000
$9,530,000
1998 '00 '02 '04 '06 '08 2009
* Center for Anti-Infective Research and Development ** Evidence-based Practice Center

External Awards
Federal, Foundation and State figures represent annual awards.
All other figures represent new initial total awards.
Federal
2008 2009
Industry: Investigator Initiated
2008 2009
Cardiology $1,529,570 $1,481,097
Emergency Medicine/
Traumatology $35,220 $35,220
Medicine $232,801 $384,551
Neurology $83,195 $89,905
Neurosurgery $12,600 $20,047
Oncology $543,355 $117,570
Pharmacy/EPC $685,361
Psychiatry $4,322,960 $4,415,887
Radiology $141,075 $72,387
CAIRD $207,758 $1,012,219
Cardiology $149,500 $115,116
Emergency Medicine/
Traumatology $18,500
Oncology* $184,640 $404,785
Pharmacy/EPC $100,000
Psychiatry $214,875
Surgery $13,306
Total: $775,273 $1,645,426
Total: $6,900,776 $7,302,025
* represents funds received
Foundation
Industry: Clinical Trials
Medicine $19,225 $23,341
Neurology $550
Oncology $47,756
Pharmacy $5,184
Psychiatry $70,000 $40,000
Radiology $1,500
Total: $89,775 $117,781
State
Cardiology $267,186
Oncology $25,000 $25,000
Psychiatry $5,000 $1,500
Total: $30,000 $293,686
CAIRD $822,428 $188,388
Cardiology $1,264,493 $1,749,326
Emergency Medicine/
Traumatology $63,516
Medicine $205,371 $144,238
Neurology $22,500 $54,835
Oncology $504,829 $509,588
Orthopedics $82,000
Pre-clinical $233,648
Psychiatry $19,000 $329,930
Radiology $143,982 $30,000
Surgery $109,850 $12,250
Women’s Health $44,163
Pathology $22,750
Total: $3,515,780 $3,041,305
4.

Internal Awards
Medical Staff Supported Awards
The following projects received awards generously
co-sponsored by the Medical Staff and the Hartford
Hospital Research Endowment Fund:
Alberghini, Tod, Transplant: Clinical significance of solid-phase assay (flow
cytometric and Luminex) detection of pre-transplant HLA antibody as
measured by graft survival in renal transplant recipients: A retrospective
analysis. $9,954
Anglade, Moise, MD, Cardiology: Use of N-Acetylcysteine for prevention of
postoperative atrial fibrillation: A meta-analysis. $5,450
Azemi, Talket, MD, Cardiology: Diagnostic and prognostic significance of
ischemic electrocardiographic changes during vasodilator stress myocardial
perfusion imaging. $9,507
Blondin, Nick, Neurology: A stroke of luck: Can cerebral hemisphere predict
thrombolysis and good outcome in an acute ischemic stroke? $2,250
Clyne, Christopher, MD, Cardiology: Identifying atrial ablation lines through
two-dimensional delayed enhancement MR imaging. $6,360
Collins, Sarah, MD, Urogynecology: Perioperative exercise tolerance and
pain control in women undergoing robotic vs. traditional abdominal sacral
colpopexy. $8,428
Corbera, Silvia, PhD, Psychiatry: Application of Event-Related Potentials
(ERPs) to evaluate the effects of coaching on cognitive rehabilitation in
schizophrenia. $300
Eagye, Kathy, MPH, Center for Anti-infective Research and Development:
Health outcomes investigation of infection in colorectal surgical procedures.
$14,854
Feeney, James, MD Traumatology and Emergency Medicine: Retrospective
review of pre-hospital HMG Co- A reductase inhibitor use in hemorrhagic
shock due to ruptured AAA. $450
Lundbye, Justin, MD, Cardiology: Elevated plasma cytokines are a marker for
unstable coronary syndrome: The Hartford Chest Pain Study. $10,777
Lyle, Brian, MD, Cardiology: Follow up of patients with coronary artery
disease who have undergone rapid aspirin desensitization
prior to percutaneous coronary intervention. $5,826
Mace, Melanie, PsyD, Psychology Testing: A survey of regional referring
providers’ use of and perceived utility of neuropsychological services. $750
Norberg, Melissa, PhD, Psychiatry: D-Cycloserine augmented CBT for prior
treatment non-responders with OCD. $9,531
Patel, Minita, MD, Urogynecology: The use of SennaS for prevention of postoperative
constipation in urogynecologic surgery: A randomized, placebocontrolled,
double blinded trial. $9,758
Silverman, David, MD, Cardiology: Freedom from atrial fibrillation following
radio-frequency ablation depends upon integrity of atrial function. $9,975
Silverman, David, MD, Cardiology: Systolic strain abnormalities to predict
hospital readmission in patients with heart failure and normal ejection
fraction. $3,680
Sood, Nitesh, MD, Cardiology: Heart rate variability and brain natriuretic
peptide. $5,760
Gross, Ronald,MD (Spinella, Phillip, MD,) Traumatology and Emergency
Medicine: Relationship between age of RBCs transfused and mortality in
critically ill trauma patients. $9,861
Suozzi, James, MD, Traumatology and Emergency Medicine: Comparison of
the Airtraq® optical laryngoscope to direct laryngoscopy by paramedics: A
randomized, controlled, clinical trial. $8,969
Thumar, Jaykumar, MD, Oncology: CD 133 expression and clinical outcome
in patients with rectal cancer. $12,462
Turner, Beth, PhD, Psychiatry: Simulated driving: Effects of road conditions.
$9,811
Open Competition Awards
The following projects received funding through the Open Competition
program in fiscal years 2008 and 2009:
D’Agostino, Darrin, DO, Medicine: DNA-guided Warfarin management.
$62,475
Fischer, Edward, PhD, Cardiology: Community and patient attitudes towards
seeking medical help: Development and standardization of a comprehensive
attitude measure. $21,146
Goethe, John, MD, Psychiatry: Research infrastructure for the Depression and
Bipolar Disorders Center. $49,760
Kuti, Joseph, PharmD, Center for Anti-infective Research and Development:
The effect of hyperbaric oxygen therapy on the penetration of Linezolid into
subcutaneous tissue of diabetics with lower extremity wounds. $74,847
Parker, Beth, PhD Cardiology: Sex differences in the mechanisms underlying
endothelial function. $78,685
Stevens, Michael, PhD, Psychiatry: Linux cluster infrastructure enhancement.
$74,513
Vergara, Cunegundo, MD, Medicine: Creation of an ambulatory database to
measure access to primary preventive care services. $61,000
Wilber, Charles, MED. Psychiatry: Cognitive training in elderly with normal
aging and mild cognitive impairments. $82,487
The Research Program extends its appreciation to the
Medical Staff for its continued support of research at
Hartford Hospital.
In addition to the projects listed above, Research Endowment and
Medical Staff funds supported statistical analysis and database
development through Small Grants, as indicated throughout this
report.

Committees
The Research Committee, Institutional Review Board
and Institutional Animal Care and Use Committee
each fulfill specific roles and responsibilities that are
crucial to the conduct of research at Hartford Hospital.
Research Committee
The responsibilities of the Research Committee are fourfold.
The Committee reviews the scientific merit of
research projects and awards internal research funding. It
also investigates any allegations of research misconduct and
evaluates potential conflicts of interest.
Institutional Review Board
The Institutional Review board is charged with the ethical
oversight of research projects involving human research
subjects at Hartford Hospital. It conducts risk/benefits
analyses of potential research studies and monitors ongoing
studies for safety.
Members
Laurine Bow, PhD, Chair
James Bowers, JD
Karyl Burns, PhD
Erika Cappelutti, MD
William Crombleholme, MD
Ellen Dornelas, PhD
John Goethe, MD
Joseph Kuti, PharmD
Jeffrey Mather, MS
Pavlos Papasavas, MD
Godfrey Pearlson, MD
Ilene Staff, PhD
Cunegundo Vergara, MD
Detlef Wencker, MD
C. Michael White, PharmD
Les Wolfson, MD
Cathy Yavinsky, RN
Members
Robert D. Siegel, MD, Chair
David O’Sullivan, PhD, Vice Chair
Christopher Clyne, MD
Cherie Bilbie, MS
Alexandra Flowers, MD
Margarita Garcia
Yvette Gauthier
John Goethe, MD
Debra Hein, CNM
Gary Heller, MD, PhD
Rev. James Ibekwe, PhD
Kevin Keating, MD
Jacqueline Lyon, MD
Leslie Lothstein, MD
Joseph Nesta, MD
James Rancourt, PharmD
Richard M. Shulman, PhD
THANK YOU!
The Research Program would like to thank those individuals
who completed their committee tenure during this report
period.
Research Committee:
Jaber Aslanzadeh, MD
Gary Heller, MD, PhD
Kevin Keating, MD
Jeffrey Kluger, MD
Joanne Roy, RN, PhD
IRB:
George Perdrizet, MD, PhD
(Vice Chair)
Benjamin Goldfarb
Jenifer Ash
Tiffany R. Hubbard
Joanne Roy, PhD
Institutional Animal Care & Use
Committee
The Institutional Animal Care and Use Committee is
charged with the ethical oversight of research projects
involving animal research subjects.
6.

Research Administration
• Supports and facilitates the growth of research at
Hartford Hospital
• Provides administrative oversight for all research activities at
Hartford Hospital
• Centralized infrastructure includes Grants Administration,
Human Research Protections, Database Design and
Development and Proposal Design and Statistical Analysis.
• The Clinical Research Center and the Preclinical Research
Facility support research activities under the auspices of
Research Administration.
• Research Administration carries out its mission under the
leadership of Laurine Bow, PhD, Vice President for Research.
Grants and Contracts
• Insures that grants and contracts are prepared according
to the appropriate regulations and policies and that
accounting procedures for research studies are followed
correctly.
• Provides financial oversight on research projects
• Assists with contract negotiations for clinical trials and
other research activities
• Provides administrative guidance for all external grant
submissions
• Assists with budget preparation and accounting
procedures
• Informs hospital research community of regulatory
changes that impact the research finances and contracts
• Processed 62 grant applications to federal, foundation
and state sources representing over $48,000,000 during
fiscal year 2008 and 2009
Grants Administration Staff:
Tammy Weirs, Manager, Grants and Contracts, 545 - 4412
Anita Fowler, Grants Administrator, 545 - 2093
Christine Harvey, Administrative Associate to VP of Research, 545 - 5620
Linda Thompson, Administrative Associate, 545 - 5611
Human Research Protections
Program (HRPP)
• Offers a combined total experience of 20 years in conducting
research studies and 32 years in Research Administration.
• Provides oversight for the protection of human research subjects in
accordance with international principles of Good Clinical Practice,
U.S. Federal Regulations, and Hospital policies.
• Provides public assurance that the rights, safety and well-being of
research subjects are protected and that all research data obtained are
credible.
• Provides outreach and education on applying research regulations to
the research community.
• Provides administrative support to the Institutional Review Board and
Institutional Animal Care and Use Committee.
• Monitors ongoing research studies for compliance with all applicable
regulations and policies.
• Processed 109 full IRB reviews of new research projects and 125
expedited reviews of new research projects during FY 2008 and 2009.
• Working toward achieving full accreditation status by the Association
for the Accreditation of Human Research Protection Programs
(AAHRPP) by the close of 2010.
HRPP Staff:
Cherie Bilbie, MS, CCRP, Director, HRPP 545 - 0088
Dottie Bearse, IRB Coordinator, 545 - 5647
Corey Glider, IRB Administrator, 545 - 4410
Susan Hughes, IRB Administrator, 545 - 4413
Pamela Johnson, IRB Administrator, 545 - 0141
Grants Administration. Left:
(from left): Linda Thompson, Tammy Weirs, Christine Harvey, Anita Fowler
HRPP Group. below:
(from left): Dottie Bearse, Pamela Johnson, Cherie Bilbie, Susan Hughes, Corey Glider

Database Design and
Development Group
Creates databases, registries and specialized data collection
instruments for numerous hospital departments including:
• Brownstone Clinics
• Diabetes Life Care
• Surgery (Bariatrics, Nephrectomy)
• Cardiology/ Cath lab
• Tissue typing and Transplant registries
• Oncology (Prostate cancer registry, Cancer Connect, TCC/Moffitt
database)
Responsible for Quality Management reporting such as:
• NDNQI National Benchmark reporting
• HCAHPS - Responsiveness initiative
• Adverse event drug triggers
• Central line insertion
• Transformation of the ICU
• Rapid Response Team Data Analysis
• Eastern Rehabilitation Health Network Quality Survey
Provides technical support to investigators processing research projects
through the department’s electronic submission system
Assists with queries of hospital’s administrative database in support of
numerous grant applications
Experienced with a range of platforms including:
• Microsoft Access
• SQL Server
• Web Development
• Teleform Design
• ADT/Lab/HL7 Interfacing
Database Design and Development
Group Staff:
Jeff Mather, MS, Director, Data Management, 545 - 3560
Gil Fortunato, MBA, Systems Analyst, 545 - 3194
Juan Gonzalez, Systems Analyst, 545 - 4474
Da-dong Li, PhD, Research Technician, 545 - 4211
Joseph Tortora, Systems Analyst, 545 - 3446
Steve Wilcox, Systems Analyst, 545 - 6056
Data Management Technical Support 545 - 5621
Collaborates on award-winning Quality Improvement and
benchmarking initiatives:
• Falls Prevention
• Pressure Ulcer Prevention
• Get With The Guidelines National Stroke Benchmarking
Database Design and Development Group
(from left): Gil Fortunato, Steven Wilcox, Jeff Mather, Joseph Tortora, Juan Gonzalez
(not pictured Da-Dong Li)
8.

Research Administration
Proposal Design and
Statistical Analysis
• Provides assistance with the scientific design of research studies and
with statistical and data analysis
• Supports the development of external grant applications
• Has conducted public health research and program evaluation for
many internal departments and external entities.
• Has published numerous peer-reviewed manuscripts and presents
research at a variety of scientific meetings
Jyoti Chhabra, PhD:
• Site-Principal Investigator on the 5-year, NIH-funded Center for
Eliminating Health Disparities (CEHDL) clinical trial on diabetes
peer-counseling
• Provides methodological review for research projects involving the
Brownstone Outpatient clinics and Nutrition Services
• Member of the Education subcommittee of the How Hartford
Hospital Works (H3W) initiative
David O’Sullivan, PhD:
Ilene Staff, PhD:
• Research Program Liaison and member, Research Committee
• Provides methodological review and consultation for:
Emergency Medicine/Trauma
Oncology/Radiation Oncology
Urology
Neurology/Stroke Center
Surgery
Anesthesiology
Infectious Disease/CAIRD
Pulmonology
Hematology
Rheumatology
Gynecologic Oncology (Breast)
Orthopedic Surgery
Integrative Medicine
Proposal Design and Statistical Analysis Staff:
Jyoti Chhabra PhD, 545 - 1004
Tara McLaughlin PhD, 545 - 5065
David O’Sullivan PhD, 545 - 4544
Ilene Staff PhD, 545 - 0178
• Vice Chairperson for the Hartford Hospital Institutional
Review Board
• Provides methodological review and consultation for:
Cardiology
Dentistry
Endocrinology
Gastroenterology
Nursing
Opthamology
Toxicology
Women’s Health
Tara McLaughlin, PhD:
• Primarily responsible for grant-writing for all research areas
• Provides methodological review and consultation for:
Preclinical research studies
Psychiatry
Pastoral/Palliative Care
Community Projects with City of Hartford
Compiles monthly newsletter, Research Rundown
Proposal Design and Statistical Analysis Group (from left): David O’Sullivan,Tara McLaughlin,
Ilene Staff, Jyoti Chhabra

Clinical Research Center
The Clinical Research Center (CRC) is an invaluable
resource for clinicians interested in conducting research
initiatives at Hartford Hospital. The CRC provides administrative
and research coordinator support for research activities
of the institution’s medical staff. Support is provided for both
investigator- initiated studies as well as industry funded trials
sponsored by pharmaceutical and medical device companies.
While the CRC staff supports many experienced investigators
they are also able to assist new investigators. As part of
Research Administration, the CRC interacts with a multidisciplinary
staff with expertise in areas of clinical research design,
grant-writing, contract negotiation and budget review, IRB
document preparation, database design and data analysis.
Phase I – IV Study Center:
The Study Center is located on the 6th floor of the
Education and Resource Center building and is available to
investigators by reservation to support Phase I – IV studies
requiring overnight accommodations. The Center has a
suite of 24 private sleep rooms with bathroom and shower
facilities for each group of 4 rooms. Each room includes a
bed with bedding, dresser, closet and desk as well as a wallmounted
television. The Center also has a shared lounge
area with television, DVD player, couches and chairs. The
kitchen facility includes a large refrigerator, microwaves,
toaster ovens and storage cabinet areas. An area for clinical
assessments is available with an exam table, scale, blood
pressure monitor and medical supplies. A specimen processing
laboratory includes a centrifuge, refrigerator/freezer, sink and
phlebotomy chair. The facility is alarmed and can be used
to monitor patients and ensure subject compliance. Trained
medical personnel with clinical trial experience are available
to staff the Study Center. Additional staffing and supplies are
available to meet the needs of individual studies
Services:
Services provided by the CRC include:
• Marketing of services to potential study sponsors and
referrals to our physician investigators
• Marketing of trial opportunities to potential subjects
• Study initiation and regulatory maintenance
• Contract and budget preparation, regulatory documentation
preparation and maintenance including IRB submission and
continuing review
• Coordinator study support
• Patient screening, enrollment, randomization
• Coordination of all study procedures (i.e., study visits, study
drug administration, study-related interventions per study
protocol)
• Availability for all sponsor monitoring visits and audits
• Data management
• Completion of case report forms, query resolution
• Reporting adverse events and other regulatory requirements
to the IRB
• Data entry
Locations:
The administrative office of the CRC is located in Research
Administration on the 2nd floor of the ERC Building.
Additionally, satellite offices are located throughout the
hospital including offices in the Stroke Center and the Division
of Cardiology. An outpatient clinical trials office is located in
the medical building to facilitate studies being conducted by
our private physician groups.
10.

Clinical Research Center
CRC Staff:
The CRC has supported the clinical research activity of
hospital investigators since 1993. The staff has grown
to include 19 research professionals committed to
providing excellence in clinical research. A Director
and Study Center Coordinator provide management of
the operational and financial areas of the department. A
Research Pharmacy Technician is part of the CRC staff
and assumes accountability for all investigational drug
use at the institution. The CRC study coordination staff
includes 14 Clinical Research Associates with clinical
research certification through the Society of Clinical
Research Associates (SOCRA) or the Association of
Clinical Research Professionals (ACRP). Two of the
coordinators also have experience in basic science
research. The CRC is also staffed by two Clinical
Research Assistants who support the study coordinators
and provide other assistance with research tasks as
needed.
New Clinical Trial Initiatives:
The CRC continues to support clinical research in
Cardiology (Divisions of Preventive Cardiology,
Arrhythmia Services, Interventional Cardiology
and Heart Failure and Transplantation), Neurology,
Gastroenterology, Orthopedic Surgery, Infectious
Disease, Pulmonary Medicine, Trauma/Emergency
Medicine, Interventional and General Radiology and
Urogynecology. We were pleased to provide study
coordination services to several additional hospital
divisions this past year.
Neurosurgery:
The Neurosurgery Department has enlisted the
coordinator support of the CRC to conduct several
clinical trials. The trials will study the use of
investigational interventions for patients requiring
neurosurgical procedures.
Colorectal Surgery:
The CRC staff is coordinating an investigator initiated
study being conducted by Kristina Johnson, MD,
Connecticut Surgical Group. Dr. Johnson’s study
will evaluate the use of a medication in laparoscopic
colectomy patients and its effect on hospital length of
stay.

PreClinical Research Facility
Hartford Hospital’s preclinical research facility was established in 1952,
and has provided support for numerous surgical specialties. The
innovative research and training supported by the facility has resulted in many
significant developments for the hospital, such as open-heart surgery, heart
and liver transplants, and intra-coronary drug delivery via balloon catheters.
The facility performs preclinical contract work including Good Laboratory
Practices (GLP) and non-GLP studies. Three surgical suites are available for
testing, training or research.
The facility is licensed by the United States Department of Agriculture
(USDA) and Accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care, International (AAALAC).
Current Collaborators:
FarmingtonPharma Corporation
Maquet (formerly Datascope)
Matrix Bioanalytical Laboratories
Facility Capabilities:
In Vivo Medical Device Testing
In Vivo Biocompatibility Testing
Surgical Research and Development
Surgical Training Courses
GLP and non-GLP studies
Quality Assurance Program
12.

Genomas
Gualberto Ruaño, MD, PhD
Director of Genetics Research, Hartford Hospital
President, Genomas
Genomas (www.genomas.com) is the biotechnology anchor
of the Hartford Hospital Genetics Research Center (GRC)
and was inaugurated in 2004 by Gualberto Ruaño, MD, PhD.
Dr. Ruaño, who holds MD and PhD degrees from Yale, and
a baccalaureate from Johns Hopkins, has been an advocate of
personalized medicine for 15 years, and is one of the leading
medical experts in the field. Genomas is located on the
Hartford Hospital campus in downtown Hartford and occupies
4,000 sq. ft. of state-of-the-art laboratory and office space in
the first floor of the Florence T. Crane building at
67 Jefferson St
Genomas® is a biomedical company advancing DNA-Guided
medicine with products for personalized prescription of
drugs used in the treatment of mental illness, diabetes, and
cardiovascular disease (CVD). Their products eliminate trialand-error
prescription with DNA-Guided medicine and enable
physicians to treat with unprecedented precision, avoiding
significant drug side effects, improving efficacy and enhancing
patient compliance. Core applications are drug treatments
of mood and thought disorders in mental illness and of
cardiometabolic risk in diabetes and CVD. The products are
developed in partnership with three leading Connecticut
medical institutions, Hartford Hospital, The Institute of
Living and the Hospital of Central Connecticut and with the
University of Puerto Rico Medical Sciences.
Andreas Windemuth, PhD
Chief Technology Officer
Genomas Inc.
Gualberto Ruaño, MD, PhD
President and CEO, Genomas Inc.
Director of Genetics Research, Hartford
Hospital
As of November 2009, the GRC and Genomas have published
32 peer-reviewed scientific articles and established an
intellectual property portfolio of 8 patents pending as US
applications. The research is being advanced in partnership
with the National Institutes of Health which have awarded
GRC and Genomas $4.8 M in grants as of November 2009
for PhyzioType System research and development. The
company has won 3 Phase II SBIR awards subsequent to
respective Phase I awards from NIH for PhyzioType product
development. Clinical research and molecular diagnostics
service are conducted at the Physiogenomics Laboratory and
Laboratory of Personalized Health, respectively.
PhysioGenomics Laboratory (PGL)
PhysioGenomics Laboratory (PGL) Resources. PGL has
installed the whole-genome Human-I BeadChip genotyping
technology from Illumina, Inc. This technology merges
parallel processing through nanoscale high resolution
scanning. The genotyping analysis has the capacity of 8
million SNP’s per day and is a proven technology. Genomas
was one of the first biomedical companies with this capability
fully deployed internally. For its genotyping approach,
PGL has access to an expanding SNP database of 1,000,000
high-confidence, mapped, and annotated SNP markers
which merges parallel processing through fiber optics and
nanoscale high resolution scanning. To increase throughput
and quality PGL has added a Tecan Robot to provide pre-and
post PCR automation of the Illumina genotyping protocol
and an Autoloader to automate loading and scanning of the
Illumina Bead Chips and Sentrix Arrays. PGL has two robotic
systems in operation. A Qiagen BioRobot EZ1 is used to
automate DNA extraction from blood or other samples, and a
Perkin Elmer Janus liquid handling system is used to automate
repetitive liquid handling tasks throughout the process.
PGL Technology
Physiogenomics Technology is a proprietary platform
integrating genotypic and phenotypic measures to correlate
gene variability with physiological variability (Fig. 1).
Genomas has established a DNA repository and clinical
registry of 6,000 patients in mental illness, diabetes and
cardiovascular disease. The clinical data from these extensive
cohorts is integrated systematically into the PhyzioClinica
Database (Fig. 2).
Mohan Kocherla MS, MS-MIS
Research Scientist and Manager
of Laboratory Operations
Genomas Inc.
David Villagra BS
Research Associate
Genomas Inc.
Physiogenomics Technology is a medical application of
sensitivity analysis and systems engineering. Sensitivity
analysis is the study of the relationship between input
and output from a system as determined by each system

component. Physiogenomics Technology utilizes the genes
as the components of the system. The gene variability,
measured by single nucleotide polymorphisms (SNPs), is
correlated to physiological responses of a population, the
output. Physiogenomics Technology determines how the SNP
frequency varies among individuals similarly
responding to the input over the entire range of the response
distribution. The mechanisms of drug resistance and of
common, clinically intensive side effects involve multiple
physiological pathways suitable for Physiogenomics analysis.
Genomas has branded their medical management products as
PhyzioType Systems.
Fig. 1 Physiogenomics Principles
Genomas analyzes the genome to derive the optimal
candidate genes for which SNPs are included in each
PhyzioType System. This approach is carried out by means of
PhyzioGenomic Arrays derived from selected cardio-metabolic
and neuro-endocrine genes, from selected pharmacokinetic
and pharmacodynamic genes, and from genome-wide
representation as well as genomic controls. Physiogenomics
utilizes nanotechnology-based platforms and biomedical
systems engineering to integrate genomic variations with
clinically validated predictions of drug response.
PhyzioType Systems
PhyzioType Systems for drug management have 3 components
(Fig. 3): an ensemble of inherited, stable DNA markers from
various genes, a bioclinical algorithm validated in clinical
studies to ascertain the medical significance of a patient’s
DNA marker configuration and a reporting portal enabling
physicians to select the best drug based on each patient’s
individual’s efficacy response and risk of developing side
effects.
Each PhyzioType Systems is designed to have the following
properties:
Clinically Actionable Information. Personalized information
regarding an individual’s drug response for major drugs in a
therapeutic class to provide treatment guidance to physicians
Objective Results. Statistically predictive analysis which
will allow the physician to objectively recommend an initial
treatment course
Noninvasive Tests. Performance using a sample of the patient’s
peripheral blood
Quality Control. All tests processed at Genomas’ Laboratory
Fig. 2 Resources of the PhysioGenomics Laboratory
Fig. 3 Components of the PhyzioType Systems
of Personalized Health to provide consistent quality and
ensure timely turnaround.
Laboratory of Personalized Health LPH
LPH Resources. Operational since 2005 as a Division of
Genomas, LPH is a high-complexity molecular diagnostic
reference laboratory licensed by the Connecticut Department
of Public Health (license #CL-0644) and certified by
the Centers for Medicare and Medicaid Services (ID
#07D1036625) under CLIA (Clinical Laboratory Improvement
Amendments). On March 2009, LPH underwent its third
biannual inspection, and successfully met all criteria for
continued operation. LPH has installed the Luminex®
100 analyzer using xMAP® technology (Luminex Corp.,
Austin, TX). LPH provides clinical DNA typing for the
14.

Genomas
HILOmet PhyzioType System for antidepressant and
anxiolytic management to psychiatrists who refer patients
for evaluation of innate drug metabolism capacity. The
molecular diagnostic analysis is performed under contract to
Clinical Laboratory Partners (a Hartford Hospital subsidiary)
for distribution throughout Connecticut.
LPH Technology: Psychiatry
The HILOmet PhyzioType product consists of 3 tests
for genotyping each of the 3 key CYP450 (Cytochrome
P450) genes: CYP2D6, CYP2C9, and CYP2C19. These
genes are critical for the metabolism of several psychiatric
and cardiovascular drugs. Altogether, the HILOmet tests
genotype a total of 34 functional variants of these 3 drug
metabolism genes. The 3 genes and 34 variants interpreted
as a combinatorial ensemble constitute the HILOmet
PhyzioType System. The HILOmet product has already
been employed to benchmark drug metabolism reserve for
600 patients referred to LPH. Genomas researchers have
compared the types and carrier prevalences of combinatorial
HILOmet PhyzioType genotypes in Major Depressive
Disorder (MDD) patients to a control group of nonpsychiatrically
ill, medical outpatients. They conducted
a case control study using 73 psychiatric outpatients
diagnosed with depression and referred to The Institute of
Living, for treatment resistance or intolerable side effects to
psychotropic drugs. The controls were 120 cardiovascular
patients from Hartford Hospital being treated for
dyslipidemia but otherwise healthy and not psychiatrically
ill. Within the psychiatric population, 57% of individuals
were carriers of non wild-type alleles for 2-3 genes,
compared to 36% in the control population (p

treatment resistant and drug intolerant patients, as well
as children and adolescents. As the field of personalized
healthcare advances to clinical practice, Genomas researchers
foresee DNA-guided medicine being used to prevent adverse
drug reactions, particularly in high-risk populations referred to
tertiary hospitals.
LPH Technology: Cardiologyw
Pharmacogenetic studies from the past decade have revealed
that common polymorphisms in 2 genes, cytochrome P450
2C9 (CYP2C9) and Vitamin K epoxide reductase complex
subunit 1 (VKORC1), greatly affect warfarin dose through
different mechanisms. Genome wide scans have confirmed
these findings. The most frequent polymorphisms of CYP2C9
include *2 and *3 which are associated with decreases in 2C9
enzyme activity to about 70% and 5% of the normal level,
respectively. The FDA revised the Coumadin® (warfarin) label
in August 2007 including discussion of these gene variants
to personalize initial dose and subsequent management. The
result is excess warfarin accumulation, elevated INR (>4.0) and
possible hemorrhagic complications.
Warfarin exerts an anticoagulant effect through its inhibition
of the Vitamin K epoxide reductase multiprotein complex
Fig.5
(VKOR), part of which is subunit 1, encoded by VKORC1.
VKOR is responsible for converting vitamin K epoxide to
vitamin K hydroquinone which is an essential co factor
required for the carboxylation of clotting factors II, VII, IX
and X. A common polymorphism of the VKORC1 promoter
sequence (-1639 G>A) results in decreased Vitamin K epoxide
reductase enzyme activity as shown by in vitro promoter
luciferase activity assays.
As an illustration, the population wide impact of combinatorial
genotyping for VKORC1 and CYP2C9 on effective warfarin
dose is predicted for a cohort of outpatients at the Hartford
Hospital Preventive Cardiology clinic. The decreases were
calculated using published algorithms that employ age,
gender, weight, height, CYP2C9 genotype, and VKORC1
genotype. Fig.5 presents the frequency of individual
combinatorial genotypes for CYP2C9 and VKORC1 found in
that population (horizontal axis) and the predicted decrease
in effective warfarin dose associated with each combinatorial
genotype (vertical axis). Warfarin therapeutic risk increases
with the number of deficient alleles.
New Projects
Seip, Richard, PhD
DNA as a Predictor of Effective Warfarin Levels. Hartford Hospital
Research Endowment Funds, $62,475.
Cumulative percentage of the population
Active Projects
Seip, Richard, PhD
Relationship of Muscle Injury to Muscle Hypertrophy. Hartford
Hospital Research Endowment Funds, $35,488.
Publications
de Leon J, Arranz MJ, Ruaño G. Products for pharmacogenetic
testing in psychiatry: A review of features and clinical realities.
Clinics in Laboratory Medicine, 28: 599-617, 2008.
de Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz
FJ. Exploring genetic variations that may be associated with the
direct effects of some antipsychotics on lipid levels. Schizophrenia
Research, 98: 40-46, 2008.
16.

Genomas
Diaz FJ, Meary A, Arranz MJ, Ruaño G, Windemuth A, de Leon J.
Acetyl-coenzyme A carboxylase α gene variations may be associated
with the direct effects of some antipsychotics on triglyceride levels.
Schizophrenia Research, 115: 136–140, 2009.
LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip RL,
Duconge J, Ruaño G. Integrating genomic based information into
clinical Warfarin (Coumadin®) management: An illustrative case
report. Connecticut Medicine, 72 (7): 399-403, 2008.
Seip RL, Volek JS, Windemuth A, Kocherla M, Fernandez ML,
Kraemer WJ, Ruaño G. Physiogenomic comparison of human fat loss
in response to diets restrictive of carbohydrate or fat. Nutrition and
Metabolism, 5: (1):4 [Epub ahead of print], 2008.
Windemuth A, Calhoun V, Pearlson G, Kocherla M, Jaganathan K,
Ruaño G. Physiogenomic analysis of localized fMRI brain activity
in schizophrenia. Annals of Biomedical Engineering, 36 (6): 877-88,
2008.
Liu J, Pearlson G, Windemuth A, Ruaño G, Perrone-Bizzozero
NI, Calhoun V. Combining fMRI and SNP data to investigate
connections between brain function and genetics using parallel ICA.
Human Brain Mapping, 30: 241-255, 2009.
Ruaño G, Bernene J, Windemuth W, Bower B, Wencker D, Seip
RL, Kocherla M, Holford TR, Petit W, Hanks S. Physiogenomic
comparison of edema and BMI in patients receiving Rosiglitazone or
Pioglitazone. Clinica Chimica Acta, 400: 48-55, 2009.
Ruaño G, Duconge J, Windemuth A, Cadilla CL, Kocherla M,
Villagra D, Renta J, Holford TR, Santiago-Borrero PJ. Physiogenomic
analysis of the Puerto Rican population. Pharmacogenomics, 10 (4):
565-577, 2009.
Ruaño G, Thompson PD, Villagra D, Bower B, Kocherla M,
Yazdanpanah G, Seip RL, Windemuth A, White CM, Duconge J,
Holford TR, Wu AHB. High carrier prevalence of combinatorial
CYP2C9 and VKORC1 genotypes affecting warfarin dosing.
Personalized Medicine, 5 (3): 225-232, 2008.
Ruaño G, Villagra D, Rahim US, Windemuth A, Kocherla M, Bower
B, Szarek BL, Goethe JW. Increased carrier prevalence of deficient
CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients
referred to a tertiary psychiatric hospital. Personalized Medicine, 5
(6): 579-587, 2008.
Ruaño G. DNA collage and personalized medicine. Connecticut
Medicine, 72 (6): 322-cover, 2008.
Ruaño G. Bringing DNA-guided medicine to the Hispanic
population. Puerto Rico Health Sciences Journal, 28 (3): 266-267,
cover, 2009.

Cardiology
Paul D. Thompson, MD
Alan Ahlberg, MA • Jeremy Barbagallo, MA • Jill Cloutier
RN • Christopher Clyne, MD • Eric Crespo, MD. • Giselle
Cyr, RN • Marcin Dada, MD • Ellen Dornelas, PhD • Edward
Fischer, PhD • Brenda Foxen, RN • Daniel Fram, MD
Dalia Giedrimiene, MD, Ph.D • Danette Guertin, APRN
Deborah Katten, RN • Francis Kiernan, MD • Jeffery Kluger,
MD •Gary Heller, MD • Jeffrey Hirst, MD • Justin Lundbye,
MD • Raymond McKay, MD • Roger Mennett, MS • Joseph
Mitchel, DO • Deborah Murphy, RN • Beth A. Parker. PhD
• Charles Primiano, MD • Donna M. Polk, MD • Joseph
Radojevic, MD • Aleksandra Ras, BS • David Silverman, MD
• Marilyn Siwy, RN • Cara Statz, PhD • Detlef Wencker, MD
• Charles White, PharmD • Steven Zweibel, MD
Research is a major emphasis for all faculty in the Division
of Cardiology because it contributes directly to improving
patient care and medical education. The Division of
Cardiology and the Henry Low Heart Center are directed
by Paul D. Thompson, MD. The Center has active research
programs in heart failure, preventive cardiology, nuclear
cardiology, electrophysiology and cardiac catheterization. In
the last two years, the Division of Cardiology has published
more than 120 empirical articles in peer reviewed publications
and been awarded more than $1.8M in federally funded
research projects, more than $2M in external and industry
funding and $135,000 in Hartford Hospital endowment
funding.
Preventive Cardiology
This division has several ongoing clinical trials focused on
developing new approaches to treating cholesterol thereby
reducing cardiovascular disease risk, evaluating the effect of
the statin cholesterol drugs on muscle strength and aerobic
performance, evaluating the effect of statins on brain function,
examining the effects of exercise training on brain function,
and utilizing smoking cessation and stress management to
improve cardiac outcomes for patients with implantable
cardioverter defibrillators. In 2009, Dr. Thompson was one
of a very selective number of researchers to be awarded a
challenge grant from the National Institute of Health. Along
with co-investigators, Drs. Polk and Parker, he will examine
the effects of Coenzyme Q10 (ubiquinol) supplementation
on severity of skeletal muscle myopathy in patients with
statin-associated myalgia. Dr. Thompson also is the principal
investigator of a multi-site, federally funded clinical trial
determining the incidence of statin-induced myalgia and
the effects of statins on skeletal muscle strength and aerobic
exercise performance. Additionally, the Department of
Preventive Cardiology is working with Dr. Gualberto Ruano
of Genomas and Dr. Eric Hoffman of Washington Children’s
National Medical Center on two other NIH funded clinical
trials investigating genetic differences underlying statinassociated
muscle symptoms and the muscle strength response
to resistance training, respectively.
Two preventive cardiology fellows, Drs. Shishir Mathur and
Afrooz Ardestani, have initiated studies which involve the
participation of local runners. Dr. Mathur studied runners
18.

Cardiology
participating in the Hartford Marathon in October to
determine whether marathon running is associated with
improvements in genetic markers of aging as well as functional
properties of high-density lipoprotein (HDL) cholesterol.
Dr. Ardestani is examining markers of muscle damage before
and after the Manchester Road Race in runners both taking
and not taking statins to determine whether chronic statin
use affects the muscle response to intense aerobic exercise.
Both studies have utilized the participation of local running
organizations and may yield valuable information about
the benefits of exercise as well as the effects of cholesterollowering
drugs on the muscle response to exercise.
Preventive Cardiology is also home to multiple industry
funded trials of cholesterol lowering medications. These
studies, lead by Dr. Donna Polk are focused on new classes
of cholesterol lowering drug aimed at raising HDL as well as
drugs targeting the inflammatory process of athereosclerosis
to try to further reduce the risk of heart disease. Additionally
we are involved in several studies designed to evaluate the
best treatment of diabetics after a heart attack to improve
outcomes in this high risk group. Dr Polk and Dr. Parker are
also involved in evaluating the role of the non invasive test
carotid intimal medial thickness (cIMT) in the behavior of
individuals with hyperlipidemia
In 2008, exercise physiologist Dr. Beth Parker joined the
Department of Preventive Cardiology and has been funded
by the CT Department of Public Health to determine the
effects of smoking cessation on vascular function in chronic
smokers. Dr. Parker is also the principal investigator of a
research study that examines whether the vascular response to
stress varies with age and sex in healthy humans. Both studies
use noninvasive imaging techniques such as brachial artery
reactivity and arterial stiffness and follow the theme as to how
simple interventions can improve cardiovascular health.
Drs. Parker, Polk and Thompson are also collaborating with
Dr. Godfrey Pearlson in the Olin Neuropsychology Research
Center to conduct studies on the effects of statin therapy
on brain neuronal activation using functional magnetic
resonance imaging. Emerging evidence suggests that statin
therapy may influence the brain as well as blood lipids, and
determining brain activation of individuals on and off statins
allows researchers a direct look at the functional consequences
of statin therapy. The collaborative research team of Drs.
Parker, Thompson and Pearlson also completed a preliminary
study on exercise training and the hippocampus, again
using magnetic resonance imaging, to determine whether
hippocampal structure changed after a 10 week program of
aerobic exercise training.
Preventive cardiology also has an active behavioral cardiology
research program under the direction of psychologist,
Ellen Dornelas, Ph.D. Working together with Matthew
Burg, Ph.D. and Rachel Lampert, MD, from Yale University
and collaboratively with Dr. Kluger from the Department
of Electrophysiology and Arrhythmia Services, Hartford
Hospital is enrolling patients with implantable cardioverter
defibrillators (ICDs) in a study funded by the National
Heart Lung and Blood Institute that will test whether stress
management effectively reduces risk of shock from ICD due
to emotional stress. Additionally, Dr. Edward Fischer and Dr.
Dornelas are co-principal investigators on a study examining
community attitudes about seeking help from medical
professionals.
The research program in preventive cardiology is
home to national recognized researchers in the fields
of lipid management, cardiac function of elite athletes,
exercise physiology, smoking cessation and behavioral
cardiology. Studies conducted in preventive cardiology are
interdisciplinary, collaborative and innovative, focused on
improving cardiovascular and behavioral health in various
patient populations.
Heart Failure and Transplant Center
(HFTC)
This Center is home to cutting edge research performed at
our newly designed, NIH funded translational research Center
of the HFTC. This research center offers new insight and
development of novel therapy and diagnosis of advanced heart
failure. To better understand the relentless progression of
heart failure, the translational research center studies the role
of death receptor signaling pathways in heart muscle, skeletal
muscle and serum as a marker for disease progression and as
a tool to provide new therapies for advanced heart failure.
Therapies involve new pharmaceutical, VAD and electro-

physiologic device therapy. The HFTC is also participating
in six multi-national heart failure trials and two ventricular
assist device (VAD) trials. These trials, headed by Dr.
Detlef Wencker, are critical for many patients in end-stage
cardiomyopathy that could offer potentially life saving
support with most advanced therapies and technologies
Nuclear Cardiology
This division has a very active research program involving
both SPECT and PET imaging techniques. Research into
SPECT imaging techniques include a large database to
evaluate outcomes for patients undergoing nuclear cardiology
studies. The SPECT imaging techniques also involve
new pharmaceuticals for stress including regadenoson
and adenoscan. In addition, a program to evaluate new
technologies developed to improve image quality and reduce
patient time and radiation exposure is an important aspect of
the research effort. PET perfusion imaging has become a very
important part of nuclear cardiology. The Nuclear Cardiology
Laboratory is conducting research into new radiotracers
which holds potential to improve identification in patients
with coronary artery disease. These tracers will identify at
risk patients for ventricular cardiac arrest and may help direct
patients towards ICD placement.
Cardiovascular Pharmacy
Research Group
Hartford Hospital is fortunate to have a longstanding
relationship with the University of Connecticut School of
Pharmacy. Dr. Jeffrey Kluger has been working collaboratively
with the Cardiovascular Pharmacy Research and the Pharmacy
Outcomes group under the leadership of Drs. Mike White
and Craig Coleman, respectively. This effort has resulted in
the UCONN/HH Evidence Based Practice Center obtaining
funding through the Federal Agency AHRQ. The contract
evaluating comparative effectiveness of ACEI and ARB in
patients with preserved cardiac function was completed.
The group now has a contract to investigate the role of
thrombolytic devices in coronary disease. The CV Pharmacy
research is now enrolling patients in AFIST IV evaluating the
role of Vitamin C in modifying inflammatory markers after
cardiac surgery. In collaboration with Dr. Craig Coleman
and Dr. Jeffrey Kluger there are multiple observational studies
ongoing in the area of antiarrhythmic drug therapy including
the role of adjuvant magnesium for atrial fibrillation. Other
outcome studies have focused on our implantable defibrillator
and syncope populations.
Cardiac Electrophysiology and
Arrhythmia Services
Hartford Hospital is home to many federally and industry
funded clinical trials focused on improving treatment for
complex electrical cardiac disorders. These include the VEST-
PREDICTS Trial –led by Dr. Zweibel, an NIH sponsored trial
that examine whether a wearable defibrillator will save lives
and improve cardiac outcomes months after an heart attack.
Dr. Zweibel is also collaborating on the APPROPRIATE
Trial –a study that will evaluate two different sensors (minute
ventilation and accelerometer) in patients receiving a dualchamber
pacemaker for the indication of chronotropic
incompetence. Additionally, the PROVIDE Trial, under
the leadership of Dr. Zweibel, will test different sets of
ICD programming parameters to minimize shock therapy
without increasing the risk of syncope or untreated ventricular
tachycardia.
Cardiac Electrophysiology is also one of 140 centers
worldwide investigating the possible benefit of early
implantation of cardiac resynchronization devices for
reduction of heart failure hospitalization and total mortality
in the MADIT-CRT trial. Dr. Christopher Clyne is principal
investigator on the first multi-center NIH-sponsored study
to investigate the effect of primary atrial fibrillation ablation
versus drug therapy on total mortality and outcome. Also
under Dr. Clyne’s direction is the Hartford Area Resuscitation
Research Trial (HARRT), a project which will advance basic
life support and AED operation into the West Hartford
Public High Schools. Dr. Eric Crespo is the site principal
investigator on the Direct His Bundle Pacing to Implement
Cardiac Resynchronization Therapy (DIRECT) Study, which
is a multi-center clinical trial investigating a novel pacing
technique (Direct His Bundle Pacing) as an alternative to
conventional cardiac resynchronization therapy in patients
with advanced heart failure.
Echocardiography
Current research projects in Echocardiography are under the
direction of Dr. David Silverman and focus on examination
diastolic dyssynchrony as a marker for diastolic heart failure
(with Sanjeev Bahvnani, MD, Detlef Wencker MD and
Sayeed Zaeem, MD) evaluation of the prognostic value
of systolic strain in a series of patients with diastolic heart
failure, analysis of appropriateness of echo ordering, and an
examination of the prognostic value of plasma cytokine levels
in patients presenting to the emergency room with chest pain.
In collaboration with Dr Isaac Silverman in Neurology and
Dr Jeffrey Kluger in Cardiology, we are building a program
to examine utilization of echocardiography for several
common diagnoses including stroke and syncope. This year
the echocardiography laboratory reported its accumulated
experience with echocardiographic imaging to guide
prognosis following percutaneous device closure of patent
foramen ovale.
20.

Cardiology
Cardiac Catheterization
Research Program
The research program of the cardiac catheterization
laboratory led by Dr. Francis Kiernan and Raymond McKay,
MD currently focuses on the development and testing of
new interventional and cardiac imaging techniques, on the
assessment of adjunctive interventional pharmacology, and
on the maintenance and analysis of a comprehensive research
database to tract clinical outcomes in all interventional
patients. Previous research accomplishments by members of
the catheterization laboratory have included the development
of balloon aortic and mitral valvuloplasty, catheter-based
local drug delivery, radiofrequency coronary angioplasty,
and intra-cardiac ultrasound. Major contributions have also
been made in the past by the catheterization laboratory
physicians in the assessment of drug-coated stents, primary
percutanaeous intervention for acute myocardial infarction,
directional coronary atherectomy, catheter-based femoral
arteriotomy closure, catheter-based thrombectomy, multiple
new intracoronary stents, intracoronary brachytherapy, and
left ventricular assist devices. In addition, catheterization
physicians have served as principal investigators for over 30
multi-center, national trials over the last five years.
Cardiac Intensive Care Unit
The CICU has multiple research projects underway under
the leadership of Justin Lundbye, MD. These include the
Hypothermia Database Project – a comprehensive database
collection project. Drs. Lundbye, Silverman, Rabdiya and
Ahmed are also working on the Cytokine Project – a study
designed to predict cardiovascular outcomes using cytokine
inflammatory markers. Drs. Lundbye and McKay are also
overseeing the Proton Pump Inhibitor (PPI) and Plavix
Projects and have analyzed outcome data from more than
3000 patients treated at Hartford Hospital. Dr Lundbye is
working on two prospective research trials, one looking at new
CHF therapies and one looking at medications in patients with
coronary artery disease to prevent future events. Multiple
industry funded trials are also underway to examine new
therapeutic approaches tested in hospitalized, critically ill
cardiac patients.
Publications
Ahlberg AW, Baghdasarian SB, Athar H, Thompsen JP, Katten DM,
Noble GL, Mamkin I, Shah AR, Leka IA, Heller GV. Symptomlimited
exercise combined with dipyridamole stress: prognostic value
in assessment of known or suspected coronary artery disease by use of
gated SPECT imaging. J Nucl Cardiol. 2008 Jan-Feb;15(1):42-56.
Akhtar S, Assaad S, Amin M, Holt NF, Barash PG, Silverman DG.
Preoperative beta-blocker use: impact of national guidelines on
clinical practice. J Clin Anesth. 2008 Mar;20(2):122-8.
Angelopoulos TJ, Miles MP, Lowndes J, Sivo SA, Seip RL, Pescatello
LS, Zoeller RF, Visich PS, Gordon PM, Moyna NM, Thompson PD.
Apolipoprotein E genotype and sex influence C-reactive protein
levels regardless of exercise training status. Metabolism. 2008
Sep;57(9):1204-10.
Angelopoulos TJ, Sivo SA, Kyriazis GA, Caplan JD, Zoeller RF,
Lowndes J, Seip RL, Thompson PD. Doage and baseline LDL
cholesterol levels determine the effect of regular exercise on plasma
lipoproteincholesterol and apolipoprotein B levels? Eur J Appl
Physiol. 2007 Nov;101(5):621-8.
Anglade MW, Kluger J, White C,M, Aberle J, Coleman C.
Thiazolidinedione use and post-operative atrial fibrillation:
a US nested case-control study. Curr Med Res Opin. 2007
Nov;23(11)2849-55.
Augeri AL, Tsongalis GJ, Van Heest JL, Maresh CM, Thompson
PD, Pescatello LS. The endothelial nitric oxide synthase-786
T>C polymorphism and the exercise-induced blood pressure and
nitric oxide responses among men with elevated blood pressure.
Atherosclerosis. 2009 Jun;204(2):e28-34. Epub 2008 Dec 16.
Awad AA, Haddadin AS, Tantawy H, Badr TM, Stout RG,
Silverman DG, Shelley KH. The relationship between the
photoplethysmographic waveform and systemic vascular resistance. J
Clin Monit Comput. 2007 Dec;21(6):365-72.
Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA,
Thompson PD, Moriarty PM. Effectiveness and tolerability of everyother-day
rosuvastatin dosing in patients with prior statin intolerance.
Ann Pharmacother. 2008 Mar;42(3):341-6.
Baggish A, Thompson PD. Thick hearts, high stakes, great
uncertainties: Screening athletes for hypertrophic cardiomyopathy.
Heart. 2008 Oct 31. [Epub ahead of print]
Baghdasarian SB, Heller GV. Patient preparation for nuclear imaging:
when should anti- schemic medications be withheld? J Nucl Cardiol.
2007 Nov-Dec;14(6):775-81.
Baghdasarian SB, Noble GL, Ahlberg AW, Katten D, Heller, GV.

Risk stratification with attenuation corrected stress Tc-99m sestamibi
SPECT myocardial perfusion imaging in the absence of ECG-gating
due to arrhythmias. J Nucl Cardiol 2009;16:533-9.
Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra
K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand
KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA,
Merli GJ, O’Gara PT, Thompson PD, Underberg JA. ACCF/
AHA/ACP 2009 competence and training statement: a curriculum
on prevention of cardiovascular disease: a report of the American
College of Cardiology Foundation/American Heart Association/
American College of Physicians Task Force on Competence and
Training (Writing Committee to Develop a Competence and Training
Statement on Prevention of Cardiovascular Disease): developed in
collaboration with the American Academy of Neurology; American
Association of Cardiovascular and Pulmonary Rehabilitation;
American College of Preventive Medicine; American College of
Sports Medicine; American Diabetes Association; American Society
of Hypertension; Association of Black Cardiologists; Centers for
Disease Control and Prevention; National Heart, Lung, and Blood
Institute; National Lipid Association; and Preventive Cardiovascular
Nurses Association. J Am Coll Cardiol. 2009 Sep 29;54(14):1336-63.
Baker WL, Anglade MW, Baker EL, White CM, Kluger J, Coleman
CI. Use of N- cetylcysteine to reduce post-cardiothoracic surgery
complications: a meta-analysis. Eur J Cardiothorac Surg. 2009
Mar;35(3):521`-7. Epub 2009 Jan 14. Review.
Baker WL,Gutierrez-Williams G, White CM, Kluger J, Coleman C.
Effect of cinnamon on glucose control and lipid parameters. Diabetes
Care. 2008 Jan;31(1):41-3.
Baker WL, Kluger J, White CM, Dale KM, Silver BB, Coleman CI.
Effect of magnesium L-lactate on blood pressure in patients with
an implantable cardioverter defibrillator. Ann Pharmacother. 2009
Apr;43(4):569-76. Epub 2009 Mar 31.
Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel AA,
Coleman CI. Dopamine agonists in the treatment of early Parkinson’s
disease: a meta-analysis. Parkinsonism Relat Disord. 2009 May;
15(4):287-94. Epub 2008 Sep 6.
Bateman TM, Heller GV, McGhie AI, Courter SA, Golub RA, Case
JA, Cullom SJ. Multicenter investigation comparing a highly efficient
half-time stress-only attenuation correction approach against standard
rest-stress Tc-99m SPECT imaging.
J Nucl Cardiol 2009;16:726-35.
Bhavnani SP, Coleman Cl, White CM, Clyne CA, Yarlagadda
R, Guertin D, Kluger J. Association between statin therapy and
reductions in atrial fibrillation or flutter and inappropriate shock
therapy. Europace. 2008 Jul;10(7):854-9
Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk
WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR,
Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth
DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS;
COURAGE Trial Research Group. Optimal medical therapy with or
without PCI for stable coronary disease.
N Engl J Med. 2007 Apr 12;356(15):1503-16.
Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk
W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw
L, Chaitman BR, Mancini GB, Berman DS, Gau G, Weintraub WS;
COURAGE Trial Co-Principal Investigators and Study Coordinators.
The evolving pattern of symptomatic coronary artery disease in the
United States and Canada: baseline characteristics of the Clinical
Outcomes Utilizing Revascularization and Aggressive DruG
Evaluation (COURAGE) trial. Am J Cardiol.
2007 Jan 15;99(2):208-12.
Bower B, Klimek J, Yeston N, Ruano G. DNA-guided decision support.
Hosp Health Netw. 2007 Nov;81(11):10.
Coleman C, Baker WL, Kluger J, White CM. Antihypertensive
medication and their impact on cancer incidence: a mixed treatment
comparison meta-analysis of randomized controlled trials. J Hypertens.
2008 Apr;26(4)622-9.
Coleman C, Kuger J, Bhavnani S, Clyne C, Yarlagadda R, Guertin D,
White CM. Association between statin use and mortality in patients
with implantable cardioverter-defibrillators and left ventricular systolic
dysfunction. Heart Rhythm. 2008 Apr;5(4):507-10.
Coleman C, Reinhart K, Kluger J, White CM. The effect of statins
on the development of new-onset type 2 diabetes: a meta-analysis of
randomized controlled trials. Med Res Opin. 2008 May;24(5):
1359-62.
Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger
J; Dofetilide and Intravenous Magnesium Evaluation (DIME)
Investigators. Intravenous magnesium sulfate enhances the ability of
dofetilide to successfully cardiovert atrial fibrillation or flutter: results
of the Dofetilide and Intravenous Magnesium Evaluation. Europace.
2009 Jul;11(7):892-5. Epub 2009 Apr 6.
Cosio-Lima LM, Seip R, Thompson PD, Lagasse MA, Hodges TH.
Intertester reliability of brachial artery flow-mediated vasodilation
using upper and lower arm occlusion in healthy subjects. Vasc Health
Risk Manag. 2008;4(3):731-4.
Crespo E, Oliveira G, Honeycutt E, Becker R, Berger P, Moliterno
D, Anstrom K, Abrams C, Kleiman N, Moll S, Rice L, Rodgers
J, Steinhubl S, Tapson V, Granger C, Ohman E. Evaluation and
management of suspected Heparin-induced thrombocytopenia in
hospitalized patients: The complications after thrombocytopenia
caused by heparin (CATCH) registry. Am Heart J. 2009;157(4):651-7.
22.

Dada MR, Hirst JA, Kiernan FJ, Smally AJ, Lundbye JB, Thompson
PD, McKay RG. Use of prehospital electrocardiograms for the
treatment of patients with ST-segment elevation myocardial
infarction. Conn Med 2009;73(2):69-72.
de Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz FJ.
Exploring genetic variations that may be associated with the direct
effects of some antipsychotics on lipid levels. Schizophr Res. 2008
Jan;98(1-3):40-6.
Denktas AE, Athar H, Henry TD, Larson DM, Simons M, Chan RS,
Niles NW, Thiele H, Schuler G, Ahn C, Sdringola S, Anderson HV,
McKay RG, Smalling RW. Reduced- dose fibrinolytic acceleration of
ST-segment elevation myocardial infarction treatment coupled with
urgent percutaneous coronary intervention compared to primary
percutaneous coronary intervention alone results of the AMICO
(Alliance for Myocardial Infarction Care Optimization) Registry.
JACC Cardiovasc Interv 2008;1(5):504-10.
Devaney JM, Tosi LL, Fritz DT, Gordish-Dressman HA, Jiang S,
Orkunoglu-Suer FE, Gordon AH, Harmon BT,Thompson PD,
Clarkson PM, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello
LS, Visich PS, Zoeller RF,Brandoli C, Hoffman EP, Rogers MB.
Differences in fat and muscle mass associated with a functional
human Polymorphism in a post-transcriptional BMP2 gene regulatory
element. J Cell Biochem. 2009 Aug 15;107(6):1073-82.
Dey D, Suzuki Y, Suzuki S, Ohba M, Slomka PJ, Polk D, Shaw
LJ, Berman DS. Automated quantitation of pericardiac fat from
noncontrast CT. Invest Radiol. 2008 Feb;43(2):145-53.
Dornelas, E.A. (2008). Psychotherapy for Cardiac Patients:
Behavioral Cardiology in Practice. Washington, DC: American
Psychological Association Press.
Fernandez AB, Ahmed S, Duncan B, Firshein S, Kluger J. Cardiac
tamponade: a rare complication of idiopathic hypereosinophilic
syndrome.
.J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):188-91.
Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins
and interstitial lung disease: a systematic review of the literature and
of food and drug administration adverse event reports. Chest. 2008
Oct;134(4):824-30.
Fernandez AB, Keyes MJ, Pencina M, D’Agostino R, O’Donnell CJ,
Thompson PD. Relation of corneal arcus to cardiovascular disease
(from the Framingham Heart Study data set). Am J Cardiol. 2009 Jan
1;103(1):64-6. Epub 2008 Oct 4.
Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg
and 10 mg) twice a week in patients intolerant to daily statins. Am J
Cardiol. 2008 Jun 15;101(12):1747-8.
Gesquiere MJ, Awad AA, Silverman DG, Stout RG, Jablonka DH,
Silverman TJ, Shelley KH. Impact of withdrawal of 450 ml of blood
on respiration-induced oscillations of the ear plethysmographic
waveform. J Clin Monit Comput. 2007 Oct;21(5):277-82.
Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS,
Heller GV, McCollough CH, McNitt-Gray MF, Mettler FA, Mieres
JH, Morin RL, Yester MV. Ionizing radiation in cardiac imaging.
Circulation. 2009;119:1056-1965.
Giedrimas A, Giedrimiene D, Guertin D, White CM, Clyne
CA, Kluger J. A comparison of outcomes for patients receiving
implantable cardioverter defibrillators for primary vs secondaryprevention.
Conn Med. 2008 Jun-Jul;72(6):329-33.
Gold M, Val-Mejias J, Leman RB, Tummala R, Goyal S, Kluger J,
Kroll M, Oza A. Optimization of superior vena cava coil position
and usage for transvenous defibrillation. Heart Rhythm. 2008
Mar;5(3):394-9.
Gonzales JU, Parker BA, Ridout SJ, Smithmyer SL, Proctor DN.
Femoral shear rate response to knee extensor exercise: an age and sex
comparison. Biorheology. 2009;46(2):145-54
Green CD, Thompson PD, Johnston PG, El-Tanani MK. Interaction
between transcription factor, basal transcription factor 3, and the
NH2-terminal domain of human estrogen receptor alpha. Mol Cancer
Res. 2007 Nov;5(11):1191-200.
Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinick
EH, Churchwell KB, Cooke CD, Corbett JR, Cullom SJ, Dahlberg
ST, Druz RS, Ficaro EP, Galt JR, Garg RK, Germano G, Heller
GV, Henzlova MJ, Hyun MC, Johnson LL, Mann A, McCallister
BD Jr, Quaife RA, Ruddy TD, Sundaram SN, Taillefer R, Ward
RP, Mahmarian JJ; American Society of Nuclear Cardiology.
Myocardial perfusion and function: single photon emission computed
tomography. J Nucl Cardiol. 2007 Nov-Dec;14(6):e39-60. Review.
Heller GV, Katanick SL, Sloper T, Garcia M. Accreditation for
Cardiovascular Imaging. JACC: Cardio Imaging 2008;1:390-7.
Hernandez AB, Ahmed S, Duncan B, Firshein S, Kluger J. Cardiac
tamponade: a rare complication of idiopathic hypereosinophilic
syndrome. J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):188-91.
Hubal MJ, Chen TC, Thompson PD, Clarkson PM. Inflammatory
gene changes associated with the repeated-bout effect. Am J Physiol
Regul Integr Comp Physiol. 2008 May;294(5):R1628-37.
Irwin ML, Cadmus L, Alvarez-Reeves M, O’Neil M, Mierzejewski E,
Latka R, Yu H, Dipietro L, Jones B, Knobf MT, Chung GG, Mayne
ST. Recruiting and retaining breast cancer survivors into a randomized
controlled exercise trial: the Yale Exercise and Survivorship Study.
Cancer. 2008 Oct 1;113(7):1716.

Jablonka DH, Awad AA, Stout RG, Silverman DG, Shelley KH.
Comparing the effect f arginine vasopressin on ear and finger
photoplethysmography. J Clin Anesth. 2008 Mar;20(2):90-3.
Jolicoeur E, Ohman E, Honeycutt E, Becker R, Crespo E, Oliveira
G, Moliterno D, Anstrom J, Granger C. Contribution of bleeding
and thromboembolic events to in- hospital mortality among patients
with thrombocytopenia treated with Heparin. American J Cardiol.
2009;104(2):292-297.
Kapetanopoulos A, Ahlberg AW, Taub CC, Katten DM,
Heller GV. Regional wall- motion abnormalities on post-stress
electrocardiographic-gated technetium-99m sestamibi single-photon
emission computed tomography imaging predict cardiac events. J
Nucl Cardiol. 2007 Nov-Dec;14(6):810-7
.
Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA,
O’Fallon KS, Gadarla M, Thompson PD. The creatine kinase
response to eccentric exercise with atorvastatin 10 mg or 80 mg.
Atherosclerosis. 2008 Sep;200(1):121-5.
Kostek MA, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna
NM, Visich PS, Zoeller RF, Price TB, Seip RL,Thompson PD,
Devaney JM, Gordish-Dressman H, Hoffman EP, Pescatello
LS. Myostatin and follistatin poly-morphisms interact with
muscle phenotypes and ethnicity. Med Sci Sports Exerc. 2009
May;41(5):1063-71.
LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R,
Duconge J, Ruaño G. Integrating genomic based information into
clinical warfarin (Coumadin) management: an illustrative case report.
Conn Med. 2008 Aug;72(7):399-403. Erratum in: Conn Med. 2008
Oct;72(9):572.
Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L,
Cullom SJ, Heller GV. Independent and incremental prognostic
value of left ventricular ejection fraction determined by stress gated
rubidium 82 PET imaging in patients with known or suspected
coronary artery disease. J Nucl Cardiol. 2008 Nov-Dec;15(6):745-53.
Lertsburapa K, White CM, Kluger J, Faheem O, Hammond
J, Coleman C. Preoperative statins for the prevention of atrial
fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg
2008 Feb;135(2):405-11.
Liu J, Pearlson G, Windemuth A, Ruano G, Perrone-Bizzozero
NI, Calhoun V. Combining fMRI and SNP data to investigate
connections between brain function and genetics using parallel ICA.
Hum Brain Mapp. 2007 Dec 10.
Mamkin I, Elkoustaf RA, Zhang Q, Mather JF, Kiernan FJ, McKay
RG. Drug-eluting stent implantation results in effective treatment
of small coronary artery disease (DESIRE Small CAD). Conn Med.
2007;71(9):517-22.
Mamkin I, Mather JF, Kiernan FJ, McKay RG. More studies are needed
on gender-based outcomes in percutaneous coronary intervention with
drug-eluting stents. Am J Cardiol. 2007;100(3):560-1.
Mamkin I, Vaksman M, Kiernan FJ, McKay RG, Boden WE. Letter to
Editor regarding “Weekend onset of acute myocardial infarction does
not have a negative impact on outcome in Japan”. Circ J 2008;72:864.
Maron BJ, Haas TS, Doerer JJ, Thompson PD, Hodges JS.
Comparison of U.S. and Italian experiences with sudden cardiac
deaths in young competitive athletes and implications for
preparticipation screening strategies. Am J Cardiol. 2009 Jul
15;104(2):276-80. Epub 2009 May 18.
McBride BF, White CM, Kalus JS, Guertin DC, Clyne CA, Baker WL,
Kluger J. The impact of carvedilol on the defibrillation threshold.
Heart Lung. 2008 Jan-Feb;37(1):67- 1.
McKay RG, Dada MR, Mather JF, Mennet RR, Murphy DJ, Maloney
KW, Hirst JA, Kiernan FJ. Comparison of outcomes and safety of
“facilitated” versus primary percutaneous coronary intervention in
patients with ST-segment elevation myocardial infarction. Am J
Cardiol. 2009;103(3):316-21.
McKay RG, Murphy DJ, Cloutier J, Mather JF, Mennett RA, Dada
MR, Shah AR, Kiernan FJ. Long-term efficacy and safety of sirolimuseluting
vs bare-metal stents. Conn Med. 2008;72(8):453-63.
Mieres JH, Shaw LJ, Hendel RC, Heller GV. The WOMEN Study:
What is the optimal method for ischemia evaluation in women? A
multi-center, prospective randomized study to establish the optimal
method for detection of coronary artery disease (CAD) risk in women
at an intermediate-high pretest likelihood of CAD: study design. J
Nucl Cardiol 2009;16:105-12.
Moore TA, Sorokin AV, Hirst C, Thornton-Thompson S, Thompson
PD. The accuracy of aneroid sphygmomanometers in the ambulatory
setting. Prev Cardiol. 2008 Spring;11(2):90-4.
Noble GL, Ahlberg AW, Kokkirala AR, Cullom SJ, Bateman TM, Cyr
GM, Katten DM, Tadeo GD, Case JA, O’Sullivan DM, Heller GV.
Validation of attenuation correction using transmission truncation
compensation with a small field of view dedicated cardiac SPECT
camera system. J Nucl Cardiol 2009;16:222-232.
Oliveira G, Crespo E, Becker R; Honeycutt E, Abrams S, Anstrom K,
Berger P, Davidson-Ray L, Eisenstein E, Kleiman N, Moliterno D,
Moll S, Rice L, Rodgers J, Steinhubl S, Tapson V, Ohman E, Granger
C. Incidence and prognostic significance of thrombocytopenia
in patients treated with prolonged heparin therapy. Arch Intern
Med. 2008;168(1):94-102.
24.

Oncken, C., Dornelas, E., Greene, J., Sankey, H., Glasmann, A.,
Feinn, R.. Krnazler, H.R. (2008). Nicotine gum for pregnant
smokers: A randomized controlled trial. Obstetrics & Gynecology,
112, 859-867.
Orkunoglu-Suer FE, Gordish-Dressman H, Clarkson PM, Thompson
PD, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS,
Visich PS, Zoeller RF, Harmon B, Seip RL, Hoffman EP, Devaney
JM. INSIG2 gene poly-Morphism is associated with increased
subcutaneous fat in women and poor response to resistance training
in men. BMC Med Genet. 2008 Dec 23;9:117.
Parker B, Proctor D. Commentary on Viewpoint: Exercise and
cardiovascular risk reduction: time to update the rationale for
exercise? Considering the role of sex in modulating direct effects of
exercise on the vasculature. J Appl Physiol 2008 August;105(2):778
Parker BA, Smithmyer SL, Pelberg JA, Mishkin AD, Herr MD,
Proctor DN. Sex differences in leg vasodilation during graded
knee extensor exercise in young adults. J Appl Physiol 2007
November;103(5):1583-91.
Parker BA, Smithmyer SL, Pelberg JA, Mishkin AD, Proctor DN.
Sex-specific influence of aging on exercising leg blood flow. J Appl
Physiol 2008 March;104(3):655-64.
Parker BA, Smithmyer SL, Proctor DN. Hormone therapy is
associated with preserved smooth muscle structure and dilation in the
arterial vasculature of the leg in older women. Maturitas 2008 January
20;59(1):46-54.
Parker BA, Smithmyer SL, Ridout SJ, Ray CA, Proctor DN. Age and
microvascular responses to knee extensor exercise in women. Eur J
Appl Physiol 2008 June;103(3):343 -51.
Parker BA, Trehearn TL, Meendering JR. Pick Your Poiseuille:
Normalizing the Shear Stimulus In Studies of Flow-Mediated
Dilation. J Appl Physiol 2008 November 13.
Patten CA, Decker PA, Dornelas EA, Barbagallo J, Rock E, Offord
K, Hurt R, Pingree S. (2008). Changes in readiness to quit and selfefficacy
among adolescents receiving a brief office intervention for
smoking cessation. Psychology, Health and Medicine, 13, 326-336.
Pescatello LS, Blanchard BE, Van Heest JL, Maresh CM, Gordish-
Dressman H, Thompson PD. The metabolic syndrome and the
immediate antihypertensive effects of aerobic exercise: a randomized
control design. BMC Cardiovasc Disord. 2008 Jun 10;8:12.
Pistilli EE, Devaney JM, Gordish-Dressman H, Bradbury MK, Seip
RL, Thompson PD, Angelopoulos TJ, Clarkson PM, Moyna NM,
Pescatello LS, Visich PS, Zoeller RF, Gordon PM, Hoffman EP.
Interleukin-15 and interleukin-15R alpha SNPs and associations with
muscle, bone, and predictors of the metabolic syndrome. Cytokine
2008 Jul;43(1):45-53.
Poirier P, Alpert MA, Fleisher LA, Thompson PD, Sugerman HJ,
Burke LE, Marceau P, Franklin BA. American Heart Association
Obesity Committee of Council on Nutrition, Physical Activity
and Metabolism, Council on Nutrition, Physical Activity and
Metabolism, Council on Cardiopulmonary Perioperative and Critical
Care, Council on Cardiovascular Surgery and Anesthesia, Council on
Cardiovas. Cardiovascular evaluation and management of severely
obese patients undergoing surgery: a science advisory from the
American Heart Association. Circulation. 2009 Jul 7;120(1)86-95.
Epub 2009 Jun 15.
Richards KA, Lleuser LP, Kluger J. Fortuitous therapeutic effect of
Taser shock for a patient in atrial fibrillation. Ann Emerg Med. 2008
Dec;52(6):686-8. epub 2008 June 2.
Ruaño G. DNA collage and personalized medicine. Conn Med. 2008
Jun-Jul;72(6):322.
Ruaño G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL,
Kocherla M, Holford TR, Hanks S. Physiogenomic comparison of
edema and BMI in patients receiving rosiglitazone or pioglitazone.
Clin Chim Acta. 2008, Oct. 26.
Ruaño G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL,
Kocherla M, Holford TR, Hanks S. Physiogenomic comparison of
edema and BMI in patients receiving rosiglitazone or pioglitazone.
Clin Chim Acta. 2008 Oct 26.
Ruffin RT Jr, Kluger J, Baker WL, Wills SM, White CM, Coleman
C. Association between perioperative NSAID use and postcardiothoracic
Esurgery atrail fibrillation, blood transfusions,
and cardiovascular outcomes: a nested cohort study from the AF
Suppression Trials (AFIST) I, II and III. Curr Med Res Opin. 2008
Apr;24(4):1131-6.
Seip RL, Volek JS, Windemuth A, Kocherla M, Fernandez ML,
Kraemer WJ, Ruaño G. Physiogenomic comparison of human fat loss
in response to diets restrictive of carbohydrate or fat. Nutr Metab
(Lond). 2008 Feb 6;5:4.
Sewright KA, Clarkson PM, Thompson PD. Statin myopathy:
incidence, risk factors, and pathophysiology. Curr Atheroscler Rep.
2007 Nov;9(5):389-96.
Shafi N. Malek A, Silverman DI. Management of hypertension in
Takayasu arteritis during pregnancy. J Clin Hypertension, 2009,
11:383-5.
Shafi N, McKay RG, Kiernan FJ, Silverman IE, Ahlquist M, Silverman
I. Determinants and clinical significance of persistent residual
shunting in patients with percutaneous patent Foramen Ovale
Closure Devices. Int J Cardiol July 2009, epublication ahead of print.

Shah SA, Clyne CA, Henyan N, Migeed M, Yarlagadda R, Silver
BB, Kluger J, White CM. Impact of magnesium sulfate on serum
magnesium concentrations and intracellular electrolyte concentrations
among patients undergoing radio frequency catheter ablation. Conn
Med. 2008 May;72(5):261-5.
Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan
PM, Weintraub WS, O’Rourke RA, Dada M, Spertus JA, Chaitman
BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G,
Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates
ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators.
Optimal medical therapy with or without percutaneous coronary
intervention to reduce ischemic burden: results from the Clinical
Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008 Mar
11;117(10):1283-91.
Shaw LJ, Berman DS, Blumenthal RS, Budoff MJ, Faber TL, Goraya
T, Halliburton SS, Hecht H, Kiat H, Koenig W, Malik S, Merhige
M, Nasir K, Min JK, O’Keefe J, Polk DM, Raggi P, Rosenblatt JA,
Schwartz RG, Taylor AJ, Thomas GS, Wijns W. Clinical imaging
for prevention: directed strategies for improved detection of
presymptomatic patients with undetected atherosclerosis--Part
I: Clinical imaging for prevention. J Nucl Cardiol. 2008 Jan-
Feb;15(1):e6-19. Review.
Shaw LJ, Hendel RC, Heller GV, Borges-Neto S, Cerqueira M,
Berman DS. Prognostic estimation of coronary artery disease
risk with resting perfusion abnormalities and stress ischemia on
myocardial perfusion SPECT. J Nucl Cardiol 2008;15:762-73.
Sheridan S, Crespo, E. Is the routine use of global coronary heart
disease risk scores associated with clinical benefits or harms? A
systematic review of the literature. BMC Health Services Research
2008, 8:60.
Siddiqi SA, Thompson PD. How do you treat patients with myalgia
who take statins? Curr Atheroscler Rep. 2009 Jan;11(1):9-14.
Singh B, Bateman TM, Case JA, Heller GV. Attenuation artifact,
attenuation correction, and the future of myocardial perfusion SPECT.
J Nucl Cardiol 2007;14:153-64.
Soman P, Lahiri A, Mieres JH, Calnon DA, Wolinsky D, Beller GA,
Sias T, Burnham K, Conway L, McCullough PA, Daher E, Walsh MN,
Wight J, Heller GV, Udelson JE. Etiology and pathophysiology of
new-onset heart failure: Evaluation by myocardial perfusion imaging.
J Nucl Cardiol 2009;16:82-91.
Sood M, Coleman Cl, Kluger J, White CM, Padala A, Baker WL. The
association among blood transfusions, white blood cell count, and the
frequency of post-cardiothoracic surgery atrial fibrillation: A nested
cohort study from the Atrial Fibrillation Suppression Trials I, II, and
III. J Cardiothorac Vasc Anesth. 2008 Aug 28.
Sorokin AV, Araujo CG, Zweibel S, Thompson PD. Atrial fibrillation
in endurance trained athletes. Br J Sports Med. 2009 Aug 11.
Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis,
hyperlipidemia, and atherosclerotic risk: a systematic review.
Atherosclerosis. 2007 Oct;194(2):293-9. Review.
Talati R, Reinhart KM, White CM, Phung OJ, Sedrakyan A, Kluger
J, Coleman CI, Outcomes of perioperative beta-blockade in patients
undergoing noncardiac surgery: a meta-analysis. Ann Pharmacother.
2009 Jul;43(7):1181-8. Epub 2009 Jun 16.
Tercius AJ, Kluger J, Coleman C, White CM. Intravenous magnesium
sulfate enhances the ability of intravenous ibutilide to successfully
convert atrial fibrillation of flutter. Pacing Clin Elcetrophysiol, 2007
Nov;30(11):1331-5.
Thompson PD, Venero CV. A history of medical reports on the
Boston Marathon: 112 years and still running. Med Sci Sports Exerc.
2009 Jun;41(6):1341-8.
Thompson PD. Pre-participation screening of competitive athletes:
seeking simple solutions to a complex problem. Circulation. 2009
Mar 3;119(8):1072-4. Epub 2009 Feb 16.
Venero CV, Heller GV, Bateman TM, McGhie AI, Ahlberg AW,
Katten D, Courter SA, Golub RJ, Case JA, Cullom SJ. A Multicenter
evaluation of a new post-processing method with depth-dependent
collimator resolution applied to full-time and half-time acquisitions
without and with simultaneously acquired attenuation correction. J
Nucl Cardiol 2009;16;714-25
Venero CV, Thompson PD, Fernandez AB. Reduced high-density
lipoprotein cholesterol in patients receiving rosiglitazone and
fenofibrate. Am J Med. 2008 Oct;121(10):e3-4.
Venero CV, Thompson PD. Managing statin myopathy. Endocrinol
Metab Clin North Am. 2009 Mar;38(1):121-36.
Venero CV, Venero JV, Seip RL, Thompson PD. Effectiveness of
thrice weekly ezetimibe. Am J Cardiol. 2008 Nov 1;102(9):1205-6.
Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE,
Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner
RE, Inzucchi SE; Detection of Ischemia in Asymptomatic Diabetics
(DIAD) Investigators. Resolution of asymptomatic myocardial
ischemia in patients with type 2 diabetes in the Detection of Ischemia
in Asymptomatic Diabetics (DIAD) study. Diabetes Care. 2007
Nov;30(11):2892-8.
Walsh S, Kelsey BK, Angelopoulos TJ, Clarkson PM, Gordon PM,
Moyna NM, Visich PS, Zoeller RF, Seip RL, Bilbie S, Thompson PD,
Hoffman EP, Price TB, Devaney JM, Pescatello LS. The CNTF 1357
G>A polymorphism and the muscle strength response to resistance
training. J Appl Physiol. 2009 Jul 23 [Epub ahead of print]
26.

vWard RP, Al-Mallah MH, Grossman GB, Hansen CL, Hendel RC,
Kerwin TC, McCallister BD Jr, Mehta R, Polk DM, Tilkemeier PL,
Vashist A, Williams KA, Wolinsky DG, Ficaro EP; American Society
of Nuclear Cardiology. American Society of Nuclear Cardiology
review of the ACCF/ASNC appropriateness criteria for single-photon
emission computed tomography myocardial perfusion imaging
(SPECT MPI). J Nucl Cardiol. 2007 Nov-Dec;14(6):e26-38.
Windemuth A, Calhoun VD, Pearlson GD, Kocherla M, Jagannathan
K, Ruaño G. Physiogenomic analysis of localized FMRI brain activity
in schizophrenia. Ann Biomed Eng. 2008 Jun;36(6):877-88.
Young LH, Wackers F J, Chyun DA, Davey JA, Barrett EJ, Taillefer
R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk, N, Ratner RE,
Inzucchi SE. Cardiac Outcomes After Screening for Asymptomatic
Coronary Artery Disease in Patients with Type 2 Diabetes. JAMA
2009;301(15):1547-1555.
Zoeller RF, Ryan ED, Gordish-Dressman H, Price TB, Seip RL,
Angelopoulos TJ, Moyna NM, Gordon PM, Thompson PD,
Hoffman EP. Allometric scaling of isometric biceps strength in adult
females and the effect of body mass index. Eur J Appl Physiol. 2008
Nov;104(4):701-10.
Abstracts
Barmpouletos D, Stavens G, Ahlberg A, O’Sullivan DM, Katten
DM, Heller GV. Risk Stratification of Diabetic Patients with Single
Photon Emission Computed Tomography Myocardial Perfusion
Imaging (SPECT-MPI): Does duration of Disease and Type of
Therapy Matter? JACC: 2009;53:A291.
Bhavnani S, Coleman C, Guertin D, White CM, Yarlagadda R, Clyne
C, Kluger J. Clinical predictors of early mortality among patients
receiving implantable cardioverter-defibrillators. Europace Journal
2009, 11(Supplement 2), Abstract 507.
Chawla D, Sood N, Guertin D, Zweibel S, Coleman C, Kluger
J, Clyne C. Predictors of Pacemaker Dependence and Pacemaker
Dependence as a Predictor of Mortality in Patients Implanted with
Implantable Cardioverter Defibrillator. Heart Rhythm Society
Meeting, May 2009.
Ching G, Li D, McKay R, Mather J, Lundbye J. Proton Pump
Inhibitors Increase Major Adverse Cardiac Events Among Post
Percutaneous Coronary Intervention Patients on Clopidogrel.
Circulation, 2009; 120:S936-S937
Faheem O, Mohyuddin Y, Iqtidar AF, Guler AL, Chawla D, Ahlberg
A, Heller, GV. Diabetics with Positive SPECT Myocardial Perfusion
Imaging Referred for Catheterization: Gender Bias? JACC:
2009;53:A297
Guler AL, Chien P, Ahlberg A, Faheem O, Katten D, Heller GV.
Attenuation Corrected SPECT Myocardial Perfusion Imaging
Provides Highly Effective Risk Stratification for Future Cardiac
Events. JACC: 2009;53:A287.
Hendel RC, Mieres JH, Heller GV, Bairey-Merz CN, Boden WE,
Shaw LJ. Prevalence of False Positive Exercise Electrocardiograms
in Women? Results from the “What is the Optimal Method
for Ischemia Evaluation in Women (WOMEN) Trial”. JACC:
2009;53:A287.
Lustgarten D, Neal S, Crespo E, Lobel R, Spector P, VanBuren P.
Direct His Bundle Pacing Results in Significant QRS Narrowing in
Patients Referred for Cardiac Resynchronization Therapy (CRT).
Abstract presented at the Heart Rhythm Society Scientific Session in
May 2009.
Padala A, Shah AR, Ahlberg A, Kokkirala AR, Katten D, Heller
GV. Value of Transient Ischemic Dilatation for Risk Stratification
of Patients Undergoing Gated Rubidium-82 Positron Emission
Tomography Imaging. JACC: 2009;53:A288.
Parker, BA, Thompson, PD, Ruopp, KC, Meda, SA, Grimaldi, AS,
Pearlson, GD (2009). Direct Effects Of Exercise Training On The
Hippocampus In Humans. American College of Sports Medicine
2009 Annual Meeting, Seattle, WA. Med Sci Sports Exerc. 41(5)
Supplement 1:8.
Shephal K Doshi, MD, Jesus E. Val-Mejias, MD, Michael Pittaro,
MD, Russell Reeves, MD, John Payne, MD, Richard Henthorn,
MD, Mauricio Hong, MD, Steven Zweibel, MD, Mark Kroll, PhD,
Robert Graumann, MS, Ashish L Oza, MS. Do similar T-Shock and
Rescue Shock Waveforms, When Altered, Affect ULV based DFT
Estimations? Heart Rhythm Society Meeting, May 2009.
Sood N, Coleman C, Padala A, Kluger J, Guertin D, Clyne C.
Association Between ICD Lead Diameter and ICD Lead Failure.
Presented at Heart Rhythm Society National Meeting, Denver,
Colorado, May 15th, 2008, published in HRS Supplement, May,
2008.
Yekta A, Ruffin R, Ahlberg A, Katten D, Heller GV. Outcomes
Analysis of Stress-Only Gated Myocardial Perfusion Imaging with
Attenuation Correction in Patients with Suspected Coronary Artery
Disease. JACC: 2009;53:A296.
New Projects
Federal
Dornelas, Ellen, PhD
Reducing Vulnerability to ICD Shock Treated Ventricular
Arrhythmias. NHLBI/ Yale University, $412,725.
Reducing Vulnerability to ICD Shock Treated Ventricular
Arrhythmias (Substudy). NHLBI/ Yale University, $46,916.

Kluger, Jeffrey, MD
Task Order 2, Project 1. Comparative Effectiveness of Medical
Therapies for Stable Ischemic Heart Disease. ACE_ARB CER/AHRQ/
University of Connecticut, $134,119.
Thompson, Paul, MD
Co Enzyme Q10 in Statin Myopathy. NIH/NCCAM, $865,207.
DNA Diagnostic System for Statin Safety and Efficacy. NIH/
Genomas, $74,812.
Wencker, Detlef, MD
Studies on Skeletal and Cardiac Muscle Apoptosis in Advanced
Cardiac Failure. NIH, $562,115.
White, Charles, PharmD
Human Growth Hormone in Cystic Fibrosis. UCONN/AHRQ,
$3,106.
Foundation
White, Charles, PharmD
The Impact of Ascorbic Acid Therapy on Inflammatory Mediators in
Cardiothoracic Surgery Patients: The Atrial Fibrillation Suppression
Trial IV (AFIST IV) Pilot Study. The Gustavus and Louise Pfeiffer
Research Foundation, $72,282.
State
Parker, Beth, PhD
Does Smoking Cessation restore Vascular Function in Chronic
Smokers? CT Department of Public Health, $267,187.
Industry
Clyne, Christopher, MD
FREEDOM: A Frequent Optimization Study Using the QuickOpt
Method. St. Jude Medical, $50,360.
Heller, Gary, PhD, MD
A Phase 2, Open-Label, Multicenter Study for the Development of
One-Day Rest/Stress Cardiac Positron Emission Tomography (PET)
Perfusion Imaging Protocols of BMS 747158. Lantheus Medical
Imaging, $19,646.
An Open-Label, Multicenter, Phase 3 Study to Demonstrate the
Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying
Subjects with Heart Failure who will Experience an Adverse Cardiac
Event during 24 Months Follow-up. GE Healthcare, $13,839.
Kiernan, Francis, MD
A Clinical Evaluation of the Medtronic Endeavor Resolute
Zotarolimus-Eluting Coronary Stent System in the Treatment of De
Novo Lesions in Native Coronary Arteries with a Reference Vessel
Diameter of 2.25 mm to 4.2 mm. Medtronic Vascular, $149,000.
Kluger, Jeffrey, MD
APPROPRIATE Assessment of Proper Physiologic Response
with Rate Adaptive Pacing Driven by Minute Ventilation or
Accelerometer. Boston Scientific Corp., $77,500.
Lundbye, Justin, MD
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-
Controlled Study to Evaluate the 6 Months Efficacy and Safety of
Aliskiren Therapy on Top of Standard Therapy, on Morbidity and
Mortality When Initiated Early After Hospitalization for Acute
Decompensated Heart Failure. Novartis Pharmaceutical Corp,
$37,479.
McKay, Raymond, MD
IntraCoronary Treatment with Integrilin to Improve Angiographic
Outcomes (IC Titan Timi-47). The Brigham and Women’s Hospital,
$74,163.
Polk, Donna, MD
A Phase III, Double-Blind, Randomized Placebo-Controlled Study,
to Evaluate the Effects of RO4607381 on Cardiovascular Risk in
Stable CHD Patients, with a Documented Recent Acute Coronary
Syndrome. Hoffman-LaRoche, $221,980.
A Randomized, Double-Blind, Double-Dummy, Parallel Group,
Phase 3 Efficacy and Safety Study of CGT-2168 Compared with
Clopidogrel to Reduce Upper Gastrointestinal Events Including
Bleeding and Symptomatic Ulcer Disease (CG 104). Parexel
International, $169,543.
Wencker, Detlef, MD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Study of the Effects of KW-3902 Injectable Emulsion on Heart
Failure Signs and Symptoms and Renal Function in Subjects with
Acute Heart Failure Syndrome and Renal Impairment Who are
Hospitalized. Averion International Corp., $103,575.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group
Study to Assess The Effects of Intravenous BG9928 on Body Weight
in Subjects with Acute Decompensated Heart Failure and Renal
Insufficiency. Biogen Idec, $79,400.
Recover II Trial: A Prospective Randomized Trial Investigating the
Use of the Impella RECOVER LP 2.5 System in Patients with Acute
Myocardial Infarction Induced Hemodynamic Instability. ABIOMED,
Inc., $56,500.
The Effect of Eplerenone Versus Placebo on Cardiovascular Mortality
and Heart Failure Hospitalization in Subjects with NYHA Class II
Chronic Systolic Heart Failure (EMPHASIS-HF). Pfizer, $60,450.
Zweibel, Steven, MD
PROVIDE: Programming Implantable Cardioverter Defibrillators in
Patients with Primary Prevention Indication to Prolong Time to First
Shock. St. Jude Medical, Scientific Studies Organization, $63,000.
The Vest Prevention of Early Sudden Death Trial (VEST)
PREDiction of ICD Therapies Study (PREDICTS). NIH/NHLBI/
University of California, San Francisco, $325,438.
28.

Industry (Investigator Initiated)
Coleman, Craig, PharmD
A Clinician’s Perspective on Rating the Strength of Evidence in a
Systematic Review. Pfizer, $45,000.
A Clinician’s Perspective on the Use of Meta-Regression in
Systematic Review: Caveats and Cautions. Pfizer, $45,000.
A Healthcare Decision Makers Guide to Reviewing and Using
Meta-Analyses: A White Paper of the Health Outcomes, Policy, and
Economics (HOPE) Collaborative Group. Pfizer, Inc., $25,000.
Cost-Effectiveness of Aggrenox® in Reduction of Graft Failures
Among Dialysis Patients: A Markov Model. Boehringer Ingelheim,
$26,616.
Evaluating the Impact of Study-Level Factors on Anticoagulation
Control in US-Based Clinical Trials: A Meta-Analysis. Boehringer-
Ingelheim, $44,500.
Meta-Analysis of Dopamine Agonists, Catechol-o-methyltransferase
Inhibitors and Monoamine Oxidase Type B Inhibitors for the
Treatment of Advanced Parkinson’s Disease. BIPI, $15,000.
Oral Hypoglycemic Medications and Their Impact on New-Onset
Diabetes Mellitus Incidence: A Mixed Treatment Comparison Meta-
Analysis of Randomized Controlled Trials. Takeda Pharmaceuticals,
$58,500.
Industry (Multi-center)
Heller, Gary, PhD, MD
A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-
Controlled Study to Evaluate the Effect of Caffeine Intake on Single
Photon Emission Computed Tomography (SPECT) Myocardial
Perfusion Imaging (MPI) in Subjects Administered Regadenoson.
Astellas Pharma Global Development, Inc., $90,242.
A Single-Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial
of LMI1195 in Healthy Subjects (Study Number: LMI1195-101).
Lantheus Medical Imaging, $153,200.
Kiernan, Francis, MD
Protocol P07-6330: A Prospective, Single-Blind, Randomized,
Multi-Center Study Comparing The Cypher Elite to The Cypher Bx
VELOCITY Sirolimus-Eluting Stent Systems. Cordis Corporation,
$85,000.
Lundbye, Justin, MD
Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3,
Randomized, Double-Blind, Evaluation of the Safety and Efficacy
of Apixaban In Subjects with a Recent Acute Coronary Syndrome.
Bristol-Myers Squibb Company, $130,606.
McKay, Raymond, MD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Study to Evaluate the Safety to Evaluate the Safety and Efficacy of
SCH530348 in Addition to Standard of Care in Subjects With a
History of Atherosclerotic Disease: Thrombin Receptor Antagonist
in Secondary Prevention of Atherothrombotic Ischemic Events (TRA
2P - TIMI 50). Schering Plough, $545,625.
Polk, Donna, MD
A Clinical Outcomes Study of Darapladib versus Placebo in Subjects
with Chronic Coronary Heart Disease to Compare the Incidence of
Major Adverse Cardiovascular Events (MACE). GlaxoSmithKline,
$274,075.
Wencker, Detlef, MD
A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-
Controlled Study to Evaluate the Efficacy and Safety of Relaxin in
Subjects with Acute Heart Failure. Corthea, Inc., $71,260.
Double-Blind, Placebo-Controlled, Multicenter Acute Study of
Clinical Effectiveness of Nesiritide in Subjects With Decompensated
Heart Failure (ASCEND-HF). Scios, Inc., $76,938.
PROTECT II: A Prospective, Multi-center, Randomized Controlled
Trial of the IMPELLA RECOVER LP 2.5 System versus Intra Aortic
Balloon Pump (IABP) in Patients Undergoing Non Emergent High
Risk PCI. ABIOMED, Inc., $85,000.
Departmental
Mathur, Shishir, MD
Effects of Acute and Chronic Physical Activity on Genetic Damage
and Lipoproteins. $19,500.
McKay, Raymond, MD
A Pilot Study to Assess the Histological Effects and Biomechanical
Strength of a Novel, Knotless Suturing Technique. $22,363.
Parker, Beth, PhD
The Effect of Statins on Cognitive Function in Individuals with
Statin-Associated Cognitive Complaints. $2,000.
Thompson, Paul, MD
Assessments of Muscle Outcomes in Clinical Patients with Statin
Myalgia. $12,000.
Hartford Hospital Research Endowment Funds
Azemi, Talhat, MD
Diagnostic and Prognostic Significance of Ischemic
Electrocardiographic Changes During Vasodilator Stress Myocardial
Perfusion Imaging. Small Grant, $9,507.

Clyne, Christopher, MD
Identifying Atrial Ablation Lines through Two-Dimensional Delayed
Enhancement MR Imaging. Small Grant, $6,300; St. Jude Medical,
Scientific Studies Organization $5,000.
Fischer, Edward, PhD
Community and Patient Attitudes Towards Seeking Medical Help:
Development and Standardization of a Comprehensive Attitude
Measure. Open Competition, $21,146.
Lundbye, Justin, MD
Elevated Plasma Cytokines are a Marker for Unstable Coronary
Syndrome: The Hartford Chest Pain Study. Small Grant, $10,777.
Parker, Beth, PhD
Sex Differences in the Mechanisms Underlying Endothelial Function.
Open Competition, $78,685.
Silverman -Cardiology, David, MD
Freedom from Atrial Fibrillation Following Radio-Frequency Ablation
Depends Upon Integrity of Atrial Function. Small Grant, $9,975.
Systolic Strain Abnormalities to Predict Hospital Readmission In
Patients with Heart Failure and Normal Ejection Fraction. Small
Grant, $3,680.
Sood, Nitesh, MD
Heart Rate Variability and Brain Natriuretic Peptide. Small Grant,
$5,760.
Unfunded
Anglade, Moise, MD
Use of N-Acetylcysteine for Prevention of Postoperative Atrial
Fibrillation: A Meta-Analysis.
Book, Gregory, BS
Automatic Extraction of Heart Valve Models from 64 Slice CT Data
Using Active Appearance Models.
Chaudhri, Priya, PhD
The Effects of Sleep Disturbance on Adherence to Cardiac
Rehabilitation.
Chemmarappally, Shiny, RN
Infusion Center Treatment Effect on Quality of Life in Congestive
Heart Failure Patients.
Coleman, Craig, PharmD
Context-Based Learning by Pharmacy Students during their Clinical
Rotations: The Role of Situated Learning in Experiential Education.
Examining the Barriers to Updating Systematic Review Research: A
Survey of Authors of Published Systematic Reviews in the Medical
Literature.
Heller, Gary, PhD, MD
The Prognostic Role of Myocardial Perfusion Imaging in Elderly
Patients Undergoing Stress Test? A Meta-Analysis. Statistical analysis
supported through Hartford Hospital Small Grant.
Humayun, Naeem, MD
Does Cardiac Resynchronization Therapy (CRT) Increase
Susceptibility to Malignant Arrhythmias?
Iqtidar, Ali, MD
Predictors of Rapid Aortic Dilatation in Adult Patients with a
Bicuspid Aortic Valve. Statistical analysis supported through Hartford
Hospital Small Grant.
Kluger, Jeffrey, MD
Simple Bedside Method of Monitoring QTc in Patients with
Pacemaker Receiving QTc Prolonging Drugs.
Lundbye, Justin, MD
A Quality Improvement Project on Congestive Heart Failure
Readmission.
Cardiac Intensive Care Unit Clinical Outcomes- A Quality
Improvement Project.
Clinical Outcomes Blanket Protocol for Induction of Hypothermia in
Patients with Cardiac Arrest.
Mendes, Beverly, APRN
Phenomena of Inner Strength in Women Recovering Post Myocardial
Infarction Coronary Stent: A Grounded Theory Study.
Morales, Donna Chelle, MD
Ethnic Differences in Depression Amongst Female Cardiac
Rehabilitation Patients.
Polk, Donna, MD
The Effects of Carotid IMT Scans on Intent and Actual Likelihood to
Change Health Behaviors.
Rabdiya, Vimal, MD
Is Left Ventricular Diastolic Dysfunction an Arrhythmogenic Marker
in Patients with Implantable Cardioverter-Defibrillator and Relatively
Preserved Left Ventricular Systolic Function?
Richards, Kyle, MD
Cardiac PET FDG and MR Imaging in Patients with Sarcoidosis: A
Retrospective Study for Clinical Outcomes.
Silverman, David, MD
Do Repeat Echocardiograms Alter Clinical Outcomes? A Prospective
Study. Statistical analysis supported through Hartford Hospital Small
Grant.
Dyssynchrony Determines Prognosis in Diastolic Heart Failure.
Evaluation of Load Independent Diastolic Function Using Velocity
Vector Imaging- A Novel Technique.
30.

Predictors of Success after Percutaneous Patent Foramen Ovale
Closure for Stroke Prevention.
Validation of Velocity Vector Imaging for Assessment of Diastolic
Function.
Wencker, Detlef, MD
Effect of Neurohormonal Agents on Ejection Fraction of Chronic
Heart Failure Patients.
INTERMACS (Interagency Registry for Mechanically Assisted
Circulatory Support).
Zafian, Ruth, APRN
An Exploratory, Descriptive Pilot Study to Examine the Quality of
Hand-offs Reports at Hartford Hospital Using the ISBAR Technique.
Active Projects
Ahmed, Shafeeq, MD
Is Cardiac Memory Blocked by Calcium Channel Blockers and
Amiodarone?
Bilbie, Stephen, MS
Upper Arm Muscle Injury, Soreness, and Strength Changes
Associated with Two Bouts of Resistance Exercise. Hartford Hospital
Research Endowment Funds, $10,000.
Clyne, Christopher, MD
Impact of Corticosteroids on Immediate Postoperative Recurrence
of Atrial Tachyarrhythmias after Radiofrequency Catheter Ablation
of Atrial Fibrillation. Interventional Electrophysiology Outcomes
Protocol.
Multicenter Automatic Defibrillator Implantation Cardiac
Resynchronization Therapy (MADIT-CRT). University of Rochester/
Guidant Corporation, $133,793.
OPTION CRT/Atx (Cardiac Resynchronization Therapy & Atrial
Therapy). BIOTRONIK, Inc., $59,698. Statistical analysis supported
through Hartford Hospital Small Grant.
Response of Cardiac Resynchronization Therapy Optimization with
V-V Timing in Heart Failure Patients (RESPONSE HF). St. Jude
Medical, $34,247.
The Impact of Intravenous Magnesium on Atrial Vulnerability in
Patients Receiving Radiofrequency Catheter Ablation for Atrial
Fibrillation. Hartford Hospital Research Endowment Funds,
$40,894.
Use of Gated Blood Pool Imaging to Predict Improvement with
Bi-Ventricular Pacing - A Pilot Study. Hartford Hospital Research
Endowment Funds, $9,295.
Coleman, Craig, PharmD
Can HMG-CoA Reductase Inhibitors Decrease Atrial Fibrillation
Following Cardiothoracic Surgery? A Retrospective Cohort
Evaluation.
Drug Assistance Program to Reduce Disparities in Health.
Meta-Analyses of the Impact of Appropriate Antibiotic Therapy on
Mortality in Patients with Ventilator-Associated Pneumonia and
Blood Stream Infections. AstraZeneca, $20,625.
Meta-Analysis of Therapies for Treatment of Early- and Late-Stage
Parkinson’s Disease. Boehringer-Ingelheim Pharmaceuticals, $17,500.
The Impact of Oral Magnesium L-Lactate on Occurrence of
Ventricular Arrhythmias and Patient Perceived Quality of Life
Among Patients with Implantable Cardioverter-Defibrillators: The
Adjuvant Magnesium (AdMag) Trial Cost-Utility Analysis. Hartford
Hospital Research Endowment Funds, $9,952.
Donahue, Stephen, BS
CRUSADE (Can Rapid Risk Stratification of Unstable Angina
Patients Suppress Adverse Outcomes with Early Implementation of
the ACC/AHA Guidelines?). Millennium Pharm. & Schering Plough
Pharm., $20,000.
Dornelas, Ellen, PhD
A 12 Week, Double-Blind, Placebo-Controlled, Multicenter Study
with a 40 Week Follow-up Evaluating the Safety and Efficacy of
Varenicline Tartrate 1 MG BID for Smoking Cessation in Subjects
with Cardiovascular Disease. Pfizer, $160,327.
Nicotine Replacement Treatment for Pregnant Smokers. NIH/
University of Connecticut, $527,683.
Study of treatment for Antepartum Depression in expecting Mothers
(SAD-Moms). Hartford Hospital Research Endowment Funds,
$73,000.
Heller, Gary, MD, PhD
A Prospective Comparison of Gated, Rest/Stress Rubidium-82
Positron Emission Computed Tomography (PET) vs. Gated, Rest/
Stress Technetium 99-M SPECT: A Pilot Study. Bracco Diagnostics,
Inc., $285,802.
An Open-Label Multi-Center, Phase 3 Study Evaluating the
Prognostic Usefulness of I123-mIBG Scintigraphy for Identifying
Subjects with Heart Failure who will Experience an Adverse Cardiac
Event? ( Protocol PC MBG311 CPR). GE Healthcare (Amersham),
$157,500.
Assessment of Myocardial Perfusion and Left Ventricular Function
from Stress and Rest Tc-99m Sestamibi Gated SPECT Imaging for
the Prediction of Future Cardiac Events in Patient with Known or
Suspected Coronary Artery Disease. Hartford Hospital Research
Endowment Funds, $44,280.

Attenuation Correction with the CardioMD Camera: Validation by
Comparison with Attenuation Correction with the Vertex Cardio 60
Camera. Nuclear Medicine Division - Philips Med. System, $100,632.
Clinical Utility of Attenuation Correction of Pharmacologic Stress
Tc-99 Sestamibi SPECT Myocardial Perfusion Imaging in Patients
with Known or Suspected Coronary Artery Disease.
Detection of Ischemia in Asymptomatic Diabetics (DiaD). Yale
University School of Medicine, $289,843.
Development of a Normal Database and Criteria for Abnormality for
b Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid (Iodofiltic Acid
I 123) for Quantitative Imaging (Protocol MIP-BP22). Molecular
Insight Pharmaceuticals, $50,094.
Evaluation of Astonish Processing Phase II. Philips Nuclear Medicine
(Cleveland), Inc., $139,583.
Impact of Stress Modality Upon Diagnosis and Risk Stratification in
Patients with Left Bundle Branch Block (LBBB).
Nuclear Cardiology Imaging Clinical Outcomes Blanket Protocol.
Statistical analysis supported through Hartford Hospital Small Grant.
Nuclear Imaging Database Research Project. Bristol Meyers Squibb
Imaging, Inc., $95,000.
Open-Label, Phase 2 Study of the Safety and Efficacy of ß-Methylp-[123I]-Iodophenyl-Pentadecanoic
Acid (Iodofiltic Acid I 123)
for Identification of Ischemic Myocardium Using Single Photon
Emission Computed Tomography (SPECT) in Adults with Symptoms
Consistent with Acute Coronary Syndrome (ACS). Molecular Insight
Pharmaceuticals, $56,445.
Progression of Coronary Artery Disease in Diabetic and Non-
Diabetic Individuals as Measured by Serial Gated Myocardial
Perfusion Imaging. Hartford Hospital Research Endowment Funds,
$10,074.
Stress technetium-99m Sestamibi Gated SPECT Imaging in the
Detection of Coronary Artery Disease in Patients with Dilated
Cardiomyopathy. Hartford Hospital Research Endowment Funds,
$50,000.
Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles
in CAD: (SPARC). Brigham & Women’s Hospital, $50,375.
The Prognostic Value of Left Ventricular Ejection Fraction From
Cardiac PET Myocardial Perfusion Imaging in Patients with Known
or Suspected Coronary Artery Disease. BRACCO, $78,738.
The Role of Cardiac PET Perfusion Imaging in the Diagnosis of
Coronary Disease in Patients with Diabetes Mellitus. Hartford
Hospital Research Endowment Funds, $48,394.
Kiernan, Francis, MD
A Randomized, Controlled Trial to Evaluate the Safety and Efficacy
of the Zomaxx Drug Eluting Coronary Stent System as Compared
to the TAXUS Express Paclitaxel-Eluting Stent in de novo Coronary
Artery Lesion. Abbott Vascular, $300,956.
ARRIVE - Taxus Peri-Approval Registry: A Multi-Center Safety
Surveillance Program. Boston Scientific Corporation, $114,410.
CSP-424 Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE). Department of Veterans
Affairs, $378,000.
Humanitarian Use Device - JOSTENT Coronary Stent Graft.
Protocol P00-6302 A Multicenter, Randomized, Double Blind Study
of the SIROLIMUS-Coated BX Velocity Balloon Expandable Stent
in the Treatment of Patients with De Novo Native Coronary Artery
Lesions. Cordis, Inc., $102,000.
Kluger, Jeffrey, MD
MASTER: Microwave T Wave Alternans Testing for Risk
Stratification of Post MI Patients. Medtronic, $120,023.
The Adjuvant Magnesium Trial (AdMag): Assessment of the Impact
of Oral Magnesium on ICD Firing and Quality of Life. Donaghue
Foundation, $162,175.
The Use of Magnesium to Improve Hemodynamics, Cholesterol and
Glucose Control: A Substudy of AdMag. Hartford Hospital Research
Endowment Funds, $47,000.
LaGasse, Marie
Exercise Training and Endothelial Vasomotor Function in Patients
with Coronary Artery Disease. Hartford Hospital Research
Endowment Funds, $52,575.
Lundbye, Justin, MD
Follow up of Patients with Coronary Artery Disease who have
Undergone Rapid Aspirin Desensitization Before or After
Percutaneous Coronary Intervention. Hartford Hospital Research
Endowment Funds, $5,826.
McKay, Raymond, MD
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute
Coronary Syndrome Subjects Who Are to Undergo Percutaneous
Coronary Intervention/TRITON-TIMI 38. Quintiles, Inc., $143,022.
A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and
Safety Study of AZD6140 Compared to Clopidogrel for Prevention
of Vascular Events in Patients with Non-ST or ST Elevation Acute
Coronary Syndromes (ACS) - PLATO. AstraZeneca Pharmaceuticals,
$182,265.
A Single-Center Registry to Investigate the Long-Term Safety and
Efficacy of the Sirolimus-Eluting CYPHER Intracoronary Stent.
Cordis, $140,410.
Clinical Outcomes Blanket Protocol of Get-with-the-guidelines -
Heart Failure (GWTG-HF) database.
32.

Cardiology
Novel Suture-based Arteriotomy Closure Device Feasibility Study.
Departmental, $105.
Percutaneous Coronary Intervention Clinical Outcomes Blanket
Protocol. Statistical analysis supported through Hartford Hospital
Small Grant.
The Role of Glycemic Control During Cardiac Catheterization
Procedures and Cardiac Events.
Polk, Donna, MD
A Preliminary Study of Statin-Associated Cognitive Impairment.
Hartford Hospital Research Endowment Funds, $34,588.
Rock, Josh, DO
Pulmonary Venous Catheter Ablation and its Effect on P-Wave
Dispersion in Patients with Atrial Fibrillatoin.
The Effects of Statin Therapy on the Development of Early Recurrent
Atrial Fibrillation after Catheter-Based Pulmonary Vein Ablation.
Ruaño, Gualberto, MD, PhD
Genetic Modulation of Lipid Metabolic Response to Aerobic
Exercise. Hartford Hospital Research Endowment Funds, $50,000.
Seip, Richard, PhD
Relationship of Muscle Injury to Muscle Hypertrophy. Hartford
Hospital Research Endowment Funds, $35,488.
Sood, Nitesh, MD
Effect of Heart Rate on Ventricular Dyssynchrony.
Thompson, Paul, MD
(JUPITER) A Randomized, Double-Blind, Placebo-Controlled,
Multicenter, Phase III Study of Rosuvastatin (Crestor\200) 20
mg in the Primary Prevention of Cardiovascular Events Among
Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of
C-Reactive Protein (JUPITER) (Protocol No. 4522US/0011). PPD
Development, LP, $102,250.
Reduction of LDL Cholesterol in Subjects with Hypercholesterolemia
Refractory to Current Conventional Treatment. B. Braun Medical,
Inc., $91,875.
A Randomized, Placebo Controlled, Parallel Group, Double-Blind
Study of the Efficacy and Safety of Rimonabant in Abdominally
Obese Subjects with Multiple Cardiovascular and Metabolic Risk
Factors and with LDL-Cholesterol at NCEP ATP III Treatment
Goal (Protocol Number L-0137). Sanofi-Aventis US, ICON Clinical
Research, $77,967.
B. Braun Medical Inc. Patient Registry for the H.E.L.P. System.
Correlation of Cytochrome P450 and Drug Transport Gene
Polymorphisms in Statin-Induced Myopathies. Hartford Hospital
Research Endowment Funds, $23,680.
Determining the Reliability and Reproducibility of Brachial Artery
Reactivity. Hartford Hospital Research Endowment Funds, $13,125.
Does Exercise Training Alter Hippocampal Size and Function
in Humans: A Preliminary Study. Hartford Hospital Research
Endowment Funds, $56,317.
Effects of Low and High Dose Atorvastatin On Exercise-Induced
Muscle Injury. Merck & Co., Inc., $408,227.
Functional SNP’s associated with Human Muscle Size and Strength (
FAMUSS). NIAMS/Children’s National Medical Center, $447,280.
Gene Expression Profiling and the Repeated Bout Effect: A
Pilot StudyHF-ACTION: Heart Failure and A Controlled Trial
Investigating Outcomes of Exercise TraiNing: Ancillary Study
- Investigation of the Role of Genetic Variation in the Clinical
Expression of Heart Failure. NHLBI, $685,000.
Lipid Treatment Assessment Project 2 (L-TAP 2) Protocol
#NRA5090005. Pfizer, $6,250.
A Multicenter, Randomized, Double-Blind, Titration Study to
Evaluate and Compare the Efficacy and Safety of Ezetimibe Added
On to Atorvastatin 40 mg Versus Up Titration to Atorvastatin 80 mg
in Hypercholesterolemic Patients at High Risk for Coronary Heart.
Merck & Co., Inc., $26,500.
A Randomized Multicenter Crossover FUTURA Trial to Compare
the Performance of the Plasmat® Futura Heparin Induced
Extracorporeal LDL Precipitation (H.E.L.P.) Apheresis System to
the Approved Plasmat® Secura H.E.L.P. Apheresis System in the

Molecular Changes in Human Muscle with Unloading/Reloading.
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group
Evaluation of the Fixed Combination Torcetrapib/Atorvastatin,
Administered Orally, Once Daily (QD), Compared with Atorvastatin
Alone, on the Occurrence of Major Cardiovascular Events in Subjects
with Coronary Heart Disease or Risk Equivalents. Pharmanet,
$347,000.
Skeletal Muscle Gene Expression in Patients with Statin-Induced
Myalgia. Donaghue Medical Research Foundation, $239,996.
The Effect of Statins on Skeletal Muscle Function. NIH, $3,007,870.
White, Charles, PharmD
Electrocardiographic (ECG) Evaluation of Transmural Dispersion
of Repolarization and QT Prolongation in Patients Receiving
Amiodarone or Pure Blockers of the Rapid Component of the
Delayed Rectifier Potassium Channel (Sotalol or Dofetilide).
The Impact of Short-Term High Intensity Statin Therapy Versus
Low Intensity Statin Therapy on Inflammatory Mediators in
Cardiothoracic Surgery Patients: The Atrial Fibrillation Suppression
Trial IV (AFIST IV) Pilot Study. Gustavus and Louise Pfeifer Research
Foundation, $74,583.
34.

Center for
Anti-Infective Research & Development
David Nicolau, PharmD, FCCP, FIDSA, Director
Charles Nightingale, PhD, Co-Director
Joseph L. Kuti, PharmD, Associate Director
Kathryn J. Eagye, MPH, Associate Director
Mary Banevicius, BS, Research Supervisor
Pamela Tessier, MS, Research Supervisor
Christina Sutherland, BS, Research Assistant
Debora Santini, BS, Research Assistant
Lindsay Tuttle, BS, Research Assistant
Henry Christensen, BS, Research Assistant
Jennifer Hull, BS, Research Assistant
Aryun Kim, PharmD, Postdoctoral Fellow
Anthony Nicasio, PharmD, Postdoctoral Fellow
Jared Crandon, PharmD, Postdoctoral Fellow
Catherine Bulik, PhD, Postdoctoral Fellow
Rebecca Keel, PhD, Postdoctoral Fellow
Dora Wiskirchen, PhD, Postdoctoral Fellow
Pashalina Konto, MD, Visiting Scholar, Papanikolaou
Hospital, Thessaloniki, Greece
Li Peng, Visiting Scholar, PUMC Hospital, Beijing, China
Pornpan Koomanachai, MD, Visiting Scholar, Siriraj Hospital,
Mahidol Univ.,Thailand
The Center for Anti-Infective Research and Development
(CAIRD) is recognized both nationally and internationally
for its efforts surrounding the development and
commercialization of anti-infective therapies. Over the
past decade efforts have been undertaken to expand the
preclinical study capabilities of CAIRD to further enhance
our services to companies involved in the drug development
of novel compounds. The CAIRD has enhanced its provision
of analytical services for both investigator-sponsored studies
and industry-sponsored investigations throughout the United
States. Additionally, over the last five years the Center
has managed and published on its global efforts to assist
the prescriber with the optimal selection of antimicrobial
therapies based on local epidemiology, resistance and
the utilization of available dosing strategies. New global
collaborative efforts will allow similar studies to be conducted
for the foreseeable future.
Within the institution, the CAIRD continues to focus its
efforts on discovering the most clinically, as well as costeffective
method of administering anti-infectives, efforts which
began nearly 30 years ago via the founding insights of Drs.
Richard Quintiliani and Charles Nightingale.
The Center for Anti-Infective Research and Development at
Hartford Hospital has a national and international reputation
for being on the leading edge of Infectious Disease research
and its clinical application. Throughout the course of the year,
members of the Center have given numerous presentations
involving both clinical practice and research related topics at
various local, national and international meetings.
New Projects
Industry
Kuti, Joseph, PharmD
Bronchopulmonary Pharmacokinetics of Micafungin in Healthy Adult
Volunteers. Astellas Pharma US, Inc., $148,862.
A Phase 4, Open Label Study to Assess the Bronchopulmonary
Pharmacokinetics of Anidulafungin and Voriconazole following
Intravenous Administration in Healthy Subjects. Pfizer, Inc.,
$259,259.
Nicolau, David, PharmD
Evaluation of AstraZeneca Novel Antimicrobials against
Streptococcus Pneumoniae and Staphylococcus Aureus in Murine
Pneumonia Models. Astra-Zeneca, Inc., $75,766.
Evaluation of Novel AstraZeneca Anti-Infectives against
Staphylococcus aureus in a Murine Thigh Model. Astra-Zeneca, Inc.,
$102,766.
Evaluation of Iclaprim against Staphylococcus aureus in a Murine
Thigh Model. Arpida, Inc., $78,725.
Evaluation of the Bactericidal Activity of High-Dose Doripenem
Human Simulated Exposures Against Pseudomonas Aeruginosa in
a Neutropenic Murine Thigh Infection Model. Johnson & Johnson
PRD, $157,050.

Industry (Developmental)
Nicolau, David, PharmD
In Vivo Evaluation of CXA-101 ± Tazobactam Versus Piperacillin-
Tazobactam using Human Simulated Exposures Against
Phenotypically Diverse Gram-Negative Organisms. Calixa
Therapeutics, Inc., $154,188.
Evaluation of Lead Therapeutics Novel Antimicrobials Against
Staphylococcus Aureus in a Murine Pneumonia Model. LEAD
Therapeutics, Inc., $34,200.
Industry (Investigator Initiated)
Kuti, Joseph, PharmD
In Vitro Pharmacodynamics of Pulmonary Exposures of Tigecycline
Alone and in Combination with Rifampin or Meropenem Against
Klebsiella spp. Producing the KPC-2 Carbapenemase. Wyeth
Pharmaceuticals, $87,000.
An in Vitro Pharmacodynamic Model of a Human Simulated
High Dose, Prolonged Infusion Meropenem Regimen Against
Klebsiella spp. Producing the KPC-2 Carbapenemase. AstraZeneca
Pharmaceuticals, $77, 250.
Daptomycin MICs against Vancomycin-Susceptible Staphylococcus
aureus with Higher Vancomycin MICs: A Comparison of Three
Testing Methods. Cubist Pharmaceuticals, $59,250.
Nicolau, David, PharmD
Comparison of Simulated Human Exposures of Telavancin and
Vancomycin against Staphylococcus aureus with Increasing
Vancomycin MICs in a Murine Pneumonia Model. Astellas Pharma,
$130,615.
Pharmacodynamic Evaluation of CB-182804 Against Acinetobacter
Baumannii and Pseudomonas aeruginosa in a Murine Pneumonia
Model. Cubist, $128,019.
Assessment of Doripenem Stability within Two Infusion Devices: A
Focus on Use in the Home Infusion Arena. Ortho McNeil Jasssen,
$52,413.
Ertapenem Utilization and Resistance Emergence Among Collateral
Antimicrobials (EURECA). Merck & Co., Inc., $259,688.
Tissue Penetration and Pharmacokinetics of Linezolid in Diabetic
Patients with Chronic Wound Infections by In Vivo Microdialysis.
Pfizer,Inc., $117,900.
Evaluation of CEN-101 as Adjunctive Therapy for Staphylococcus
aureus Pneumonia in a Murine Model. Centegen Inc., $50,719.
In Vitro Evaluation of CXA-101 Potency Against Selected Isolates of
Pseudomonas Aeruginosa. Calixa Inc., $19,688
Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic
Patients with Chronic Wound Infections by In Vivo Microdialysis.
Wyeth, $122,927.
Pharmacodynamic Profiling of Intravenous Antibiotics Against
Prevalent US Derived Gram-Negative Organisms. Ortho McNeil
Janssen, $71,000.
A Hospital Specific Program to Assess Anti-Infective Minimum
Inhibitory Concentrations (MICs) and Pharmacodynamic Target
Attainment against Methicillin-Resistant Staphylococcus aureus
Strains. Pfizer, Inc., $16,625.
Evaluation of AlphaRx Novel Antimicrobials Against Staphylococcus
Aureus in a Murine Pneumonia Model. AlphaRx, Inc., Ontario,
Canada, $26,883.
Hartford Hospital Research Endowment Funds
Kuti, Joseph, PharmD
The Effect of Hyperbaric Oxygen Therapy on the Penetration
of Linezolid into Subcutaneous Tissue of Diabetics with Lower
Extremity Wounds. Open Competition, $74,847.
Eagye, Kathy, MPH
Health Outcomes Investigation of Infection in Colorectal Surgical
Procedures. Small Grant, $14,854.
Unfunded
Nicolau, David, PharmD
Subcutaneous and Intravenous Tissue Levels of Cefazolin During
Abdominoplasty: A Pilot Study.
Active Projects
Kuti, Joseph, PharmD
Clinical Outcomes and Costs Associated with a Ventilator Associated
Pneumonia Clinical Pathway in Intensive Care Units.
Cost-effectiveness of telavancin versus vancomycin in the treatment
of complicated gram-positive skin and skin structure infections.
Theravance, Inc., $102,375.
Pharmacoeconomics of Antifungals in the Treatment of Invasive
Aspergillosis with a Focus on the Polyenes. Enzon Pharmaceuticals,
$118,250
Nicasio, Anthony, PharmD
The Impact of Automated Testing on the Clinical Outcomes and
Economics of Infections Due to Extended Spectrum Beta-lactamase
Producing Enterobacteriaceae. Small Grant, $9,390.
Nicolau, David, PharmD
Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals
Systemic Antibacterials in the Rat Thigh Infection Model. Vertex
Pharmaceuticals, Inc. $29,814.
36.

Blanket Protocol: Efficacy Evaluation of Affinium Pharmaceuticals
Novel Systemic Antibacterials in the Murine Model of Staphylococcus
Aureus Intra-Abdominal Sepsis. Affinium Pharmaceuticals, $34,045.
Bioanalytical Validation and Sample Analysis of Aztreonam in Human
Plasma by HPLC for the Telavancin Clinical Program. Theravance,
$28,000.
Blanket Protocol: Efficacy Evaluation of Affinium Pharmaceuticals
Novel Systemic Antibacterials in the Murine Staphylococcus Aureus
Thigh Infection Model. Affinium Pharmaceuticals, $40,030.
Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals
Novel Systemic Antibacterials in the Mouse S. aureus Thigh Infection
Model. Vertex Pharmaceuticals, $85,095.
Blanket Protocol: Efficacy Evaluation of Vertex Pharmaceuticals Novel
Systemic Antibacterials in the Murine (Mouse) Model of Intra-
Abdominal Sepsis. Vertex Pharmaceuticals, Inc., $16,706.
Blanket Protocol: Efficacy of Vertex Pharmaceuticals Novel Systemic
Antibacterials in the Murine (Rat) Model of Pneumococcal Intra-
Abdominal Sepsis. Vertex Pharmaceuticals, Inc., $38,889.
Bronchopulmonary Pharmacokinetic and Pharmacodynamic Profiles
of Leofloxacin 750mg in Adults Undergoing Treatment of Acute
Exacerbaction of Chronic Bronchitis. Orth-McNeil Pharmaceuticals,
$211,341.
Clinical and Economic Implication of Antibiotic Prophylaxis Failure in
Elective Colorectal Surgery. Merck & Co., Inc., $57,505.
Clinical Pharmacodynamics of Beta-lactam Antibiotics in Patients
with Pseudomonas Aeruginosa Infections.
Determination of Gatifloxacin Concentrations in Biological Matrixes.
Armed Forces Radiobiology Research Institute, $6,300.
Determination of Piperacillin and Tazobactam in Biological Matrixes.
Wyeth Pharmaceuticals, $35,000.
Efficacy Evaluation of Affinium Pharmaceuticals Novel Systemic
Antibacterials in the Murine Staphylococcus Aureus Pneumonia
Model. Affinium Pharmaceuticals, $86,288
Evaluation of Ceftobiprole Against Staphylococcus aureus in a
Murine Pneumonia Model Blanket Protocol. Johnson & Johnson
Pharmaceuticals, $110,494.
Evaluation of Destiny Pharma’s Novel Antimicrobials Against
Staphylococcus Aureus in a Murine Thigh Model. Destiny
Pharmaceuticals, $59,635.
Evaluation of Novexecel Inc. Novel Antimicrobials Against
Staphylococcus aureus in a Murine Thigh Model Blanket Protocol.
Novexel, Inc., $125,231.
Evaluation of Novexel Inc. Novel Antimicrobials against
Staphylococcus aureus in a Murine Pneumonia Model. Novexel, Inc.,
$111,010.
Evaluation of Polymedix Inc. Novel Antimicrobials Against
Staphylococcus aureus in a Murine Thigh Model - Blanket Protocol.
PolyMedix, Inc., $92,542.
Evaluation of the Bactericidal Activity of Doripenem Human
Simulated Exposures Against Pseudomonas aeruginosa in
a Neutropenic Mouse Thigh Model. Johnson & Johnson
Pharmaceutical R&D, $169,040.
Evaluation of the Impact of Inadequate Empirical Therapy Against
Pathogens Causing Complicated Skin & Soft Tissue Infections.
Wyeth Pharmaceuticals, $81,413.
Evaluation of the Pharmacodynamic Profile of Novel Vertex
Pharmaceuticals Compounds in Murine Models of Infection (Blanket
Protocol). Vertex Pharmaceuticals, Inc., $52,186.
HPLC Analysis of Daptomycin in Human Serum. Cubist
Pharmaceuticals, $35,000.
Identificeftazidime Susceptible Pseudomonas aeruginosa
Among Clinical Isolates from Hartford Hospital. AstraZeneca
Pharmaceuticals, $11,250.
Murine (Rat) Staphylococcus aureus intra-abdominal sepsis model:
efficacy of affinium pharmaceuticals novel systemic antibacterials.
Affinium Pharmaceuticals, $18,625.
Murine (Rat) Thigh Infection Model: Efficacy Evaluation of Affinium
Pharmaceuticals Systemic Antibacterials. Affinium Pharmaceuticals,
$19,569.
OPTAMA: Evaluating in vivo Potency Against Important Gram-
Negative Rods over the Period of 2002 to 2006. AstraZeneca
Pharmaceuticals, $46,250.
Pharmacodynamic Comparison of the Carbapenems against
Extended-Spectrum Beta-Lactamases from the MYSTIC Surveillance
Program. AstraZeneca, $51,875.
Pharmacodynamic comparison of tigecycline versus other
intravenous antimicrobials in the treatment of serious nosocomial
infections #3074A1-102039. Wyeth Pharmaceuticals, $195,625.
Pharmacodynamic Evaluation of Tigecycline Against Phenotypically
Diverse S. sureus and E. coli in a Murine Thigh Model. Wyeth
Pharmaceuticals, $235,823.
Pharmacodynamic Evaluation of Tigecycline Against Staphylococcus
Aureus and Acinetobacter Baumannii in a Murine Pneumonia Model.
Wyeth Pharmaceuticals, $218,328.
Pharmacodynamic Modeling of Antimicrobials in the Treatment
of Hospital Acquired Pneumonia: Comparison with 2003
OPTAMA Report and Agreement with ATS/IDSA Guidelines for
the Management of Hospital Acquired Pneumonia. AstraZeneca
Pharmaceuticals, $40,625.

Pharmacokinetics of Daptomycin in Patients Receiving Continuous
Veno-Venous Hemodiafiltration (CVVHDF). Cubist Pharmaceuticals,
$99,599.
Provision and Reporting of Susceptibility Testing for Hospital Based
Anti-Infectives. AstraZeneca Pharmaceuticals, $399,375.
Risk Factors for Infection with Meropenem High-level Resistant
Pseudomonas Aeruginosa and Impact on Mortality and Hospital
Costs. AstraZeneca Pharmaceuticals, $62,188.
Tigecycline Concentration Determinations. Wyeth Pharmaceuticals,
$35,000.
Tissue Penetration and Pharmacokinetics of Daptomycin in
Healthy and Diabetic Volunteers by In Vivo Microdialysis. Cubist
Pharmaceuticals, $119,285.
Trends in MIC Distributions of Several Antibiotics Against
Pseudomonas aeruginosa over a 5-Year Period at a Large Urban
Teaching Hospital. Wyeth Pharmaceuticals, $56,250.
Urea Determination in Human Plasma and Bronchial Alveolar Lavage
Fluid by a Colorimetric Method for the Telavancin Clinical Program.
Theravance, $10,000. projects continued
Publications
Beneri CA, Nicolau DP, Seiden HS, Rubin LG. Successful treatment
of a neonate with persistent vancomycin-resistant enterococcal
bacteremia with a Daptomycin-containing regimen. Infection and
Drug Resistance 2008;1:9-11.
Bulik CC, Kuti JL, Nicolau DP. Clostridium difficile infection – not just
a burden anymore. Connecticut Medicine 2009;73(3):407-411.
Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon
S, Deininger DD, Drumm JE, Gross CH, LeTriran A, Liao Y, Mani
N, Nicolau DP, Perola E, Ronkin S, Swenson LL, Tang Q, Tesier PR,
Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. Novel
dual targeting Aminobenzimidazole Urea Inhibitors of DNA Gyrase &
Topoisomerase IV possessing potent antibacterial activity: Intelligent
design and evolution through the judicious use of structure and SAR.
Journal of Medicinal Chemistry 2008;51(17):5243-5263.
Courter J, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal
exposure for-lactams via extended infusions in the pediatric
population. Pediatric Blood & Cancer 2009;53:379-385.
Crandon J, Nicolau DP. Oritavancin, a potential weapon in the
battle against serious gram-positive pathogens. Future Microbiology
2008;3:251-263.
Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of
Tigecycline against phenotypically diverse Staphylococcus aureus
in a murine thigh model. Antimicrobial Agents & Chemotherapy
2009;53(3):1165-1169.
Crandon JL, Bulik CC, Nicolau DP. In Vivo Efficacy of 1- and
2-Gram human simulated prolonged infusions of Doripenem against
Pseudomonas aeruginosa. Antimicrobial Agents & Chemotherapy
2009;53(10):4352-4356.
Crandon JL, Kim A, Nicolau DP. Comparison of Tigecycline
penetration into the epithelial lining fluid of infected and uninfected
murine lungs. Journal of Antimicrobial Chemotherapy 2009;64:837-
839.
Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of the
2002-2006 OPTAMA programs for the US Hospitals: Focus on gramnegative
resistance. Annals of Pharmacotherapy 2009;43(2):220-227.
Crandon JL, Kuti JL, Nicolau DP. Antimicrobial efficacy review.
Pharmacy Practice News. 2009;(9):29-32 ; Infectious Disease Special
Edition. 2009. McMahon Publishing Group.
Dandache P, Nicolau DP, Sakoulas G. Tigecycline for the treatment
of multidrug-resistant Klebsiella pneumoniae meningitis. Infectious
Diseases in Clinical Practice 2009;17:66-68.
Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Surgical
site infections: Does inadequate antibiotic therapy affect patient
outcomes? Surgical Infections 2009;10(4):323-331.
Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated
with infection with Meropenem high-level resistant Pseudomonas
aeruginosa. Infection Control and Hospital Epidemiology
2009;309(8):746-752.
Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital
length of stay and costs in patients with ventilator-associated
pneumonia. Seminars in Respiratory and Critical Care Medicine
2009;30:116-124.
Eagye KJ, Nicolau DP. Incidence of infection and impact on hospital
length of stay and costs in patients undergoing elective colorectal
surgery. American Journal of Surgery 2009;198:359-367.
Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP.
Pharmacodynamic target attainment of oral α-lactams for the
empiric treatment of acute otitis media in children. Pediatric Drugs
2008;10(5):329-335.
Gerding DN, Friedenberg FK, Nicolau DP. Clostridium Difficile
infection: Guidance on optimal diagnosis and treatment. Continuing
Medical Education Supplement, Advancing Knowledge in
Healthcare, Inc., 2009;1-8.
38.

Kiffer CRV, Kuti JL, Nicolau DP. Optimization of therapy using
pharmacodynamic principles: The case for prolonged infusion
-lactam antibiotic therapy. Brazilian Journal of Infectious Diseases
2008;12(Suppl. 2):22-28.
Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic
profiling of Doripenem against Pseudomonas aeruginosa by
simulating human exposures. Antimicrobial Agents & Chemotherapy
2008;52(7):2497-2502.
Kim A, Sakoulas G, Kuti JL, Nicolau DP. Prevalence of Methicillinresistant
Staphylococcus aureus (MRSA) strains with Vancomycin
MIC 2 μg/mL in New York City area hospitals and implications on
pharmacodynamic target attainment. Infectious Diseases in Clinical
Practice 2009;7(2):95-98.
Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP.
Penetration of Daptomycin into soft tissues in diabetic versus
healthy volunteers by in vivo microdialysis. Antimicrobial Agents &
Chemotherapy 2008;52(11):3941-3946.
Kim SW, Kuti JL, Nicolau DP. Review on inhaled antimicrobial
therapies for respiratory infections. Current Infectious Disease
Reports 2008;10:29-36.
Kioumis IP, Kuti JL, Nicolau DP. Antibiotic therapy: General
considerations. Pharmacologic management of the orthopedic
trauma patient. In Browner BB, Jupiter JB, Levine AM, Trafton PG,
Krettek C, eds. Skeletal Trauma: Basic Science, Management, and
Reconstruction, Volume I: General Principles, Spine, Pelvis. 4th ed,
Philadelphia, PA: Saunders Elsevier 2009:258-264.
Kontou P, Kuti JL, Nicolau DP. Ceftobiprole: The first anti-MRSA
Cephalosporin. Formulary 2008;43:66-79.
Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases
Society of America/American Thoracic Society Criteria to Predict
Severe Community Acquired Pneumonia Caused by Streptococcus
pneumoniae. American Journal of Emergency Medicine 2009;27:968-
974.
Koomanachai P, Crandon JL, Kuti JL, Nicolau DP. Comparison
of the cumulative fraction of response for 19 antibiotic regimens
against nosocomial pathogens in Europe between 2002 and 2006.
International Journal of Antimicrobial Agents 2009;33(4):348-353.
Koomanachai P, Kim A, Nicolau DP. Pharmacodynamic evaluation of
Tigecycline against Acinetobacter Baumannii in a murine pneumonia
model. Journal of Antimicrobial Chemotherapy 2009;63(5):982-987.
Kuti JL, Dowzicky M, Nicolau DP. A pharmacodynamic model to
assess Tigecycline predicted efficacy for hospital-acquired pneumonia.
Journal of Chemotherapy 2008;20(1): 69-76.
Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance
of Tigecycline versus common intravenous antibiotics for the empiric
treatment of complicated skin and soft tissue infections. Surgical
Infections 2008;9(1):57-66.
Kuti JL, Kiffer CRV, Mendes CMF, Nicolau DP. Pharmacodynamic
comparison of Linezolid, Teicoplanin, and Vancomycin against
clinical isolates of Staphylococcus aureus and coagulase-negative
Staphylococci collected from hospitals in Brazil. Clinical
Microbiology & Infection 2008:14:116-123.
Kuti JL, Nicasio AM, Sutherland CA, Nicolau DP. Elevated
Vancomycin minimum inhibitory concentrations among Methicillinresistant
Staphylococcus aureus isolated from patients with ventilator
associated pneumonia at a Connecticut hospital. Connecticut
Medicine 2009;73(6):337-340.
Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empiric antibiotic
therapy for ventilator-associated pneumonia in your ICU: Guidelines
for implementing the guidelines. Seminars in Respiratory and Critical
Care Medicine 2009;30:102-115.
Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Costeffectiveness
of Telavancin versus Vancomycin for the treatment of
complicated skin and skin structure infections. Pharmacotherapy
2008;28(12):1471-1482.
Laohavaleeson S, Lolans, Quinn JP, Kuti JL, Nicolau DP.
Identification of the MexXY-OprM Efflux System in Pseudomonas
aeruginosa with discordant Cefepime / Ceftazidime dusceptibility
profiles. Infection and Drug Resistance 2008;1:51-55.
Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic
characterization of Ceftobiprole in experimental pneumonia
model caused by phenotypically diverse Staphylococcus aureus.
Antimicrobial Agents & Chemotherapy 2008;52(7):2389-2394.
Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti
JL, Nicolau DP. Population pharmacokinetics of extended infusion
high dosed-Cefepime in adult critically-ill patients with ventilator
associated pneumonia. Antimicrobial Agents & Chemotherapy
2009;53(4):1476-1481.
Nicasio Am, Crandon JL, Nicolau DP. In vivo pharmacodynamic
profile of Tigecycline against phenotypically diverse Escherichia coli
and Klebsiella pneumoniae. Antimicrobial Agents & Chemotherapy
2009;53(7):2756-2761.
Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of
automated screening and confirmation of extended spectrum
-lactamase producing Enterobacteriaceae on antibiotic prescribing.
Journal of Medical Microbiology 2008;57:1147-1151.

Nicasio AM, Kuti JL, Nicolau DP. Pharmacotherapy of complicated
urinary tract and intra-abdominal infections with Doripenem. Clinical
Medicine: Therapeutics 2009;1:787-799.
Nicasio AM, Kuti JL, Nicolau DP. The current state of multipledrug
resistant gram-negative bacilli in North America: Insights from
the Society of Infectious Diseases Pharmacists. Pharmacotherapy
2008;28(2):235-249.
Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Shore E,
Russomanno J, Kuti JL. Bronchopulmonary disposition of Micafungin
in healthy adult volunteers. Antimicrobial Agents & Chemotherapy
2009;53(3):1218-1220.
Nicolau DP. Bugs vs. drugs: What is the pharmacist’s challenge?
American Journal of Health-System Pharmacy 2008;65(1) Suppl
2:S2-S3.
Nicolau DP. Carbapenems: A potent class of antibiotics. Expert
Opinion on Pharmacotherapy 2008;9(1):23-37.
Nicolau DP. Containing costs and containing bugs: Are they
mutually exclusive? Journal of Managed Care Pharmacy
2009;15(Suppl)2:S12-S17.
Nicolau DP. Management of complicated infections in the era of
antimicrobial resistance: The role of Tigecycline. Expert Opinion on
Pharmacotherapy 2009;10(7):1213-1222.
Nicolau DP. Pharmacodynamic optimization of α -lactams in the
patient care setting. Critical Care 2008;12(Suppl 4):S1-5.
Nicolau DP. Pharmacokinetic and pharmacodynamic properties of
Meropenem. Clinical Infectious Diseases 2008;47(Suppl 1):S32–40.
Nicolau DP. Spotlight on Clostridium difficile infection: An
educational resource for pharmacists. Pharmacy Times 2009;2:91-100.
Nicolau DP. What is the 360-degree approach to defining success for
VAP? Journal of Managed Care Pharmacy 2009;15(Suppl)5:S3-S4.
Pichichero ME, Doern GV, Kuti JL, Nicolau DP. Probability of
achieving requisite pharmacodynamic exposure for oral α -lactam
regimens against Hemophilus influenzae in children. Pediatric Drugs
2008;10(6):391-397.
Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel G, Kahn
JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier
PR, Drusano GL. Identifying exposure targets for the treatment of
Staphylococcal Pneumonia with Ceftobiprole. Antimicrobial Agents
& Chemotherapy 2009;53(8):3294-3301.
Stein GE, Schooley S, Tyrrell KL, Citron DM, Nicolau DP, Goldstein
EJ. Serum bactericidal activities of Moxifloxacin and Levofloxacin
against aerobic and anaerobic intra-abdominal pathogens. Anaerobe
2008;14(1):8-12.
Abstracts
Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of
single doses (250, 500, 750, 1000 milligrams) of Levofloxacin against
Fluoroquinolone-resistant strains of Escherichia coli. International
Journal of Antimicrobial Agents 2008;32:320-325.
Bulik CC, Christensen H, Li P, Nicolau DP, Kuti JL. An In Vitro
Pharmacodynamic Model of a Human Simulated High Dose,
Prolonged Infusion Meropenem Regimen against Klebsiella spp.
producing the KPC Carbapenemase. (Abstract No. 231). 2009
ACCP/ESCP International Congress on Clinical Pharmacy, Orlando,
FL, April 2009.
Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti
JL. Pharmacodynamics (PD) of Human Simulated, High Dose,
Prolonged Infusion Meropenem (MEM) Against Pseudomonas
aeruginosa (PSA) and Carbapenemase Producing Klebsiella
pneumoniae (KPC). (Abstract No. A1-019). 49th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA, September 12-15, 2009.
Bulik CC, Fauntleroy KA, Jenkins SG, Nicolau DP, Kuti JL.
Comparison of Meropenem (MEM) MICs for Carbapenemase
Producing Klebsiella pneumoniae (KPC) by E-Test, Broth
Microdilution (BMD), and VITEK 2 Methods. (Abstract No.
D-721). 49th Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, CA, September 12-15, 2009.
Bulik CC, Nicolau DP. In Vivo Efficacy of 1g Human Simulated
Prolonged Infusion DOR (DOR) against Carbapenemase
Producing Klebsiella pneumoniae (KPC). (Abstract No. A1-
014). 49th Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, CA, September 12-15, 2009.
Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing Bactericidal
Exposure For -lactams Using Extended Infusions in the Pediatric
Population. (Abstract No. 332). 2009 ACCP/ESCP International
Congress on Clinical Pharmacy, Orlando, FL, April 2009.
Crandon J, Kuti JL, Jones R, Nicolau DP. Pharmacodynamic Target
Attainment Rates for 9 Antibiotics against Escherichia coli, Klebsiella
spp., and Pseudomonas aeruginosa isolates in USA Hospitals.
(Abstract No. 44). American College of Clinical Pharmacy, 2008
Spring Research and Practice Forum, Phoenix, AZ, April 5 - 9, 2008.
40.

Center for
Anti-Infective Research & Development
Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft
RF, Pope J, Russomanno J, Shore E, Nicolau DP, Kuti JL.
Bronchopulmonary Disposition of Intravenous (IV) Voriconazole
(VRC) and Anidulafungin (ANI) Given in Combination to Healthy
Adults. (Abstract No. A1-423). 49th Interscience Conference
on Antimicrobial Agents and Chemotherapy, San Francisco, CA,
September 12-15, 2009.
Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of
Tigecycline Against Phenotypically Diverse Staphylococcus aureus
in a Murine Thigh Model. (Abstract No. A-987). 48th Interscience
Conference on Antimicrobial Agents and Chemotherapy / Infectious
Diseases Society of America 46th Annual Meeting, Washington, DC,
October 25-28, 2008.
Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical
Pharmacodynamics (PD) of Cefepime (FEM) in Patients Infected
with Pseudomonas aeruginosa (PSA). (Abstract No. A1-011).
49th Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, CA, September 12-15, 2009.
Crandon JL, Bulik CC, Nicolau DP. In Vivo Efficacy of 1 and
2g Human Simulated Prolonged Infusion Doripenem Against
Pseudomonas aeruginosa. (Abstract No. A1-013). 49th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA, September 12-15, 2009.
Crandon JL, Kim A, Nicolau DP. Tigecycline Penetration into the
Epithelial Lining Fluid of Infected and Uninfected Murine Lungs.
(Abstract No. 228). 2009 ACCP/ESCP International Congress on
Clinical Pharmacy, Orlando, FL, April 2009.
Crandon JL, Kuti JL, Nicolau DP. Comparison of Simulated Human
Exposures of Telavancin (TLV) and Vancomycin (VAN) against
Methicillin Resistant Staphylococcus aureus (MRSA) with Ranging
Vancomycin MICs in a Murine Pneumonia Model. (Abstract No. A1-
1292). 49th Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, CA, September 12-15, 2009.
Eagye KJ, Kuti JL, Nicolau DP. Prior Carbapenem Use Not
Associated with Infection with Meropenem High-Level Resistant
Pseudomonas aeruginosa (MRP). (Abstract No. K-3492). 48th
Interscience Conference on Antimicrobial Agents and Chemotherapy
/ Infectious Diseases Society of America 46th Annual Meeting,
Washington, DC, October 25-28, 2008.
Eagye KJ, Nicolau DP. Change in Anti-pseudomonal Carbapenem
Susceptibility (ACS) in 25 Hospitals Is Not Associated with the
Use of Ertapenem (ERT). (Abstract No. K-2061). 49th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA, September 12-15, 2009.
Eagye KJ, Sutherland CA, Christensen H, Kuti JL, Nicolau DP.
Prevalence of Pseudomonas aeruginosa (PSA) with Reduced
Susceptibility to Piperacillin-Tazobactam (TZP) at 39 Hospitals.
(Abstract No. C2-201). 48th Interscience Conference on
Antimicrobial Agents and Chemotherapy / Infectious Diseases
Society of America 46th Annual Meeting, Washington, DC, October
25-28, 2008.
Kim A, Banevicius MA, Nicolau DP. In Vivo Efficacy of Doripenem
Human Simulated Exposures against Pseudomonas aeruginosa.
(Abstract No. 109E). American College of Clinical Pharmacy, 2007
Annual Meeting, Denver, CO, October 14-17, 2007.
Kim A, Nicolau DP, Kuti JL. Hospital Costs and Outcomes of
Patients Discharged with a Diagnosis of Pulmonary Aspergillosis in
the United States. (Abstract No. 189). American College of Clinical
Pharmacy, 2007 Annual Meeting, Denver, CO, October 14-17, 2007.
Kim A, Sakoulas G, Kuti JL, Nicolau DP. Pharmacodynamic Analysis
of Vancomycin versus Linezolid against Methicillin-Resistant
Staphylococcus aureus Strains in New York (Abstract No. RP18).
American Society of Hospital Pharmacists, 42nd Annual Midyear
Clinical Meeting, Las Vegas, Nevada, December 2-6, 2007.
Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP.
Penetration of Daptomycin into Soft Tissues in Diabetic versus
Healthy Volunteers by In Vivo Microdialysis. (Abstract No.
A-1884). 48th Interscience Conference on Antimicrobial Agents and
Chemotherapy / Infectious Diseases Society of America 46th Annual
Meeting, Washington, DC, October 25-28, 2008.
KimA, Koomanachai P, Nicolau DP. Pharmacodynamic Evaluation of
Tigecycline against Acinetobacter Baumannii in a Murine Pneumonia
Model. (Abstract No. A-041). 48th Interscience Conference on
Antimicrobial Agents and Chemotherapy / Infectious Diseases
Society of America 46th Annual Meeting, Washington, DC, October
25-28, 2008.

Kontou P, Kuti JL, Nicolau DP. Validation of the 2007 Infectious
Diseases Society of America/American Thoracic Society (IDSA/
ATS) Criteria in Predicting Severe Community Acquired Pneumonia
(CAP) Caused by Streptococcus pneumoniae (SP). (Abstract No.
L-677). 48th Interscience Conference on Antimicrobial Agents and
Chemotherapy / Infectious Diseases Society of America 46th Annual
Meeting, Washington, DC, October 25-28, 2008.
Koomanachai P, Crandon JL, Banevicius MA, Li P, Nicolau DP.
Pharmacodynamic Evaluation of Tigecycline against Staphylococcus
aureus in a Murine Pneumonia Model. (Abstract No. A1-552). 49th
Interscience Conference on Antimicrobial Agents and Chemotherapy,
San Francisco, CA, September 12-15, 2009.
Kuti JL, Nicasio A, Shore E, Palter M, Pepe J, Nicolau DP. Outcomes
of an Empiric Antibiotic Algorithm (EAA) for Ventilator Associated
Pneumonia (VAP) that Considers Local MIC Distributions and
Pharmacodynamics (Abstract No. 1026). 45th Annual Meeting of
Infectious Diseases Society of America, San Diego, CA, October 4-7,
2007.
Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness
of Telavancin versus Vancomycin for the Treatment of Complicated
Skin and Skin Structure Infections. (Abstract No. 185E). American
College of Clinical Pharmacy, 2007 Annual Meeting, Denver, CO,
October 14-17, 2007.
Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti
JL, Nicolau DP. Population Pharmacokinetics of Extended Infusion
High Dosed-Cefepime in Adult Critically-Ill Patients with Ventilator
Associated Pneumonia. (Abstract No. A-1880). 48th Interscience
Conference on Antimicrobial Agents and Chemotherapy / Infectious
Diseases Society of America 46th Annual Meeting, Washington, DC,
October 25-28, 2008.
Nicasio AM, Eagye KJ, Shore E, Palter M, Pepe J, Nicolau DP, Kuti
JL. A Pharmacodynamic (PD) Based Clinical Pathway (CP) for
Empiric Antibiotic Choice in Patients with Ventilator Associated
Pneumonia (VAP). (Abstract No. K-490). 48th Interscience
Conference on Antimicrobial Agents and Chemotherapy / Infectious
Diseases Society of America 46th Annual Meeting, Washington, DC,
October 25-28, 2008.
Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Shore E,
Russomanno J, Kuti JL. Bronchopulmonary Pharmacokinetics (PK)
of Micafungin (MICA) in Healthy Adult Volunteers. (Abstract No.
A-010). 48th Interscience Conference on Antimicrobial Agents and
Chemotherapy / Infectious Diseases Society of America 46th Annual
Meeting, Washington, DC, October 25-28, 2008.
Stein GE, Smith C, Kepros J, Ji A, Nicolau DP, Dybas L, Saunders
JP. Tigecycline Skin Penetration and Activity against Methicillin-
Resistant Strains of Staphylococcus aureus (MRSA). (Abstract No.
A1-554). 49th Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, CA, September 12-15, 2009.
Tessier PR, Love W, Hayter I, Rhys- Williams W, Nicolau DP. A
Novel XF Antibacterial, DPD-207, against Staphylococcus aureus
(SA) in a Murine Thigh Infection Model. (Abstract No. F1-
3969). 48th Interscience Conference on Antimicrobial Agents and
Chemotherapy / Infectious Diseases Society of America 46th Annual
Meeting, Washington, DC, October 25-28, 2008.
Nicasio AM, Crandon JL, Nicolau DP. Pharmacodynamic Profile
of Tigecycline Against Phenotypically Diverse Escherichia coli and
Klebsiella pneumoniae in a Murine Thigh Model. (Abstract No.
A-040). 48th Interscience Conference on Antimicrobial Agents and
Chemotherapy / Infectious Diseases Society of America 46th Annual
Meeting, Washington, DC, October 25-28, 2008.
Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Hospital
Costs Associated with a Pharmacodynamic Based Clinical Pathway
for Empiric Antibiotic Choice in Patients Infected with Ventilator
Associated Pneumonia. (Abstract No. 227). 2009 ACCP/ESCP
International Congress on Clinical Pharmacy, Orlando, FL, April
2009.
42.

Medicine
New Projects
Federal
King, Mary, MD, Gerontology
FOCUS Cognitive Ancillary Study. NHLBI/University of Maryland, $18,144.
Foundation
Kates, Richard, MD, Medicine
Preventive IVIG Therapy for Congenital Heart Block (PITCH). Alliance for
Lupus Research/ New York Univ School of Med, $10,100.
Knauft, R. Frederic, MD, Pulmonology
Cystic Fibrosis Foundation Therapeutics: Clinical Research Facilitation Award.
Cystic Fibrosis Foundation/ University of Connecticut Health center, $9,125.
Industry
Cappa, Joseph, MD, Gastroenterology
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50
mg Versos Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to
Moderate Erosive Gastroesophageal Reflux Disease (GERD) E3810-G000-303.
Eisai/Quintiles, $64,140.
A Randomized Double-Blind Parallel Study off Rabeprazole Extended-Release 50
mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate
to Severe Erosive Gastroesophageal Reflux Disease E3810-G000-301. Eisai/
Quintiles, $64,140.
A Multi-Center, Investigator-blinded, Randomized, 12-Month, Parallel-group,
Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4g Asacol® Therapy
QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative
Colitis. Proctor and Gamble Pharmaceuticals (Multicenter), $27,400.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging
Study of COLAL-PRED in the Treatment of Patients with Moderate to Severe
Ulcerative Colitis. Prometheus (Multicenter), $111,663.
Israel, Jonathan, MD, Medicine
Prospective Observational Study on Predictors of Early On-Treatment Response
and Sustained Virological Response in a Cohort of Treatment Naive HCV-
Infected Patients Treated with Pegylated Interferons. Roche Laboratories, Inc.,
$24,970.
Knauft, R. Frederic, MD, Pulmonology
A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial
Evaluating Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis
and Pseudomonas aeruginosa. Gilead Sciences (Multicenter), $32,575.
Wettstein, Markus, MD, Endocrinology
A Multi-center, Randomized, Double-blind, Active-controlled Clinical Trial to
Evaluate the Safety and Tolerability of 24 weeks Treatment with Vildagliptin
(50 mg gd or 100 mg qd) versus Sitagliptin (25 mg qd) in Patients with Type 2
Diabetes and Severe Renal Insufficiency. Novartis (MultiCenter), $24,721.
Hartford Hospital Research Endowment Funds
Seip, Richard, PhD, Medicine
DNA as a Predictor of Effective Warfarin Levels. Open Competition, $62,475.
Vergara, Cunegundo, MD, Ambulatory Care
Creation of an Ambulatory Database to Measure Access to Primary Preventive
Care Services. Open Competition, $61,000.
Departmental
D’Agostino, Darrin DO, MPH, Ambulatory Care
The Effects of Massage on Bronchodilation in Asthmatics Enrolled in the ACE
Program. $29,340.
Reagan, Louise, APRN, Medicine
The Effect of a Peer Delivered Motivational Message on Intention to Exercise for
Hispanic Persons with Type 2 Diabetes (T2DM): An Experimental Pilot Study.
$454.
Unfunded
Brown, Seth, Medicine
Endoscopic Repair of Frontal Sinus Cerebrospinal Fluid Leaks.
Karabin-Mah, Tessa, RD, Nutrition Services
Food Frequency in Cystic Fibrosis.
King, Mary, MD, Gerontology
Do Properly Functioning Bed Alarms Reduce the Number of Hospital Falls?
Pope, Samuel, MD, Pulmonology
Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with
Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited
Treatment Options and Are at Risk for Disease Progression.
Ranga, Kasturi, MD, Medicine

Does Hydration Status Impact Outcomes at the End of the First Year Post Renal
Transplantation? Analytic support provided through Hartford Hospital Small
Grant.
Effects of Rapid Steroid Taper on Patient and Graft Survival Following Transplant.
HLA Identical Renal Transplant: Single Center Outcome Study.
Incidental Kidney Biopsies, Neither Indicated nor Protocol: Any Lessons to Learn?
Prevalence of Malignancy in Renal Transplant Recipients: A Single Center
Experience.
Utility Of Renal Isotopic Scans In Predicting Delayed Graft Function Post Renal
Transplant. Analytic support provided through Hartford Hospital Small Grant.
Reagan, Louise, APRN, Medicine
A Narrative Analysis Pilot Study: Hispanic Patients’ Perspective of Managing their
Chronic Illness.
Vergara, Cunegundo, MD, Ambulatory Care
Misperceptions and Barriers to Seeking Dermatologic Care in Minority
Populations.
The Effect of an Educational Intervention for Older Adults’ Osteoarthritis Pain: A
Pilot Study.
Active Projects
Albino, Susan, BS, Pulmonology
NICO Non-Invasive Cardiac Output/Respiratory Profile Monitor with Software
for Spontaneous Breathing. Respironics, Inc., $7,000.
Clinical Evaluation of the Respironics Capnostat 5 CO2 Sensor. Respironics, Inc.,
$4,500.
Clinical Evaluation of a Non-Invasive Cardiac Output (NICO2) and Respiratory
Profile Monitor.
Cappa, Joseph, MD Gastroenterology
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter
Study to Evaluate the Efficacy and Safety of DNK333 25mg B.I.D. Given Orally
for 4 Weeks in Female Patients with Diarrhea-Predominant Irritable Bowel
Syndrome (IBS-D). Novartis Pharmaceuticals, $12,300.
A Double-Blind, Randomized, 6-week, Parallel-Group Clinical Trial to Assess
the Safety and Efficacy of Asacol® 4.8 g/day (800 mg mesalamine tablet) versus
Asacol® 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately
Active Ulcerative Colitis. Proctor and Gamble Pharmaceuticals, $58,700.
Chhabra, Jyoti, PhD, Research Administration
Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic and
Health Outcomes Among Latinos. NIH subcontract through the University of
Connecticut, $1,081,928.
Cooper, Brian, MD, Infectious Diseases
A Randomized Trial of Hypertonic Saline/Heparin Flush Solution in the
Prevention of Hemodialysis Catheter Related Bloodstream Infection. Hartford
Hospital Research Endowment Funds, $48,000.
Czarnecki, Gregory, DO, Medicine
Internal Medicine Clinical Assessment Program.
King, Mary, MD, Gerontology
Examining the Use of the Safety Screen to Predict Risk of Hospital Falls.
Statistical analysis supported through Hartford Hospital Small Grant.
Knauft R. Frederic, MD, Pulmonology
Evaluation of Multiple Bioassays in Serum and Pleural Fluid to Estimate the
Probability of Cancer in Patients Presenting with Undiagnosed Pleural Effusion.
Fujirebio Diagnostic, Inc., $72,000.
NOVARTIS TBM100C2302 - A Randomized, Open-label, Multicenter, Phase 3
Trial to Assess Safety of Tobramycin Inhalation Powder Compared to TOBI® in
Cystic Fibrosis Subjects. Novartis Pharmaceuticals, $47,845.
Participation in the Cystic Fibrosis Patient Registry.
Meyer, Ariel, DO, Medicine
Evaluation of Systems Based Practice Changes on Patient Care Near Misses on
the Medical Teaching Service at the University of Connecticut.
Paquette, Anthony, MPH, Medicine
Case Review: Successful Multi-Organ Donation from a Donor with Idiopathic
Thrombocytopenia Purpura.
Post, Jarrod, MD, Dialysis
Hemodynamic Responses to Dialysate Sodium Individualization in Hemodialysis.
Satellite Research Foundation LLC/Yale University, $27,751.
Quintiliani Jr. Richard, MD, Infectious Diseases
Linezolid in the Treatment of Subjects with Complicated Skin and Soft Tissue
Infections Proven to Be Due to Methicillin-Resistant Staphylococcus Aureus.
Covance Inc., $63,556.
Clonal Outbreak of Clostridium Difficile-Associated Disease with High
Morbidity and Mortality. Hartford Hospital Research Endowment Funds,
$58,500.
Ranga, Kasturi, MD, Medicine
Thymoglobulin: Now or Later?
Evaluation of long-term outcomes amongst living donor kidney transplant
recipients from donors older than 50 years: Are they comparable to recipients
of kidneys from donors less than 50 years of age? Statistical analysis supported
through Hartford Hospital Small Grant.
Assessment of Changes in Renal Function in Living Kidney Donors Post-
Nephrectomy in the First Year After Donation.
Robbins, Karen, RN, Dialysis
Reiki: What are its Effects for Patients During Hemodialysis? Hartford Hospital
44.

Research Endowment Funds, $9,963.
Rosson, Robert, MD, Gastroenterology
A Multi-Center, Longitudinal Study of Drug- and CAM-Induced Liver Injury
(Version 2.2). NIDDK/UCONN, $10,000.
Incidence of Positive Screening Gastric Biopsies for Helicobacter Pylori in Clinic
Patients at Hartford Hospital: Comparison with Chinese Patients at Shandung
University Hospital.
Shore, Eric, MD, Pulmonology
Roche Integrin Antagonist Follow-up for Undetected PML. Roche, $600.
Spada, Michael, MD, Ambulatory Care
A Comparison of Symptoms of Acute Coronary Syndrome and Length of Time to
Seeking Treatment Based on Gender and Race.
Sundararajan, Lavanya, MD, Ambulatory Care
A Pilot Study for Increasing Osteoporosis Awareness in Internal Medicine
Residency Clinics.
Vergara, Cunegundo, Ambulatory Care
Hypertension Compliance and the Factors that Affect the Health Status and
Behaviors of Hispanics in the Ambulatory Care Setting.
Using Preoperative Electrocardiograms as a Predictive Marker for Perioperative
Adverse Outcomes in Hispanic Patients Undergoing Elective Non-cardiac
Surgery. Statistical analysis supported through Hartford Hospital Small Grant.
Publications, Presentations
and Abstracts
Calle C, Vega-López S, Puglisi M, Chhabra J, Pérez-Escamilla R,
Volek J, and Fernandez M. Effects of a peer-counseled intervention
on diet and risk factors for cardiovascular disease in Hispanics
diagnosed with type 2 diabetes. Results from the DIALBEST trial.
FASEB J. 2009. 23; 4: 910.3.
Calle M, Vega-López S, Pérez-Escamilla R, Chhabra J, D’Agostino
D, Damio G, and Fernandez M. Dietary habits and cardiovascular
disease risk factors in Hispanics with type 2 diabetes mellitus enrolled
in the DIALBEST trial. Preliminary results. FASEB J. 2008 22:1084.11.
Chhabra J, Vega-López S, Calle M, Putnik P, Fernandez M,
D’Agostino D, Damio G, and Pérez-Escamilla R. Relationship
between energy intake and weight in Latino adults with type 2
diabetes, preliminary results: DIALBEST Trial. FASEB J. 2008
22:875.4.
Chhabra J, Vega-López S, D’Agostino D, and Pérez-Escamilla R.
Does calcium intake relate to weight/BMI in Latinos with type 2
Diabetes? Preliminary Results: DIALBEST Trial. Obesity. 2008:
Abstract Presentation/Publication Number: 681-P.
Chhabra J, Vega-López S, D’Agostino D, Fernandez M, Segura-
Pérez M, Damio G, Pérez-Escamilla R. Relationship of dietary
micronutrient intake with fasting plasma glucose and HbA1c:
DIALBEST Trial Preliminary Results. FASEB J. 2009. 23; 4: 550.3.
Colby J, Wang F, Chhabra J, Pérez-Escamilla R. Predictors of
medication non-adherence in an urban community with healthcare
disparities. Presented at Eastern States Conference for Pharmacy
Residents and Preceptors, American Society for Health-system
Pharmacists Foundation Research Abstracts, Hershey Lodge,
Hershey, PA, April 29 to May 1, 2009.
Czarnecki, G. The diabetic patient. In Busconi B, Stevenson JH, eds.
Sports Medicine Consult. New York, NT; Lippincott, Williams and
Wilken. 2009.
Czarnecki, G. The mature patient. In Busconi B, Stevenson JH, eds.
Sports Medicine Consult. New York, NT; Lippincott, Williams and
Wilken. 2009.
Ghuman N, Patel V, de Palma J, Datla A, Nataraj S, Ranga K.
De novo minimal change disease (MCD) following kidney
transplantation. American Journal of Kidney Diseases, 2008, 51 (4):
B49.
Kannan S, Bansal R, Nataraj S, Sathyan S, Ricci A, Ranga K. Need for
diagnostic criteria for antibody mediated rejection (AMR) in pancreas
after kidney transplantation. American Journal of Kidney Diseases,
2008, 51(4): B56.
Knauft W, Chhabra J, McCullough L. Gender differences in the
time of presentation to the emergency department and outcome in
patients with acute ischemic stroke. Stroke. 2009; 40(2): Abstract #
2315.
Kopecky R, Wang F, Vega-López S, D’Agostino D, Chhabra J, Pérez-
Escamilla R. Evaluation of medication appropriateness in Latinos
enrolled in the DIALBEST Trial. Presented at the 27th Annual
Eastern States Conference for Pharmacy Residents and Preceptors.
Hershey, PA May 2008.
Nataraj S, Vellanki V, Dada A, Balarezo F, Ranga K. De novo focal
segmental glomerulosclerosis following renal transplant in a patient
with autosomal dominant polycystic kidney disease. American
Journal of Kidney Diseases, 2008, 51(4): B73.
Ojo P, Ranga KV, Brown M, Hull D, Charpentier KP. Transplantation
of a unilateral fused kidney with inferior ectopia: revascularization
utilizing donor aorta and vena cava. Connecticut Medicine.
72(10):585-8, 2008 Nov-Dec.
Pérez-Escamilla R, Damio G, De Jesús J, Bow L, Chhabra J, and Bull
N. (2008). The Connecticut Center of Excellence for Eliminating

Health Disparities among Latinos (CEHDL). Journal of Higher
Education, Outreach and Engagement, 12(3):167-177.
Pérez-Escamilla R, Vega-López S, Damio G, Segura-Pérez S,
Fernandez M, Calle M, Samuel G, Chhabra J, D’Agostino D. Short
and long term impact of diabetes peer counseling on HbA1c among
Latinos: DIALBEST Trial preliminary results. FASEB J. 2009. 23; 4:
336.8.
Perez-Escamilla R, Vega-Lopez S, Segura-Perez S, Damio G,
Fernandez M, Calle M, Samuel G, Chhabra J, and D’Agostino D.
Impact of diabetes peer counseling on glycosylated hemoglobin
among Latinos enrolled in the DIALBEST Trial: Preliminary results.
FASEB J. 2008 22:677.19.
Putnik P, Calle M, Fernandez M, Damio G, Segura-Pérez S, Vega-
López S, Chhabra J, and Perez-Escamilla R. Influence of acculturation
on food label use and nutrient intakes among Latinos participating in
the DIALBEST trial: Preliminary results. FASEB J. 2008 22:681.5.
Samuel G, Fernandez M, Chhabra J, Vega-López S, Segura-Pérez S,
Damio G, Calle M, D’Agostino D, Pérez-Escamilla R. Determinants
of fasting plasma glucose and HbA1c among Latinos with type 2
diabetes: DIALBEST trial preliminary results. FASEB J. 2009. 23; 4:
736.7.
between fast food and fried food intake and metabolic risk factors in
Latinos with type 2 diabetes: Preliminary results from the DIALBEST
study. FASEB J. 2009. 23; 4: 550.1.
Vega-López S, Chhabra J, D’Agostino D, and Pérez-Escamilla R.
Socioeconomic and lifestyle determinants of increased body weight
in a subgroup of Latinos with diabetes enrolled in the DIALBEST
peer counseling trial: Preliminary findings. Obesity. 2008: Abstract
Presentation/Publication Number: 309-P.
Vergara C, Richards K, Faucher J. Using preoperative
electrocardiograms as a predictive marker for perioperative adverse
outcomes in Hispanic patients undergoing elective non-cardiac
Surgery. New England SGIM Meeting, March 13, 2009. Boston, MA.
Vergara C. Creating an ambulatory preventive care database. 4th
Annual CEDHL Conference: Social Determinants of Health.
University of Connecticut, Storrs. Rome Ballroom. May 19, 2009.
Zar T, Aglieco F, Ranga KV. Quiz page April 2008: deafness,
preauricular pits, and renal failure. BOR syndrome or Melnick-Fraser
syndrome. American Journal of Kidney Diseases.
51(4):A44-6, 2008 Apr.
Sathyan S, Khan F, Ranga K. A case of recurrent immunotactoid
glomerulopathy in an allograft treated with Rituximab.
Transplantation Proceedings, 2009, 41 (9): 3953-3955.
Sathyan S, Khawaja Z, de Palma J, Brown M, Lally A, Hull D, Ranga
K. Co-Existing peritubular capillary basement membrane lamination
and podocyte effacement on EM in kidney transplant on CNI-free
regimen. American Journal of Kidney Diseases, 2008, 51(4): B86.
Sathyan S, Nataraj S, Dada M, Ranga K. Clinical improvement in
nephrogenic systemic fibrosis following renal transplantation: Should
‘NSF Points’ be considered in allocation? American Journal of Kidney
Diseases, 2008, 51 (4): B86.
Tausif Z, Fabio A, Ranga KV. Deafness, preauricular pits, and renal
failure. American Journal of Kidney Diseases, 2008 (51): xliv-xlvi.
Vega-López S, Calle M, Fernandez M, Chhabra J, D’Agostino D,
Samuel G, Segura- Pérez S, Damio G, and Pérez-Escamilla R. Threemonth
effect of diabetes peer counseling on plasma lipids of Latinos
enrolled in the DIALBEST trial: Preliminary findings. FASEB J. 2008
22:44.8.
Vega-López S, Chhabra J, D’Agostino D, Calle M, Samuel G, Segura-
Pérez S, Fernandez M, Damio G, Pérez-Escamilla R. Associations
46.

Neurology
The Departments of Neurology at Hartford Hospital and the
University of Connecticut continue to receive NIH grants,
foundation grants, drug studies and internal grant support
exceeding one-million dollars. Active participation of faculty
in the department strengthens its educational and clinical
activities.
Dr. Leslie Wolfson:
Dr. Wolfson is the Principal Investigator (PI) on “Brain
Changes and Risk Factors Causing Impaired Mobility”
(RO1AG022092), an NIA funded 4-year longitudinal study
to define vascular disease risk factors leading to ischemic
white matter lesions that compromise mobility, cognitive
and urinary function. In conjunction with collaborator
Dr. Godfrey Pearlson (Director of the Olin Center at the
Institute of Living), the study includes magnetic resonance
imaging performed at the Olin Center. Baseline results have
demonstrated that damage to specific white matter structures is
associated with slowed thinking, impaired mobility and urinary
function and that that there is a stereotyped distribution/
evolution to the development of white matter lesions making
the total lesion volume an index of the severity of these
impairments. The total white matter lesion volume accounts
for ~10% of the variability of each of the three functions and
is relatively easy to measure making it a valuable measure for
geriatricians. We have begun to collect two year follow-up
data and have already determined that ambulatory blood
pressure predicts change in white matter lesion volume as
well as changes in mobility. Thus blood pressure control may
mitigate deterioration. A renewal application is planned for
March 2010, the focus of which will be to determine whether
blood pressure control leads to decreased white matter lesion
accrual and better functional outcomes.
Dr. Louise McCullough:
Dr. McCullough is the Research Director of the Stroke Center.
She was awarded two NIH RO1 grants studying ischemic
mechanisms of cell death at UCHC.
Stroke Center
Over the past year we have continued to utilize the Stroke
Center database at Hartford Hospital for research endeavors,
both to better understand our own patient population and as
a resource to support students and residents as they pursue
research projects. Results from these projects are currently in
press in the Journal of Stroke and Cerebrovascular Diseases
(under the authorship of Dr. Blondin), and in the Journal of
Women’s Health (under the authorship of Dr. Knauft). Two
papers are in preparation under the authorship of Dr. Neer
Zeevi. Three abstracts have also been prepared over the past
year, two were presented at the American Geriatric Society
and one is scheduled for presentation at the International
Stroke Meeting (February 2010). We continue to encourage
residents and fellows to utilize this database to obtain
retrospective data for future studies.
The Stroke Center has continued its strong involvement
in acute and secondary stroke prevention trials. Dr. Isaac
Silverman is the PI on the IMS-3 trial, an NINDS-sponsored
Phase-3 randomized clinical trial (RCT) investigating IV t-PA
+ endovascular approaches (e.g., MERCI, Penumbra, EKOS
ultrasound, or IA t-PA) versus IV t-PA alone in the treatment
of acute ischemic stroke. This trial includes patients with
NIHSS >10 points who are randomized within the first 40
minutes after starting IV t-PA infusion. Three patients have
been enrolled to date.
Dr. Joao Gomes will be the PI on the planned ICTUS trial.
This NINDS-sponsored Phase-3 RCT will investigate the
use of an endovascular cooling device (

a safety (Phase-1) evaluation for patients with ICH (

Trexima (sumatriptan 85mg/naproxen sodium 500 mg) Administered
During the Mild Pain Phase for the Acute Treatment of Multiple
Migra. Glaxo Smith Kline, $41,594.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled,
Single Dose, Efficacy & Safety Outpatient Study of Staccato
Prochlorperazine for Inhalation in Patients with Migraine Headaches.
Alexza Pharmaceuticals, Inc., $41,400.
A Study of Combination Product (Sumitriptan Succinate and
Naproxen Sodium) in Migraine Subjects Who Report Poor Response
or Intolerance to Eletriptan (Study 1 of 2). Glaxo Smith Kline
Pharmaceuticals, $40,000.
Gomes, João, MD
NeuroThera Effectiveness and Safety Trial - 2 (NEST-2): A Double
Blind, Randomized, Controlled, Parallel Group, Multicenter, Pivotal
Study to Assess the Safety and Effectiveness of the Treatment of
Acute Ischemic Stroke with the NeuroThera Laser System within 24
hours from stroke onset. Parexel International, $16,130.
PRoFESS: Prevention Regimen For Effectively Avoiding Second
Strokes: A double-blind, active and placebo controlled study of
Aggrenox vs. Clopidogrel, with and without Micardis. Boehringer-
Ingelheim, $149,994.
Siblings With Ischemic Stroke (SWISS). NIH / NINDS, $34,320.
Spiegel, Gary, MD
Evaluation of the Penumbra Stroke System in the Revascularization
of Patients with Acute Ischemic Stroke Secondary to Intracranial
Large Vessel Occlusive Disease. Penumbra, Inc., $22,500.
Staff, Ilene, PhD
Evaluation of Outcomes of Patients with Stroke Across the
Continuum. Departmental, $24,600.
Wolfson, Leslie, MD
Brain Changes and Risk Factors Causing Impaired Mobility. Federal/
University of Connecticut, $185,805.
Phase I Study of Intravenous Thrombolysis plus Hypothermia
for Acute Treatment of Ischemic Stroke. NINDS/University of
California, $25,000.
Hassan, Mohamed, MD
A Multi-center, Open label Extension Study to Evaluate the Longterm
Safety, Tolerability and Efficacy of E2007 as an Adjunctive
Therapy in Levodopa Treated Parkinson’s Disease Patients with
Motor Fluctuations. Eisai Medical Research Inc., $16,781.
A Multi-Center, Randomized, Double-Blind Placebo-Controlled,
Parallel Group Study of the Efficacy, Safety, & Tolerability of E2007
in Levodopa Treated Parkinson’s Disease Patients with Motor
Fluctuations. Quintiles, Inc., $84,435.
Lee, Nora, MD
Variability in stroke outcomes across the population.
Silverman, Isaac, MD
Insulin Resistance Intervention After Stroke (IRIS) Trial. NIH/Yale
University Medical Center, $328,591.
Publications
Kaplan RF, Cohen RA, Moscufo N, Guttmann C, Chasman J, Buttaro
M, Hall CH, Wolfson L. Demographic and biological influences on
cognitive reserve. J Clin Exp Neuropsychol, 31:1-9, 2009.
Kuchel GA, Moscufo N, Guttmann C, Zeevi N, Wakefield D,
Schmidt J, DuBeau CE, Wolfson L. Localization of brain white
hyperintensities and urinary incontinence in community dwelling
older persons. J Gerontol Med Sci, 64A:902-909, 2009.
Moscufo N, Guttmann CRG, Meier D, Csapo I, Hildenbrand PG,
Schmidt JA, Wolfson L. Brain regional lesion burden and impaired
mobility in the elderly. Neurobiol Aging, May 8, 2009.
White WB, Salzman P, Schwid SR for the Parkinson’s Rasagiline:
Efficacy and Safety in the Treatment of “Off” Parkinson Study
Group, Mohamed N. Hassan, Principal Site Investigator, UCHC.
Hypertension, 2008; 52:1-7.
Multicenter, Randomized Controlled Trial to Evaluate the Safety and
Efficacy of the STARFlex Septal Closure System Versus Best Medical
Therapy in Patients with Stroke and/or Transient Ischemic Attack
Due to Presumed Paradoxical Embolism Through a Patent Foramen
Ovale (CLOSURE I Trial). NMT Medical, Inc., $120,000.

Nurses
Participating in Research
On Thursday, October 8, 2009, The Connecticut Nursing
Research Alliance and the Institute for Healthcare Education
held its 13th Annual Conference, “Raising the Voice of
Nursing in Quality and Patient Safety” at Hartford Hospital.
Over 300 nurses, faculty and nursing students attended from
across Connecticut and neighboring states.
Barbara Mackoff EdD, Visiting Professor at the Adelphi
University School of Nursing, presented the keynote address
titled “Nurse Manager Engagement: the Power of Positive
Deviance.” Dr. Mackoff’s qualitative research, funded by the
Robert Wood Johnson Foundation, identifies characteristics
of successful, engaged nurse managers and reveals the cultural
elements needed to grow ‘engaged’ nurse managers. Her
forthcoming book on her research is due in early 2010. Dr.
Mackoff is a consulting psychologist, a leadership educator
and a core faculty member of The Nurse Management
Fellowship Program of The American Association of Nurse
Executives. The plenary address, “Quality and Safety
Education for Nursing: Update on the National Initiative” was
presented by Dori Taylor Sullivan PhD, RN, NE-BC, CNL,
CPHQ. Dr. Sullivan is the Associate Dean for Academic
Affairs at the Duke University School of Nursing.
In addition to the keynote and plenary speakers, conference
participants were given the opportunity to choose from a
variety of oral abstract presentations and four skill-building
sessions. These sessions included “The Process of Evidence
Based Practice: From Formulating the Question to Writing the
Abstract” by Barbara Aronson APRN, PhD, CNE, Associate
Professor, Southern Connecticut State University; “Searching
the Research Literature: Pub Med” by Lisa Carter MSLIS,
Clinical Librarian for Nursing, Hartford Hospital; “From
Pondering to Publication: Nurse-Author Panel” moderated
by Karen Robbins MS, RN, CNN Nurse Educator, Dialysis,
Hartford Hospital; and “Choosing a Research Design: Finding
the Right Approach to Answer Your Research Questions”
by Cynthia Adams, EdD, Director of Nursing, Capitol
Community College.
Several prizes were awarded in order to recognize excellence
in nursing research and evidence based practice. The
Excellence in Nursing Research Award was presented to
Bonnie Edelen PhD, RN from Capitol Community College
for her study “Measuring and Enhancing Clinical Decision-
Making Ability Among Students in an Associate Degree
Nursing Program.” Dr. Edelen’s study offers strategies
that nurse educators can use to maximize and promote
optimal student learning across a variety of clinical practice
environments. The Excellence in Evidence-Based Practice
Award went to Susan Thibeault MS, APRN, CRNA, EMTP
of LIFESTAR at Hartford Hospital for her work in improving
patient outcomes by enhancing infection control practices.
Additionally Poster Awards were given to three recipients
whose posters were judged by conference attendees to be of
highest quality. First place went to Lynn Deasy RN, MPH,
Danette Alexander RN, MSN, NEA-BC, Carolyn Bauer RNC,
Kristen McClure RN, Susan Smith RN, Kim Murphy RN,
and Laura Collins RN of Hartford Hospital for their poster
“Partnering with Patients and their Families.” Second place
went to Deborah Gingras MS, RN, CNS and Michelle Connor
ASN, BA, RN of Hartford Hospital for “Use of Aromatherapy
with Patients Undergoing Induction of Labor.” Third
place went to Jacquelyn Calamari MSN, MS, RN, CEN of
Middlesex Hospital for “Medication Errors in the Context of
an Acute Care Setting.”
Several attendees received raffle prizes including research
books generously donated by Jeane Kalanta of Elsevier
Medical Publishing. The food service, provided by Wayne
Oden and his staff from Hartford Hospital’s Food & Nutrition
Services, was superb. Special thanks are extended to the
Hartford Hospital Research Department for an Education
Grant that supported this conference.
CT Nursing Research Alliance
Conference Planning Team
Hartford Hospital: Nancy Bafundo RN, MS, BC, Dawn
Beland RN, MSN, Cynthia Belonick APRN, BC, Lisa Carter
MSLIS, Cathy Chance RN, BS, Karen Cudworth RN, MSN,
Deborah Gingras, MS, RN, CNS, Ginger Goddu RN, MSN,
Andrea Hagstrom RN, MSN, CNOR, Eileen Hermann RN,MHS,
Beverly Mendes APRN, PhD, Amy Schröder RNC, MSN, Linda
Spivack RN, MSN
50.

Linda Berger-Spivack, RN, MSN,
VP Patient Care Services, Hartford
Hospital (at left) and Amy Schröder
RNC, MSN, Chair CT Nursing
Research Alliance welcome
conference attendees.
Dr. Barbara Mackoff delivers
keynote address on Nurse Manager
Engagement.
Bristol Hospital: Shannon Grad RN, MSN
and Fran Leach RN, MSN
Capitol Community College: Cynthia Adams RN, EdD
Central Connecticut State University: Meg Levvis MSN, PhD
Eastern Connecticut Health Network: Linda Quirici RN,
MSN, CCRN, APRN, BC
Midstate Medical Center: Joanne Roy RN, PhD and
Kathy Barta RN, MS, MSN, CCRN
Quinnipiac University: Mary Ann Cordeau PhD, RN
Saint Joseph College: Joyce Fontana RN, PhD
Southern Connecticut State University: Barbara Aronson
RN, PhD, CNE
University of Connecticut: Jennifer Telford PhD, APRN
University of Hartford: Anne Marie Buonocore PhD, RNC
Windham Hospital: Anne Schmidt RN, MSN, APRN-BC
New Projects
The following list of projects highlights the role that nurses
play in research at Hartford Hospital. Many of these projects
are also listed in this report under other departments.
Dr. Dori Taylor Sullivan shares an
update from the Quality and Safety
Education for Nursing National
Initiative
State
Servodidio, Camille, RN, MPH, Oncology
Will Housing a Research Nurse on site in a Private Practice Increase
Recruitment and Enrollment into Cancer Clinical Trials? CCOT
through Yale University, $25,000.
Departmental
Gail Nelson MS, RN, NEA-BC,
Director of Professional Development
and Performance Improvement,
Hartford Hospital (at left) presents
the Excellence in Evidence-Based
Practice Award to Susan Thibeault
MS, APRN, CRNA, EMTP of
LIFESTAR, Hartford Hospital
Reagan, Louise APRN, Medicine
The Effect of a Peer Delivered Motivational Message on Intention
to Exercise for Hispanic Persons with Type 2 Diabetes (T2DM): An
Experimental Pilot Study. Departmental, $454.
Unfunded
Chemmarappally, Shiny, RN, Cardiology
Infusion Center Treatment Effect on Quality of Life in Congestive
Heart Failure Patients.
Gingras, Deborah, RN, Women’s Health
Use of Aromatherapy with Patients Undergoing Induction of Labor.
Nancy Bafundo RN, MS, BC,
Nurse Educator, Hartford Hospital
(at left) presents the Excellence
in Nursing Research Award to Dr.
Bonnie Edelen of Capitol Community
College.
Kessler, Jeanne, RN, Medicine
Risk Assessment for Skin Breakdown in a Geriatric Psychiatric In-
Patient Population - A Pilot Study.

Ratcliffe, Tammy, RN, BSN, Nursing
Central Line Infection Prevention (or Reduction) Implementation
of and Evidence-Based Central Line Dressing Change Policy and
Education in the ICU setting: A pilot Study.
Roy, Joanne, RN, PhD, Nursing
Hospital Nurses’ Lived Experience of Power.
Reagan, Louise, APRN, Medicine
A Narrative Analysis Pilot Study: Hispanic Patients’ Perspective of
Managing their Chronic Illness.
Shanaman, Jennifer, MS, Nursing
Comparison of Team Behavior Assessment Between Different
Surgical Specialty Staff Groups in a Large Teaching Hospital’s
Operating Room Department.
Thibeault, Susan, APRN, Emergency Medicine
Reasons for Cancellation of LIFE STAR Transport by Requester.
Mendes, Beverly, APRN, Cardiology
Phenomena of Inner Strength in Women Recovering Post Myocardial
Infarction Coronary Stent: A Grounded Theory.
Zafian, Ruth, APRN, Cardiology
An Exploratory, Descriptive Pilot Study to Examine the Quality of
Hand-offs Reports at Hartford Hospital Using the ISBAR Technique.
Active Projects
Blair, Ellen, APRN, Psychiatry
Inpatient Psychiatric Unit Medications and Falls Outcomes.
Brown, Susanne, RN, MSN
Women’s HealthDoes Simulation Training Improve Nursing and
Resident’s Clinical Performance?
Duclos-Miller, Patricia, MSN, Nursing
Transition from Student to Graduate Nurse.
Frakes, Michael, APRN, Emergency Medicine
Effectiveness of a Read-and-Respond Checklist in Assuring Safety
Behavior Compliance at a Rotor Wing Air Medical Program.
• A Comparison of Pre-hospital Trauma Analgesia By Air and
Ground EMS Providers. • Evaluation of Helicopter Air Medical
Transport Utilization by Prospective Application of Consensus
Criteria. • Effect of Line Oriented Flight Training On Team
Behaviors and Beliefs at a Helicopter Air Medical Program.
• Evaluation of a Modified Sign-Out Procedure on Hospital
Documentation of Medications Administered by Critical Care
Transport Teams.
Gonci, Mary-Ellen, APRN, Women’s Health
Oral Health and its Implications During Pregnancy.
Lloyd, Jennifer, RN, Nursing
Nurses’ Experience in Caring for Patients with Substance Abuse.
McDaniel, Aimee, RN, Nursing
Evaluation of Dialysis/Transplant Nurses Knowledge and Selfefficacy
Regarding Advance Directives.
Murphy, Mary, RN, Nursing
Pilot-Testing of a Tool Titled: Confidence Assessment in the
Management of Simulated Patient “Cardiac Arrest” Situations.
Nelson, Gail, RN, MSN, Nursing
National Database of Nursing Quality Indicators.
Robbins, Karen, RN, MSN, Medicine
Reiki: What are its Effects for Patients During Hemodialysis?
Hartford Hospital Small Grant, $9,963.
Roy, Joanne, RN, PhD, Nursing
Evidence Based Practice Fellowship Program: Prospective and
Systematic Evaluation of an Organizational-level Evidence Based
Practice Initiative.
Satherlie-Deasy, Lynn, RN, Women’s Health
Food Insecurity, Meal Skipping, Nutrient Intakes and Pregnancy
Outcomes Among Low-Income Latinas.
Waszynski, Christine, APRN, Nursing
Assessment of the Prevalence of Delirium in Three Unique
Populations of Hospitalized Persons. Pauline A. Toner Fund
UCONN School of Nursing, $1,500.
Perspectives of Clinicians and Social Service Personnel on the Needs
of Older Adults With HIV/AIDS. University of Connecticut, $750.
Nursing Assessment, Management and Treatment of Delirium in
Hospitalized Older Adults: Identifying Related Outcomes.
Nursing Geriatric Resource Nurse Program Evaluation.
Yavinsky, Cathy, RN, MSN, Nursing
The Effect of a Specialized RN Intervention Designed to Maximize
Patient-Provider Relationships on Adherence to Anti-depressant
Medication. Donaghue Medical Research Foundation, $48,350.
Young, Sara, MSN, Women’s Health
Breastfeeding Education and Support Trial for Obese Women: Early
Dyad Dynamics (BESTOW:EDD). University of Connecticut,
$16,796.
Breastfeeding Education and Support Trial for Obese Women
(BESTOW). Donaghue Medical Research Foundation through the
University of Connecticut, $20,590.

Andrew L. Salner, MD
Director, Helen & Harry Gray Cancer Center
Donna Handley
VP, Cancer Services
Oncology
Cancer Clinical Research Office
Camille Servodidio, RN, MPH, CRNO,
OCN Coordinator
Robert Siegel, MD, Medical Director, Cancer
Clinical Research
The Cancer Clinical Research Office (CCRO) is an active
participant in a variety of national cooperative group research
studies and several industry-supported trials. In 2007, Hartford
Hospital was selected as one of 16 community hospitals to
participate in the NCI Community Cancer Centers Program
Pilot (NCCCP). One of the charges of the NCCCP is to
expand clinical trials and reduce disparities. The NCCCP pilot
created a network of community hospitals that shared best
practices and pooled strategies to recruit patients and endorse
particular trials. Abstracts highlighting accomplishments were
presented at both national meetings of the American Society
of Clinical Oncologists and the Oncology Nurses Society.
Through Hartford Hospital’s continuing affiliation with
Dana Farber Partners/Cancer Care, the CCRO has had the
opportunity to open several additional cancer clinical trials.
The CCRO participates in multiple National Cancer Institute
(NCI) trials sponsored by the Cancer and Leukemia Group B
(CALGB), the Gynecologic Oncology Group (GOG), and the
National Surgical Adjuvant Breast and Bowel Project (NSABP)
as well as several pharmaceutical/industry trials. The NSABP
has recently opened several new breast cancer treatment
trials, active at Hartford Hospital under the leadership of Dr.
Patricia DeFusco, principal investigator and the coordination
of Susan Zahorodni, RN. NSABP B-40 involves chemotherapy
before surgery for women with palpable breast masses with
half of the women receiving bevacizumab, a drug which
blocks a tumor’s blood supply, after surgery. NSABP B-42
involves post-menopausal ER+/PR+ women diagnosed with
invasive breast cancer to determine if five years of additional
Letrozole will improve survival. The PACCT-1 trial will assign
treatment regimens based on pathology specimens of women
with ER+/PR+ node negative breast cancer.
The CCRO has continued to recruit gynecologic oncology
patients into GOG trials under the leadership of principal
investigators Dr. Stacy Nerenstone and Dr. Amy Brown.
Karen Cuddy, RN has joined the team this year as the GOG
trial coordinator. GOG continues to sponsor cutting edge
chemotherapy trials for gynecologic cancers. GOG # 212
provides women who have recently received chemotherapy
for ovarian cancer an opportunity for additional chemotherapy
(standard of care Taxol vs. Xyotax, a drug which can be
delivered over a shorter period of time) and compares them
to women who receive standard of care physician observation
prior to tumor recurrence. GOG # 213 is a treatment trial for
women diagnosed with platinum-sensitive, recurrent ovarian,
peritoneal primary or fallopian tube cancer. Women who are
surgical candidates are randomized to cytodreductive surgery
or none. If they are not surgical candidates they may be
randomized to chemotherapy treatments of carboplatin and
paclitaxel alone or in combination with bevacizumab.

Hartford Hospital participates in several Dana Farber and
CALGB trials under the leadership of Dr. Robert Siegel,
principal investigator and the coordination of Kathleen
VanGelder, RN. CALGB 40101 compares Cytoxan and
Adriamcyin chemotherapy versus Taxol in women with node
negative breast cancer and CALGB 70301 is a companion
study focusing on quality of life and employment. CALGB
50501 is a phase II trial of bortezomib vs. lenalidomide for
relapsed /refractory mantle cell lymphoma. Dana Farber 06-
116 involves patients diagnosed with metastatic transitional
cell carcinoma in which patients receive docetaxel with or
without Zactima, a drug that inhibits blood vessel growth
in cancers. The ASSURE trial compares sorafenib versus
Sunitinib vesus a placebo for unfavorable renal carcinoma.
The CCRO is involved in several pharmaceutical /industry
trials under the leadership of Dr. Todd Alekshun, principal
investigator and the coordination of Karen Burnham, RN,
BSN, OCN. SNDX- 275-0301 is a Phase II randomized double
blind study of exemestane with and without SNDX-275, a pill,
in post-menopausal women diagnosed with local recurrent
or metastatic ER+ breast cancer progressing on treatment
with a non-steroidal aromatase inhibitor. The Sanofi-Aventis
ECF6546 (VENICE) is a phase II randomized double
blind trial comparing Aflibercept to placebo for metastatic
androgen-independent prostate cancer.
Finally, the best “treatment” for cancer is to either prevent it
or detect it early. Since 1995, the CCRO has been involved
in the Connecticut Breast & Cervical Cancer Early Detection
Program (CBCCEDP), a state sponsored outreach program
that provides clinical breast examinations, mammograms and
cervical cancer screening to the underserved and underinsured
women of the greater Hartford area. A total of 82 cancers
have been detected since the inception of the program.
These outreach efforts are funded by the Centers for Disease
Control and Prevention (CDC) and organized by the State
of Connecticut Department of Public Health. Dr. Merwood
Jones serves as medical director, Nora Brugueras is the
case manager, and Damaris Perez is the outreach educator.
The CCRO continues in its ninth year of the CDC funded
WISEWOMAN grant, which offers glucose and cholesterol
screening, nutrition counseling, cooking and exercise
demonstrations for women over 40 years old. The CBCCEDP
has partnered with the American Heart Association to
offer CBCCEDP participants under age 39 the opportunity
to receive free cholesterol screenings and cardiovascular
educational materials. The AVON Foundation Breast Care
Fund grant supports community outreach and breast cancer
education for underserved and underinsured women.
These are intriguing times in cancer research and treatment.
The CCRO remains committed to our patients and families
through education, screening, and participation in clinical
trials.
CHESS Program
Sherri Storms, BSN, RN-BC, Cancer Program
Project Coordinator
CHESS (Comprehensive Health Enhancement Support
System) is an internet-based information and support system
for patients with breast and prostate cancer who often have
difficulty finding good information, who may be hesitant or
unable to attend support groups, and who often feel pressured
to make difficult decisions with little information. The CHESS
program helps patients and their families become more
actively involved in their treatment and recovery, making
high quality information and social support easily accessible
and helping patients make choices and decisions based on
their individual needs. In partnership with the University
of Wisconsin, Hartford Hospital has offered CHESS to its
patients for more than 12 years, reaching over 1400 women
with breast cancer and 400 men with prostate cancer. Thanks
to our generous donors, we own 40 laptop computers available
for loan to patients, who also receive training on how to
use them. In addition to serving Hartford Hospital patients,
we collaborate with Windham Hospital to offer CHESS to
patients in the Eastern part of the state.
This year we completed enrollment of 95 men into an
innovative NCI-sponsored study, “Human and Computer
Mentors for Prostate Cancer Patients” which aims to test
the effectiveness of a Human Cancer Mentor vs. CHESS vs.
a combination of CHESS and the Human Cancer Mentor
on improving quality of life for men with prostate cancer.
While the primary outcome measure is patient quality of
life, secondary outcomes include patient preparedness for
interactions with clinicians and mentors, self-efficacy, health
care use, decision satisfaction, and considerations of treatment
alternatives. This study will help us learn how a human cancer
mentor might affect a prostate cancer patient’s quality of life
and we expect that it will provide valuable information about
ways that the Internet and other communication tools may be
54.

used to improve the quality of life for all cancer patients.
We are also collaborating with the University of Connecticut-
Storrs Departments of Psychology and Family Studies on
two Quality of Life studies, “Adjustment to Breast Cancer”
and “Lifestyle Change Intervention for Recently Diagnosed
Breast Cancer Survivors: Pilot Study”. The first study focuses
on newly diagnosed breast cancer patients. Currently 55
patients have been recruited into the study, the goals of which
are: (1) to examine differences in treatment decision-making
between African-American, Hispanic and Caucasian women
with breast cancer at two time points post-surgery; (2) to
examine whether specific socio-cultural and psychosocial
factors are associated with treatment decision-making among
African-American and Hispanic women with breast cancer; and
(3) to examine whether certain coping strategies commonly
employed by African-American and Hispanic women with
breast cancer are associated with treatment decision-making.
This study will provide valuable information how socio-cultural
and psychosocial factors impact treatment decision-making
and health disparities among minority breast cancer patients
and will inform the development of interventions in this area.
Our participation underscores our ongoing commitment to
providing the very best in care to all of our cancer patients.
“Lifestyle Change Intervention for Recently Diagnosed Breast
Cancer Survivors” is a pilot study of health behavior change
among breast cancer survivors completing their primary
treatment. The study evaluates the effectiveness of mail-based
lifestyle interventions in helping breast cancer survivors make
and maintain important changes in diet and exercise, factors
that are important for survivorship among breast cancer
patients completing their primary treatment. Thus far we have
recruited 22 patients from Hartford Hospital into the pilot
study and we expect that the results will provide a springboard
for Hartford Hospital and the University of Connecticut to
collaborate on a larger Lifestyle Change Intervention Study.
The Cancer Registry
at Hartford Hospital
Debra Jacques, MSM, CTR, Manager,
Cancer Registry
The Cancer Registry at Hartford Hospital was established in
1928 and contains over 85,000 cancer cases. It submits over
2,500 new cancer cases to the Connecticut Tumor Registry
each year, accounting for approximately 15% of all cancers
reported statewide. All Connecticut hospitals and labs are
required by Connecticut State statute to report all diagnoses
of cancer to the Connecticut State Tumor Registry at the
Department of Health, the oldest and most widely used
central registry in the nation. The information housed in
Hartford Hospital’s Cancer Registry provides valuable data on
patient demographics and cancer incidence, information that
has been used to support presentations, research, certificates
of need and grant applications in addition to identifying areas
for improvement in patient care.
New Projects
Federal
Baker, William-Jeffrey, MD
CALGB 50303: A Phase III Study of R-CHOP V. Dose-Adjusted
EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse
Large B-Cell Lymphomas. Cancer And Leukemia Group B, $53,400.
CALGB 50501: A Phase II Trial of Bortezomib + Lenalidomide for
Relapsed/Refractory Mantle Cell Lymphoma. Cancer And Leukemia
Group B, $10,000.
Brown, Amy, MD
A Phase II Evaluation of AMG 706 in the Treatment of Persistent or
Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal
Carcinoma. GOG, $8,361.
GOG 205: A Phase II Trial of Radiation Therapy and Weekly
Cisplatin Chemotherapy for the Treatment of Locally-Advanced
Squamous Cell Carcinoma of the Vulva. GOG, $16,500.
GOG 126R: A Phase II Evaluation of Abraxane® in the Treatment
of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian
Tube, or Primary Peritoneal Cancer. GOG, $3,300.
GOG 136: Acquisition of Human Gynecologic Specimens and
Serum to be Used in Studying the Causes, Diagnosis, Prevention
and Treatment of Cancer. GOG/HOCCT, $33,000.
GOG 213: A Phase III Randomized Controlled Clinical
Trial of Carboplatin and Paclitaxel Alone or in Combination
with Bevacizumab Followed by Bevacizumab and Secondary
Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian,
Peritoneal Primary and Fallopian Tube Cancer. GOG, $27,720.
GOG 224: A Randomized Controlled Phase II Evaluation of
(MEGACE) Megestrol in Different Dose and Sequence in the
Treatment of Endometrial Intraepithelial Neoplasia (EIN) from a
Referred Cohort of a Typical Endometrial Hyperplasia (AEH) or
EIN. GOG, $9,350.

GOG 229F: A Phase II Evaluation of VEGF-Trap (Aflibercept, NSC
#724770, IND #BB100137, NCI Supplied Agent) in the Treatment of
Recurrent or Persistent Endometrial Carcinoma. GOG, $5,280.
GOG 239: A Phase II Trial of AZD6244 In Women with Recurrent
Low-Grade Serous Carcinoma of the Ovary. GOG, $6,160.
GOG 87M: A Phase II Evaluation of Trabectedin (Yondelis®,
R279741, IND #75,111) In The Treatment of Advanced, Persistent,
or Recurrent Uterine Leiomyosarcomas. GOG, $3,300.
GOG 0232C: A Phase II Evaluation of Paclitaxel (Taxol®,NSL
#673089) Carboplatin (Paraplatin®, NSL #241240) and BSI-201
(NSC #7466045, IND #71,677) in the Treatment of Advanced,
Persistent, or Recurrent Uterine Carcinomas. GOG/HOCCT,
$2,860.
GOG 0235: A Prospective, Longitudinal Study of YKL-40 in
Patients with FIGO Stage III or IV Invasive Epithelial Ovarian,
Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary
Chemotherapy. GOG, $19,800.
GOG-0238: A Randomized Trial of Pelvic Irradiation with or
without Concurrent Weekly Cisplatin in Patients with Pelvic-Only
Recurrence of Carcinoma of the Uterine Corpus. GOG, $11,000.
DeFusco, Patricia, MD
B-44-I: A Multicenter Phase III Randomized Trial of Adjuvant
Therapy for Patients with HER2 Positive Node-Positive or High
Risk Node-Negative Breast Cancer Comparing Chemotherapy
Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus
Bevacizumab. NSABP (Genetech), $160,600.
Nerenstone, Stacy, MD
A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the
Treatment of Recurrent or Persistent Endometrial Carcinoma. GOG,
$4,290.
GOG 170M: A Phase II Evaluation of Dasatinib in the Treatment of
Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary
Peritoneal Cancer. GOG/HOCCT, $2,860.
GOG-0249: A Phase III Trial Of Pelvic Radiation Therapy Versus
Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin
Chemotherapy In Patients With High Risk, Early Stage Endometrial
Carcinoma. GOG, $25,300.
Siegel, Robert, MD
A Phase III Randomized, Double-Blind, Placebo Controlled Trial
of North American Ginseng Extract (CVT-E002; COLD-fX®) to
Prevent Respiratory Infection and Reduce Antibiotic Use in Patients
with Chronic Lymphocytic Leukemia. CALGB, $1,818.
CALGB 10404: A Randomized Phase II Study of Three Fludarabine
/ Antibody Combinations for Patients with Symptomatic, Previously
Untreated Chronic Lymphocytic Leukemia. CALGB, $10,000.
CALGB 30607: A Randomized, Phase III, Double-Blind Placebo-
Controlled Trial of Sunitinib (NSC #736511, IND #74019) as
Maintenance Therapy in Non-Progressing Patients Following an
Initial Four Cycles of Platinum-Based Combination Chemotherapy
in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer. CALGB,
$8,000.
CALGB 30704: A Randomized Phase II Study To Assess The
Efficacy Of Pemetrexed Or Sunitinib (NSC #736511, IND #74019)
Or Pemetrexed Plus Sunitinib In The Second-Line Treatment Of
Advanced Non-Small Cell Lung Cancer. CALGB, $10,000.
CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin
or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab
(C225), or with the Combination of Bevacizumab and Cetuximab for
Patients with Untreated Metastatic Adenocarcinoma of the Colon or
Rectum. CALGB, $25,800.
CALGB 9665: The Leukemia Tissue Bank (companion to CALGB
10404). CALGB, $2,000.
CALGB90203: Randomized Phase III Study Of Neo-Adjuvant
Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy
Versus Immediate Radical Prostatectomy in Patients with High-Risk,
Clinically Localized Prostate Cancer. CALGB, $17,500.
DF07-199: A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab
for Node-Negative HER2-Positive Breast Cancer. Dana Farber Cancer
Institute, $26,000.
DF05-043: Randomized Controlled Study of Docetaxel plus 6-month
Androgen Suppression and Radiation Therapy vs. 6-Month Androgen
Suppression and Radiation Therapy for patients with High-Risk
Localized or Locally Advanced Prostate Cancer. Dana-Farber,
$27,000.
DF06-116: A Randomized Phase II Study of Docetaxel +/- Zactima
(ZD6474) in Metastatic Transitional Cell Carcinoma. Dana Farber,
$25,000.
DFCI07-214: A Phase II Study of Bevacizumab in Combination with
Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast
Cancer. Dana Farber, $16,800.
E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin
and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab
in Patients with Stage II Colon Cancer at High Risk for Recurrence to
Determine Prospectively the Prognostic Value of Molecular Markers.
ECOG via CTSU, $12,510.
56.

ECOG E2805 ASSURE: Adjuvant Sorafenib or Sunitinib for
Unfavorable Renal Carcinoma. ECOG via CTSU, $8,000.
ECOG 1505: A Phase III Randomized Trial of Adjuvant
Chemotherapy with or without Bevacizumab for Patients with
Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer.
ECOG via CTSU, $25,500.
ECOG E1A06: An Intergroup Phase III Randomized Controlled
Trial Comparing Melphalan, Prednisone and Thalidomide (MPT)
Versus Melphalan, Prednisone and Lenalidomide (Revlimid)
(MPR) in Newly Diagnosed Multiple Myeloma Patients Who
Are Not Candidates for High-Dose Therapy. ECOG Via CTSU,
$11,250.
COG E2804: The BeST Trial: A Randomized Phase II Study of
VEGF, RAF kinase, and mTOR Combination Targeted Therapy
(CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced
Renal Cell Carcinoma. ECOG via CTSU, $10,000.
Sorosky, Joel, MD
GOG-0237: Comparative Analysis of CA-IX, p16, Proliferative
Markers and Human Papilloma Virus (HPV) in the Diagnosis of
Significant Cervical Lesions in Patients with a Cytologic Diagnosis
of Atypical Glandular Cell (AGC). GOG, $6,600.
Foundation
Salner, Andrew, MD
Assessing Quality of Life in Young Adult Cancer Survivors. Lance
Armstrong Foundation/UCONN Storrs, $30,000.
Breast Cancer Survivorship: A Patient Navigator Program. Lance
Armstrong Foundation, $47,756.
Lifestyle Change Intervention for Recently Diagnosed Breast Cancer
Survivors: Pilot Study. UCONN Research Foundation, $2,000.
DeFusco, Patricia, MD
NSABP Protocol B 41: A Randomized Phase III Trial of Neoadjuvant
Therapy for Patients with Palpable and Operable HER2-Positive
Breast Cancer Comparing the Combination of Trastuzumab Plus
Lapatinib to Trastuzumab and to Lapatinib Administered with
Weekly Paclitaxel Following AC Accompanied by Correlative
Science Studies to Identify Predictors of Pathologic Complete
Response. NSABP Foundation Inc., $32,813.
Industry
Siegel, Robert, MD
ACORN/Onyx NU07B1: A Double Blind, Randomized Phase IIb
Study Evaluating the Efficacy and Safety of Sorafenib Compared
to Placebo when Administered in Combination with Paclitaxel
in Patients with Locally Recurrent or Metastatic Breast Cancer.
ACORN, $43,815.
C10953/2036/ON/US: A Randomized, Double Blind, Placebo
Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy
of Armodafinil Treatment (150 mg/day) for Patients with Fatigue
Associated with Taxane Chemotherapy. CEPHALON, INC., $80,081.
GTx, Inc. Protocol Number: G200502 Double-Blind, Placebo-
Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle
Wasting (cachexia) in Patients with Cancer. GTx Inc., $56,520.
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry. Alexion
Pharmaceuticals Inc., $19,625.
Pfizer A6181094: A Phase 3 Study of SU011248 in Combination
with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-line
Advanced Disease Setting in Patients Having Breast Cancer. North
American Shared Services, $185,381.
Pfizer A7471028: A Randomized Phase II Trial of PF-00299804 versus
Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer
After Failure of at Least One Prior Chemotherapy Regimen. Pfizer
Inc./ North American Shared Services, $180,686.
Industry (Investigator Initiated)
Salner, Andrew, MD
Total Cancer Care: A Partnership with High Risk and/or Diagnosed
Cancer Patients For Life. H. Lee Moffitt Cancer Center & Research
Institute, Inc., $2,942,143.
Industry (Multicenter)
Baker, William-Jeffrey, MD
A Worldwide, Observational Registry collecting Longitudinal Data on
the management of Chronic Myelogenous Leukemia (CML) patients
(The WORLD CML Registry) in routine practice. Novartis, $38,375.
Siegel, Robert, MD
A Prospective, Non-Interventional Multicenter Registry in Iron
Overloaded Lower-Risk Myelodysplastic Patients. Novartis, $69,000.
EFC10203: A Multicenter, Open-Label, Randomized Study
Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/
m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with
Advanced Pancreatic Cancer Previously Treated with a Gemcitabine
Based-Regimen. Sanofi-aventis, $79,350.
EFC6546, A Multicenter, Randomized, Double blind Study
Comparing the efficacy and Safety of Aflibercept Versus Placebo
administered Every 3 Weeks in Patients Treated with Docetaxel /
Prednisone for Metastatic Androgen-Independent Prostate Cancer.
Sanofi Aventis, $155,788.

Protocol PGT307: Paclitaxel poliglumex (CT-2103)/Carboplatin vs
Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve
Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with
Estradiol >25 pg/mL. Cell Therapeutics, $72,983.
State
Salner, Andrew, MD
Development of Culturally Appropriate Educational Approaches
to Enhance Clinical Trial Participation Among Underserved
Populations in the Greater Hartford Area. Connecticut Clinical
Oncology Trials Network/Yale University, $25,000.
Servodidio, Camille, RN, MPH
Will Housing a Research Nurse on site in a Private Practice
Increase Recruitment and Enrollment into Cancer Clinical Trials?
Connecticut Clinical Oncology Trials Network/Yale University,
$25,000.
Departmental
Salner, Andrew, MD
Chart Review- Treatment of Base of Tongue Cancer. $200. Analytic
support provided through Hartford Hospital Small Grant.
Evaluation of Community Based Prostate Cancer Screening Program.
$23,910.
Hartford Hospital Research
Endowment Funds
Thumar, Jaykumar, MD
CD133 Expression and Clinical Outcome in Patients with Rectal
Cancer. Small Grant, $12,462.
Unfunded
Brown, Amy, MD
A Retrospective Comparison of Clinical Outcomes Between
Laparotomy and Robotic Hysterectomy for Endometrial Cancer.
Buckley, Judith, MD
Prevalence and Significance of Perineural Invasion as a Feature of
Invasive Breast Cancer.
Salner, Andrew, MD
Outcomes and Survival Rates of Adenoid Cystic Carcinoma in 62
Patients: A Hospital Registry Based Study.
Survivors of Cancer in Adolescents and Young Adults (YES Project).
Active Projects
Baker, William-Jeffrey, MD
A Phase II Study Of Fludarabine + Rituximab Induction Followed
by Alemtuzumab (Campath-1H, NSC #715969, IND #10864)
Consolidation in Untreated Patients with B-Cell Chronic
Lymphocytic Leukemia. CALGB / Dana-Farber, $8,400.
Brown, Amy, MD
GOG # 210: A Molecular Staging Study of Endometrial Carcinoma.
GOG/ Tufts New England Medical Center, $11,616.
GOG 209: Randomized Phase III Trial of Doxorubicin / Cisplatin /
Paclitaxel and G-CSF Versus Carboplatin / Paclitaxel in Patients with
Stage III & IV or Recurrent Endometrial Cancer. GOG, $6,313.
GOG 219: A Phase III, Randomized Trial of Weekly Cisplatin and
Radiation Versus Cisplatin and Tirapazamine (IND #46525) and
Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervival Carcinoma
Limited to the Pelvis. GOG, $6,601.
GOG 215: A Phase II Randomized Study of the Effect of Zoledronic
Acid (Zometa) versus Observation on Bone Mineral Density of the
Lumbar Spine in Women who Elect to Undergo Risk-Reducing
Surgery that Results in Removal of Both Ovaries. GOG, $3,960.
GOG0170K (0170): A Phase II Evaluation of Mifepristone in the
Treatment of Recurrent or Persistent Ovarian or Primary Peritoneal
Cancer. GOG, $6,313.00
The Utility of Coronal CT Reformatting in Predicting Extent of
Disease in Ovarian Cancer and Pelvic Mass Patients.
Buckley, Judith, MD
Partial Breast Radiation Therapy-A Paradigm Shift.
Standardized Uptake Value in PET as a Predictor of Survival in
Esophageal Cancer.
DeFusco, Patricia, MD
NSABP B-34: A Clinical Trial Comparing Adjuvant Clodronate
Therapy vs. Placebo in Early Stage Breast Cancer Patients Receiving
Systemic Chemotherapy and/or Tamoxifen or No Therapy. NSABP,
$15,000.00
A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin
(LV) and Oxaliplatin with 5-FU Plus LV for the Treatment of Patients
with Stages II and III Carcinoma of the Colon (C-07 NSABP).
NSABP Protocol - P-2 Study of Tamoxifen and Raloxifene (STAR) for
the Prevention of Breast Cancer MIN21-CON. NSABP, $75,000.
NSABP B-33: A Randomized, Placebo-Controlled, Double-Blind Trial
Evaluating the Effect of Exemestane in Clinical Stage T1-3 NO-1 MO
58.

Postmenopausal Breast Cancer Patients Completing at Least Five
Years of Tamoxifen Therapy. NSABP, $1,000.
A Clinical Trial Comparing Anastrozole with Tamoxifen in
Postmenopausal Patients with Ductal Carcinoma In Situ (DCIS)
Undergoing Lumpectomy with Radiation Therapy. NSABP,
$21,000.
A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of
5-Flouroracil, Epirubicin and Cyclophosphamide (FEC) to Four
Cycles of Adriamycin and Cyclophosphamide (AC), With or
Without Celocoxib, in Patients with Node-Negative Breast Cancer.
NSABP, $16,000
NSABP B-38 A phase III Adjuvant Trial Comparing Three
Chemotherapy Regimens in Women with Node-Positive Breast
Cancer: Docetaxel / Doxorubicin / Cyclophosphamide (TAC);
Dose-Dense (DD) Doxorubicin / Cyclophosphamide Followed by
DD Paclitaxel (DD AC>P). NSABP, $19,000.
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-
FU), Leucovorin, And Oxaliplatin (mFOLFOX6) Every Two Weeks
With Bevacizumab To The Same Regimen Without Bevacizumab
For The Treatment Of Patients With Resected Stages II And III
Carcinoma of the Colon. NSABP, $19,000.
A Randomized Phase III Study of Conventional Whole Breast
Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women
With Stage 0, I or II Breast Cancer. NSABP/RTOG, $20,900.
NSABP B-42: A Clinical Trial to Determine the Efficacy of Five
Years of Letrozole Compared to Placebo in Patients Completing
Five Years of Hormonal Therapy Consisting of an Aromatase
Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging
Disease-Free Survival in Postmenopausal Women with Hormone
Receptor Positive Breast Cancer. NSABP, $23,100.
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients
with Palpable and Operable Breast Cancer Evaluating the Effect on
Pathological Complete Response (pCR) of Adding Capecitabine
or Gemcitabine to Docetaxel when Administered Before AC
(Adriamycin - Cytoxan) -with or without Bevacizumab and
Correlative Science Studies Attempting to Identify Predictors of
High Likelihood for pCR with Each of the Regimens. NSABP,
$10,450.
NSABP-B-31. A Randomized Trial Comparing The Safety And
Efficacy of Adriamycin And Cyclophosphamide Followed By Taxol
(AC-T) To That Of Adriamycin And Cyclophosphamide Followed
By Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer
Patients Who Have Tumors That Overexpress HER2.
A Randomized Trial Comparing Preoperative Doxorubicin
(Adriamycin) Cyclophosphamide (AC) to Preoperative AC
Followed by Preoperative Docetaxel (Taxotere) and to Preoperative
AC Followed by Postoperative Docetaxel in Patients with Operable
Carcinoma of the Breast.
A Trial to Evaluate the Worth of Tumor Biomarkers Obtained by FNA
or Core Biopsy in Predicting Response to Preoperative Chemotherapy
and Long-Term Outcome in Patients with Operable Breast Cancer
Who are Participating in NSABP Protocol B-27.
A Trial to Evaluate the Worth of Serum ErbB-2 Extracellular Domain
and Serum ErbB-2 Antibodies in Predicting Response to Preoperative
Chemotherapy and Long-Term Outcome in Patients with Operable
Breast Cancer Who are Participating in NSABP Protocol B-27.
NSABP B-30: A Three Arm Randomized Trial to Compare Adjuvant
Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T);
Adriamycin and Cyclophosphamide (ATC) in Breast Cancer Patients
with Positive Axillary Lymph Nodes.
A Clinical Trial to Evaluate the Worth of Tamoxifen in Conjunction
with Lumpectomy and Breast Irradiation for the Treatment of
Noninvasive Intraductal Carcinoma (DCIS) of the Breast (B-24).
A Clinical Trial to Determine the Worth of Tamoxifen and the
Worth of Breast Radiation in the Management of Patients with
Node-negative, Clinically Occult, Invasive Breast Cancer Treated by
Lumpectomy (B-21).
Breast Conservation Rates in Breast Cancer Surgery: Comparison
Based On Ethnicity, Race, and Insurance Status.
A Randomized Trial Evaluating the Worth of Paclitaxel (Taxol)
Following Doxorubicin (Adriamycin)/Cyclophosphamide in Breast
Cancer Patients with Positive Axillary Nodes (B-28)
.
A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus
Leucovorin (LV) with 5-Fluorouracil (5-FU) Plus LV in the Treatment
of Patients with Stages II and III Carcinoma of the Colon (C-06).
Angiogenesis in Breast Cancer: A Retrospective Analysis of
Patients with Stage III or IV Disease Before and After Neoadjuvant
Chemotherapy.
Flowers, Alexandra, MD
Pilot Study of Combination Temozolamide and 6-Thioguanine
Chemotherapy for Patients with Recurrent Malignant Gliomas.
NOVARTIS EPO906: An Open-Label, Multi-Center, Phase II Study
to Evaluate the Activity of Patupilone (EPO906), in the Treatment of
Recurrent or Progressive Brain Metastases in Patients with Non-Small
Cell Lung Cancer. Novartis Pharmaceuticals, $180,339.
Leopold, Kenneth, MD
RTOG 0232, A Phase III Study Comparing Combined External Beam
Radiation And Transperineal Interstitial Permanent Brachytherapy

With Brachytherapy Alone for Selected Patients with Intermediate
Risk Prostatic Carcinoma. RTOG, $20,700.
RTOG 0214, A Phase III Comparison Of Prophylactic Cranial
Irradiation Versus Observation In Patients With Locally Advanced
Non-Small Cell Lung Cancer. RTOG, $18,200.
Nerenstone, Stacy, MD
GOG #182: A Phase III Randomized Trial of Paclitaxel and
Carboplatin Versus Triplet or Sequential Doublet Combinations in
Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma.
GOG, $1,500.
GOG #199: Prospective Study of Risk-Reducing Salpingo-
Oophorectomy and Longitudinal CA-125 Screening Among
Women at Increased Genetic Risk of Ovarian Cancer. GOG,
$20,000.
GOG 212: A Randomized Phase III Trial of Maintenance
Chemotherapy Comparing 12, Monthly Cycles of Single Agent
Paclitaxel or Ct-2103 (Ind #70177), Versus No Treatment Until
Documented Relapse in Women With Advanced Ovarian or
Primary Peritoneal Cancer who Achieve a Complete Clinical
Response to Primary Platinum/Taxane Chemotherapy. GOG,
$49,500.
GOG 218: A Phase III Trial of Carboplatin and Paclitaxel Plus
Placebo versus Carboplatin and Paclitaxel Plus Concurrent
Bevacizumab (RhuMab VEGF, NSC #704865, IND#7921) Followed
by Placebo, versus Carboplatin and Paclitaxel Plus Concurrent
and Extended Bevacizumab in Women with Newly Diagnosed,
Previously Untreated Suboptimal Advanced Stage Epithelial
Ovarian and Peritoneal Cancer. GOG/The Hospital of Central
Connecticut at New Britain, $49,368.
Phase III Randomized Trial of 12 Months vs 3 Months of Paclitaxel
in Patients with Advanced Ovarian Cancer Who Attain a Clinically
Defined Complete Response (CR) Following Platinum/Paclitaxelbased
Chemotherapy (GOG 178)
.
Randomized Clinical Trial for the Treatment of Women with
Selected Stage IC and II (A,B,C) and Selected Stage IA and IB
Ovarian Cancer (GOG95).
A Randomized Phase III Trial of IV Carboplatin (AUC6) and
Paclitaxel 175 mg/m2 Q 21 days x 3 courses Plus Low Dose
Paclitaxel 40 mg/m2/wk versus IV Carboplatin (AUC6) and
Paclitaxel 175/mg/m2 Q 21 days x 3 courses Plus Observation in
Patients with Early Stage Ovarian Carcinoma (GOG 175).
Rotondaro, Roxanne, MPH
Pilot Study on Mobile Mammography: Estimating Eligibility and
Participation in a Senior Housing Setting.
Salner, Andrew, MD
Prognostic Value of HER2 Status in High Risk Node Negative Breast
Cancer. Departmental, $3,200.
Clinical and Quality of Life Outcomes Following Diagnosis of Prostate
Adenocarcinoma. Departmental, $27,000; matching funds generously
provided by the Medical Staff.
Centers of Excellence in Cancer Communication: Component and
Couple Analysis of Cancer Communication (CHESS Program). NCI/
University of Wisconsin, $101,362.
Center of Excellence in Cancer Communications - Mentor Integration
Project (CHESS Program). NCI/University of Wisconsin, $101,362.
Web-Based Support for Informal Caregivers in Cancer (CHESS
- Comprehensive Health Enhancement Support System). The
University of Wisconsin/NIH, $127,244.
Human and Computer Mentors for Prostate Cancer Patients - CHESS
Program. NCI/University of Wisconsin, $111,559
NCI NCCP Pilot Program. NCI/SAIC-Fredericks, $1,457,633.
Reaching Urban African American Men with Prostate Cancer
Screening Information. CDC/National Cancer Prevention & Control
Program, $258,670.
The Effects of Training and Follow-up Patients Contact on Utilization
of the Internet-Based Information and Support Program CHESS
(Comprehensive Health Enhancement Support System). Hartford
Hospital Research Endowment Funds, $10,000.
City of Hartford Comprehensive Cancer Prevention and Control Plan.
City of Hartford-Health & Human Services Dept., $25,000.
Environment, Gene, and Testicular Cancer Risk (Hartford Hospital).
Environment, Gene, and Testicular Cancer Risk (Windham Hospital).
Meningioma: Risk Factors and Quality of Life (Windham Hospital).
Meningioma: Risk Factors and Quality of Life (Hartford Hospital).
Psychosocial Needs Assessment of Colorectal Cancer Patients and
Partners in the First Year After Diagnosis (Qualitative Research Phase).
Self-Determined Length and Patterns of Usage for the Internet-Based
Information and Support Program CHESS (Comprehensive Health
Enhancement Support System) “Living with Breast Cancer.”
Psychosocial Needs of Colorectal Cancer Patients and Partners in the
First Year After Diagnosis
60.

Siegel, Robert, MD
Retrospective Analysis of Breast Cancers Negative for Estrogen
Receptor, Progesterone Receptor and HER-2/neu (Basal Like Cancers).
Departmental, $1,600.
Phase III Chemoprevention Trial of Selenium Supplementation in
Persons with Resected Stage I Non-Small Lung Cancer (CALGB
79803/E5597) CALGB, $1,500.
CALGB #99811 - A Phase II Study of Neo-Adjuvant Paclitaxel,
Estramustine and Carboplatin (TEC) Plus Androgen Ablation Prior to
Radiation Therapy in Patients with Poor Prognosis Localized Prostate
Cancer. Dana Farber / Partners Cancer Care, $8,000.
Cyclophosphamide and Doxorubicin (CA x 4 cycles) versus Paclitaxel
(4 cycles) as Adjuvant Therapy for Breast Cancer in Women with
0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study
(CALGB 40101). CALGB / Dana Farber Cancer Institute, $8,000.
Phase III Trial Evaluating the Role of Ovarian Function Suppression
and the Role of Exemestane as Adjuvant Therapies for Premenopausal
Women with Endocrine Responsive Breast Cancer (IBCSG 24002
SOFT). CTSU/IBCSG , $8,000.
CALGB 80101: Phase III Intergroup Trial of Adjuvant Chemoradiation
After Resection of Gastric or Gastroesophageal Adenocarcinoma.
Dana Farber Cancer Institute, $4,000.
A Randomized, Phase III Trial Of Exemestane Versus Anastrozole
In Postmenopausal Women With Receptor Positive Primary Breast
Cancer (CALGB). NCIC/CALGB, $6,000.
ECOG PACCT-1: Program For The Assessment Of Clinical Cancer
Tests: Trial Assigning Individualized Options for Treatment: The
TAILORx Trial. ECOG, $21,000.
ECOG E2603: A Double-blind, Randomized, Placebo-Controlled
Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus
Carboplatin, Paclitaxel and placebo in Patients with Unresectable
Locally Advanced or Stage IV Melanoma. ECOG via CTSU, $15,400.
NCCTG N0147: A Randomized Phase III Trial Of Oxaliplatin
(OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without
Cetuximab (C225) After Curative Resection For Patients With Stage
III Colon Cancer CALGB via Dana-Farber, $20,000.
CALGB 70301: A Clinical Trial to Determine The Quality of Life,
Employment and Informal Care Cost d, Placebo-controlled, Phase
III Study of AE941 in Addition to Combined Modality Treatment
Chemotherapy/ Radiotherapy) for Locally Advanced Unresectable
Non-Small-Cell Lung Cancer (AE-941). NCI/Cancer Treatment
Evaluation Program, $40,750.
Phase III Trial of Novel Epothilone Plus Capecitabine versus
Capecitabine alone in Patients with Advanced Breast Cancer
Previously Treated with or Resistant to an Anthracycline and
who are Taxane Resistant. Bristol Myers Squibb via Dana Farber,
$24,375.
S0016, “A Phase III Trial Of CHOP + Rituximab Vs CHOP +
Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab)
For Treatment Of Newly Diagnosed Follicular Non-Hodgkin’s
Lymphomas. SWOG via Dana Farber/CALGB, $6,000.
A Phase III, Randomized Study of Gemcitabine [fixed-dose rate
infusion] and Oxaliplatin (NSC2666046) versus Gemcitabine
[fixed-dose rate infusion] versus Gemcitabine [30-min infusion] in
Pancreatic Carcinoma. Eastern Cooperative Oncology Group- Dana
Farber Cancer Institute,$8,000.
A Phase III, Open-Label, Extension Study of Eculizumab in Patients
with Transfusion Dependent, Hemolytic Paroxysmal Nocturnal
Hemoglobinuria (PNH) Who Have Participated in the TRIUMPH
(C04-001), SHEPHERD (C04-002) or X03-001 Studies. Alexion
Pharmaceuticals, Inc., $50,988.
An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase
2 Study of S-1 as 2nd Line Therapy for Patients with Metastatic
Pancreatic Cancer, Protocol Number TPU-S1201. TAIHO Pharma
USA, Inc., $84,812.
GPC Protocol SAT3-03-01: A Multi-Center, Multi-National,
Double-Blind, Randomized Phase III Study Of Satraplatin Plus
Prednisone or Placebo Plus Prednisone In Patients With Hormone
Refractory Prostate Cancer Previously Treated With One Cytotoxic
Chemotherapy Regimen. Pharmanet, $66,176.
A Phase II Randomized Double-blinded Efficacy and Safety Study of
Three Doses of TAS-108, Administered Orally in Postmenopausal
Patients with Locally Advanced or Locally Recurrent Inoperable or
Progressive Metastatic Breast Carcinoma Following Standard First or
Second Line Endocrine Therapy. Quintiles, Inc., $138,113.
Protocol 2055-003 - A Phase 2, Multi-Center, Randomized, Open-
Label Study of Two Dose Levels of IMOxine (TM) (HYB2055 for
injection) in Patients with Metastatic or Locally Recurrent Clear
Cell Renal Carcinoma. Idera Pharmaceuticals, $70,638.
TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction
Efficacy and Safety Clinical Investigation, Randomized, Multi-
Center, Double-Blind, Placebo-Controlled, Using Eculizumab in
Paroxysmal Nocturnal Hemoglobinuria Patients (C04-001). Alexion
Pharmaceuticals, Inc., $40,910.
A Multicenter, Open-Label, Single-Arm, Two-Stage Phase II Study
of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered
Intravenously Every 2 Weeks in Subjects with Platinum-,
Taxane-, and Erlotinib-Resistant Advanced Non-Small-Cell Lung

Adenocarcinoma. Sanofi Aventis, $246,775.
Alexion EXPLORE: EXamination of PNH, by Level Of CD59 on REd
and white blood cells, in bone marrow failure syndromes. Alexion
Pharmaceuticals, Inc., $27,100.
Phase III Double-blinded Randomized Trial of 13-Cis Retinoic Acid
(13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage I Nonsmall
Cell Lung Cancer (ECOG-91025).
A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil vs
Fludarabine Phosphate + Chlorambucil in Previously Untreated B-Cell
Chronic Lymphocytic Leukemia (C9011).
A Phase II Study of Neoadjuvant Chemotherapy and Radiation
Therapy in the Management of High-risk, High-grade, Soft Tissue
Sarcomas of the Extremities and Body Wall (ECOG R9514).
Phase III Trial of CHOP versus CHOP and Chimeric Anti-CD20
Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse
Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology
Non-Hodgkin’s Lymphoma (CALGB 9793, formerly ECOG E4494).
A Randomized Phase III Trial of Sequential Chemotherapy Using
Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent
Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or
21 Day Intervals in Women with Node Positive Stage II/IIIA Breast
Cancer (ECOG C9741)
A Phase III Randomized Double Blinded Study of Letrozole Versus
Placebo in Women with Primary Breast Cancer Completing Five or
More Years of Adjuvant Tamoxifen (CALGB Study #49805)
Stein, Kevin, PhD
National Quality of Life Study (Study of Cancer Survivors).
National Quality of Life Study (Study of Cancer Survivors)/ Windham
Hospital.
Publications
Alekshun TJ, Rezania D, Ayala E, Cualing H, Sokol L. Skeletal muscle
peripheral T-cell lymphoma. Journal of Clinical Oncology, 26: 501-
503, Jan 20, 2008.
Brown AK, Madom L, Moore R, Granai CO, DiSilvestro P. The
prognostic significance of lower uterine segment involvement in
surgically staged endometrial cancer patients with negative nodes.
Gynecologic Oncology, 105:55-58, 2007.
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of
bevacizumab in persistent or recurrent epithelial ovarian cancer or
primary peritoneal cancer: a Gynecologic Group Study. Journal of
Clinical Oncology, 25: 5165-71., November 20, 2007.
Fernandez AB, Ahmed S, Duncan BV, Firshein S and Kluger J. Cardiac
tamponade: a rare complication of idiopathic hypereosinophilic
syndrome. Journal of Cardiovascular Medicine, 10: 188-91, February
2009.
Goldstein M, Siegel R. Thymoma developing 30 years after mantle
radiation for Hodgkin’s lymphoma. Connecticut Medicine, 73: 521-
523. 2009.
Kapadia P and Bona R. Acquired deficiency of vitamin K-dependent
clotting factors due to brodifacoum ingestion. Connecticut Medicine,
72: 207-09, April 2008.
Madom LM, Brown AK, Lui F, Moore RG, Granai CO, Disilvestro
PA. Lower uterine segment involvement as a predictor for lymph node
spread in endometrial cancer. Gynecologic Oncology,
107:75-78, 2007.
Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard JW,
Granai CO, Bast Jr., RC, Lu K. Utility of a novel serum tumor
biomarker HE4 in patients with endometrioid adenocarcinoma of the
uterus. Gynecologic Oncology, 110: 196-201, 2008.
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T,
Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast Jr.
RC. The use of multiple novel tumor biomarkers for the detection
of ovarian carcinoma in patients with a pelvic mass. Gynecologic
Oncology, 108:404-408, 2008.
Moore RG, McMeekin SD, Brown AK, DiSilvestro PA, Miller
CM,Allard JW, Gajewski W, Kurman RJ, Bast RC, Skates SK.
A novel multiple marker bioassay utilizing HE4 and CA125 for
the prediction of ovarian cancer in patients with a pelvic mass.
Gynecologic Oncology, 112:40-46, 2009.
Moore RG, Robison K, Brown AK, DiSilvestro PA, Steinhoff M,
Noto R, Brard L, Granai CO. Isolated Sentinel lymph node dissection
with conservative management in patients with squamous cell
carcinoma of the vulva: A prospective trial. Gynecologic Oncology,
109:65-70, 2008.
Nieves L, Currie J, Hoffman J, Sorosky JI. Ototoxicity after
intraperitoneal chemotherapy: a case report. International Journal of
Gynecological Cancer, 17: 1133-5. September – October 2007.
Nieves L, Hoffman J, Allen G, Currie J and Sorosky JI. Placental-site
trophoblastic tumor with PET scan-detected surgically treated lung
metastasis. International Journal of Clinical Oncology, 13: 263-5,
June 2008.
Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz
62.

Oncology
HI, Dev I, Nixon AB, Lyerly HK, Clay T, Morse MA The effect of
anti-VEGF therapy on immature myeloid cell and dendritic cells in
cancer patients. Cancer Immunol Immunother, 2008 Aug;57(8):1115-
24. Epub 2008 Jan 10.
Schnatz PF, Murphy JL, O’Sullivan DM, Sorosky JI. Patient choice:
comparing criteria for selecting an obstetrician-gynecologist based
on image, gender, and professional attributes. American Journal of
Obstetrics & Gynecology, 197: 548. November 2007.
Servodidio CA. What Makes a Community Clinical Research Program
Successful? ONS Connect, 15: December 2008.
Servodidio CA. Technology is Illuminating the Full Spectrum. MGND
New Media. December 30, 2008.
Sharma R, Usmani S, Siegel R. Primary squamous cell carcinoma of
breast in background of phyllodes tumor-A case report. Connecticut
Medicine, 73: 341-343; 2009.
Sorosky JI. Endometrial cancer. Obstetrics & Gynecology, 112: 186,
February 2008.
Weren J, Schnatz PF, Mandavilli S, Allen G, Murphy JL, Greene JF,
Egan JF, Sorosky JI. Prevalence of the human papillomavirus in an
inner-city indigent population with previously normal Pap tests.
Journal of Lower Genital Tract Disease, 12: 287-92, October 2008.
Abstracts
Grubbs SS, Gonzalez M, Krasna M, Siegel R, Bryant D, Tsechetter L
et al. Tracking clinical trial accrual strategies and barriers via a webbased
screening tool. Proc ASCO # 6586. 2009.
Hawkins RP, Pingree S, Shaw B, Serlin RC, Swoboda C, Han J,
Carmack-Taylor C. and Salner A. Mediating processes and effects
of two communication interventions for breast cancer patients.
Presented at the annual meeting of the International Communication
Association, TBA, Montreal, Quebec, Canada, May 21, 2008.
Karak S and Ricci A Jr. Prevalence and significance of perineural
invasion (PIN) in invasive breast carcinoma. USCAP (United State and
Canadian Academy of Pathology), March 2009.
Rustagi T, Siegel R. ‘Zollinger-Ellison Syndrome with subsequent
association of insulinoma. Presented at the 6th Annual ISGIO
Conference, 2009.

Orthopedics
New Projects
Industry
Kime, Charles, MD
A Prospective and Randomized Controlled Trial to Evaluate the Safety and Effectiveness
of Total Facet Arthroplasty in the Treatment of Degenerative Spinal
Stenosis. Archus Orthopedics, $82,000.
Active Projects
Browner, Bruce, MD
Evaluation of Osteoporosis Outreach and Education Initiative. Merck & Co., Inc,
$100,365.
Caputo, Andrew, MD
FDA-HDE (Humanitarian Device Exemption) Approved Ascension PIP Finger
Joint.
Krompinger, W. Jay, MD
Evaluation of Outcomes Following Lumbar Spine Fusion Surgery at Hartford
Hospital: Phase I. Hartford Hospital Small Grant, $9,725.
Lewis, Courtland, MD
Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients
Undergoing Surgical Hip Fracture Repair (FOCUS). National Heart, Lung &
Blood Institute, University of Medicine & Dentistry of New Jersey, $700.
Functional Status, Morbidity and Mortality in Cemented versus Uncemented
Hemiarthroplasty: A Prospective Randomized Trial. Zimmer Corporation,
$166,492.
A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel
Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban
in Subjects Undergoing Elective Total Knee Replacement Surgery. Bristol-Myers
Squibb, $172,860.
Mastella, Daniel, MD
Does Simultaneous Carpal Tunnel Release Improve Outcomes Following Distal
Radius Open Reduction and Internal Fixation: A Retrospective Review.
Sullivan, Raymond, MD
A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical
Trial to Evaluate the Safety and Effectiveness of GEM OS1 Compared to
Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions.
Biomimetic Therapeutics, $168,825.
64.

Pathology
William T. Pastuszak, MD, Chairman, Jaber Aslanzadeh, PhD
Margaret Assaad, MD, Fabiola Balarezo, MD, Richard Cartun, PhD
Thomas Ciesielski, MD, Joseph DiGiuseppe, MD, Jonathan Earle, MD
Mary Fiel-Gan, MD, Lisa Laird, MD, Saverio Ligato, MD
Gregory Makowski, PhD, Srinivas Mandavilli, MD, Laila Mnayer, PhD
Richard Muller, MD, William Rezuke, MD, Andrew Ricci, MD
Peter Shen, MD, Bradford Sherburne, MD, Dean Uphoff, MD
Terry Voytek, MD, Rebecca Williams, MD
The Department of Pathology and Laboratory Medicine (DPLM)
through its biomedical and chemical research initiatives seeks to
improve the understanding of the mechanisms of human disease and
acquire knowledge that will assist in clinical diagnosis and development
of new therapies that will improve cellular, molecular and genetic disease
manifestations. Research-based knowledge provides the fundamental
basis for translating information into clinically useful diagnostic testing
and treatment for patients served at Hartford Hospital. DPLM oversees
state-of-the-art equipment and technologies that support complex analysis
of biochemical, infectious, molecular, cytogenetic and tissue markers of
disease as demonstrated by the Department’s current research projects.
Several divisions of DPLM conduct independent research and
development. The Division of Hematology conducts research in use of
immunologic and molecular techniques in the diagnosis and classification
of hematologic and lymphoid malignancies. Anatomic Pathology uses
immunohistochemistry to investigate a variety of pathologic disorders.
Microbiology has investigated the application of molecular diagnostics to
infectious diseases. The Department is fortunate to have a staff member
with credentials in both Molecular Pathology and Cytogenetics which has
opened new opportunities for research and development in both Anatomic
and Clinical Pathology within the Department.
New Projects
Industry
Mnayer, Laila, PhD
A Multi-Center Blinded Reproducibility Study of the XTAG Cystic Fibrosis Core
Panel v2 and XTAG Cystic Fibrosis Expanded Panel v2. Luminex Molecular
Diagnostics, $22,750.
Unfunded
Cartun, Richard, PhD
The Role of Lymphangitis in Crohn’s Disease.
DiGiuseppe, Joseph, MD
Flow Cytometric Evaluation of CD49f in Precursor B-cell Acute Lymphoblastic
Leukemia.
Active Projects
Bowers, George, MD
Development of a Reference System for the Measurement of the Activity
of Erythrocyte Choline Estrase “Eche” in Human Blood. Hartford Hospital
Research Endowment Funds, $6,500.
Roper, Liz, MS
Use of Laboratory Tests and a Neural Network for the Detection of Myocardial
Ischemia in Patients with Acute Coronary Syndromes. Hartford Hospital
Research Endowment Funds, $10,000.
Robert McComb recieved support through med staff funds for manuscript
preperation during this reporting period.
Publications
Anderson WF, Luo S, Chatterjee N, Rosenberg PS, Matsuno RK, Goodman MT,
Hernandez BY, Reichman M, Dolled-Filhart MP, O’Regan RM, Garcia-Closas M,
Perou CM, Jatoi I, Cartun RW, Sherman ME. Human epidermal growth factor
receptor-2 and estrogen receptor expression, a demonstration project using the
residual tissue repository of the Surveillance, Epidemiology, and End Results
(SEER) program. Breast Cancer Res Treat. 2009 Jan;113(1):189-96.
Aslanzadeh J, Zheng X, IL H, Tetreault J, Ratkiewicz I, Meng S, Hamilton1
P, Tang YW. Prospective evaluation of rapid antigen tests for diagnosis of
Respiratory Syncytial Virus and Human Metapneumovirus Infections. J Clin
Microbiol 46(5):1682-1685, 2008.
Asthana N, Mandich D, Ligato S. Esophageal polypoid dysplasia of gastric
foveolar phenotype with focal intramucosal carcinoma associated with Barrett’s
Esophagus. Am J Surg Pathol Vol. 32 (10), pp1581-1585, 2008.
Berzolla C, Mandavilli S, Sorosky J. Dysplasia and malignancy in endocervical
polyps. J Women’s Health. 16(9):1317-1321, 2007.

Csako G, Makowski GS. Clinical chemistry of neurological and psychiatric
diseases and body fluids. In Self Assessment in Clinical Laboratory Sciences II, Wu
AHB (ed.), AACC Press, Washington, DC pp 219-234, 2008.
DiGiuseppe JA. Acute lymphoblastic leukemia: Diagnosis and detection of
minimal residual disease following therapy. Clin Lab Med 27:533-549, 2007.
DiGiuseppe JA. Flow cytometric immunophenotyping of plasmacytic neoplasms.
Am J Clin Pathol 127:172-174, 2007.
DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor
B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residual
disease detection. Cytometry Part B (Clinical Cytometry). 76B:150-155.
Glaser SL, Gulley ML, Clarke CA, Keegan TH, Chang ET, Shema SJ, Craig FE,
DiGiuseppe JA, Dorfman RF, Mann RB, Anton-Culver H, Cozen W, Ambinder RF.
Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California
populations. Int J Cancer 123:1499-1507, 2008.
Hurford MT, Altman AJ, DiGiuseppe JA, Sherburne BJ, Rezuke WN. Unique
pattern of nuclear TdT immunofluorescence distinguishes normal precursor B cells
(hematogones) from lymphoblasts of precursor B-lymphoblastic leukemia. Am J
Clin Pathol 129:700-705, 2008.
Lee CJ, Park JH, Ciesielski TE, Thomson JG, Persing JA. Retinoids, 585-nm laser,
and carbon dioxide laser: A numeric comparison of neocollagen formation in
photoaged airless mouse skin. Aesth Plast Surg 32:894-901, 2008.
Ligato S, Mandich D, Cartun RW. Utility of Glypican-3 in differentiating
hepatocellular carcinoma from other primary and metastatic lesions in FNA of the
liver: An immunocytochemical study. Mod Pathol Vol. 21, 5, 626-631, 2008.
Ligato S. Zhao H. Mandich D, Cartun RW. KOC and S100A4 protein
immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology
for diagnosing pancreatobiliary malignancies. Diag Cytopath Vol. 36, No 8, 561-
567, 2008.
Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of automated screening
and confirmation of extended-spectrum b-lactamase-producing members of the
Enterobacteriaceae on prescribing of antibiotics. J Med Microbiol 57:1147–1151,
2008.
Schnatz PF, Mandavilli SR, O’Sullivan DM. The prevalence of cervical HPV and
cytologic abnormalities in association with reproductive factors of rural Nigerian
women. J Women’s Health (Larchmt). 17(2):279-85, March 2008.
Stetler-Stevenson M, Ahmad E, Barnett D, Braylan RC, DiGiuseppe JA, Marti G,
Menozzi D, Oldaker TA, Orfao de Matos A, Rabellino E, Stone EC, Walker C.
Clinical flow cytometric analysis of neoplastic hematolymphoid cells; Approved
Guideline-Second Edition. CLSI document H43-A2, Clinical and Laboratory
Standards Institute, 2007.
Werden J, Schnatz PF, Mandavilli S, Sorosky JI. Prevalence of the HPV in an
inner-city indigent population with previously normal Pap tests. J Low Genit
Tract Dis 12(4):287-92, October 2008.
Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker
T, Shenkin M, Stone E, Wallace P. Bethesda International Consensus
recommendations on the immunophenotypic analysis of hematolymphoid
neoplasia by flow cytometry: Optimal reagents and reporting for the flow
cytometric diagnosis of hematopoietic neoplasia. Cytometry Part B (Clin
Cytometry) 2007; 72B:S14-22, 2006.
Yang XR, Pfeiffer RM, Garcia-Closas M, Rimm DL, Lissowska J, Brinton LA,
Peplonska B, Hewitt SM, Cartun RW, Mandich D, Sasano H, Evans DB, Sutter
TR, Sherman ME. Hormonal markers in breast cancer: coexpression, relationship
with pathologic characteristics, and risk factor associations in a population-based
study. Cancer Res. 2007 Nov 1;67(21):10608-17.
Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd
AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson
PE, Hewitt SM, Vyberg M, Hicks DG; Members of the Standardization Ad-Hoc
Consensus Committee. Consensus recommendations on estrogen receptor
testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol
Morphol. 2008 Dec;16(6):513-20.
Zhao HD, Davydova L, Mandich D, Cartun RW, Ligato S. S100A4 protein and
Mesothelin expression in dysplasia and carcinoma of extrahepatic bile duct. Am J
Clin Pathol 127, 3:374-384, March 2007.
Zhao HD, Mandich D, Cartun RW, Ligato S. Expression of KOC in pancreatic
FNA cytology for diagnosing invasive pancreatic adenocarcinoma. Diag
Cytopath Vol. 35, 700-704, 2007.
Ogawa F, Mino-Kenudson M, Shimizu M, Ligato S, Lauwers G. Gastroduodenitis
associated with yttrium 90-microsphere selective internal radiation. Arch Pathol
Lab Med Vol. 132, 1734-1738. November 2008.
66.

Pathology
Abstracts and Presentations
Aslanzadeh J, Bisaillon C, Pajor J, Meng S, White-Abell J, Gauthier C, Newsom B,
Missett C, Ratkiewicz I, Li, Frankin J, Chappell, Tang YW. Detection of Human
Meta Pneumovirus in Respiratory Samples from an Adult Patient Population. 25th
Annual Clinical Virology Symposium and Annual Meeting of the Pan-American
Society for Clinical Virology, 2009.
Aslanzadeh J, Hamilton P, Miller J, Maldonada Y, Ratkiewicz I. Evaluation of Gen-
Probe APTIMA COMBO 2 Assay Performed on Tigris DTS System for Detecting
Chlamydia trachomatis and Neisseria gonorrhoeae. 108th Annual Meeting of the
American Society for Microbiology, 2008.
Aslanzadeh JH, Li J, Tetreault J, Ratkiewicz I, Meng S, Hamilton P, Tang YW.
Performance of Rapid Tests for Detection of Respiratory Syncytial Virus and
Human Meta Pneumovirus. 23rd Annual Clinical Virology Symposium and Annual
Meeting of the Pan-American Society for Clinical Virology, 2007.
Aslanzadeh J, Zheng X, Li H, Tetreault J, Ratkiewicz I, Meng S, Hamilton P, Tang
YW. Prospective Evaluation of Rapid Antigen Tests for Diagnosis of Respiratory
Syncytial Virus and Human Meta pneumovirus Infections. 18th Annual Meeting of
European Society of Clinical Microbiology and Infectious Diseases, 2008.
Cartun RW. Technical Issues in Immunohistochemistry. Invited address at the
Third Annual International Retreat on Applied Immunohistochemistry and
Molecular Morphology. January 26-30, 2009 - Duck Key, FL.
Cartun RW. Advances in Histology and Immunohistochemistry Techniques.
Invited address at Leica-Microsystems 2009 Educational Symposia Series. May 13,
2009 - Jersey City, NJ. Invited address at Leica-Microsystems 2009 Educational
Symposia Series August 12, 2009 - Dallas, TX.
Currie C, Brown A, Sorosky J, Mandavilli S, Joyner A, Currie, J. (Abstract #27)
Endometrioid Carcinoma of Fallopian Tube with Metastasis and Extension to
the Obturator Space: A Case Report. New England Association of Gynecologic
Oncologists, 2009 Meeting.
Gorusu M, Menon M, Firshein SI, Dekker PT, DeFusco PA, Rezuke W, Sharma
R, Mnayer LO. Philadelphia Chromosome–Negative Chronic Myeloid Leukemia:
Tailored Monitoring. Clinical Lymphoma & Myeloma, Vol. 9, No. 2, 171-182,
2009.
Gull, Batti, Balarezo. Vascularity in Obstructive vs. Infected Tonsils.
Otolaryngology – Head & Neck Surgery, Vol. 137, Issue 2, pp. P96, 2007.
He W, Hodges K, Windemuth K, Mnayer LO, Mandavilli S, , UroVysion Tm
FISH Assay for Detection of Urothelial Carcinoma: A Tertiary Care Hospital
Experience with149 Cases. American Society of Cytopathology, Houston,
Texas, 2007.
He W, Mandavilli S. Utility of p63 and CK34BE12 Antibodies in Diagnosis of
Urothelial Carcinoma in Cytology Specimens. Cancer Cytopathology. Oct 25,
2008. 114 (5), page 363.
Ibrahim G, White S, Karak SG, Ricci Jr. A. Histopathologic and Staging
Characteristics of ER/PR/HER “triple positive” Mammary carcinoma. Mod
Pathol 22(1) supp 47A.
Joyner A, Sorosky J, Currie C, Mandavilli S, Brown A, and Currie J. (Abstract
#29) Neuroendocrine Tumor of Uterus and Cervix after Uterine Artery
Embolization for Leiomyomas: A Case Report. New England Association of
Gynecologic Oncologists, 2009 Meeting.
Karak SG and Ricci Jr A. Prevalence of Significance of Perineural Invasion in
Invasive Breast Carcinoma. Mod Pathol. 22(1) supp 49A.
Ligato S, Mandich D, Cartun RW. Is Immunohistochemical Analysis of
DNA Mismatch Repair Proteins (MMR) in Unselected Sebaceous Neoplasms
Warranted as a Screening Test for Muir-Torre Syndrome? 98th USCAP Annual
Meeting. Section E – Dermatopathology Section Proffered paper Denver
Colorado, 2008.
Mandavilli S. Effusion Cytology with an Emphasis on Ancillary Studies. Invited
lecturer at IX Internal CME Meeting on Surgical Pathology and Cytology at
NIMHANS, Bangalore, India (January 26-28, 2008).
Nataraj, Vellanki, Dada, Balarezo, Ranga. De Novo Foal Segmental
Glomerulosclerosis (FSG) Following Renal Transplant in a Patient with
Autosomal Dominant Polycystic Kidney Disease (ADPKD). American Journal
of Kidney Diseases, Vol. 51, Issue 5, pp. B73, 2008.
Parab MS, Ahmad N, Fuller SG, DiGiuseppe JA. Changes in Antigen Density
During Remission Induction in Precursor B-cell Acute Lymphoblastic Leukemia
Detected by Flow Cytometric Immunophenotyping. Mod Pathol 20:353-4A,
2007.
Parab M, Mandich D, Cartun RW, Ligato S. Biliary Brush Cytology Combined
with Immunocytochemical Staining for IMP3 Provides Superior Diagnostic
Sensitivity for Detection of Pancreatobiliary Malignancies. 22nd European
Congress of Pathology. Florence, Italy. Cytopathology Section, 4-9 September
2009.

Platt L., Brown A.K., Mandavilli S., Currie J., Sorosky J. Hartford Hospital,
Hartford, CT. Complex Atypical Hyperplasia and the Incidence of Endometrial
Cancer at the Time of Hysterectomy. New England Association of Gynecologic
Oncologists, 2009 Meeting, June 2009.
Rotundo E, Waszczak W, O’Donell M, Mandavilli SR. Thyroid FNA Diagnosis
of Cellular Follicular Lesion: A Clinico-pathologic Study of 161 Cases. American
Society of Cytology, Houston, TX, November 2007.
Shinoda-Matsuoka H, DiGiuseppe JA. Overexpression of CD49f in Precursor
B-cell Acute Lymphoblastic Leukemia: Efficiency of Minimal Residual Disease
(MRD) Detection by Flow Cytometric Immunophenotyping Compared with
Commonly Used Markers. Mod Pathol 22:388A, 2009.
Sun Y, Waszczak W, Mandavilli S. Significance of Ductal Epithelial Cells in
Nipple Discharge Cytology Specimens. Cancer Cytopathology. Oct 25, 2008.
114 (5), page 352. Presented American Society of Cytopathology Meeting,
November 20, 2008.
Tetreault J, Aslanzadeh J. Measures to Control False Negative and False Positive
Blood Cultures in a Large Tertiary Care Hospital. 107th Annual Meeting of the
American Society for Microbiology, 2007.
Umenyi C, Schnatz P, Waszczak W, Mandavilli SR. Incidence of HR-HPV and
Cervical Dysplasia in Nigeria. American Society of Cytology, Houston, TX,
November 2007.
White S, Ibrahim G, Karak SG, Mnayer L, Ricci Jr. A. Proliferative Activity and
HER2-FISH Results on Hormone Receptor Positive/HER2 Positive (Luminal Type
B) Breast Cancer. Mod Pathol 22(1) supp 74A.
68.

Psychiatry
Harold I. Schwartz, MD
Psychiatrist-in-Chief; Vice President, Behavioral Health
The research enterprise at The Institute of Living is organized in four
specialized centers. The Olin Neuropsychiatry Research Center, directed
by Godfrey Pearlson, M.D., focuses on studies of the major psychiatric
disorders using brain imaging and electrophysiological techniques along
with genetic analysis. The Anxiety Disorders Center, directed by David
Tolin, Ph.D., researches treatments for Obsessive-Compulsive Disorder
(OCD), Panic Disorder, Compulsive Hoarding and other disorders on
the anxiety spectrum. The Braceland Center for Mental Health and
Aging (Karen Blank, M.D., Director) addresses issues related to memory
in normal aging and in individuals with Alzheimer’s Disease or other
dementing processes. Finally, the Burlingame Center for Psychiatric
Research and Education, directed by John Goethe, M.D., focuses on
outcomes and best practices research as well as pharmacogenetics,
metabolic syndrome and treatment resistant mood disorders.
The success of our research enterprise can be measured through grants
awarded, the dissemination of important findings and the synergy
between our research efforts and our training and clinical programs. As
for grants, the Olin Neuropsychiatry Research Center alone was awarded
$7.2 million in new federal funding in fiscal year 2009. A reflection of
the huge dissemination of information from these centers can be seen in
the lists of publications from each. The synergy between our research
and clinical and training programs is a building block of excellence at the
IOL and continues to grow stronger every year.
Godfrey Pearlson, MD: Director
Faculty:
Godfrey Pearlson, MD, Center Director and Director of COBBRA Lab
(COgnition, Brain, Behavior, Research and Allelic Variation)
Michael Stevens, PhD, Director, CND Lab (Clinical Neurosciences and
Development) and Director of Child and Adolescent Research at IOL
David Glahn, PhD, Director ADAPTING Lab (Affective Disorders and
Clinical Trials, Imaging, Neurocognition and Genetics)
Michal Assaf, MD, Senior Scientist,
Pawel Skudlarski, PhD, Senior Scientist
Post-Doctoral Fellows:
Beth Anderson, PhD, Christopher Hyatt, PhD, Suzanne Witt, PhD,
Anderson Winkler, PhD
The mission of the Olin Center is to be at the forefront of research
in major psychiatric and psychological disorders, in particular
schizophrenia, mood disorders and addictions. Techniques employed
by Center faculty include functional and structural magnetic resonance
imaging (MRI) and electrophysiology (EED, ERPs). Our newly designed
Website is at http://www.nrc-io.org.
Center faculty have active research interests in many aspects of cognitive
function including normal aging, working and long term memory,
spatial navigation, salience detection, orienting processes, response
inhibition, error monitoring, language emotional processing, theory of
mid and attention. We examine these cognitive and emotive processes
in schizophrenia, Alzheimer’s disease, manic-depressive illness, Major
Depressive Disorder, disruptive behavior disorders such as ADHD or
Conduct Disorder, alcohol & drug abuse, post-traumatic stress disorder
and psychopathy. The Center is supported in part by multiple grants
from the National Institute of Health, (NIAAA, NIMN, NINDS, NIA
and NIDA) totaling several million dollars annually. Center faculty have
been exceptionally successful in being awarded NIH grants in the past
year. Faculty also provide mentorship and training for IOL residents and
undergraduate, graduate, and postdoctoral fellows.
With the publication of the Human Genome and the arrival of
GENOMAS at Hartford Hospital, genetic testing is becoming an integral

OLIN Neuropsychiatry Research Center
part of research at the Olin Research Center. All research subjects now
have samples taken for genetic characterization, and neuroimaging
projects are increasingly taking on a genetic component. Notably, a
recent collaborative study between ONRC and Genomas identified a
series of risk genes for schizophrenia that contribute to abnormal brain
activation during an attention task. This finding is the basis of a new grant
seeking biological risk markers of schizophrenia.
Increasing attention is being paid to Alzheimer’s disease and joint projects
involving both the Olin Research Center and the Memory Disorders
Center were recently refunded. Additional collaborations have begun
with Child and Adolescent Psychiatry in the areas of ADHD, adolescent
depression, and autism and with the addictions program for research on
alcohol and drug abuse. These include collaborations with Yale, Trinity
College and CCSU. Research scanning on the Olin Center’s 3 Tesla
scanner continues to grow – we have scanned over 7000 research subjects
since the Center opened in 2002. We have been able to hire more staff.
At a time when federal grant dollars are shrinking, and only about 5% of
federal grant submissions are being funded, the Olin Center continues to
have large-scale new grants funded.
OLIN Center Publications
Acheson A, Robinson JL, Glahn DC, Lovallo WR, Fox PT. Differential activation
of the anterior cingulate cortex and caudate nucleus during a gambling simulation
in persons with a family history of alcoholism: studies from the Oklahoma Family
Health Patterns Project. Drug Alcohol Depend. 2009 Feb 1;100(1-2):17-23.
Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in
schizophrenia: a selective review. Schizophr Res. 2009 Apr;109(1-3):24-37.
Allen AJ, Meda SA, Skudlarski P, Calhoun VD, Astur R, Ruopp KC, Pearlson GD.
Effects of alcohol on performance on a distraction task during simulated driving.
Alcohol Clin Exp Res. 2009 Apr;33(4):617-25.
Almeida S, Glahn DC, Argyropoulos SV, Frangou S. Acute citalopram
administration may disrupt contextual information processing in healthy males. Eur
Psychiatry. 2009 Aug 18. PMID: 19695841.
Almeida S, Glahn DC, Argyropoulos SV, Frangou S. Acute citalopram
administration may disrupt contextual information processing in healthy males. Eur
Psychiatry. 2009 Aug 18.
Arango C, McMahon RP, Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan
RW. Patterns of cranial, brain and sulcal CSF volumes in male and female
deficit and nondeficit patients with schizophrenia. Psychiatry Res. 2008 Feb
28;162(2):91-100.
Assaf M, Jagannathan K, Calhoun V, Kraut M, Hart J Jr, Pearlson G. Temporal
sequence of hemispheric network activation during semantic processing: a
functional network connectivity analysis. Brain Cogn. 2009 Jul;70(2):238-46.
PMID: 19307050.
Astur RS, Shipman SL. Factors affecting the hippocampal BOLD response during
spatial memory. Behav Brain Res. 2008 Mar 5;187(2):433-41.
Astur RS, Newhouse P, Newhouse C. Sex differences in visual-spatial learning
using a virtual water maze in pre-pubertal children. Behav Brain Res. 2007 Oct
1;183(1):1-7.
Bearden CE, Cannon TD, Chiang MC, Glahn DC, Lee AD, Reiss AL,
Thompson PM, Toga AW, van Erp TG. Neural phenotypes of common and rare
genetic variants. Biol Psychol. 2008 Sep;79(1):43-57.
Bearden CE, Thompson PM, Dutton RA, Frey BN, Peluso MA, Nicoletti
M, Dierschke N, Hayashi KM, Klunder AD, Glahn DC, Brambilla P, Sassi
RB, Mallinger AG, Soares JC. Three-dimensional mapping of hippocampal
anatomy in unmedicated and lithium-treated patients with bipolar disorder.
Neuropsychopharmacology. 2008 May;33(6):1229-38.
Bearden, C.E., Glahn DC, Thompson, P.M., Dalwani, M., Hayashi, K.M., Lee,
A.D., Nicoletti, M., Trakhtenbroit, M., et al., Reply: Lithium and Increased
Cortical Gray Matter-More Tissue or More Water? Biol Psychiatr, 2007.
Bearden, C.E., Thompson, P.M., Dalwani, M., Glahn DC, Hayashi, K.M.,
Lee, A.D., Nicoletti, M., Trakhtenbroit, M., et al., Greater cortical gray matter
density in lithium-treated patients with bipolar disorder. Biol Psychiatry, 2007.
62(1): p. 7-16.
Bearden, C.E., van Erp, T.G., Glahn DC, Dutton, R.A., Tran, H., Zimmermann,
L., Sun, D., Geaga, J.A., et al., Mapping cortical thickness in children with
22q11.2 deletions. Cereb Cortex, 2007. 17(8): p. 1889-98.
Bearden, C.E., Thompson, P.M., Glahn DC, Dutton, R.A., Frey, B.N., Peluso,
M.A., Nicoletti, M., Dierschke, N., et al., Three-dimensional mapping of
hippocampal anatomy in unmedicated and lithium-treated patients with bipolar
disorder. Neuropsychopharmacology, 2008. 33(6): p. 1229-38.
70.

Calhoun VD, Maciejewski PK, Pearlson GD, Kiehl KA. Temporal lobe and
“default” hemodynamic brain modes discriminate between schizophrenia and
bipolar disorder. Hum Brain Mapp. 2008 Nov;29(11):1265-75.PMID: 17894392.
Calhoun VD, Kiehl KA, Pearlson GD. Modulation of temporally coherent brain
networks estimated using ICA at rest and during cognitive tasks. Hum Brain Mapp.
2008 Jul;29(7):828-38.
Caprihan A, Pearlson GD, Calhoun VD. Application of principal component
analysis to distinguish patients with schizophrenia from healthy controls based on
fractional anisotropy measurements. Neuroimage. 2008 Aug 15;42(2):675-82.
Cascella NG, Testa SM, Meyer SM, Rao VA, Diaz-Asper CM, Pearlson
GD, Schretlen DJ. Neuropsychological impairment in deficit vs. non-deficit
schizophrenia. J Psychiatr Res. 2008 Sep;42(11):930-7.
Contreras J, Hare L, Camarena B, Glahn D, Dassori A, Medina R, Contreras S,
Ramirez M, Armas R, Munoz R, Mendoza R, Raventos H, Ontiveros A, Nicolini
H, Palmer R, Escamilla M.The serotonin transporter 5-HTTPR polymorphism is
associated with current and lifetime depression in persons with chronic psychotic
disorders. Acta Psychiatr Scand. 2009 Feb;119(2):117-27. PMID: 19016667.
Cykowski MD, Coulon O, Kochunov PV, Amunts K, Lancaster JL, Laird AR, Glahn
DC, Fox PT. The central sulcus: an observer-independent characterization of sulcal
landmarks and depth asymmetry. Cereb Cortex. 2008 Sep;18(9):1999-2009. PMID:
18071195.
Demirci O, Clark VP, Magnotta VA, Andreasen NC, Lauriello J, Kiehl KA,
Pearlson GD, Calhoun VD. A Review of Challenges in the Use of fMRI for Disease
Classification / Characterization and A Projection Pursuit Application from Multisite
fMRI Schizophrenia Study. Brain Imaging Behav. 2008 Sep 1;2(3):147-226.
PMID: 19562043.
Demirci O, Stevens MC, Andreasen NC, Michael A, Liu J, White T, Pearlson
GD, Clark VP, Calhoun VD. Investigation of relationships between fMRI brain
networks in the spectral domain using ICA and Granger causality reveals distinct
differences between schizophrenia patients and healthy controls. Neuroimage.
2009 Jun;46(2):419-31.
Driesen NR, Leung HC, Calhoun VD, Constable RT, Gueorguieva R, Hoffman
R, Skudlarski Impairment of working memory maintenance and response in
schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry.
2008 Dec 15;64(12):1026-34. PMID: 18823880.
Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E. The anatomy of
first-episode and chronic schizophrenia: an anatomical likelihood estimation metaanalysis.
Am J Psychiatry. 2008 Aug;165(8):1015-23. PMID: 18381902.
Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, Lancaster JL,
Bullmore E, Fox PT. Meta-analysis of gray matter anomalies in schizophrenia:
application of anatomic likelihood estimation and network analysis. Biol Psychiatry.
2008 Nov 1;64(9):774-81. PMID: 18486104.
Glahn D, Reichenberg A, Frangou S, Ormel H. Psychiatric neuroimaging: joining
forces with epidemiology. Eur Psychiatry. 2008 Jun;23(4):315-9.
Glahn, D.C., Almasy, L., Blangero, J., Burk, G.M., Estrada, J., Peralta,
J.M., Meyenberg, N., Adjudicating neurocognitive endophenotypes for
schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 2007. 144B(2): p.
242-9.
Glahn, D.C., Lovallo, W.R. and Fox, P.T. Reduced amygdala activation in young
adults at high risk of alcoholism: studies from the Oklahoma family health
patterns project. Biol Psychiatry, 2007. 61(11): p. 1306-9.
Glahn, D.C., Paus, T. and Thompson, P.M. Imaging genomics: mapping the
influence of genetics on brain structure and function. Hum Brain Mapp, 2007.
28(6): p. 461-3.
Glahn, D.C., Thompson, P.M. and Blangero, J. Neuroimaging endophenotypes:
strategies for finding genes influencing brain structure and function. Hum Brain
Mapp, 2007. 28(6): p. 488-501.
Glahn, D., Reichenberg, A., Frangou, S. and Ormel, H., Psychiatric
neuroimaging: Joining forces with epidemiology. Eur Psychiatry. 2008
Jun;23(4):315-9.
Goldstein G, Panchalingam K, McClure RJ, Stanley JA, Calhoun VD, Pearlson
GD, Pettegrew JW. Molecular neurodevelopment: an in vivo 31P-1H MRSI
study. J Int Neuropsychol Soc. 2009 Sep;15(5):671-83.
Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E. Cognitive impairment in
bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert
meeting report. Eur Neuropsychopharmacol. 2008 Nov;18(11):787-93.
Gordon RJ, Seamon JG, Pearlson GD. An fMRI study of neurocognitive
functioning in schizophrenia with a mere exposure paradigm. Schizophr Res.
2009 Mar;108(1-3):290-2. PMID: 18835759.
Guo Y, Pagnoni G. A unified framework for group independent component
analysis for multi-subject fMRI data. Neuroimage. 2008 Sep 1;42(3):1078-93.
PMID: 18650105.
Hare E, Glahn DC, Dassori A, Raventos H, Nicolini H, Ontiveros A, Medina R,
Mendoza R, Jerez A, Muñoz R, Almasy L, Escamilla MA. Heritability of age of
onset of psychosis in schizophrenia. Am J Med Genet B Neuropsychiatr Genet.
2009 Apr 6. PMID: 19350535.
Holmes M, K., Bearden CE, Barguil M, Fonseca M, Serap Monkul E, Nery FG,
Soares JC, Mintz J, Glahn DC. Conceptualizing impulsivity and risk taking in
bipolar disorder: importance of history of alcohol abuse. Bipolar Disord. 2009
Feb;11(1):33-40.PMID: 19133964.
Hong CC, Harris JC, Pearlson GD, Kim JS, Calhoun VD, Fallon JH, Golay
X, Gillen JS, Simmonds DJ, van Zijl PC, Zee DS, Pekar JJ. fMRI evidence for
multisensory recruitment associated with rapid eye movements during sleep.
Hum Brain Mapp. 2009 May;30(5):1705-22.PMID: 18972392.

Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung
MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer’s Disease
Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment
and Alzheimer’s disease: implications for sequence of pathological events in
Alzheimer’s disease. Brain. 2009 May;132(Pt 5):1355-65. PMID: 19339253.
2008 Mar;2(1):21-26.PMID: 19096528.
Meda SA, Bhattarai M, Morris NA, Astur RS, Calhoun VD, Mathalon DH,
Kiehl KA, Pearlson GD. An fMRI study of working memory in first-degree
unaffected relatives of schizophrenia patients. Schizophr Res. 2008 Sep;104(1-
3):85-95. Epub 2008 Aug 3.PMID: 18678469.
Jafri MJ, Pearlson GD, Stevens M, Calhoun VD. A method for functional
network connectivity among spatially independent resting-state components in
schizophrenia. Neuroimage. 2008 Feb 15;39(4):1666-81. PMID: 18082428.
Meda SA, Calhoun VD, Astur RS, Turner BM, Ruopp K, Pearlson GD. Alcohol
dose effects on brain circuits during simulated driving: an fMRI study. Hum
Brain Mapp. 2009 Apr;30(4):1257-70.PMID: 18571794.
Karlsgodt, K.H., Glahn, D.C., van Erp, T.G., Therman, S., Huttunen, M.,
Manninen, M., Kaprio, J. The relationship between performance and fMRI signal
during working memory in patients with schizophrenia, unaffected co-twins, and
control subjects. Schizophr Res, 2007. 89(1-3): p. 191-7.
Kiehl KA, Pearlson GD, Stevens MC. An FMRI auditory oddball study of
combined-subtype attention deficit hyperactivity disorder. Am J Psychiatry. 2007
Nov;164(11):1737-49.PMID: 17974940.
Kim D, Burge J, Lane T, Pearlson GD, Kiehl KA, Calhoun VD. Hybrid ICA-
Bayesian network approach reveals distinct effective connectivity differences in
schizophrenia. Neuroimage. 2008 Oct 1;42(4):1560-8. PMID: 18602482.
Kim D, Pearlson GD, Kiehl KA, Bedrick E, Demirci O, Calhoun VD. A method
for multi-group inter-participant correlation: abnormal synchrony in patients
with schizophrenia during auditory target detection. Neuroimage. 2008 Feb
1;39(3):1129-41. PMID: 17996465.
Liotti M, Pliszka SR, Perez R 3rd, Luus B, Glahn D, Semrud-Clikeman M.
Electrophysiological correlates of response inhibition in children and adolescents
with ADHD: influence of gender, age, and previous treatment history.
Psychophysiology. 2007 Nov;44(6):936-48. PMID: 17666028.
Meda SA, Giuliani NR, Calhoun VD, Jagannathan K, Schretlen DJ, Pulver A,
Cascella N, Keshavan M, Kates W, Buchanan R, Sharma T, Pearlson GD. A large
scale (N=400) investigation of gray matter differences in schizophrenia using
optimized voxel-based morphometry. Schizophr Res. 2008 Apr;101(1-3):95-
105. Epub 2008 Apr 18.PMID: 18378428.
Michael AM, Calhoun VD, Pearlson GD, Baum SA, Caprihan A. Correlations
of diffusion tensor imaging values and symptom scores in patients with
schizophrenia. Conf Proc IEEE Eng Med Biol Soc. ;2008:5494-7.PMID:
19163961.
Michael AM, Baum SA, White T, Demirci O, Andreasen NC, Segall JM, Jung
RE, Pearlson G, Clark VP, Gollub RL, Schulz SC, Roffman JL, Lim KO, Ho
BC, Bockholt HJ, Calhoun VD. Functional brain networks in schizophrenia:
a review. Front Hum NeuGlahnci. 2009;3:17. Epub 2009 Aug 17.PMID:
19738925.
Michael AM, Baum SA, White T, Demirci O, Andreasen NC, Segall JM, Jung
RE, Pearlson G, Clark VP, Gollub RL, Schulz SC, Roffman JL, Lim KO, Ho
BC, Bockholt HJ, Calhoun VD. Does function follow form?: Methods to fuse
structural and functional brain images show decreased linkage in schizophrenia.
Neuroimage. 2009 Sep 3 PMID: 19733247.
Liu J, Kiehl KA, Pearlson G, Perrone-Bizzozero NI, Eichele T, Calhoun VD.
Genetic determinants of target and novelty-related event-related potentials in the
auditory oddball response. Neuroimage. 2009 Jul 1;46(3):809-16. PMID: 19285141.
Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of
41 functional neuroimaging studies of executive function in schizophrenia. Arch
Gen Psychiatry. 2009 Aug;66(8):811-22.PMID: 19652121.
Liu J, Pearlson G, Windemuth A, Ruano G, Perrone-Bizzozero NI, Calhoun V.
Combining fMRI and SNP data to investigate connections between brain function
and genetics using parallel ICA.
Hum Brain Mapp. 2009 Jan;30(1):241-55.PMID: 18072279.
Matsuo, K., Glahn, D.C., Peluso, M.A., Hatch, J.P., Monkul, E.S., Najt, P., Sanches,
M., et al., Prefrontal hyperactivation during working memory task in untreated
individuals with major depressive disorder. Mol Psychiatry, 2007. 12(2): p. 158-66.
Meda SA, Stevens MC, Potenza MN, Pittman B, Gueorguieva R, Andrews MM,
Thomas AD, Muska C, Hylton JL, Pearlson GD. Investigating the behavioral and
self-report constructs of impulsivity domains using principal component analysis.
Behav Pharmacol. 2009 Sep;20(5-6):390-9.PMID: 19724194.
Meda SA, Gelernter J, Gruen JR, Calhoun VD, Meng H, Cope NA, Pearlson GD.
Polymorphism of DCDC2 Reveals Differences in Cortical Morphology of Healthy
Individuals-A Preliminary Voxel Based Morphometry Study. Brain Imaging Behav.
Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller
BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ; Alzheimer’s Disease
Neuroimaging Initiative. Episodic memory loss is related to hippocampalmediated
beta-amyloid deposition in elderly subjects. Brain. 2009 May;132(Pt
5):1310-23. Epub 2008 Nov 28.PMID: 19042931.
Najt, P., Perez, J., Sanches, M., Peluso, M.A., Glahn, D. and Soares, J.C.,
Impulsivity and bipolar disorder. Eur Neuropsychopharmacol, 2007. 17(5):313-
20.
Nery FG, Hatch JP, Glahn DC, Nicoletti MA, Monkul ES, Najt P, Fonseca
M, Bowden CL, Cloninger CR, Soares JC. Temperament and character traits
in patients with bipolar disorder and associations with comorbid alcoholism
or anxiety disorders. J Psychiatr Res. 2008 Jun;42(7):569-77. Epub 2007 Aug
6.PMID: 17675066.
72.

Pearlson G. Multisite collaborations and large databases in psychiatric
neuroimaging: advantages, problems, and challenges. Schizophr Bull. 2009
Jan;35(1):1-2. Epub 2008 Nov 20. PMID: 19023121.
Pearlson GD, Folley BS. Endophenotypes, dimensions, risks: is psychosis analogous
to common inherited medical illnesses? Clin EEG Neurosci. 2008 Apr;39(2):73-7.
Review. PMID: 18450172.
Pearlson GD, Folley BS. Schizophrenia, psychiatric genetics, and Darwinian
psychiatry: an evolutionary framework. Schizophr Bull. 2008 Jul;34(4):722-33.
Epub 2007 Nov 21. Review.PMID: 18033774.
Peluso MA, Glahn DC, Matsuo K, Monkul ES, Najt P, Zamarripa F, Li J, Lancaster
JL, Fox PT, Gao JH, Soares JC. Amygdala hyperactivation in untreated depressed
individuals. Psychiatry Res. 2009 Aug 30;173(2):158-61. Epub 2009 Jun 28.PMID:
19545982.
Peluso, M.A., Hatch, J.P., Glahn, D.C., Monkul, E.S., Sanches, M., Najt, P.,
Bowden, C.L. Trait impulsivity in patients with mood disorders. J Affect Disord,
2007. 100(1-3): p. 227-31.
Rabins PV, Pearlson G. Treating dementia: progress and promise. Am J Geriatr
Psychiatry. 2009 Sep;17(9):723-5. PMID: 19700945.
Ragland JD, Laird AR, Ranganath C, Blumenfeld RS, Gonzales SM, Glahn DC.
Prefrontal activation deficits during episodic memory in schizophrenia. Am J
Psychiatry. 2009, Aug;166(8):863-74. Epub 2009 May 1. Review. PMID: 19411370.
Rapin I, Dunn MA, Allen DA, Stevens MC, Fein D. Subtypes of language disorders
in school-age children with autism. Dev Neuropsychol. 2009;34(1):66-84. PMID:
19142767.
Robinson JL, Bearden CE, Monkul ES, Tordesillas-Gutiérrez D, Velligan DI,
Frangou S, Glahn DC. Fronto-temporal dysregulation in remitted bipolar patients:
an fMRI delayed-non-match-to-sample (DNMS) study. Bipolar Disord. 2009
Jun;11(4):351-60.PMID: 19500088.
Robinson JL, Laird AR, Glahn DC, Lovallo WR, Fox PT. Meta-analytic
connectivity modeling: Delineating the functional connectivity of the human
amygdala. Hum Brain Mapp. 2009 Jul 14. [Epub ahead of print]PMID: 19603407.
Robinson JL, Monkul ES, Tordesillas-Gutiérrez D, Franklin C, Bearden CE, Fox
PT, Glahn DC. Fronto-limbic circuitry in euthymic bipolar disorder: evidence for
prefrontal hyperactivation. Psychiatry Res. 2008 Nov 30;164(2):106-13. Epub 2008
Oct 19.PMID: 18930635.
Rogers, J., Kochunov, P., Lancaster, J., Shelledy, W., Glahn, D., Blangero, J. and
Fox, P., Heritability of brain volume, surface area and shape: an MRI study in an
extended pedigree of baboons. Hum Brain Mapp, 2007. 28(6): p. 576-83.
Sabb FW, Bearden CE, Glahn DC, Parker DS, Freimer N, Bilder RM. A
collaborative knowledge base for cognitive phenomics. Mol Psychiatry. 2008
Apr;13(4):350-60. Epub 2008 Jan 8.PMID: 18180765.
Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, Pearlson GD, Gordon
B, Jinnah HA. Serum uric acid and brain ischemia in normal elderly adults.
Neurology. 2007 Oct 2;69(14):1418-23.PMID: 17909154.
Schretlen DJ, Testa SM, Winicki JM, Pearlson GD, Gordon B. Frequency
and bases of abnormal performance by healthy adults on neuropsychological
testing. J Int Neuropsychol Soc. 2008 May;14(3):436-45.PMID: 18419842.
Schretlen DJ, Winicki JM, Meyer SM, Testa SM, Pearlson GD, Gordon B.
Development, psychometric properties, and validity of the Hopkins Adult
Reading Test (HART). Clin Neuropsychol. 2009 Aug;23(6):926-43.PMID:
19191072.
Shane MS, Stevens MC, Harenski CL, Kiehl KA. Double dissociation between
perspective-taking and empathic-concern as predictors of hemodynamic
response to another’s mistakes.
Soc Cogn Affect Neurosci. 2009 Jun;4(2):111-8. Epub 2009 Feb 25.PMID:
19244454.
Shipman SL, Baker EK, Pearlson G, Astur RS. Absence of established sex
differences in patients with schizophrenia on a two-dimensional object array
task. Psychiatry Res. 2009 Apr 30;166(2-3):158-65. Epub 2009 Mar 10.PMID:
19278735.
Skelly LR, Calhoun V, Meda SA, Kim J, Mathalon DH, Pearlson GD. Diffusion
tensor imaging in schizophrenia: relationship to symptoms. Schizophr Res.
2008 Jan;98(1-3):157-62. Epub 2007 Nov 26.PMID: 18031994.
Skudlarski P, Jagannathan K, Calhoun VD, Hampson M, Skudlarska BA,
Pearlson G. Measuring brain connectivity: diffusion tensor imaging validates
resting state temporal correlations. Neuroimage. 2008 Nov 15;43(3):554-61.
Epub 2008 Aug 15.PMID: 18771736.
Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, Filippini N,
Watkins KE, Toro R, Laird AR, Beckmann CF. Correspondence of the brain’s
functional architecture during activation and rest. Proc Natl Acad Sci U S A.
2009 Aug 4;106(31):13040-5. Epub 2009 Jul 20.PMID: 19620724.
Stevens MC, Skudlarski P, Pearlson GD, Calhoun VD. Age-related cognitive
gains are mediated by the effects of white matter development on brain network
integration. Neuroimage. 2009 Dec;48(4):738-46. Epub 2009 Jul 3.PMID:
19577651.
Stevens MC, Pearlson GD, Calhoun VD. Changes in the interaction of restingstate
neural networks from adolescence to adulthood. Hum Brain Mapp. 2009
Aug;30(8):2356-66.PMID: 19172655.
Stevens MC, Pearlson GD, Kiehl KA. Brain network dynamics during error
commission. Hum Brain Mapp. 2009 Jan;30(1):24-37.
Stevens MC. The developmental cognitive neuroscience of functional
connectivity.
Brain Cogn. 2009 Jun;70(1):1-12. Epub 2009 Jan 29. Review.PMID: 19185406.

Sui J, Adali T, Pearlson GD, Calhoun VD. An ICA-based method for the
identification of optimal FMRI features and components using combined groupdiscriminative
techniques. Neuroimage. 2009 May 15;46(1):73-86. Epub 2009 Feb
10.PMID: 19457398.
Sui J, Adali T, Pearlson GD, Clark VP, Calhoun VD. A method for accurate group
difference detection by constraining the mixing coefficients in an ICA framework.
Hum Brain Mapp. 2009 Sep;30(9):2953-70.PMID: 19172631.
van Erp TG, Therman S, Pirkola T, Tuulio-Henriksson A, Glahn DC, Bachman P,
Huttunen MO, Lönnqvist J, Hietanen M, Kaprio J, Koskenvuo M, Cannon TD.
Verbal recall and recognition in twins discordant for schizophrenia. Psychiatry Res.
2008 Jun 30;159(3):271-80. Epub 2008 Apr 28.PMID: 18442861.
Vannorsdall TD, Waldstein SR, Kraut M, Pearlson GD, Schretlen DJ. White matter
abnormalities and cognition in a community sample. Arch Clin Neuropsychol.
2009 May;24(3):209-17. Epub 2009 Jul 18.PMID: 19617597.
Velligan DI, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, Miller AL.
Comparing the efficacy of interventions that use environmental supports to
improve outcomes in patients with schizophrenia. Schizophr Res. 2008 Jul;102(1-
3):312-9. Epub 2008 Apr 18.PMID: 18374542.
Velligan, D.I., Diamond, P., Glahn, D.C., Ritch, J., Maples, N., Castillo, D.
and Miller, A.L., The reliability and validity of the Test of Adaptive Behavior in
Schizophrenia (TABS). Psychiatry Res, 2007. 151(1-2): p. 55-66
Velligan, D.I., Diamond, P.M., Maples, N.J., Mintz, J., Li, X., Glahn, D.C. and
Miller, A.L., Comparing the efficacy of interventions that use environmental
supports to improve outcomes in patients with schizophrenia. Schizophr Res. 2008
Jul;102(1-3):312-9.
Weiser M, Reichenberg A, Kravitz E, Lubin G, Shmushkevich M, Glahn DC, Gross
R, Rabinowitz J, Noy S, Davidson M. Subtle cognitive dysfunction in nonaffected
siblings of individuals affected by nonpsychotic disorders. Biol Psychiatry. 2008
Mar 15;63(6):602-8. Epub 2007 Sep 7.PMID: 17825797.
Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE,
Cannistraro P, Jenike MA, Rauch SL. Augmentation of behavior therapy
with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008
Mar;165(3):335-41; quiz 409. Epub 2008 Feb 1.PMID: 18245177.
Windemuth A, Calhoun VD, Pearlson GD, Kocherla M, Jagannathan K, Ruaño
G. Physiogenomic analysis of localized FMRI brain activity in schizophrenia. Ann
Biomed Eng. 2008 Jun;36(6):877-88. Epub 2008 Mar 11.PMID: 18330705.
Wynn JK, Green MF, Engel S, Korb A, Lee J, Glahn D, Nuechterlein KH, Cohen
MS. Increased extent of object-selective cortex in schizophrenia. Psychiatry Res.
2008 Nov 30;164(2):97-105. Epub 2008 Oct 19.PMID: 18938066.
Xu L, Pearlson G, Calhoun VD. Joint source based morphometry identifies linked
gray and white matter group differences. Neuroimage. 2009 Feb 1;44(3):777-89.
Epub 2008 Oct 18.PMID: 18992825.
Xu L, Groth KM, Pearlson G, Schretlen DJ, Calhoun VD. Source-based
morphometry: the use of independent component analysis to identify gray
matter differences with application to schizophrenia. Hum Brain Mapp. 2009
Mar;30(3):711-24.PMID: 18266214.
Zhao, X., Li, G., Glahn, D.C., Fox, P.T. and Gao, J.H., Derivative temporal
clustering analysis: detecting prolonged neuronal activity. Magn Reson Imaging,
2007. 25(2): p. 183-7.
Zuo L, Luo X, Listman JB, Kranzler HR, Wang S, Anton RF, Blumberg HP,
Stein MB, Pearlson GD, Covault J, Charney DS, van Kammen DP, Price
LH, Lappalainen J, Cramer J, Krystal JH, Gelernter J. Population admixture
modulates risk for alcohol dependence. Hum Genet. 2009 Jun;125(5-6):605-13.
Epub 2009 Mar 22.PMID: 19306106.
Olin Center Abstracts
Assaf M, Jagannathan K, Miller L, Sahl R, Schultz R and Pearlson
G. Mentalization Network Gray Matter Volume Abnormalities
in Autism Spectrum Disorders. International Meeting for Autism
Research 2008 Annual Meeting Proceedings.
Assaf M, Jagannathan K, Moult M, Lorenzoni R, Kraut K, Hart J
and Pearlson G. Semantic Memory Retrieval Brain Abnormalities
in Schizophrenia: State vs. Trait? 2009 International Congress on
Schizophrenia Research, San Diego, CA.
Assaf, M, Jagannathan, K., Miller, L, O’Boyle, J., Pearlson, G., Sahl,
R., Schultz, R. T. Stevens, M. Default Mode Network in Patients
with High Functioning Autism Spectrum Disorders during Resting
State fMRI. Presented at the International Meeting for Autism
Research, 2009: Chicago, IL.
Bellis C, Freed KA, Curran JE, Winkler AM, Carless M, Johnson MP,
Göring HH, Dyer TD, Almasy L, Fox PT, Kochunov P, Duggirala
R, Glahn DC, Moses EK, Blangero J. Deep sequencing of VPS13A
reveals effects on brain function and structure. 59th Annual Meeting
of the American Society of Human Genetics, 20-24 October 2009,
Honolulu, HI, USA.
Book GA, Thomas AD, Johnson MR, Hylton JL, Andrews MM,
Assaf M and Pearlson GD. Reward Processing in Social Competitive
Task in Subjects with Familial History of Alcoholism. 2008 ICANA
conference.
Calhoun, V.D, Folley, B.S., Meda, S.A., Pearlson, G.D, Stevens,
M.C. Evidence for anomalous network connectivity during working
memory in schizophrenia: An ICA based analysis. Poster presented
at the annual meeting of the Society for Biological Psychiatry, 2008:
Washington, DC.
74.

Cykowski M, Lancaster JL, Ingham RJ, Ingham J, Winkler AM,
Kochunov P, Fox PT.An omnibus test for case-control studies utilizing
Tract-Based Spatial Statistics (TBSS). 14th Human Brain Mapping, 15-
19th June 2008, Melbourne, Victoria, Australia.
Della-Justina HM, Winkler AM, Manczak T, de Oliveira PH, de
Araújo DB, Carvalho Neto A, Zwick A, Gamba HR. Development of
a galvanic vestibular stimulator for fMRI exams. 15th Human Brain
Mapping, 18-23 June 2009, San Francisco, CA, USA.
Jagannathan K, Pearlson G, Calhoun VD, Kraut MA, Hart J Jr and
Assaf M. Functional network connectivity in schizophrenia during
semantic memory task. Society of Biological Psychiatry 2008 Annual
Meeting.
Jagannathan K, Assaf M, Calhoun VD, Kraut MA, Hart J Jr and
Pearlson G. Functional network connectivity in semantic memory.
CNS 2008 Anuual Meeting.
Jagannathan K, Assaf M, Calhoun VD, and Pearlson G. Functional
network connectivity in semantic object recall task using independent
component analysis. ISMRM 2008 Annual meeting.
Jagannathan K, Moult M, Pearlson GD and Assaf M. Abnormal
Functional Connectivity in the Default Mode Network in
Schizophrenia: State vs. Trait? Society of Biological Psychiatry 2009
Annual Meeting, Vancouver, CA.
Jagannathan K, Calhoun VD, Gelernter J, Liu J, Bolognani F,
Assaf M, Pearlson GD. Genetic associations of brain structural
networks in schizophrenia-a preliminary study. American College
of Neuropsychopharmacology. ACNP 2009 Annual Meeting,
Hollywood, FL.
Jagannathan, K, Moult, M, Pearlson, G.D., Sharma, R., Stevens,
M.C., von Pechmann, D. Event-Related Spectral Perturbations In
Schizophrenia And Healthy Controls During Auditory Oddball
Performance. Presented at EPIC XV: The 15th International Congress
on Event-Related Potential of the Brain, 2009: Indianapolis, IN.
Kochunov P, Glahn DC, Winkler AM, Duggirala R, Olvera RL,
Cole S, Dyer TD, Almasy L, Fox PT, Blangero J. Analysis of genetic
variability and whole genome linkage of whole-brain, subcortical,
and ependymal hyperintense white matter volume. Stroke
2009;40(12):3685-90
Kochunov P, Winkler AM, Blangero J, Lancaster JL, Almasy L, Fox PT,
Glahn DC.
Genetics of DTI-derived parameters of cerebral white matter. A
track-based heritability and linkage study in extended pedigree. 15th
Human Brain Mapping, 18-23 June 2009, San Francisco, CA, USA.
Kochunov P, Blangero J, Winkler AM, Cole S, Almasy L, Lancaster
JL, Fox PT, Glahn DC. Heritability and linkage analysis of
hyperintense (FLAIR) white matter lesion volumes in normal aging.
15th Human Brain Mapping, 18-23 June 2009, San Francisco, CA,
USA.
Kochunov P, Blangero J, Winkler AM, Lancaster JL, Kochunova
V, Mangin JF, Cachia A, Fox PT, Glahn DC. Heritability of gyral
surface area and gyral gray matter thickness. 15th Human Brain
Mapping, 18-23 June 2009, San Francisco, CA, USA.
Kochunov P, Glahn DC, Cole S, Dyer TD, Almasy L, Winkler AM,
Lancaster JL, Kochunova V, Fox PT. Genetics of cerebral aging.
Heritability and linkage analysis of cerebral health markers in a large
multifamily pedigree. 15th Human Brain Mapping, 18-23 June 2009,
San Francisco, CA, USA.
Miller L, Assaf M, Book G and Pearlson G. Face Building: An fMRI
investigation of brain activation of faces versus houses, objects, and
patterns in individuals with high functioning autism. 2008 Cognitive
Neuroscience Society Annual Meeting, San Francisco, CA.
Miller L, Jagannathan K, O’Boyle J, Schultz R, Stevens M, Sahl R,
Pearlson G and Assaf M. Default Mode Network in Patients with
High Functioning Autism Spectrum Disorders During Resting State
fMRI. International Meeting for Autism Research 2009 Annual
Meeting Proceedings. Chicago, IL.
Pearlson G.D., Stevens M.C. Szeles D.M. Age-related Differences in
Mental Timekeeping: an fMRI study. Poster presented at the annual
meeting of the Society for Biological Psychiatry, 2008: Washington,
DC.
Skudlarski P, Skudlarska B, Pearlson G. Age Related Changes in the
Brain Connectivity Revealed and Characterized by Fusion of Two
Neuroimaging Modalities : Diffusion Tensor Imaging and Resting
State Functional Connectivity. American Geriatric Society 2009,
Chicago, IL.
Skudlarski P, Anderson K, Stevens M, Pearlson G. Schizophrenia
Disconnection Analyzed by Conjunction of fMRI Resting
Connectivity and Diffusion Tensor Imaging. Human Brain Mapping
2009, San Francisco, CA.
Skudlarski P, Anderson K, Pearlson G. Functional Connectivity Is
More Closely linked to Anatomical Connectivity in Schizophrenia.
International Conference Schizophrenia Research 2009, San Diego,
CA.
Winkler AM, Kochunov P, Dierschke NA, Lancaster JL, Fox PT,
Glahn DC. An automatic segmentation tool for white matter
hyperintensities using FLAIR and T1-weighted images. 15th Human
Brain Mapping, 18-23 June 2009, San Francisco, CA, USA.

Anxiety Disorders Center
Winkler AM, Kochunov P, Fox PT, Duggirala R, Almasy L,
Blangero J, Glahn DC. Heritability of volume, surface area and
thickness for anatomically defined cortical brain regions estimated
in a large extended pedigree. 15th Human Brain Mapping, 18-23
June 2009, San Francisco, CA, USA.
Winkler AM, Kochunov P, Dierschke NA, Fox PT, Blangero
J, Glahn DC. Heritability of gray matter density estimated in
large extended pedigrees. 64th Annual Meeting of the Society of
Biological Psychiatry, 14-16 May 2009, Vancouver, BC, Canada.
Winkler AM, Nichols TE, Glahn DC. On non-normality, nonparametric
tests and pooling permutations over space for Voxel
Based Morphometry. 14th Human Brain Mapping, 15-19th June
2008, Melbourne, Victoria, Australia.
David F. Tolin, PhD, Director
Faculty and Staff:
David F. Tolin, PhD, ABPP, Director
Gretchen J. Diefenbach, PhD, Senior Scientist
Scott Hannan, PhD, Staff Psychologist
Elizabeth Moore, PhD, Staff Psychologist
Christina Gilliam, PhD, Staff Psychologist
Samantha Morrison, PhD, Postdoctoral Fellow
Anna Villavicencio, PhD, Postdoctoral Fellow
Christina Ryan, Research Assistant
Dianna Hidalgo, Research Assistant
Diana Harrington, Research Assistant
The mission of the Anxiety Disorders Center (ADC) at The Institute
of Living is to provide evidence-based psychosocial treatment
for anxiety-related problems, to conduct meaningful research on the
nature and treatment of anxiety, and to provide education for students,
staff, and the community. Areas of clinical emphasis include obsessivecompulsive
disorder and obsessive-compulsive spectrum disorders,
generalized anxiety disorder, panic disorder, social phobia, and
posttraumatic stress disorder.
Compulsive Hoarding Research: The ADC has developed the nation’s
largest and most comprehensive program of research on compulsive
hoarding. In one recently-completed study, Psychopathology of
Compulsive Hoarding (sponsor: NIMH), we interviewed large
numbers of patients with compulsive hoarding, patients with obsessivecompulsive
disorder, and participants without mental disorders in order
to define the phenomenon of compulsive hoarding and differentiate
it from obsessive-compulsive disorder. An ongoing study, Neural
Mechanisms of Compulsive Hoarding (sponsor: NIMH), uses functional
magnetic resonance imaging (fMRI) to examine brain activity during a
decision-making task in compulsive hoarding patients with and without
major depressive disorder, obsessive-compulsive disorder patients,
and individuals without mental disorders. In Neuropsychological
Functioning in Compulsive Hoarding (sponsor: Hartford Hospital),
we are examining brain-behavior relationships by assessing a variety
of cognitive functions in individuals with and without compulsive
76.

hoarding. Finally, we recently completed Treatment of Compulsive
Hoarding (sponsor: NIMH), the aim of which was to develop and test a
cognitive-behavioral intervention for patients with compulsive hoarding.
This year, Dr. Tolin submitted three additional NIMH grants related
to compulsive hoarding. Two of these propose to augment cognitivebehavioral
therapy with the stimulant medication methylphenidate
(study 1) or cognitive remediation exercises (study 2). The third grant,
a continuation of the fMRI study, proposes to examine changes in neural
activity among hoarders receiving cognitive-behavioral therapy.
Obsessive-Compulsive Disorder (OCD) and Obsessive-Compulsive
Spectrum Research: We recently completed enrollment for the study
Stepped Care for Obsessive-Compulsive Disorder (sponsor: NIMH),
the aim of which is to develop and test a variant of cognitive-behavioral
therapy for OCD in which patients start with a largely self-directed
treatment and move to progressively more intensive treatment as needed.
We also finished D-Cycloserine Augmentation of Behavior Therapy
for Obsessive-Compulsive Disorder (unfunded), a pilot study in which
the n-methyl d-aspartate (NMDA) receptor agonist d-cycloserine was
added to traditional cognitive-behavioral therapy. Results of that study
(published in American Journal of Psychiatry) were promising and
led to the development of a multi-site grant proposal to the National
Institute of Mental Health. We are currently conducting a follow-up
study, D-Cycloserine for OCD Treatment Nonresponders (sponsor:
Hartford Hospital), in which cognitive-behavioral therapy plus openlabel
d-cycloserine are provided for patients who have failed to respond
to cognitive-behavioral monotherapy. We have also partnered with
Columbia University and the University of Pennsylvania to collaborate
on the study Maximizing Treatment Outcome for OCD (sponsor:
NIMH), which compares cognitive-behavioral therapy and the
medication risperidone for OCD patients who have not responded fully
to antidepressant medications.
Older Adult Research: Dr. Gretchen Diefenbach has developed several
studies investigating anxiety-related concerns in older adults. In one
study, Screening for GAD among Frail Elderly (sponsor: NIMH), we
examined optimal ways to assess frail older individuals receiving home
care services for generalized anxiety disorder and related concerns.
Another study, The Nature and Impact of Anxiety Symptoms upon
Psychosocial Functioning of Older Adults with Major Depressive
Disorder (sponsor: Hartford Hospital), examined differences between
older depressed patients with and without anxiety symptoms who
were attending the Geriatric Day Program at the Institute of Living.
Finally, the recently-completed study Cognitive Enhancing Effects
of D-Cycloserine among Non-Demented Elderly (sponsor: Hartford
Hospital) examined whether d-cycloserine can affect cognitive processes
such as learning, memory, and attention in older adults with ageappropriate
cognitive function.
Panic Disorder Research: We recently completed the study Augmenting
Exposure Therapy with an NMDA Agonist: A Pilot Study (sponsor:
Hartford Hospital), in which we examined the effect of adding
d-cycloserine to brief cognitive-behavioral therapy for adults with panic
disorder. Results of that study (currently in preparation for submission)
led to the development of our current study, Exposure, D-Cycloserine
Enhancement, and Genetic Modulators in Panic Disorder (sponsor:
NIMH), in which we are conducting a larger version of the study
and examining genetic factors associated with response to cognitivebehavioral
therapy and d-cycloserine. A parallel study, A Multi-Center,
Double-Blind, Fixed Dose Trial Examining the Safety and Efficacy of Org
25935 vs. Placebo as Augmentation to Cognitive Behavioral Therapy in
Subjects with Panic Disorder (sponsor: Organon/Schering-Plough), tests
whether an alternative NMDA receptor agonist can augment cognitivebehavioral
therapy.
Anxiety Disorders Center
Peer Reviewed Publications
Aikins, D.E., Johnson, D.C., Borelli, J.K., Klemanski, D., Morrissey, P.M., Southwick,
S., & Tolin, D.F. (2009). Thought suppression failures in combat PTSD: A
cognitive load hypothesis. Behaviour Research and Therapy, 47, 744-751.
Corcoran, K. M., Woody, S. R., & Tolin, D. F. (2008). Recognition of facial
expressions in obsessive-compulsive disorder. Journal of Anxiety Disorders, 22,
56-66.
Diefenbach, G.J., Abramowitz, J.S., Norberg, M., & Tolin, D.F. (2007). Changes
in quality of life following cognitive-behavior therapy for obsessive-compulsive
disorder. Behaviour Research and Therapy, 45, 3060-3068.
Diefenbach, G. J., Tolin, D. F., Meunier, S. A., & Gilliam, C. M. (2009). Assessment
of anxiety in older home care recipients. The Gerontologist, 49, 141-153.
Diefenbach, G. J., Tolin, D. F., Meunier, S., & Worhunsky, P. (2008). Emotion
regulation and trichotillomania: a comparison of clinical and nonclinical hair pulling.
Journal of Behavior Therapy and Experimental Psychiatry, 39, 32-41.
Frost, R. O., Steketee, G., Tolin, D. F., & Renaud, S. (2008). Development and
validation of the Clutter Image Rating. Journal of Psychopathology and Behavioral
Assessment, 32, 401-417.
Frost, R. O., Tolin, D. F., Steketee, G., Fitch, K. E., & Selbo-Bruns, A. (2009).
Excessive acquisition in hoarding. Journal of Anxiety Disorders, 23, 632-639.
Norberg, M. M., Diefenbach, G. J., & Tolin, D. F. (2008). Quality of life and
anxiety and depressive disorder comorbidity. Journal of Anxiety Disorders, 22,
1516-1522.
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008). A meta-analysis of d-
cycloserine and the facilitation of fear extinction and exposure therapy. Biological
Psychiatry, 63, 1118-1126.

Olatunji, B.O., Cisler, J., & Tolin, D.F. (2007). Quality of life in the anxiety disorders:
A meta-analytic review. Clinical Psychology Review, 27, 572-581.
Olatunji, B. O., Williams, B. J., Haslam, N., Abramowitz, J. S., & Tolin, D. F.
(2008). The latent structure of obsessive-compulsive symptoms: A taxometric
study. Depression and Anxiety, 25, 956-968.
Olatunji, B.O., Williams, N.L., Tolin, D.F., Sawchuk, C.N., Abramowitz, J.S.,
Lohr, J.M., & Elwood, L. (2007). The Disgust Scale: Item analysis, factor structure,
and suggestions for refinement. Psychological Assessment, 19, 281-297.
Tolin, D. F., Brady, R. E., & Hannan, S. E. (2008). Obsessional beliefs and symptoms
of obsessive-compulsive disorder in a clinical sample. Journal of Psychopathology
and Behavioral Assessment, 30, 31-42.
Tolin, D.F., Diefenbach, G.J., Flessner, C.A., Franklin, M.E., Keuthen, N.J., Moore,
P., Piacentini, J., Stein, D.J., & Woods, D.W. (2008). The Trichotillomania Scale
for Children: Development and validation. Child Psychiatry and Human Development,
39, 331-349.
Tolin, D.F., Franklin, M.E., Diefenbach, G.J., Anderson, E., & Meunier, S.A.
(2007). Pediatric trichotillomania: Descriptive psychopathology and an open trial
of cognitive-behavioral therapy. Cognitive Behaviour Therapy, 36, 129-144.
Tolin, D.F., Frost, R.O., & Steketee, G. (2007). An open trial of cognitivebehavioral
therapy for compulsive hoarding. Behaviour Research and Therapy, 45,
1461-1470.
Tolin, D. F., Frost, R. O., Steketee, G., & Fitch, K. E. (2008). Family burden of
compulsive hoarding: Results of an internet survey. Behaviour Research and
Therapy, 46, 334-344.
Tolin, D. F., Frost, R. O., Steketee, G., Gray, K. D., & Fitch, K. E. (2008). The
economic and social burden of compulsive hoarding. Psychiatry Research, 160,
200-211.
Tolin, D.F., Hannan, S., Maltby, N., Diefenbach, G.J., Worhunsky, P., & Brady,
R.E. (2007). A randomized controlled trial of self-directed versus therapistdirected
CBT for OCD patients with prior medication trials. Behavior Therapy,
38, 179-191.
Tolin, D. F., Kiehl, K. A., Worhunsky, P., Book, G. A., & Maltby, N. (2009). An
exploratory study of the neural mechanisms of decision-making in compulsive
hoarding. Psychological Medicine, 38, 1-12.
Tolin, D.F., Robison, J.T., Gaztambide, S., Horowitz, S., & Blank, K. (2007).
Ataques de nervios and psychiatric disorders in older Puerto Rican primary care
patients. Journal of Cross-Cultural Psychology, 38, 659-669.
Tolin, D. F., Whiting, S., Maltby, N., Diefenbach, G. J., Lothstein, M. A.,
Hardcastle, S., Catalano, A., & Gray, K. D. (2009). Intensive (daily) behavior
therapy for school refusal: A multiple baseline case series. Cognitive and
Behavioral Practice, 16, 332-344.
Tolin, D.F., Worhunsky, P., Brady, R.E., & Maltby, N. (2007). The relationship
between obsessive beliefs and thought control strategies in a clinical sample.
Cognitive Therapy and Research, 31, 307-318.
Wilhelm, S., Buhlmann, U., Tolin, D.F., Meunier, S.A., Pearlson, G.D., Reese, H.E.,
Cannistraro, P., Jenike, M.A., & Rauch, S.L. (2008). Augmentation of behavior
therapy with d-cycloserine for obsessive-compulsive disorder. American Journal of
Psychiatry, 165, 335-341.
Anxiety Disorders Center Non-Peer
Reviewed Articles
Tolin, D. F. (2009). Alphabet soup: ERP, CT, and ACT for OCD. Cognitive and
Behavioral Practice, 16, 40-48.
Tolin, D.F., & Breslau, N. (2007). Sex differences in risk of PTSD. PTSD Research
Quarterly, 18, 1-7.
Tolin, D.F., & Lohr, J.M. (2009, Fall). Psychologists, American Psychological
Association, and torture. Clinical Science, 4-10.
Books and Book Chapters
Edelberg, M., & Tolin, D. F. (2008). The Posttraumatic Cognitions Inventory. In G.
Reyes, J. D. Elhai, & J. Ford (Eds.), Encyclopedia of psychological trauma (pp. 480-
481). New York: John Wiley & Sons.
Franklin, M.E., & Tolin, D.F. (2007). Treating trichotillomania: Cognitive behavior
therapy for hair pulling and related problems. New York: Springer.
Franklin, M.E., Tolin, D.F., & Diefenbach, G.J. (2007). Trichotillomania. In
Abramowitz, D. McKay S., & Taylor, J.S. (Eds.), Obsessive-compulsive disorder:
Subtypes and spectrum conditions (pp. 139-159). New York: Elsevier.
Frost, R.O., & Tolin, D.F. (2008). Compulsive hoarding. In S. Taylor, J. S.
Abramowitz, & D. McKay (Eds.), Clinical handbook of obsessive-compulsive
disorder and related problems (pp. 76-94). Baltimore: Johns Hopkins University
Press.
Meunier, S.A., Maltby, N.A., & Tolin, D.F. (2008). Compulsive hoarding. In M.
Hersen (Series & Vol. Ed.) & J. Rosqvist (Vol. Ed.), The handbook of assessment,
conceptualization, and treatment: Vol. 1 (pp. 728-752). New York: John Wiley &
Sons.
Tolin, D.F., Frost, R.O., & Steketee, G. (2007). Buried in treasures: Help for
compulsive acquiring, saving and hoarding. New York: Oxford University Press.
Tolin, D.F., & Maltby, N. (2008). Motivating treatment-refusing patients with
obsessive-compulsive disorder. In H. Arkowitz, H.A. Westra, W.R. Miller, & S.
Rollnick (Eds.), Motivational interviewing in the treatment of psychological problems
(pp. 85-108). New York: Guilford Press.
78.

Tolin, D.F., & Meunier, S.A. (2007). Contamination and decontamination. In
Abramowitz, D. McKay S., & Taylor, J.S. (Eds.), Obsessive-compulsive disorder:
Subtypes and spectrum conditions (pp. 3-18). New York: Elsevier.
Tolin, D.F., & Steketee, G. (2007). General issues in psychological treatment for
OCD. In M.M. Antony, C.L. Purdon, & L.J. Summerfeldt (Eds.), Psychological
treatment of OCD: Fundamentals and beyond (pp. 31-59). Washington, DC:
American Psychological Association.
Treadwell, K. R. H., & Tolin, D. F. (2007). Clinical challenges in the treatment of
pediatric OCD. In E. A. Storch, T. K. Murphy, & G. R. Geffken (Eds.), A comprehensive
handbook of child and adolescent obsessive-compulsive disorder (pp.
273-294). Mahwah, NJ: Lawrence Erlbaum Associates.
Anxiety Disorders Center Abstracts
Chasson, G.S., Buhlmann, U., Tolin, D.F., Rowley, T., Welsh, K.S., & Wilhelm,
S. (2009, March). How much quicker? Accelerating OCD recovery using
d-cycloserine to enhance exposure and response prevention. Paper presented at
the Annual Meeting of the Anxiety Disorders Association of America, Santa Ana
Pueblo, NM.
Cisler, J., Lohr, J. M., Tolin, D. F., Olatunji, B. O., Willems, J. L., & Brady, R. E.
(2008, November). Development and initial validation of the Contamination
Aversion Scale. Paper presented at the Annual Meeting of the Association of
Behavioral and Cognitive Therapies, Orlando, FL.
Diefenbach, G.J., Tolin, D.F., & Edelberg, M. (2007, November). Predicting
quality of life among older adults with major depressive disorder: The potential
role of worry severity. Presented to the Annual Meeting of the Association of
Behavioral and Cognitive Therapies, Philadelphia.
Diefenbach, G.J., Tolin, D.F., Meunier, S.A., Gilliam, C., & Edelberg, M. (2007,
November). Psychometric properties of anxiety measures among elderly receiving
home health care services. Presented to the Annual Meeting of the Association of
Behavioral and Cognitive Therapies, Philadelphia.
Fabricant, L., Frost, R.O., Tolin, D.F., & Steketee, G. (2007, November). The role
of homework in the treatment of compulsive hoarding. Presented to the Annual
Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia.
Fitch, K.E., Ring, K.M., & Tolin, D.F. (2008, November). Long-term effectiveness
of cognitive-behavioral therapy for anxiety in an adult outpatient clinic sample.
Presented to the Annual Meeting of the Association of Behavioral and Cognitive
Therapies, Orlando, FL.
Fitch, K.E., Tolin, D.F., Frost, R.O., & Steketee, G. (2007, November).
Compulsive hoarding: Assessing insight. Presented to the Annual Meeting of the
Association of Behavioral and Cognitive Therapies, Philadelphia.
Frost, R.O., Steketee, G., Tolin, D.F., Sorrentino, C., Carlson, S., & Brady, R.E.
(2007, November). Cognitive-behavioral therapy for compulsive hoarding:
Results from a controlled trial. In D.F. Tolin (Chair), The nature and treatment
of compulsive hoarding. Symposium presented to the Annual Meeting of the
Association of Behavioral and Cognitive Therapies, Philadelphia.
Gibson, A., Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (2008,
November). Ethical considerations in the treatment of compulsive hoarding.
Presented to the Annual Meeting of the Association of Behavioral and Cognitive
Therapies, Orlando, FL.
Gilliam, C.M., Brady, R.E., & Tolin, D.F. (2007, November). Changes in obsessive
beliefs following CBT among individuals with OCD. Presented to the Annual
Meeting of the Association of Behavioral and Cognitive Therapies, Philadelphia.
Gilliam, C.M., Diefenbach, G.J., Catayong, K.D., Pearlson, G.D., Blank, K.,
& Tolin, D.F. (2008, November). Emotion regulation and anxiety disorders: A
lifespan perspective. Presented to the Annual Meeting of the Association of
Behavioral and Cognitive Therapies, Orlando, FL.
Gilliam, C.M., Diefenbach, G.J., Tolin, D.F., & Edelberg, M.L. (2007, November).
The role of metacognitive beliefs and experiential avoidance in late-life anxiety.
Presented to the Annual Meeting of the Association of Behavioral and Cognitive
Therapies, Philadelphia.
Gilliam, C.M., Tolin, D.F., Diefenbach, G.J., Carlson, S.E., Whiting, S.E.,
Norberg, M.M., & Meunier, S.A. (2008, November). Stepped care for obsessivecompulsive
disorder: A replication and extension. Presented to the Annual
Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL.
Gilliam, C.M., Tolin, D.F., & Pineault, J. (2007, November). Attentional bias
in panic disorder: The impact of cognitive behavioral treatment. Presented to
the Annual Meeting of the Association of Behavioral and Cognitive Therapies,
Philadelphia.
Hannan, S.E., Diefenbach, G.J., Meunier, S.A., Norberg, M.M., & Tolin, D.F.
(2008, November). Intensive treatment for pediatric OCD: Results from an
outpatient treatment setting. Presented to the Annual Meeting of the Association
of Behavioral and Cognitive Therapies, Orlando, FL.
Hannan, S.E., Edelberg, M., & Tolin, D.F. (2007, November). Factors associated
with work impairment in individuals with diagnoses of anxiety and depressive
disorders. Presented to the Annual Meeting of the Association of Behavioral and
Cognitive Therapies, Philadelphia.
Hannan, S.E., & Tolin, D.F. (2007, November). Examination of the validity of
therapist rated and patient rated Clinical Global Impression scores. Presented to
the Annual Meeting of the Association of Behavioral and Cognitive Therapies,
Philadelphia.
Hannan, S.E., Tolin, D.F., Meunier, S.A., Norberg, M.M., Gilliam, C.M., &
Diefenbach, G.J. (2008, November). Intensive treatment for OCD: Results
from a psychiatric hospital outpatient treatment setting. Presented to the Annual
Meeting of the Association of Behavioral and Cognitive Therapies, Orlando, FL.
Koby, D. G., Tartar, S., Carlson, S., Meunier, S. A., Lovejoy, D. W., Kurtz, M., &
Tolin, D. F. (2008, November). Emerging evidence for frontal lobe dysfunction
in compulsive hoarding. Paper presented at the Annual Meeting of the National
Academy of Neuropsychology, New York.

Loew, B., Talbott, S. N., Khanna, M., Diefenbach, G. J., Tolin, D. F., & Franklin,
M. E. (2008, November). Family functioning in pediatric trichotillomania: Results
from a randomized, controlled trial. Paper presented at the Annual Meeting of
the Association of Behavioral and Cognitive Therapies, Orlando, FL.
Meunier, S.A., Tolin, D.F., Frost, R.O., & Steketee, G. (2007, November). The
impact of significant life events on hoarding symptom severity and course. In D.F.
Tolin (Chair), The nature and treatment of compulsive hoarding. Symposium
presented to the Annual Meeting of the Association of Behavioral and Cognitive
Therapies, Philadelphia.
Muroff, J., Steketee, G., Rasmussen, J., Gibson, A., Frost, R.O., & Tolin, D.F.
(2007, November). Group cognitive and behavioral treatment (CBT) for
compulsive hoarding. In D.F. Tolin (Chair), The nature and treatment of
compulsive hoarding. Symposium presented to the Annual Meeting of the
Association of Behavioral and Cognitive Therapies, Philadelphia.
Oh, M., Frost, R. O., Tolin, D. F., Steketee, G., & Fitch, K. E. (2008, November).
Indecisiveness and compulsive hoarding. Paper presented at the Annual Meeting
of the Association of Behavioral and Cognitive Therapies, Orlando, FL.
Olatunji, B. O., Ciesielski, B. G., & Tolin, D. F. (2009, March). A meta-analytic
review of the specificity of anger in PTSD. Paper presented at the Annual
Meeting of the Anxiety Disorders Association of America, Santa Ana Pueblo,
NM.
Pekareva-Kochergina, A., Frost, R. O., Tolin, D. F., Steketee, G., & Fitch, K.
E. (2008, November). OCD symptoms and associated features in early- versus
late-onset hoarding. Paper presented at the Annual Meeting of the Association of
Behavioral and Cognitive Therapies, Orlando, FL.
Rasmussen, J. L., Muroff, J., Steketee, G., Tolin, D. F., & Frost, R. O. (2008,
November). Family psychopathology in an internet study of compulsive
hoarding. Paper presented at the Annual Meeting of the Association of Behavioral
and Cognitive Therapies, Orlando, FL.
Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November).
Prevalence and associated characteristics of squalor in an internet sample of
compulsive hoarders. Presented to the Annual Meeting of the Association of
Behavioral and Cognitive Therapies, Philadelphia.
Rasmussen, J., Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November). The
Home Environment Index: A measure of squalor in compulsive hoarding.
Presented to the Annual Meeting of the Association of Behavioral and Cognitive
Therapies, Philadelphia.
Steketee, G., Frost, R.O., & Tolin, D.F. (2007, November). Enhancing motivation
in treatment for compulsive hoarding. Presented to the Annual Meeting of the
Association of Behavioral and Cognitive Therapies, Philadelphia.
Tolin, D. F. (2008, July). Enhancing the efficacy of behavior therapy for OCD with
d-cycloserine. Presented to the International Congress of Psychology, Berlin.
Tolin, D.F., Diefenbach, G.J., Flessner, C.A., Franklin, M.E., Woods, D.W.,
Keuthen, N.J., Moore, P., Piacentini, J., & Stein, D.J. (2007, November). The
Trichotillomania Scale for Children: Development and validation. Presented to
the Annual Meeting of the Association of Behavioral and Cognitive Therapies,
Philadelphia.
Tolin, D. F., Frost, R. O., & Steketee, G. (2008, July). Buried in treasures:
Cognitive-behavioral therapy for compulsive hoarding. Presented to the British
Association of Behavioural and Cognitive Psychotherapies, Edinburgh.
Tolin, D.F., Frost, R.O., Steketee, G., Gray, K.D., & Fitch, K.E. (2007,
November). The economic and social burden of compulsive hoarding. In D.F.
Tolin (Chair), The nature and treatment of compulsive hoarding. Symposium
presented to the Annual Meeting of the Association of Behavioral and Cognitive
Therapies, Philadelphia.
Tolin, D. F., Norberg, M. M., & Krystal, J. H. (2008, August). A meta-analysis
of d-cycloserine and the facilitation of fear extinction and exposure therapy.
Presented to the Annual Meeting of the Obsessive-Compulsive Foundation,
Boston.
Tolin, D.F., Steketee, G., Frost, R.O., Monteiro, M., & Fitch, K.E. (2007,
November). Compulsive hoarding: Assessing family burden. Presented to the
Annual Meeting of the Association of Behavioral and Cognitive Therapies,
Philadelphia.
Treadway, M., Frost, R.O., Steketee, G., Tolin, D.F., & Fabricant, L. (2007,
November). Compulsive hoarding and generalized anxiety disorder: Features and
correlates. Presented to the Annual Meeting of the Association of Behavioral and
Cognitive Therapies, Philadelphia.
Whiting, S.E., & Tolin, D.F. (2008, November). Psychosocial impairment in
childhood anxiety: Utility and validation of the Sheehan Disability Scale-Child/
Parent Version. Presented to the Annual Meeting of the Association of Behavioral
and Cognitive Therapies, Orlando, FL.
Whiting, S.E., Tolin, D.F., Maltby, N., & Gray, K.D. (2008, November). Intensive
(daily) cognitive behavior therapy for school refusal: A multiple baseline case
series. Presented to the Annual Meeting of the Association of Behavioral and
Cognitive Therapies, Orlando, FL.
Wilhelm, S., Buhlmann, U., Tolin, D.F., Meunier, S.A., Pearlson, G.D., Reese, H.,
Cannistraro, P., Jenike, M.A., Pitman, R., & Rauch, S. (2008, July). D-cycloserine
augmentation of behavior therapy for obsessive-compulsive disorder. Presented to
the British Association of Behavioural and Cognitive Psychotherapies, Edinburgh.
Tolin, D.F. (2007, November). The nature and treatment of compulsive hoarding.
Symposium presented to the Annual Meeting of the Association of Behavioral
and Cognitive Therapies, Philadelphia.
80.

Braceland Center
for Mental Health and Aging
Director: Karen Blank, MD
Assistant Director: Charles Wilber MEd
Faculty and Staff:
Denise Fogel, PsyD • Jackie Cmero, OT
Meghan Lawrence, LCSW • Gretchen Difenbach, PhD
Karen Raigaisis, RN • Ilene West, PsyD
Kheera Bandari, BS
The Braceland Center’s research programs address issues related to normal
aging, to medical and psychiatric disorders such as Alzheimer’s disease,
and to the physical, emotional and overall well being of the elderly. As
one of the four research centers at the Institute of Living, we actively
collaborate with the other centers. Our research accomplishments include
the following:
Memory Disorders Center Electronic research database: The Memory
Disorders Center (MDC) has successfully designed a comprehensive
intake form for all new patients to the Memory Disorders Center. The
form is electronically scanned into a database that supports a vast array
of research questions and proposals. To date 103 new intakes have
been entered and we have obtained written consent for inclusion in the
electronic database for 100% of new MDC patients.
Alzheimer’s Disease Neuroimaging Initiative (ADNI): The Braceland
Center, in collaboration with the Olin Center, has been an active site
for this NIH-funded multi-site, 80+ million dollar study. We have
nearly completed three years of data collection with a total of 14
participants. Through the Alzheimer’s Disease Neuroimaging Initiative
– Grand Opportunity (ADNI-GO) Study, our site will participate in the
recruitment of additional Early MCI (EMCI) participants and includes
follow-up of participants originally enrolled as Cognitively Normal (CN)
or Late MCI (LMCI) in the original ADNI.
Cognitive training in the elderly: We have been awarded a grant from
the Hartford Hospital Research Program to develop a novel approach for
cognitive training in the elderly with normal aging and mild cognitive
impairments including persons with mild depression. We are currently
recruiting our second group of subjects into this manualized training
program. Subjects receive group and computerized training sessions,
genetic testing, and a subset will receive functional neuroimaging all
with before and after assessment of neuropsychological and functional
performance and Quality of life.
Anxiety disorders, mild memory disorders and early dementia: We
have gained research office approval for a study on anxiety disorders
and symptoms among patients with mild memory disorders and early
dementia aimed to better delineate those anxiety features that correlate
with and possible help identify those at risk for cognitive decline and
dementia.
D-cycloserine in neuropsychological test performance in older
adults: We have collaborated with researchers from the Anxiety
Disorders Center on a study examining the effects of D-cycloserine on
neuropsychological test performance in older adults.
Financial decisional capacity and psychiatric disability: In collaboration
with faculty at Yale University School of Medicine, we have received
funding on two new NIH intervention grants to assess and improve
financial decisional capacity in individuals with serious psychiatric
disabilities, “Benefits Management for People with Psychiatric
Disabilities (R34)” and “Improving Clinician Ratings of Money
Mismanagement: Addictions Impact (R01)”.
fMRI/PET study: We collaborate in the NIMH funded fMRI/PET study
designed to advance the early detection of significant cognitive decline
and early Alzheimer’s disease. To date the Memory Disorders Center
has identified and recruited 14 subjects for this project.
Driving simulation: Two manuscripts are in preparation from our
driving study done in collaboration with the Olin Center using their
virtual driving simulator. The MDC has contributed to this research by
improving the assessment of decisional capacity to continue or terminate
driving among normal elderly and those with cognitive decline and early
dementia.

Burlingame Center for Psychiatric
Research and Education
Services for persons with early onset Alzheimer’s Disease : We are in
the process of submitting two research proposals aimed at improving
specialized services for persons with early onset Alzheimer’s Disease
(occurring younger than age 65) and their families entitled “When
Alzheimer’s disease strikes the young and middle aged: Improving care,
family adjustment, and reducing caregiver depression”.
MDC Publications and Abstracts
Bullock K, Blank K. Factors that influence the completion of advance directives
between Black and White older adults: A pilot investigation. Gerontological
Society of America, San Francisco. Nov. 2008.
Bullock K, Blank K. Diversity in Geriatric Psychiatry, AAGP committee. American
Association for Geriatric Psychiatry Annual Meeting, March 2008.
Gilliam CM, Diefenbach GJ, Catayong K, Pearlson G, Blank K, Tolin DT.
Emotion Regulation and Anxiety Disorders: A Lifespan Perspective. Association
for Behavioral and Cognitive Therapies, October 2008.
Goethe JW, Szarek BL, Blank, K, Caley CF. Metabolic syndrome in patients with
major depressive disorder. Psychiatric Times 26:18-19, 2009.
Tolin D, Robinson J, Gaztambide S, Horowitz S, Blank K. Ataques de nervios
and psychiatric disorders in older Puerto Rican primary care patients. J of Cross-
Cultural Psychology 2007; 38(6)659-669.
John W. Goethe, MD, Director
Faculty and Staff:
Stephen Woolley, DSci • Charles Wilber, MEd
Alex Cardoni, MSPharm. • Brenda Woznicki, BA
Bonnie Szarek, RN • Charles Caley, PharmD
Megan Ehret, PharmD
The mission of the Burlingame Center for Psychiatric Research and
Education is to promote excellence in psychiatric care through
applied research. The Center maintains the Institute’s research
infrastructure (e.g., clinical research database, Outcome Assessment
Program) and utilizes this infrastructure for studies of best practices,
patient outcomes and comparisons of interventional strategies. Other
areas of ongoing research include:
Pharmacogenetics – the goal of these studies is to utilize genotyping
technology to optimize medication.
Prediction and management of metabolic syndrome in psychiatric
patients – the goal of these studies is to identify clinical, treatment and
demographic variables that are associated with this syndrome, now
widely recognized as a major health risk in psychiatric patients.
Treatment resistant mood disorders – the goal of these studies is to
develop optimal treatments for individuals who have not responded
to conventional therapies; this research and clinical initiative includes
the development of an extensive infrastructure for comprehensive
patient assessment as well as novel treatments for these disorders (e.g.,
Transcranial Magnetic Stimulation (TMS)).
Burlingame Center Publications
Blair EW, Szarek BL. Exploring the relationship of psychotropic medications to
fall events in an inpatient geriatric psychiatric population. International Journal
of Psychiatric Nursing Research, 14: October 2008.
Diefenbach GJ, Woolley SB, Goethe JW. The association between selfreported
anxiety symptoms and suicidality. Journal of Nervous and Mental
Disease,197:92-97, 2009.
82.

Goethe JW, Szarek BL, Blank, K, Caley CF. Metabolic syndrome in patients with
major depressive disorder. Psychiatric Times 26:18-19, 2009.
Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms associated
with metabolic syndrome in psychiatric inpatients receiving antipsychotics.
Journal of Clinical Psychiatry, 68:22-28, 2007.
Goethe JW, Szarek BL, Caley CF. Metabolic syndrome and depression: a review.
Depression: Mind and Body 3:138-149, 2008.
Goethe JW, Szarek BL, Caley CF. Metabolic syndrome in psychiatric inpatients
treated for depression. In Thakore J, Leonard BE (eds). Modern Trends in
Pharmacopsychiatry: Metabolic Effects of Psychotropic Drugs 26:90-104, 2009.
Goethe JW, Woolley SB, Cardoni AC, Woznicki B, Piez D. Selective serotonin
reuptake inhibitor discontinuation: side effects and other factors that influence
medication adherence. Journal of Clinical Psychopharmacology, 27:451-58, 2007.
Goethe JW. A time of change: challenges and choices. Invited article.
Connecticut Medicine 73:367-8, 2009.
Goethe JW. Expanding the do no harm mandate. Invited article. Connecticut
Medicine, 71:499-500, 2007.
Grgas M, Ehret MJ. Psychopharmacology: much the same. Connecticut Medicine
73:281-284, 2009.
Ruaño G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman Y, Pearlson G,
Goethe JW, Schwartz HI. Somatic complications of psychotropic medications in a
patient with multiple CYP2 drug metabolism deficiencies. Connecticut Medicine,
71:197-200, 2007.
Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocheria M, Windemuth
A, de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and
risperidone-treated patients. Molecular Psychiatry, 12:474–82, 2007.
Ruaño G, Villagra D, Rahim US, Windemuth A, Kocherla M, Bower B, Szarek
BL, Goethe JW. Increased carrier prevalence of deficient BYP2C9, CYP2C19 and
CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital.
Personalized Medicine 5:579-587, 2008.
Sopko MA Jr. Ehret MJ. Grgas M. Desvenlafaxine: another “me too” drug? Annals
of Pharmacotherapy 42:1439-46, 2008.
Szarek BL, Goethe JW, Woolley SB: Assessing metabolic syndrome: waist
circumference versus BMI. Schizophrenia Research 108:295-296, 2009.
Woolley SB, Goethe JW, Lincoln AK, Heeren T. Headache complaints and the
risk of suicidal thoughts or behaviors in community-dwelling adults: results from
the ECA study. Journal of Nervous and Mental Disease 196:822-828, 2008.
Burlingame Center Abstracts
Bullock K, Szarek BL, Goethe JW. Ethnic differences in length of stay
and choice of antipsychotic medication among in-patients diagnosed with
schizophrenia. Presented at the annual meeting of the American Psychiatric
Association, San Francisco, CA, May 2009.
Caley CF. Antipsychotics for anxiety disorders: What is the evidence? Presented
at the annual Northeastern Psychiatric Pharmacotherapy Symposium, Mystic,
CT, September 2008.
Caley CF. Utilizing a psychiatric pharmacy specialist in a college health
setting. Presented at the annual meeting of the New England College Health
Association, Mystic, CT, October 2008.
Caley CF. Optimizing ADHD medication therapy in college health: evaluating
the issues. Presented at the annual meeting of the American College Health
Association, San Francisco, CA, May 2009.
Caley CF. Psychotropic drug–drug interactions—the most important you
should know about. Presented at the annual meeting of the American College
Health Association, San Francisco, CA, May 2009.
Caley CF, Goethe JW, Woolley SB, Bardack D, Martello T, Azhar N, Ruano G,
Windemuth A. Lifestyle, socioeconomics, and health history versus medications
as predictors of metabolic syndrome. Presented at the annual meeting of the
American Psychiatric Association May, 2009.
Caley CF. Staying on your medications—a perspective from pharmacy.
Presented at the 2009 National Alliance of the Mentally Ill (NAMI), San
Francisco, CA, July 2009.
Christensen A, Ehret M, Szarek B, Goethe J. Treatment of major depressive
disorder for elderly inpatients at a psychiatric facility. Presented at the annual
meeting of the American Society of Health-System Pharmacists, Orlando, FL,
December 2008.
Ehret MJ, Goethe JW, Szarek BL. Who receives guideline-based
pharmacotherapy for bipolar depression? Presented at the annual meeting of
the American Psychiatric Association, San Francisco, CA, May 2009.
Goethe JD Blank K, Szarek BL. Metabolic risk factors in geriatric inpatients
with major depressive disorder. Presented at the annual meeting of the
American Psychiatric Association, San Diego, CA, 2007.
Goethe JW, Szarek BL. Is schizoaffective disorder a distinct clinical entity?
Presented at the annual meeting of the American Psychiatric Association, San
Francisco CA, May 2009.
Grgas M, Woolley SB, Goethe JW, Ruaño G, Szarek BL, Caley C, Ehret M. An
analysis of CYP450 genotype and patients’ perceived response and tolerance to
their antidepressants. Presented at the College of Psychiatric and Neurologic
Pharmacists, Jacksonville, FL, April 2009.

Szarek BL, Goethe JW. Diagnostic stability in patients with schizoaffective
disorder compared to schizophrenia and bipolar disorder. Presented at the annual
meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T. Severe headaches
and the risk of subsequent suicidal thoughts or behaviors. Presented at the annual
meeting of the American Psychiatric Association, San Diego, CA, 2007.
Woolley SB, Goethe JW, Fredman L, Lincoln A. Heeren T. Schizophreniaspectrum
disorders were associated with cardiovascular disease symptoms,
independent of known risk factors for symptoms. Presented at the annual meeting
of the American Psychiatric Association, San Francisco, CA, May 2009.
Woznicki BA, Woolley SB, Goethe JW, Bardack S, Azhar N. Locus of control, life
events, treatment history and longitudinal outcomes of treatment for depression.
Presented at the annual meeting of the American Psychiatric Association, May
2009.
New Projects
Federal
Glahn, David, MD
Influence of Psychosis on Brain-Behavior Endophenotypes for Bipolar Disorder.
NIMH through Yale University, $1,351,780.
Pearlson, Godfrey, MD
Bipolar & Schizophrenia Consortium for Parsing Intermediate Phenotypes. NIMH
through Yale University, $2,816,321.
Multivariate Methods for Identifying Multi-Task Multimodal Brain Imaging
Biomarkers. NIBIB through MIND Institute, $10,943.
Informed Data-Driven Fusion of Behavior, Brian Function, and Genes. NIMH
through MIND Institute, $38,528.
Stevens, Michael, PhD
Language Functioning in Optimal-Outcome Children with ASD: An fMRI Study.
NIMH through the University of Connecticut, $203,401.
Characterizing Two Distinct ADHD Neurobiologies with fMRI. NIMH,
$378,246.
Tolin, David, PhD
Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic
Disorder. NIMH, $1,144,599.
Maximizing Treatment Outcome in OCD. NIMH through (University of
Columbia) Research Foundation for Mental Hygiene, Inc., $34,372.
Wilber, Charles, MEd
Reducing the Adverse Impact of Mental Illness Stigma Among Family Caregivers.
Mount Sinai School of Medicine, $264,507.
Foundation
Assaf, Michal, PhD
Buspirone Efficacy and its Brain Correlates in the Treatment of Anxiety in Autism
Spectrum Disorders. Private Donor, $40,000.
Stevens, Michael, PhD
Measuring Differences in Brain Activity in Adolescents with Major Depressive
Disorder (MDD) using fMRI. American Foundation for Suicide Prevention,
$70,000.
Industry
Goethe, John, MD
A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-
Controlled Efficacy and Safety Study of Adjunctive AzD6765 in Subjects with
Major Depressive Disorder (MDD) with at Least Moderate Symptomatology
and a History of Poor Response to Antidepressants. AstraZeneca (MultiCenter),
$109,850.
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect
of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients.
AstraZeneca (Multicenter), $19,000.
Tolin, David, PhD
A 3-Arm, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy,
Safety, and Tolerability of Pagoclone for the Treatment of Adults with Stuttering.
Indevus Pharmaceuticals, $71,688.
A Phase 3, Randomized, Double Blind, Parallel Group, 10 Week Placebo
Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the
Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety
Disorder. Pfizer, Inc., $148,392.
A Multi-Center, Double-Blind, Fixed Dose Trial Examining the Safety and
Efficacy of Org 25935 vs. Placebo as Augmentation to Cognitive Behavioral
Therapy in Subjects with Panic Disorder. Organon USA Inc. (Investigator
Initiated), $214,875.
State
Bullock, Karen, PhD
Factors Influencing Breast and Cervical Cancer Screening Among Racially/
Ethnically Diverse Women. UCONN Storrs, $1,500.
Ehret, Megan, PharmD
Feasibility of Administering a Pharmacist Consultation Service Targeting
Inpatients with Bipolar Disorder, Most Recent Episode Depressed. ASHP through
the University of Connecticut, $5,000.
84.

Departmental Funds
Astur, Robert, PhD
Hippocampal Structure and Function in People with Depression. $8,100.
Stevens, Michael, PhD
An fMRI Study of the Effect of Working Memory Training on ADHD Brain
Dysfunction. $1,000.
Hartford Hospital Research Endowment Funds
Goethe, John, MD
Research Infrastructure for the Depression and Bipolar Disorders Center. Open
Competition, $49,760.
Stevens, Michael, PhD
Linux Cluster Infrastructure Enhancement. Open Competition, $74,513.
Wilber, Charles, MEd
Cognitive Training in Elderly with Normal Aging and Mild Cognitive
Impairments. Open Competition, $82,487.
Corbera, Silvia, PhD
Application of Event-Related Potentials (ERPs) to Evaluate the Effects of
Coaching on Cognitive Rehabilitation in Schizophrenia. Small Grant, $300
Mace, Melanie, PsyD
A Survey of Regional Referring Providers’ Use of and Perceived Utility of
Neuropsychological Services. Small Grant, $750.
Tolin, David, PhD
D-Cycloserine-Augmented CBT for Prior Treatment Nonresponders with OCD.
Small Grant, $9,531.
Turner Anderson, Beth, PhD
Simulated Driving: Effects of Road Conditions and Visibility. Small Grant,
$9,811.
Unfunded
Diefenbach, Gretchen, PhD
Anxiety Symptoms and Disorders Among Patients with Mild Cognitive
Impairment and Early Stage Dementia.
Unified Treatment for Geriatric Emotional Disorders.
Jacobs, Barbara, PhD
Staff Nurses as Expert Judges for Content Validity of the Empowerment and
Autonomy Measurement Survey.
Use of an Ethics Consultation Service Registry to Identify Moral Triggers For
Requesting Ethics Consultations.
Niego, Sara, MD
Media Literacy in Eating Disorder Treatment.
Pearlson, Godfrey, MD
An MRI Study of Neurobiological Markers of Trait Dysfunction in Major
Depressive Disorder.
Sex-Gender Differences in the Effects of Marijuana on Behavioral and Cognitive
Tests.
Seltzer, Jim, PhD
Evaluation of BrainDance.
Shagan, Dana, PsyD
A Study of the Effect of Social Cognition and Interaction Training on People with
Schizophrenia.
Stevens, Michael, PhD
ADHD Medications: Are The Benefits Worth The Risks?
Tolin, David, PhD
Psychological and Physiological Correlates of Anxiety.
Active Projects
Aikins, Deane, PhD
fMRI Investigation of PTSD-Related Cognitive Deficits and DNA Tissue Banking.
National Center for PTSD, $48,293.
Assaf, Michal, MD
Differential Diagnosis of Psychotic Patients. Donaghue Medical Research
Foundation, $239,179.
FMRI, PET and the Default Mode Network Classify MCI and AD. NIA, $147,600.
Implicit Mentalizing in Adults with Autistic Spectrum Disorders. Hartford
Hospital Research Endowment Funds, $54,938.
Neuronal Correlates of Implicit Social Interaction in Autism Spectrum Disorders:
A Functional MRI Study. National Alliance for Autism Research, $118,968.
Social Interactions in Developmental Disorders: Functional MRI Study.
Departmental, $500.
The Neuronal Correlates of Theory of Mind in Schizophrenia. NIMH, $164,000.
Astur, Robert, PhD
Amphetamine and Memory in Virtual Reality. Departmental, $3,000.
Attention and Memory in Eating Disorder Populations.
Cocaine-Induced Place Preference in Virtual Reality Environments R21
DA020013-01. National Institute of Drug Abuse, $290,852.

Fear Conditioning During Functional Magnetic Resonance Imaging.
Departmental, $400.
fMRI of Virtual Reality Navigation. Departmental, $2,000.
Neuroimaging Cognition in Post-Traumatic Stress Disorder.
Neuroimaging of Mothers Overcoming and Managing Stress “Breaking the
Cycle.” Office of Juvenile Justice and Delinquency Program/University of
Connecticut, $49,500.
Prospective Memory in Schizophrenia. Trinity College, $938.
Sleep Dependent Consolidation of Spatial Memory. Hartford Hospital Research
Endowment Funds, $7,750.
Virtual Navigation in Individuals with Alzheimer’s Disease During fMRI.
Hartford Hospital Research Endowment Funds, $49,950.
Blair, Ellen, APRN
Inpatient Psychiatric Unit Medications and Falls Outcomes.
Bullock, Karen, PhD
Dying Experiences Among Racially Diverse Hospitalized Patients: Are There
Differences Between Older African Americans and Whites in End-Of-Life
Treatment Outcomes? Departmental, $10,593.
Caley, Charles, PharmD
A Controlled, Cross-sectional Comparison of Total Homocysteine
concentrations in Schizophrenic Outpatients Treated With Risperidone or
Olanzapine. Jannsen Pharmaceutical, $30,000; Hartford Hospital Research
Endowment Funds,$11,537.
Tenex (guanfacine) Augmentation for the Remediation of Attention and Working
Memory Deficits in Patients with Schizophrenia: A Pilot Study. Hartford
Hospital Research Endowment Funds, $7,198.
Calhoun, Vincent, PhD
Collaborative Research: Spatiotemporal Fusion of fMRI, EEG, and Genetic
Data Using Independent Component Analysis. National Institute of Biomedical
Imaging and BioEngineering, $886,292.
Choi, James, PhD
Comparison of Remediation Techniques on the WCST in Schizophrenia.
Hartford Hospital Research Endowment Funds, $9,851.
Diefenbach, Gretchen, PhD
Clinical Characteristics of OCD Spectrum Disorders: A Comparison of OCD
and Trichotillomania. Hartford Hospital Research Endowment Funds, $9,329.
Screening for GAD Among Frail Elderly. NIMH, $147,200.
The Cognitive-Enhancing Effects of D-Cycloserine Among Non-Demented
Elderly. Hartford Hospital Research Endowment Funds, $74,923.
The Nature and Impact of Anxiety Symptoms upon Psychosocial Functioning
of Older Adults with Major Depressive Disorder. Hartford Hospital Research
Endowment Funds, $33,371.
Treatment of Late-Life Anxiety Among Home Health Care Recipients: A
Feasibility Study.
Ferrand, Jennifer, APRN
Long-term Psychological Adjustment in Patients with Implantable Cardioverter
Defibrillators. Hartford Hospital Research Endowment Funds, $7,559.
Folley, Bradley, PhD
Modulation of Neuroimaging and Neurocognitive Correlates of Attention and
Memory by Nicotine and Nicotinic Alpha-7 Receptor Genotype Polymorphisms
in Schizophrenia and Healthy Controls. Philip Morris USA, Inc., $86,400.
Goethe, John, MD
A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing
the Safety and Efficacy of Asenapine with Olanzapine in Subjects who Completed
Protocol A7501014 (Pfizer 1014). Pfizer, $47,693.
A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the
Efficacy and Safety of Asenapine with Olanzapine in Stable Subjects with
Predominant, Persistent Negative Symptoms of Schizophrenia (Pfizer 1013).
Pfizer, $86,125.
A Randomized, Parallel Group, Multiple Dose, 6-week Study to Evaluate Safety,
Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects with
Psychosis. Pfizer, $47,362.
A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating
the Efficacy and Safety of Add-on Oral Ziprasidone in Subjects with Acute Mania
Treated with Lithium or Divalproex. Pfizer, $57,005.
Adjunctive Treatment with Bupropion in Major Depressive Disorder. Glaxo Smith
Kline, $60,700.
DNA Diagnostics for Minimizing Side-Effects of Antipsychotics. NIH/SBIR,
Genomas, $150,000.
Enhancing Short-Term Memory in Patients with Schizophrenia.
Information Dissemination as a Method of Improving Patient Outcome: A
Demonstration Project and Study of the Outcomes of Patients with Major
Depressive Disorder. Hartford Hospital Research Endowment Funds, $119,375.
Physiogenomic Analysis of Antipsychotic Therapies and their Metabolic Side
Effects. Genomas/NIH, $100,000.
Psychiatric Treatment Practices and Patient Outcomes.
SSRIs in the Treatment of Major Depressive Disorder: Side Effects and Patient
Choices of Treatment. Merck, $112,500.
86.

The Utility of Routine Cytochrome P450 Genotyping in the Selection of
Type and Dosage of Antidepressant Medication. Hartford Hospital Research
Endowment Funds, $74,797.
Griss, Melina, PhD
White Matter Changes in Normal Aging: Impact on Everyday Functioning.
Hartford Hospital Research Endowment Funds, $16,563.
Jaffe, Adam, PhD
Expectancy Therapy and Medication for Smoking Cessation. Hartford Hospital
Research Endowment Funds, $54,432.
Kiehl, Kent, PhD
Brain Mechanisms of Interpersonal Judgment. Departmental, $2,400.
Electrophysiological Assessment of Error Monitoring in Psychotic Illnesses.
Hartford Hospital Research Endowment Funds, $50,000.
Functional Magnetic Resonance Imaging Correlates of Decision-Making. Yale
University, $50,000.
Syntactic Development and Learning Processes in Autism Spectrum Disorders.
University of Connecticut, $18,250.
Kurtz, Matthew, PhD
Cognitive Remediation for Schizophrenia: Effects on Distal Outcome Measures
and Relationship to Social-Skills Training. NARSAD, $51,130.
Facial Affect Recognition, Social Functioning, and Neurocognitive Deficits in
Schizophrenia.
FMRI Assessment of Treatment Response in the Schizophrenia Rehabilitation
Program at the Institute of Living. Hartford Hospital Research Endowment
Funds, $46,447.
Neurocognitive Predictors of Response to Cognitive Remediation in Patients
with Schizophrenia. National Alliance for Research on Schizophrenia and
Depression, $60,000.
Neurocognitive Remediation for Schizophrenia. NIH, $749,579; Hartford
Hospital Research Endowment Funds, $9,362.
Predictors of Treatment Response to Rehabilitation in Schizophrenia. NIH,
$71,450.
Virtual Reality Assessment of Psychosocial Status in Patients with
Schizophrenia. Hartford Hospital Research Endowment Funds,$9,690.
Lothstein, Leslie, PhD
Assessment of Thought Disorder in Adults: The Relationship of the Rorschach
Perceptual Thinking Index, Other Rorschach Variables, and the Millon Clinical
Multiaxial Inventory - III Thought Disorder Index to Diagnoses in a Psychiatric
Sample. Intimacy - Sexuality Group Therapy for Impaired and Distressed
Professionals.
Lovejoy, David
Patterns of Verbal List Learning in Mild Traumatic Brain Injury: The Role of
Effort and Motivation.
Meda, Shashwath, MS
Characterizing the Dyslexia Phenotype Using Genetics and MR Morphology.
Hartford Hospital Research Endowment Funds, $9,722.
Meunier, Suzanne, PhD
Group Treatment for Compulsive Hoarding.
Understanding Repetitive Behavior and Associated Experiences.
Pearlson, Godfrey, MD
A Unified Framework for Flexible Brain Image Analysis. NIH/MIND Institute,
$1,000,000.
Aberrant Functional Connectivity in Psychosis. NIMH, $1,564,000.
Alcohol and Driving: A Functional MRI Study . NIAAA/Yale University,
$1,283,384.
Alzheimer’s Disease Neuroimaging Initiative . University of California, San
Diego, $292,959.
Amphetamine and Reward Mechanisms: fMRI Study. Yale University, $15,000.
Brain Structure and Function in Schizophrenia: Neuroanatomical and
Neurophysiological Predictors of Clinical Outcome in Prodromal Schizophrenia.
NARSAD,$530.
Computer-Based Driving Assessment in Early Alzheimer’s Disease. Hartford
Hospital Research Endowment Funds, $47,488.
fMRI of Brain Activation During Menstrual Migraine. Departmental, $8,955.
fMRI Studies of Healthy Volunteers at 3.0 Tesla. Departmental, $2,000.
Human 31 - IH MRI and MRI Brain Studies of Nicotine. NIH, $53,767.
Marijuana and Driving: A Functional MRI Study.
Molecular Studies of Cognition and Chronic Alcoholism. NIAAA/University of
Pittsburgh, $134,843.
Neurocognitive Changes Associated with Behavioral Treatment in Cocaine
Abusers. NIDA, $2,647,970.
Physiogenomic Arrays for Clinical Neuropsychiatry. NIH subcontract through
Genomas, $294,576.
Quantitative Neuroimaging in Psychosis. NIMH, $2,753,077.
Schizophrenia Biomarkers: Memory, Genes and fMRI. NIMH, $1,493,033.

Sex Differences in Schizophrenia. NIMH, $776,448.
The Effects of Tobacco on Brain Structure and Function are Amplified by
Genotype. Dept. of Public Health/University of Connecticut, $200,730.
Ventral Striatal Functional Deficits and Familial Alcoholism Risk. Yale
University, $466,956.
Roffer, Wayne, PsyD
Accuracy of a Mental Status Exam for Assessing Cognitive Dysfunction in
Patients with Schizophrenia.
Stevens, Michael, PhD
Diffusion Tensor Magnetic Resonance Imaging Correlates of Cognitive and
Functional Outcome After Closed-Head Traumatic Brain Injury. Hartford
Hospital Research Endowment Funds, $65,000.
fMRI of CBT and CM Cocaine Dependence. Yale University, $172,183.
Functional Genomics of Behavioral Control.
Functional MRI Activation in Children to Monaural, Binaural and Dichotic
Words. University of Connecticut, $14,000.
Girls in Recovery from Life Stress (GIRLS) Study. Office of Juvenile Justice and
Delinquency Program, University of Connecticut, $49,500.
Neural Correlates of Trauma and Stress Treatment Change. Departmental,
$6,688.
Neuroimaging Cognition in Adolescent Behavior Disorders. NIMH, $798,709.
Response Inhibition in Attention-Deficit/Hyperactivity Disorder. Hartford
Hospital Research Endowment Funds, $65,000.
Reward, Impulsivity and Cocaine Addiction: fMRI Studies. Yale University,
$1,303,559.
Cognitive Processes in Anxiety Disorders.
Cognitive-behavioral Bibliotherapy for the Treatment of Obsessive Compulsive
Disorder in Children and Adolescents.
Dismantling the Neural Systems of Obsessive-Compulsive Disorder: A Symptom
Provocation Study of Compulsive Hoarding. Hartford Hospital Research
Endowment Funds, $53,602.
Long-Term Follow-Up of Cognitive-Behavioral Therapy Patients with Anxiety
Disorders.
Neural Mechanisms of Compulsive Hoarding. NIMH, $1,062,000.
Neuropsychological Functioning in Compulsive Hoarding.
Hartford Hospital Research Endowment Funds, $74,898.
Psychopathology of Compulsive Hoarding. Smith College, $365,563.
Stepped Care for Obsessive-Compulsive Disorder. NIMH, $596,160.
Treatment of Compulsive Hoarding. Boston University, $113,072.00
Virtual Reality Exposure Treatment for Combat-Related Posttraumatic Stress
Disorder in Operation Iraqi Freedom and Operation Enduring Freedom Veterans.
Hartford Hospital Research Endowment Funds, $73,894.
Woolley, Stephen, DSci
Assessment of a Suicide Screening Program to Improve Detection of Post-
Discharge Suicide Risk. Hartford Hospital Research Endowment Funds, $27,662.
Extension of the Longitudinal Study of “SSRIs in the Treatment of Depressive
Disorder: Side Effects and Patient Choices of Treatment”. Hartford Hospital
Research Endowment Funds, $9,494.
Prospective Follow-up Study of the Effects of Locus-of-Control and Life Stressors
on Long-Term Outcome of Treatment for Major Depressive Disorder. Hartford
Hospital Research Endowment Funds, $9,723.
The Effect of Pharmacotherapy on Trauma-Related Sleep Disturbance in
Pediatric Populations.
Tolin, David, PhD
A Randomized, Double-Blind, Placebo-Controlled Trial of D-Cycloserine
Augmentation of Behavior Therapy for Obsessive-Compulsive Disorder.
Departmental, $245.
An Internet Survey of Compulsive Hoarding.
Anxiety Disorders Outcomes Protocol.
Augmenting Exposure Therapy with an NMDA Agonist: A Pilot Study.
Hartford Hospital Research Endowment Funds, $64,865.
Cognitive Differences Between Generalized Anxiety Disorder and Obsessive-
Compulsive Disorder. Hartford Hospital Research Endowment Funds, $10,062.
88.

Radiology
New Projects
Federal
Cronin, Edward, MD
Near Infrared Optical Imaging Guided by Ultrasound: Assessing Neoadjuvant
Chemotherapy Response. NIH subcontract through the University of Connecticut,
$287,124.
Industry
Foster, John, MD
Investigational Plan to Evaluate the Use of the Endologix 34mm Powerlink Cuff
for Continued Access, IDE: G990139, Protocol Number: 03-023CA - Revision A.
Endologix, Inc., $50,875.
The SIR-Spheres(R) Registry. Sirtex Medical, $30,000.
Hallisey, Michael, MD
CRUX Biomedical Evaluation of the Crux Inferior Vena Cava Filter System -
(“Retrieve”) Study. Crux Biomedical, Inc., $38,792.
Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft System
in the Treatment of Descending Thoracic Aneurysms of Degenerative Etiology in
Subjects Who are Candidates for Endovascular Repair. Medtronic Vascular, Inc.
$54,315.
Unfunded
Kallen, Joshua, MD
Retrospective Validation of Limited Scan Range CTA for Suspected Pulmonary
Embolism for Diagnostic Accuracy and Prevalence and Clinical Significance of
Alternative and Secondary Diagnoses. Statistical analysis generously supported by
Medical Staff funds.
Coughlin, Bret, MD
Gadolinium-Enhanced Tissue Visualization: A Feasibility Study.
Hallisey, Michael, MD
Evaluation of Prototype Inferior Vena Cava Filtration Device in Ovine.
Screening Abdominal Aortic Aneurysms Based on the Stability of the Aneurysm.
Evaluation of BW2R Paperwork for Patient Prescriptions.
Jacunski, Joanna, MD
Assessment of the GE Vascular Pack Noncontrast MRA Techniques.
Kallen, Joshua, MD
Exploratory Retrospective Review to Determine the Location of Pulmonary
Emboli as Defined as within a Limited Scan Range or not within a Limited Scan
Range.
O’Loughlin, Michael, MD
Evaluation of GE Healthcare’s MSLAB, MFGRE and Viz Pack.
Spiegel, Gary, MD
CORDIS Enterprise Vascular Reconstruction Device and Delivery System.
Stein, Barry, MD
AW Enterprise Application Server Prototype Evaluation.
Active Projects
Hallisey, Michael, MD
(VALOR) Evaluation of the Medtronic AVE Thoracic Stent Graft System for the
Treatment of Thoracic Aortic Aneurysms. Medtronic AVE, $52,000.
Treatment IDE for use of the GORE TAG Thoracic Endoprosthesis in Subjects
with Descending Thoracic Aortic Aneurysms Requiring Surgical Repair. W.L.
Gore & Associates, $10,220.
Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy
- SAPPHIRE WW - Protocol Number P06-3603. Cordis Corporation,
a Johnson and Johnson Company, $47,200.
TAG) A Clinical Study Comparing Use of the Thoracic EXCLUDER Endoprosthesis
to Open Surgical Repair in the Primary Treatment of Descending Thoracic
Aortic Aneurysms. W.L. Gore & Associates, Inc., $78,750.
An Investigation of the Talent Endoluminal Spring Stent-Graft System for the
Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are Candidates
for Standard Surgical Intervention. Medtronic AVE / Talent, $72,000.
An Investigation of the Talent Endoluminal Spring Stent-Graft System for the
Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are
Not Candidates for Standard Surgical Intervention. Medtronic AVE / Talent,
$50,000.
An Investigation of the TALENT LPS A Low Profile Endoluminal Stent-Graft
System for the Treatment of Sub-renal Abdominal Aortic Aneurysms in Patients

who are Candidates for Standard Surgical Intervention (LOW RISK). Medtronic
Vascular, $10,000.
An Investigation of the TALENT Endoluminal Spring Stent-Graft System for the
Treatment of the Sub-Renal Abdominal Aortic Aneurysms in Patients Who Are
Candidates for Standard Surgical Intervention (Low Risk Stock Device Study).
Medtronic AVE, $20,000.
An Investigation of the Talent Endoluminal Spring Stent-Graft System for the
Treatment of Sub-Renal Abdominal Aortic Aneurysms in Patients Who are Not
Candidates for Standard Surgical Intervention - Emergency Protocol. Medtronic
AVE, $40,000.
Emergency Use of the Talent Endoluminal Spring Stent-Graft System in High
Surgical Risk Patients with Thoracic Aortic Aneurysms. Medtronic AVE, $80,000.
Evaluation of the Enhanced TALENT LPS Stent Graft System for the Treatment
of Abdominal Aortic Aneurysm. Medtronic AVE, $50,000.
The EXACT Study - Emboshield(R) and Xact(R) Post Approval Carotid Stent
Trial. Abbott Vascular Devices, $22,000.
Hauser, Stephen, MD
Compassionate Use Protocol DMS: A Prospective Study of Adjuvant Radiation
Therapy After Resection of Borderline and Malignant Phyllodes Tumors.
Jacunski, Joanna, MD
Retrospective Analysis of the Utility of MRI for Evaluation of Acute Abdominal
Pain in Pregnant Patients.
Use of 18F-FDG PET/CT for Diagnosis of Osteomyelitis of the Foot.
Norton, Timothy, MD
Trends in the Utilization of Radiologic Studies at Hartford Hospital.
O’Loughlin, Michael, MD
MRI Evaluation of the Contralateral Breast in Women with a Recent Diagnosis of
Breast Cancer/ACRIN 6667. American College of Radiology Imaging Network,
$170,000.
Prospective Analysis of Breast MRI Outcomes in a Large Hospital Population. CT
Breast Health Initiative, $49,939.
Silk, Portia, MD
Analysis of CT Perfusion and Salvageable Penumbra as a Function of Time in
Acute Stroke. Small Grant, $10,000.
Spiegel, Gary, MD
Humanitarian Use Device: Neuroform Microdelivery Stent.
Tubbs, Daniel, MD
Contrast Enhanced Multi-Detector Computed Tomography (MDCT) as a Noninvasive
Modality for the Evaluation of Active Lower Gastrointestinal Bleeding:
Initial Prospective Assessment of Contrast Enhanced MDCT Verses Technetium
99m Tagged Red Blood Cell Scanning at a Large Community Hospital. Berlex
Laboratories, Inc., $99,769.
Zink, Stephen, MD
Incidental Non-cardiac Findings Seen Prospectively on Cardiac CT
Angiogram (CTA).
Publications and Abstracts
Kallen J, Coughlin B, O’Loughlin MT, Stein B, Chhabra J. Reduced
Z-axis coverage CTA versus standard Z-axis coverage CTA for pulmonary
embolism. Abstract LL-CH4342-R08. Radiological Society
of North America, posted online May, 2009. Available at http://
rsna2009.rsna.org
Kallen JA, Coughlin BF, O’Loughlin MT, Stein B. Reduced Z-axis
coverage multidetector CT angiography for suspected acute pulmonary
embolism could decrease dose and maintain diagnostic accuracy.
Emergency Radiology 2009;17:31-35.
Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB,
Postoak DW, Rajan DK, Sacks D, Schwartzberg MS, Zuckerman
DA, Cardella JF, Standards of Practice Committee with Cardiovascular
and Interventional Radiological Society of Europe (CIRSE) Endorsement.
Consensus guidelines for periprocedural management of
coagulation status and hemostasis risk in percutaneous image-guided
interventions. Journal of Vascular & Interventional Radiology, 20 (7):
S240-S249, 2009.
Malloy PC. Management of pelvic hemorrhage in trauma. In Mauro
MA, Murphy K, Thomson K, Venbrux A, Zollikofer CL. (Eds.) Image
Guided Intervention. Saunders, pp. 907-913, 2008.
O’Loughlin M, McLaughlin T, Staff I, Cronin E. Prospective outcome
of BIRADS category 3 “Probably Benign” breast MRI lesions. Abstract
SSA01-01. Radiological Society of North America, posted online
May, 2009. Available at http://rsna2009.rsna.org
Richard HM, Widlus DM, Malloy PC. Percutaneous fluoroscopically
guided jejunostomy placement. J Trauma, 65(5):1072-7, 2008.
Wingspan Stent System with Gateway PTA Balloon Catheter, a Humanitarian
Use Device.
Stein, Barry, MD
MRI Image and Clinical Application Development Protocol.
90.

Surgery
Orlando C. Kirton, MD, FACS, FCCM, FCCP,
Ludwig J. Pyrtek MD Chair in Surgery, Director of
Surgery, Chief, Division of General Surgery
The Department of Surgery continues to participate in clinical and
scientific research and has contributed significantly to the surgical body
of knowledge. Members of the department have presented their findings
at several prestigious forums and have published in a variety of refereed
journals. The Department continues to encourage its members to be
involved in academic as well as clinical endeavors. It seeks to engage
its staff in a variety of experiences that contribute to the growth of the
department, the reputation of the institution as well as the enhancement
of the individuals themselves.
The faculty of the department continues to be actively involved in
the education process within the institution and the community and
continues to encourage the residents and fellows to pursue research
activities. The Department of Surgery currently supports two surgical
residents as they participate in research fellowships at the University
of Connecticut. Both have been involved in conducting clinical
research and basic science research and have published and presented
their findings. Dr. Pavlos Papasavas, the Director of Research for the
Department of Surgery has provided presentations to residents and
medical students to encourage participation in research projects. In
addition, he selected and trained residents for the Skills competition of
the CT-Chapter of the ACS and the selected group won first prize.
The Department of Surgery and the Section of Bariatric Surgery are
working on establishing a Bariatric Database to provide valid data to
conduct meaningful research. The Department continues to identify
ways to access data for the purpose of trending and quality improvement.
The Department’s own database (ORBIT) has been redesigned to
facilitate the input and download of specific data from other databases
(i.e. SIS). The Division of Colo-Rectal Surgery has created an on-going
database for ileoanal pouch procedures and is collaborating with UConn
(Storrs) on a project entitled “Psychosocial Needs Assessment of Patients
with Colorectal Cancer and Partners” with the goal of addressing the area
of patient and family support systems.
New Projects
Industry
Cheema, Mohiuddin, MD
PRICELESS: PRessure and Imaging - using the CardioMEMS EndoSure Sensor
for Long-term follow-up after EVAR with Standard Surveillance (PRICELESS
PROSPECTIVE REGISTRY). CardioMEMS, Inc., $12,250.
Hull, David, MD
Deceased Donor Vessel Storage: A Study of Tissue Viability for Organ
Transplantation. Essential Pharmaceuticals, $3,000.
A Double-Blind, Randomized, Placebo Controlled, Multi-Center Trial of
Oseltamivir for the Seasonal Prophylaxis of Influenza in Immunocompromised
Patients. F. Hoffman-La Roche LTD, $62,000.
Mah, John, MD
Assessment of the Economic Impact on Fecal Containment in Bedridden Patients
Comparing Zassi Bowel Management System (BMS) with Flexi-Seal Fecal
Management System (FMS). Hollister, Inc., $17,000.
McKay, Raymond, MD
A Pilot Study to Assess the Histological Effects and Biomechanical Strength of a
Novel, Knotless Suturing Technique in the Repair of Rotator Cuff Injury. Cordis
Corporation (Investigator Initiated), $13,306.
Papasavas, Pavlos, MD
A Multi-Center Open-Label Clinical Evaluation of the LAP-Band AP System in
Severely Obese Patients. Allergan (Multicenter), $27,850.
Unfunded
Allen, Brian, MD
A Successful Wound Care Algorithm to Heal Venous Stasis Ulcers.
Butler, Karyn, MD
Is Delayed DVT Prophylaxis in the Neurocritical Care Unit Effective?
Cohen, Jeffrey, MD
Recurrent Diverticulitis After Laparoscopic Colectomy.
Divinagracia, Thomas, MD
The Natural History of Moderate Stenosis of the Carotid Artery.

Feeney, James, MD
The Use of a Simulator to Improve Technique and Procedural Confidence In
Emergency Cricothyroidotomy. Statistical analysis supported through Hartford
Hospital Small Grant.
Gallagher, Robert, MD
Aortic Valve Replacement - Is Age an Independent Predictor of Risk? Statistical
analysis supported through Hartford Hospital Small Grant.
Incidence and Risk Factors Associated with Post Procedure Hypotension Following
Carotid Artery Endarterectomy and Carotid Artery Angioplasty.
Hammond, Jonathan, MD
Benefit of Prophylactic Donor Tricuspid Annuloplasty in Bicaval Orthotopic Heart
Transplantation. Data support provided through Hartford Hospital small grant.
Hull, David, MD
Retrospective Study of Liver Transplant Pre-Procedure MELD Scores and Post-
Surgical Outcomes. Statistical analysis supported through Hartford Hospital Small
Grant.
Orlando, Rocco, MD
A Prospective Study of Early Outcomes After Stapled Versus Unstapled Preformed
Mesh in Laparoscopic Extraperitoneal Inguinal Herniorrhaphy.
Papasavas, Pavlos, MD
Bariatric Outcomes Longitudinal Database (BOLD).
Hartford Hospital Bariatric Registry.
Hiatal Hernia Repair at the Initial Laparoscopic Adjustable Gastric Band Operation.
Massive Hernia Repair with Separation of Components Technique: A General and
Plastic Surgery Combined Approach.
Weight Loss Surgery and Diabetes Mellitus in Patients Undergoing Weight Loss
Surgery.
Paquette, Anthony, MPH
Reliability of a Donation after Cardiac Death (DCD) Assessment Tool in Predicting
Time to Cardiac Death after Withdrawal of Support.
Ranga, Kasturi, MD
Depression, Anxiety, and Quality of Life in Living Kidney Donors. Statistical
analysis supported through Hartford Hospital Small Grant.
Active Projects
Alberghini, Tod, BS
Clinical Significance of Solid-Phase Assay (Flow Cytometric and Luminex)
Detection of Pre-Transplant HLA Antibody as Measured by Graft Survival in
Renal Transplant Recipients: A Retrospective Analysis. Hartford Hospital Small
Grant, $9,954.
Histocompatability Determination for Highly Sensitized Patients.
Bass, David, MD
McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical
Study.
Brown, Matthew, MD
A Randomized, Open-Label, Comparative Evaluation of Conversion from
Calcineurin Inhibitor Treatment to Sirolimus Treatment versus Continued
Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing
Maintenance Therapy. Wyeth Pharmaceuticals, $213,147.
Cohen, Jeffrey, MD
Safety, Feasibility and Long-term Outcomes of Laparoscopic Ileal-Pouch-Anal
Anastomosis: A Single Institution Case-Matched Experience.
DeLucia, Orlando, MD
Allergan Corporation Style 410 Silicone-Filled Breast Implant Continued Access
Reconstruction/Revision Expansion (CARE) Clinical Study. Inamed, $8,300.
McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical
Study.
Drezner, David, MD
A Comparison of CT Venography to Duplex Ultrasonography in the Diagnosis
of DVT.
Outcomes of Patients Undergoing Lower Limb Amputations.
Gallagher, Robert, MD
Oxygen Mapping of the Peri-sternal Chest Wall in Post-Operative Open Heart
Surgery Patients.
Graydon, James, MD
Post-Prostatectomy Erectile Dysfunction and Urinary Incontinence: Effect of
Hyperbaric Oxygen Therapy.
Hull, David, MD
Does Beta 2 Microglobulin Correlate with Creatinine as a Marker of Renal Function
in Renal Transplant Recipients at Points of Transition, and During Stable Renal
Function? Statistical analysis supported through Hartford Hospital Small Grant.
92.

Intimal Hyperplasia in Arteriovenous Fistulas. Roche, $18,162.
Oral Infection and Inflammation in Transplant Patients. NIH/University of
Connecticut, $25,000.
An open label randomized, multicenter study to evaluate the efficacy and safety
of early calcineurin inhibitor withdrawal in recipients of primary renal allografts
maintained long-term on mycophenolate mofetil; MMF (CellCept) and sirolimus
(Rapamune). Roche Hoffman - La Roche, $430,709.
Transplant Clinical Outcomes Blanket Protocol.
Ivy, Michael, MD
Intraoperative and Preoperative Parameters That Predict Abdominal Compartment
Syndrome After Repair of Ruptured Abdominal Aortic Aneurysm.
Keating, Kevin, MD
A Randomized, Double-Blind, Placebo-Controlled, Phase-2b Study to Assess the
Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated
Intravascular Coagulation. Artisan Pharma Inc., $96,000.
Kirton, Orlando, MD
Advanced Laparoscopic Training Course. Departmental, $17,500.
Evaluation of Sublingual Capnometry in Critically Ill Surgical Patients Subjected to
a Resuscitation Protocol (SLT). Tyco Healthcare/Nelcor, $66,250.
Surgery Clinical Outcomes Blanket Protocol.
Mah, John, MD
Application of a Web-Based Teaching Module for Instruction and Standardization
of Post-Pyloric Feeding Tube Insertion.
Mavanur, Arun, MD
Differences Between Male and Females in the Operative Findings and Outcome of
Laparoscopic Cholecystectomy.
Indeterminate for Dysplasia, What Next?
McIsaac, Joseph, MD
Surgical Cooling Garment Phase III. Hartford Hospital Research Endowment
Funds, $65,625.
Miranda, Michael, MD
Humanitarian Use Device: OP-1 Implant.
NasirKhan, Mohammad, MD
Role of Intravenous Chromium in Reducing Insulin Requirements in Critically Ill
Patients.
Norton, Timothy, MD
Cryoablation of Irresectable Lung Tumors.
Papasavas, Pavlos, MD
Enterra Therapy Humanitarian Device Exemption.
Pepe, Judith, MD
Training Organ Procurement Organization Coordinators to Use an Esophageal
Doppler Monitor for Donor Management to Improve Organs Transplanted per
Donor. HRSA, $94,253.
Poultsides, George, MD
Hand Assisted Laparoscopic Transduodenal Resection: Initial Experience.
Laparoscopic Gastric Resection: Technique and Outcomes in 25 Patients.
Safety and Long-term Efficacy of Angiographic Embolization for Upper
Gastrointestinal Hemorrhage: A Single Institution Experience.
Reed, Michael, MD
McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical
Study.
Tamim, Patrick, MD
An Analysis of Subclavian Stenosis by Duplex Ultrasonography as Evaluated in
Tandem with Arterial Angiography.
Tishler, Darren, MD
A Randomized, Prospective Study Comparing Needle Stick Injuries with Hand
versus SuturTek Device Closure of Abdominal Fascia. SutruTek Inc., $27,000.
Underhill, David, MD
Study 98-1 Carpentier-Edwards PERIMOUNT Plus Pericardial Bioprosthesis,
Model 6900P. Edwards LifeSciences, LLC, $110,250.
Publications and Abstracts
Allen B, Cuzzone D, Rowin C, Perdrizet G, Babigian A. Fluoroscopic radiation
burn following embolization of a spinal arteriovenous malformation. Journal of
Burn Care and Research, 2009; 30(2): 349-351.
Allen B, Rader C, Babigian A. Giant lipomas of the upper extremity. Canadian
Journal of Plastic Surgery 2007;15(3):141-144.
Antonetti M, Kirton OC, Bui D, Ademi A, Staff I, Hudson-Civetta J, Lilly R:
The effects of pre- operative rofecoxib, metoclopramide, dexamethasone, and
ondansetron on postoperative pain and nausea in patients undergoing elective
laparoscopic cholecystectomy. Surg Endosc 2007; 21:1855-1861.
Banever, T, Brautigam, RT, Pressure Ulcer Assessment Work Group. Pressure
Ulcer Assessment for Physicians and Licensed Independent Practitioners
Education Program. Hartford Hospital Intranet, 2008.
Barnes SL, Richards T, Pritts TA, Robinson BR, Tsuei BJ, Butler KL, Muskat PC,
Davis K, Johannigman JA. Devil is in the details: maximizing revenue for daily
trauma care. Surgery 2008; 144(4): 670-676.
Bokhari F, Phelan H, Holevar M, Brautigam R, Collier B, Como J, Clancy K,

Cumming J, Cullinane D, and Smith L. Diagnosis and management of pancreatic
trauma. Posted on EAST.org, 2009.
Brautigam RT, Schott E, and Burns K. A simulation education course for the initial
management of blunt trauma. Connecticut Medicine, May 2009; 73(5): 267-271.
Brautigam RT, Sheppard R, Robinson K and Jacobs LM. Evaluation and treatment
of the multiple-trauma patient. In: Browner BD, Jupiter JB, Levine AM and Trafton
PG. Skeletal Trauma: Basic Science, Management and Reconstruction, 4th ed.,
2009.
Cheema M, Lukose B, Kirton OC, Gallagher J: Ligation of the subclavian artery
after blunt trauma presenting as massive hemothorax.. J Trauma 2008;
64(4):1126-1130.
Clarke CN, Tsuei B, Butler KL. Equine-related injury: a retrospective analysis of
outcomes over a 10 year period. Am. J. Surg. 2008;195:702-704.
Crisanti, Koutzaki, Mondrinos, Lelkes, Finck. Novel methods for delivery of cellbased
therapies. Journal of Surgical Research May 2008;146(1):3-10.
Cuzzone D, Allen B, Rowin C, Tulikangas P, Babigian A. Development of vaginal
erosion and vesico-cutaneous fistula following midurethral transvaginal tape with
Pelvilace for treatment of stress urinary incontinence. International Wound Journal,
2009; 6:55-58.
Feeney JM, Burns K, Staff I, Bai J, Rodrigues N, Fortier, Jacobs LM. Prehospital
HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal
aortic aneurysm. J Am Coll Surg. 2009.
Finck, Moront, Newton, Timmapuri, Lyons, Rozans, DeChadarevian, Halligan.
Pediatric granular cell tumor of the tracheobronchial tree. Journal of Pediatric
Surgery, 2008;43(3):568-70.
Folcik MA, Kirton OC, Ivy ME: A two-tiered quality management program :
morbidity and mortality conference data applied to resident education. Connecticut
Medicine, 2007; 71(8):417-424.
Fortuna GR, Mueller EW, James L, Shutter LA, Butler KL. The impact of preinjury
anti-platelet or anticoagulant pharmacotherapy and outcomes following
hemorrhagic brain injury. Surgery 2008; 144(4): 598-605.
Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating risk: a role for
jak-stat signaling in post-conditioning? Am J Physiol Heart Circ Physiol. 2008 Oct;
295(4):H1649-56.
Goodman MD, Koch SE, Reid MD, Caldwell CC, Butler KL. Thermal injury
activates myocardial JAK-STAT signaling. J Surg. Res. 2008;144(2):342.
Gross RI, Jacobs LM. Initial Assessment and Resuscitation. Airway
Management: What Every Trauma Surgeon Should Know, From Intubation to
Cricothyroidotomy. In Current Therapy of Trauma and Surgical Critical Care.
Eds. Juan A. Asensio and Donald D. Trunkey. 2008.
Huffman LC, Koch SE, Butler KL. Coronary effluent from a preconditioned heart
activates the JAK-STAT pathway and induces cardioprotection in a donor heart.
Am J Physiol Heart Circ Physiol. 2008;294:H257-H262.
Hyman NH, Kozol RA, Kirton OC, Berger DL. Attending surgeon work hours
restriction. Archives of Surgery. 2008; 143(5): 443.
Jackson S, Mueller EW, Ernst NE, Butler KL. Utility of bilateral bronchoalveolar
lavage for the diagnosis of ventilator-associated pneumonia in critically ill
surgical patients. Am J Surg. 2008; 195:159-163.
Jacobs LM, Abbensetts JMK. Acute care surgery. In A Guide for General
Surgeons. Emergency Management of the Oropharynx and Neck. (Eds)
Vicente H. Gracias, Patrick Reilly, Mark G. McKenney George C. Velmahos.
Publisher: McGraw Hill. 2009.
Jacobs LM, Burns K, Jacobs BB. Trauma death: Views of the public and
trauma professionals on death and dying from injuries. Archives of Surgery.
2008;143(8):730- 735.
Jacobs LM, Luk SS, Sproviero J. TRAUMA Sociedad Panamericana De Trauma
2nd Edition. “Trauma Hepatico”. Editors. Ricardo Ferrada, MD, Aurelio
Rodriguez, MD. Pp 369-278. Published by Distribuna Editorial. Pittsburgh, PA
2009.
Kirton OC, Folcik M, Calabrese E, Ivy M, Keating K, Mah, J, Pepe, J, Dobkin
et al: Mid Level Practitioner (MLP) work force analysis at a university affiliated
teaching hospital. Arch Surg. 2007; 142:336-341.
Kowal-Vern A, Poulakidas S, Barnett B, Conway D, Culver D, Ferrari M,
Potenza B, KoenigM, Mah J, Majewski M, Morris L, Powers J, Stokes E, Tan
M, Salstrom SJ, Zaletel C, Ambutas S, Casey K, Stein J, DeSane M, Berry K,
Konz EC, Riemer MR, Cullum ME. Fecal containment in bedridden patients:
economic impact of 2 commercial bowel catheters systems. Am J Crit Care.
2009. 18(Suppl 3):S2-14.
Mah J, Kirton O. Pharmacologic support of cardiac failure. In Asenio J, Trunkey
D, editors: Current Therapy of Trauma and Surgical Critical Care. 1st ed.
Philadelphia, Mosby, 2008 pp 598-602.
Mah J, Kirton O. Splanchnic flow and resuscitation. In Gabrielli, Layon AJ, and
Yu M, editors: Civetta, Taylor, and Kirby’s Critical Care. 4th ed. Philadelphia,
Lippincott Williams & Wilkins,2009, pp 941-948.
Mah JW, Bingham K, Dobkin ED, Malchiodi L, Russell A, Donahue S, Staff I,
Ivy ME, Kirton OC. Mannequin simulation identifies common surgical ICU
teamwork errors long after introduction of sepsis guidelines. Simul Healthc
2009 Vol.4, No. 4
Mami, Moront, Pascasio, Schlichting, Finck. Ruptured abdominal aortic
aneurysm in an 11-year-old boy. Journal of Pediatric Surgery 2008;43(4):762-4.
Master D, Piorkowski J, Zani S, Babigian A. Snowblower injuries to the hand:

Epidemiology, patterns of injury, and strategies for prevention. Annals of Plastic
Surgery, 2008; 61(6):613- 617.
Mondrinos, Koutzaki, Poblete, Crisanti, Lelkes, Finck. In vivo pulmonary
tissue engineering: contribution of donor-derived endothelial cells to construct
vascularization. Tissue Engineering Part A 2008 Mar; 14(3):361-8.
Orenstein S, Kreutzer D, Novitsky Y. Human monocyte activation by biologic and
biodegradable meshes in vitro. Surgical Endoscopy. Vol. 23; Supp 1; April 2009.
Orenstein S, Kaur M, Qiao Y, Klueh U, Kreutzer D, Novitsky Y. Activation of
human monocytes by human biologic meshes in vitro. Journal of Surgical Research.
Vol. 151; Issue 2; pg 290.
Orenstein SB, Qiao Y, Klueh U, Kreutzer DL, Novitsky YW. Role of mast cells
in the biocompatibility of synthetic mesh in mice. Hernia. Vol. 13; Supp. 1; Sept.
2009.
Rader C, Piorkowski J, Bass D, Babigian A. Epulis garavidarum manum: Pyogenic
granuloma of the hand occurring in pregnant women. Journal of Hand Surgery
2008;33A:263-265.
Rangel EL, Butler KL, Johannigman JA, Tsuei BJ, Solomkin JS. Risk factors for
relapse of ventilator-associated pneumonia in trauma patients. J Trauma. 2009
Jul;67(1):91-5.
Roszell BR, Mondrinos MJ, Seaton A, Simons DM, Koutzaki SH, Fong GH, Lelkes
PI, Finck CM. Efficient derivation of alveolar type II cells from embryonic stem
cells for in vivo application. Tissue Eng Part A. 2009 Apr 23 epub ahead of print.
Roszell, Seaton, Fong, Finck. Cell-based therapy improves cell viability and
increases airway diameter in an explant model of pulmonary hypoplasia,
Experimental Lung Research 1521- 0499, Volume 35, Issue 6, 2009, Pages 501 - 513
Sobieraj DM, Wang F, Kirton OC. Warfarin resistance after total gastrectomy and
Roux-en-Y Esophagojejunostomy. Pharmocotherapy 2008; 28(12):1537- 1541
Tandon, M., Poi, M., Shapiro, D. Chapter 4: Surgical nutrition. In: Kozol R.A.,
Novitsky, Y.W. (Eds.) Surgery Mentor - Your Clerkship & Shelf Exam Companion,
2nd edition. Philadelphia, PA. F.A. Davis Company. 2009; 31-37.
Tisherman SA, Kirton OC, Ivy M, Frangos S: Acute care surgery (ACS): Are
surgeons ready for a new training paradigm? Crit Care Med 2007;35/12:A122.
Vignati, P. Anastomotic leaks: What is the best imaging study?
DCR 2007;50:97-203
Vignati, P. The efficacy and durability of super selective embolization in the
treatment of lower gastrointestinal bleeding. DCR 2008 51(3);301-5
Zani S, Babigian A. Necrotizing fasciitis of the shoulder following routine rotator
cuff repair. Journal of Bone and Joint Surgery 2008; 90:1117-1120.
Presentations
Allen B, Babigian A. Breast Reconstruction in a 19 Year Old Female with
Anhydrotic Ectodermal Dysplasia. Presented at the CTACS Scientific and
Annual Meeting, Meriden, CT, 11/07.
Allen B, Caputo AE, Babigian A. Pediatric Revascularization and Replantation
in the Hand: Our Experience at Hartford Hospital and Connecticut Children’s
Medical Center. Presented at the New England Hand Society Thirty-Sixth
Annual Meeting and Scientific Program, Sturbridge, MA 12/08.
Allen B, Perdrizet G, Babigian A. Hyperbaric Oxygen Therapy for Treatment of
Delayed Radiation Tissue Injury. Presented at the New England Society of Plastic
and Reconstructive Surgery 2008 Annual Meeting, Manchester, VT 6/08.
Babigian, A. Moderator, Scientific Session. New England Society of Plastic and
Reconstructive Surgery 2008 Annual Meeting, Manchester, VT 6/08.
Babigian, A. Moderator, Scientific Session. New England Society of Plastic and
Reconstructive Surgery 2009 Annual Meeting, Boston, MA 6/09.
Babigian, A. Panel Member. University of Massachusetts Plastic Surgery Practice
Management Strategies Panel, Worcester, MA 12/07.
Babigian, A. Soft Tissue Coverage of the Upper Extremity. Presented at the
University of Massachusetts Plastic Surgery Educational Conference, 6/09.
Barnes SL, Richards T, Pritts TA, Robinson BR, Tsuei BJ, Butler KL, Muskat PC,
Davis K, Johannigman JA. Devil is in the Details: Maximizing Revenue for Daily
Trauma Care. Proceedings of the Central Surgical Association, March 2008.
Butler KL, Goodman MD, Koch SE, Friend L, Afzal MR. STAT Subtype Switch
in Pressure-overload Hypertrophy Improves Ischemic Tolerance in STAT-3 KO
Mice. Presented at the American College of Surgeons, Papers Session, October
2008.
Butler, K. Academic Surgery: The Road Less Traveled. Keynote Speaker SNMA
Banquet Cincinnati, OH February 4, 2008.
Butler, K. Cardiac Specific STAT-3 Deletion Prevents Myocardial
Decompensation Following Pressure Overload. Society of Black Academic
Surgeons Cleveland, OH April 2008.
Butler, K. Critical Illness Related Corticosteroid Insufficiency: The Heart of the
Matter. Cardiology Grand Rounds Hartford Hospital, August 18, 2009.
Butler, K. Gender, Science and Serendipity. Annual William Matory MD
Lecture, National Medical Association July 27, 2009.
Butler, K. Heparin-induced Thrombocytopenia: Who Gets HIT? Society of
Black Academic Surgeons Cleveland, OH April 2008.
Butler, K. Procalcitonin: A Novel Biomarker for Infection in the Critically Ill

Patient. Division of Critical Care Research Forum, Hartford Hospital, March 11,
2009.
Butler, K. STAT Subtype Switch in Pressure-overload Hypertrophy Improves
Ischemic Tolerance in STAT-3 KO Mice. American College of Surgeons, San
Francisco, CA, October 2008.
Butler, K. Thermal Injury Activates Myocardial JAK-STAT Signaling. Academic
Surgical Congress Huntington Beach, CA February 6, 2008.
Butler, K. Intimate Partner Violence. University of Cincinnati Brown Bag Lunch
Series, May 2008.
Butler, K. The Impact of Pre-injury Anti-platelet and Anticoagulant
Pharmacotherapy on Outcomes Following Hemorrhagic Brain Injury. Central
Surgical Association Cincinnati, OH March 4, 2008.
Butler, K. Women in Medicine. Howard University Hospital Department of
Surgery Grand Rounds November 17, 2008.
Clarke CN, Keegan SP, Mueller EW, Ernst NE, Butler KL. Heparin-induced
Thrombocytopenia: Who Gets HIT? Proceedings of the Society of Black Academic
Surgeons, April 2008.
Finck, C. Pulmonary Tissue Engineering. Invited Speaker, Stem Cells and Cellular
Therapies in Lung Biology and Lung Diseases Conference University of Vermont,
Burlington, VT 7/28/09.
Finck, C. Stem Cells and Pulmonary Hypoplasia. Invited Speaker, American
Thoracic Society International Conference San Diego, CA 5/19/09.
Finck, C. Stem Cells and Treatment of Pulmonary Hypoplasia. Invited speaker,
New England Surgical Society 2008 Boston, MA 9/08.
Fortuna GR, Mueller EW, James LE, Shutter LA, Butler KL. The Impact of Preinjury
Anti-platelet and Anticoagulant Pharmacotherapy on Outcomes Following
Hemorrhagic Brain Injury. Proceedings of the Central Surgical Association, March
2008.
Goodman MD, Koch SE, Afzal MR, Butler KL. Compensatory STAT Subtype
Activation Does Not Limit Ischemia-reperfusion Injury in Mice with Cardiac
Restricted STAT-3 Deletion. Presented at the Society of University Surgeons,
February 2009.
Goodman MD, Koch SE, Butler KL. JAK-STAT Activation in Postconditioning
is not Without RISK. Presented at the American College of Surgeons, Surgical
Forum, October 2008.
Goodman MD, Koch SE, Butler KL. Regulating Risk: A Role for Jak-stat Signaling
in Postconditioning. University of Cincinnati Dept of Surgery Resident Research
Competition, First Place. June 2008.
Ohio Chapter, American College of Surgeons, May, 2008.
Goodman MD, Koch SE, Lou Ann Friend, Butler KL. Cardiac Specific STAT-3
Deletion Prevents Myocardial Decompensation Following Pressure Overload.
Proceedings of the Society of Black Academic Surgeons, April 2008.
Jackson L, Drezner D, Freund J, Palter M, Butler KL. Is Delayed DVT
Prophylaxis in the Neurocritically Ill Patient Effective? Presented at the Society
of Black Academic Surgeons, April 2009.
Jacobs LM, Burns KJ, Luk S, Hull D. Advanced Trauma Operative Management
(ATOM) Course: Participant Survey. Poster presentation. New England
Surgical Society, Newport, RI. September 12, 2009.
Jacobs, L. Acute Care Surgeon: Should Critical Care Management Be An
Essential Component? American College of Surgeons Point/Counterpoint
Trauma Conference. National Harbor, Maryland. June 9, 2009.
Jacobs, L. The Advanced Trauma Operative Management Course: An
Innovative Response to the technical Challenges of Trauma Surgery. Visiting
Professor. Cedars-Sinai Medical Center. Los Angeles, CA. November 12, 2008.
Jacobs, L. An Innovation in Surgical Education in Trauma, Grand Rounds.
University of Iowa. February 25, 2009.
Jacobs, L. Invasive Procedures Performed by Prehospital Personnel: The
Indications Should be Broad. American College of Surgeons Point/Counterpoint
Trauma Conference. National Harbor, Maryland. June 8, 2009.
Jacobs, L. Necrotizing Soft Tissue Infections: Is Hyperbaric Oxygen Therapy
Even An Essential Adjunct? American College of Surgeons Point/Counterpoint
Trauma Conference. National Harbor, Maryland. June 8, 2009.
Jacobs, L. Pediatric Trauma Moderator. CT Trauma Conference. Foxwoods
Resort. Ledyard, CT. April 2, 2009.
Jacobs, L. Simulated Education in Trauma. Grand Rounds Speaker. Rush
University, Chicago, IL. October 28, 2008.
Kirton O, Jacobs L, Brautigam R, Hyman N, Kaplan L and Ferguson C.
Rationalization of Acute Care Surgery. Panel Discussion, New England Surgical
Society Annual Meeting. Newport, RI. September 12, 2009.
Kowal-Vern A, Barnett B, Ferrari M, Koenig M, Mah J, Morris L, Powers J,
Stokes E, Tan M, Zaletel C, Cullum M. Comparison of Economic Value of Two
Indwelling Bowel Catheters in the Acute and Critical Care Setting. (Abstract
396). Society of Critical Care Medicine, Gaylord Conference Center, Nashville,
TN, Jan 29-Feb 2, 2009.
Orenstein S, Kaur M, Qiao Y, Klueh U, Kreutzer D, Novitsky Y. Activation of
Goodman MD, Koch SE, Lou Ann Friend, Butler KL. Cardiac Performance is
Preserved Following Pressure-overload Stress in STAT-3 KO Mice. Presented at the
96.

Surgery
Human Monocytes By Human Biologic Meshes In Vitro. Association for Academic
Surgery-2009 Academic Surgical Congress (February 2009) Fort Myers, FL.
Orenstein S, Kreutzer D, Novitsky Y. Human Monocyte Activation by Biologic
and Biodegradable Meshes In Vitro. Society of American Gastrointestinal and
Endoscopic Surgeons - 2009 Annual Meeting (April 2009) Phoenix, AZ.
Orenstein SB, Qiao Y, Klueh U, Kreutzer DL, Novitsky YW. Role of Mast
Cells in the Biocompatibility of Synthetic Mesh in Mice. Fourth International
Hernia Congress -Joint Meeting of the American and European Hernia Societies
(September 2009) Berlin, Germany.
Park B, Madej O, McPhelimy C, Piccirillo B, Dahn M, Burleson JA and Menzoian
JO. Predictors of Clinically Significant Post-Procedure Hypotension Following
Carotid Endarterectomy and Carotid Angioplasty with Stenting. The Society for
Clinical Vascular Surgery Podium Presentation, Ft. Lauderdale, FL, March 8, 2008.
Perdrizet G, Rader C, Allen B, Bass D, Cech A, Castiglione C, Babigian A.
Coverage of Complex Scalp Wounds. Presented at the Northeast Chapter of
the Undersea and Hyperbaric Medical Society Conference/Chapter Meeting,
Newport RI, 11/07.
Rectal Surgeons, Hollywood, Fl, 2009.
Vignati P. Instructor, Laparoscopic Colon Course. American College of Surgeons,
New Orleans, LA 2008.
Vignati P. Instructor, Laparoscopic Hartmann Closure Penn Lap Colon Course.
Philadelphia, PA 2007.
Vignati P. Recurrent Diverticulitis Following Laparoscopic Colectomy. American
Society of Colon and Rectal Surgery, Hollywood Fl 2009.
Zani S, Allen B, Babigian A. “Black Belt” Fracture: A Characteristic Injury in
Trained Martial Artists. Presented at the New England Hand Society Thirty-Fifth
Annual Meeting and Scientific Program, Sturbridge, MA 12/07.
Zani S, Nelson S, Finck C, Babigian A. Congenital/ Infantile Fibrosarcoma of the
Hand: A Multimodality Therapeutic Approach Aimed At Limb Salvage. Presented
at the New England Hand Society Thirty-Sixth Annual Meeting and Scientific
Program, Sturbridge, MA, 12/08.
Poi MJ, Novitsky Y. Laparoscopic Ventral Hernia Repair with Closure of the
Defect: The Shoelace Technique. Presented at the 4th Joint Meeting of the
American Hernia Society (AHS) and The European Hernia Society (EHS); Berlin,
Germany. September 2009.
Poi, MJ, Liang Y, Senatus P, Onyiuke H, Novitsky YW. Laparoscopic-assisted
Ventriculoperitoneal Shunt Placement. Presented at the American College of
Surgeons 95th Annual Clinical Congress; Chicago, IL. October 2009 (Mead/
Pyrtek Fund).
Poi, MJ, Novitsky, Y. Abdominal Wall Reconstruction for Multiple Recurrent
Incisional Hernia with Marked Loss Of Domain. Presented at: The Hernia Repair
2008; Scottsdale, AZ. March 2008 (Mead fund).
Raad W, Onayemi A, Nelson S, Babigian A. Traumatic Forearm Arterio-Venous
Malformation. Presented at the CTACS Scientific and Annual Meeting,
Waterbury, CT, 10/08.
Rowin C, Luu X, Nelson M, Babigian A. Squamous Cell Carcinoma of the Hand
Presenting as a Painless Volar Mass. Presented at the New England Hand Society
Thirty-Sixth Annual Meeting and Scientific Program, Sturbridge, MA, 12/08.
Vignati P. Instructor, Laparoscopic Colon Course. American Society of Colon and

Traumatology
and Emergency Medicine
Lincoln Abbott, MD • Lauri Bolton, MD • Kevin Borrup, JD, MPA
Karyl Burns, PhD • Brendan Campbell, MD, MPH • João Delgado, MD
Michael Drescher, MD • Susan Dufel, MD • James Feeney, MD
Catherine Glazer, MD • Ronald Gross, MD • Jennifer Hiscoe, RN
Lenworth Jacobs, MD, MPH • Kelly Johnson-Arbor, MD
Richard Kamin, MD • Joanne Kuntz, MD • Garry Lapidus, PA-C, MPH
Stephen Luk, MD • Charles McKay, MD • Jacqueline McQuay, RN, MS
Tahira Mirza, MD • Thomas Nowicki, MD • George Perdrizet, MD, PhD
Kenneth Robinson, MD, MHCM • Hassan Saleheen, MBBS, MPH •
Alan Jon Smally, MD
Research is integral to the activities of the Department of Traumatology
and Emergency Medicine at Hartford Hospital. Our mission
includes the conduct of research to improve the clinical, operational, and
educational endeavors across all divisions in the department. The divisions
include the LIFE STAR Critical Care Helicopter Service, the Emergency
Department, the Trauma Program, the Center for Wound Healing and
Hyperbaric Medicine, Toxicology, and the Center for Emergency Medical
Preparedness.
Life Star
The LIFE STAR Critical Care Helicopter Service has a long history of
quality research. Recent projects have included studies regarding the
documentation of medications administered by critical care transport
teams, the use of bispectral analysis to assess sedation in patients requiring
sedation and transported by helicopter, and reasons why LIFE STAR is
cancelled. A recently completed study was a comparison of intra-osseous
and central venous access in helicopter transport.
Emergency Medicine
The Division of Emergency Medicine has had numerous projects relating
to the diagnosis and treatment of medical emergencies. For instance, one
study is examining the interventional management of stroke in a phase III,
randomized, multi-center clinical trial. This study seeks to determine if
a combined IV and IA approach to recanalization is superior to standard
IV rt-PA (Activase) alone. A recently completed study investigated the
relationship of family history and appendicitis. Another study looked
at thrombocytopenia and antiheparin antibodies in adult patients in the
emergency department. A comparison of the Airtraq®α airway device
versus direct laryngoscopy by paramedics in the simulated airway was
also completed by our emergency physicians. A current project is a
study of intimate partner violence in patients with acute overdose.
Research regarding emergency department operations included a study
of over crowding and another about patients who left without being
seen. On the international scene a study was conducted in Israel by
our Associate Chief. It was a randomized, placebo controlled trial of
etoricoxib taken prophylactically to prevent Yom Kippur headache.
The study was funded by Merck, Sharp, Dohme.
Trauma Program
A highlight of projects by the Trauma Program is the TELOS (Trauma
end-of-life optimum support) best practice model supported by the
Aetna Foundation. The model was developed and implemented at
Hartford Hospital and will soon be disseminated nationally. Data
continue to be collected to assess the Advanced Trauma Operative
Management (ATOM) course that is now offered in 26 sites in the
United States, Canada, Ghana, Qatar, Saudi Arabia, and Japan. A
survey of over 1,000 participants in the ATOM Course was recently
completed. Other projects have included examinations of the
relationships of the prehospital use of HMG-Co-A Reductase Inhibitor
and mortality due to hemorrhagic shock associated with ruptured
abdominal aneurysm and hemorrhagic shock due to trauma. A current
study is investigating the relationship of pre-hospital HMG-Co-A
Reductase Inhibitor use in traumatic brain injury. Another ongoing
study is examining the use of a simulator to improve technique
and procedure confidence of surgical residents for emergency
cricothyroidotomy. A study that was recently completed was a
retrospective review of the utilization and costs of routine pelvic x rays
in trauma.
Toxicology and the Center for
Emergency Medical Preparedness
In collaboration with the Center for Emergency Medical Preparedness
at Hartford Hospital the Toxicology Division has been working on a
project to identify normative distributions of plasma and erythrocyte
cholinesterase activity based on demographic and clinical data for
use as a rule-out screen for significant nerve agent toxicity. Other
projects by the Toxicology Division include a study that investigated
98.

cyanmethemoglobin as an alternate laboratory test for the diagnosis of
cyanide toxicity and cyanide and cyanmethemoglobin determinations
in cyanide-exposed individuals. Another study was a retrospective
comparison of safety and efficacy between the oral and the intravenous
form of N-acetylcysteine. Other studies by members of the Toxicology
Division include a comparative pharmacokinetic study of intranasal
Naloxone versus intravenous Naloxone and a poison center surveillance
project regarding the prescription of opioid and amphetamine-related
medication mis-use and abuse. A recently approved study is an
examination of the contribution of lactate, lactate dehydrogenase, and
hemoglobin concentration to alterations in the plasma enzymatic/whole
blood gas chromatography-flame ionization detector ratio for ethanol
determinations.
Center for Wound Healing and
Hyperbaric Medicine
Research in the Center for Wound Healing and Hyperbaric Medicine
includes a collaboration with the Center for Anti-Infective Research and
Development to examine the effect of hyperbaric oxygen therapy on
the penetration of linezolid into subcutaneous tissue of diabetic patients
with lower extremity wounds. Another project is a collaboration with the
Division of Urology to study the effect of hyperbaric oxygen therapy postprostatectomy
erectile dysfunction and urinary incontinence.
As a community of clinicians and researchers, members of the Department
of Traumatology and Emergency Medicine strive to answer research
questions that will ultimately improve patient care. To achieve this goal,
the department has a strong focus on scientific inquiry, scholarship, and
mentoring of young professionals. Our research agenda for the future is to
participate in practice-oriented translational research to promote effective
dissemination and use of evidence-based guidelines, new technologies, and
new ways to educate health care professionals.
New Projects
Industry
Montminy, John, DO
An Investigation of Topical Application of Gaseous Nitric Oxide on Safety and
Efficacy in Venous Stasis Ulcers of the Lower Extremities. Nitric BioTherapeutics,
$63,516.
Drescher, Michael, MD
Randomized, Placebo Controlled Trial of Etoricoxib Taken Prophylactically
to Prevent Yom Kippur Headache. Merck, Sharp & Dohme (Israel-1996) Ltd.
(Investigator Initiated), $18,500. Statistical analysis supported through Hartford
Hospital Small Grant.
Hartford Hospital Research Endowment Funds
Gross, Ronald, MD (Spinella, Philip, MD)
Relationship Between Age of RBCs Transfused and Mortality in Critically Ill
Trauma Patients. Small Grant, $9,861.
Departmental Funds
McKay, Charles M.D.
Contribution of Lactate, Lactate Dehydrogenase, and Hemoglobin
Concentration to Alterations in the Plasma Enzymatic/Whole Blood Gas
Chromatography-flame Ionization Detector Ratio for Ethanol Determinations.
$1,500.
Unfunded
Abbott, Lincoln M.D.
Validation of Core Measure Pneumonia Keyword Filter.
Bolton, Lauri, MD
Comparison of IO and Central Venous Access in Helicopter Transport.
Statistical analysis supported through Hartford Hospital Small Grant.
Burns, Karyl, PhD
Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in
Hemorrhagic Shock Due to Trauma. Statistical analysis supported through
Hartford Hospital Small Grant.
Dufel, Susan, MD
A Survey of Current Emergency Medicine Residents and Graduates of 2002-
2007 Classes Regarding the ABEM Oral Board Certification Examination.
Statistical analysis supported through Hartford Hospital Small Grant.
Feeney, James, MD
Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in
Traumatic Brain Injury. Statistical analysis supported through Hartford Hospital
Small Grant.
Retrospective Review of Pre-hospital HMG Co-A Reductase Inhibitor Use in
Hemorrhagic Shock Due to Ruptured Abdominal Aortic Aneurysm (AAA): An
Exploratory Study. Statistical analysis supported through Hartford Hospital
Small Grant.
Retrospective Review of the Utilization and Costs of Routine Pelvic X rays in
Trauma. Statistical analysis supported through Hartford Hospital Small Grant.
Jacobs, Lenworth, MD
Nonoperative Management of Grade IV and V Splenic Injuries: A RECONECT
(Research Consortium of New England Center for Trauma) Study.
Development of Best Clinical Practice Guidelines for the Mature Trauma Patient
with Rib Fractures.

Kuntz, Joanne, MD
Delivering Bad News: Perceptions of Residency Directors Regarding Current
Practice and Resident Education.
Luk, Stephen, MD
Calciphylaxis and Chronic Dialysis Therapy.
Retrospective Review of Post-Hospital Complications in Victims of Blunt
Abdominal Trauma (BAT).
McKay, Charles, MD
Digoxin Toxicity in Renal Failure with Hyperkalemia.
Mirza, Tahira, MD
CT Chest or CTA Chest for the Diagnosis of Blunt Aortic Injury.
Thibeault, Susan, APRN
Reasons for Cancellation of LIFE STAR Transport by Requester.
Active Projects
Abbott, Lincoln, MD
Interventional Management of Stroke: A Phase III, Randomized, Multi-Center
Clinical Trial to Examine Whether a Combined IV and IA Approach to
Recanalization is Superior to Standard IV rt-PA (Activase) Alone. NIH subcontract
through University of Cincinati, $33,221.
Brautigam, Robert, MD
Evaluation of the Trauma Simulation Education Course.
The Development of Lower Extremity Compartment Syndrome Following
Fractures of the Tibia and Fibula.
Corson, Thomas, DO
Reliability of Emergency Department Patients Contact Information.
Delgado, João, MD
Bispectral Analysis of Air Transport Patients.
Prevalence of Intimate Partner Violence in Acute Overdose Patients
Retrospective Comparison of Safety and Efficacy Between the Oral and the
Intravenous Form of N-acetylcysteine. Rocky Mountain Poison and Drug Center,
$2,200.
Drescher, Michael, MD
Can Family History be used as a Predictor for Appendicitis? Statistical analysis
supported through Hartford Hospital Small Grant.
Overcrowding in the Emergency Department.
Frakes, Michael, APRN
A Comparison of Pre-hospital Trauma Analgesia By Air and Ground EMS
Providers.
Effect of Line Oriented Flight Training On Team Behaviors and Beliefs at a
Helicopter Air Medical Program.
Effectiveness of a Read-and-Respond Checklist in Assuring Safety Behavior
Compliance at a Rotor Wing Air Medical Program.
Evaluation of a Modified Sign-Out Procedure on Hospital Documentation of
Medications Administered by Critical Care Transport Teams.
Evaluation of Helicopter Air Medical Transport Utilization by Prospective
Application of Consensus Criteria.
Glazer, Catherine, MD
Is the Use of D Dimers in A Low Risk Population Cost Effective and Safe in
Ruling Out PE? Statistical analysis supported through Hartford Hospital small
grant
Gross, Ronald, MD
Evaluation of Outcomes After Pancreato-Duodenal Injuries In New England
Hospitals.
Role of Ultrasound in Pre-Hospital Aeromedical Evacuation and Triage. Hartford
Hospital Research Endowment Funds, $10,128.
Jacobs, Lenworth, MD
Advanced Trauma Operative Management (ATOM) Course.
American College of Surgeons Advance Trauma Life Support Course (ATLS).
Bioterrorism Surveillance and Response Preparedness and Training. University of
Connecticut, $50,000.
Development, Implementation, and Testing of a Best Practice Model for End-of-
Life Care in Trauma. Aetna Foundation, $295,000.
Evaluation of the Advanced Trauma Operative Management (ATOM) Course.
Multi-Center Trial of the Advanced Trauma Operative Management (ATOM)
Course.
QuikClot versus Packing For Hemostasis After Grade V Liver Injury in Swine.
Z-Medica, $224,000.
Kuntz, Joanne, MD
Thrombocytopenia and antiheparin antibodies in adult ED patients. Glaxo Smith
Kline, $9,800.
Lewis, Myra, DO
History Taking in Emergency Department Patients Presenting with Acute
Chest Pain.
Luk, Stephen, MD
Crush Injuries and Hyperbaric Oxygen Therapy: Inital Experience at a Level 1
Trauma Center with a Multiplace Hyperbaric Chamber.
Radionecrosis Research Registry.
The Role of Hyperbaric Oxygen Therapy in the Treatment of Severe Soft-Tissue
Infections.
Lynch, John, MD
Emergency Procedures for Emergency Medicine Residents.
100.

McKay, Charles, MD
Comparative Pharmacokinetic Study of Intranasal Naloxone Versus Intravenous
Naloxone. Hartford Hospital Research Endowment Funds, $6,981
Cyanmethemoglobin: An Alternative Laboratory Test for the Diagnosis of Cyanide
Toxicity. Departmental, $2,460.
Normative Distributions of Plasma and Erythrocyte Cholinesterase Activity in a
Tertiary Care Emergency Department, Based on Demographic and Clinical Data,
for Use as a Rule-Out Screen for Significant Nerve Agent Toxicity. HRSA c/o State
of Connecticut, $60,250.
Relationship between CPK and Aminotransferase Elevations in Rhabdomyolysis
Patients. Statistical analysis supported through Hartford Hospital small grant
Nowicki, Thomas, MD
Airtraq Airway Device in Emergency Airway Management. Statistical analysis
supported through Hartford Hospital Small Grant.
Management of the Difficult Airway (CME - Educational Course).
Perdrizet, George, MD
Chart review of the treatment of delayed radiation tissue injury of soft tissue and
bone with hyperbaric oxygen therapy.
Development of a Stress-Sensitive Assay Using Discarded Human Red Blood Cells.
Geriatric Trauma: A Comparison of Bone Fracture Healing Rates. Hartford
Hospital Research Endowment Funds, $43,164.
Minimally Invasive Treatment of the Abdominal Compartment Syndrome: Initial
Experience.
Outcomes of Patients with Diabetic Foot Ulcers Treated with Hyperbaric
Oxygen Therapy.
Prevention of Complicated Alcohol Withdrawal Syndrome in the Hospitalized
Trauma Patient: A Comparison of Intravenous Benzodiazepine vs. Ethyl Alcohol
Therapies. Hartford Hospital Research Endowment Funds, $65,650.
Regan, Thomas, MD
Variations in Usage of Emergency Medicine.
Robinson, Kenneth, MD
Flight Nurse Training of Surgical Skills.
Patients who leave without being seen at the Hartford Hospital Emergency
Department. Statistical analysis supported through Hartford Hospital Small Grant.
Schott, Eric, PA
Evaluation Of Trauma Orientation.
Publications
Brautigam RT, Sheppard R, Robinson K, Jacobs LM. Evaluation and treatment of
the multiple-trauma patient. In: Browner BD, Jupiter JB, Levine AM, Trafton PG.
Skeletal Trauma: Basic Science, Management and Reconstruction, 4th ed. 2009.
Brautigam RT, Schott E, Burns KJ. A simulation education course for the initial
management of blunt trauma. Conn Med. 2009;73:267-271.
Campbell BT, Saleheen H, Borrup K, McQuay J, Luk S, Hiscoe J, Lapidus G.
Epidemiology of trauma at a level 1 trauma center. Conn Med.
2009;73:389-394.
Cronin D, Dufel S. Plague. E-Medicine chapter July, 2009. Available at:http://
emedicine.medscape.com.
Dada MR, Hirst JA, Kiernan FJ, Smally AJ, Lundbye JB, Thompson PD, McKay
RG. Use of prehospital electrocardiograms for the treatment of patients with
ST-segment elevation myocardial infarction. Conn Med. 2009;73(2):69-72.
Drescher M J, Aharonson L, Peleg J, Liebman J. A study of the workforce in
emergency medicine in Israel 2003. J of Emerg Med. 2007;33(4):433-437.
Drescher M. Guest editorial: Patient satisfaction in the ED: nicety or necessity?
Israeli J Emerg Med. 2009;9(1):3-4.
Feeney J M, Burns K J, Staff I, Bai J, Rodrigues N, Fortier J, Jacobs LM.
Prehospital HMG Co-A Reductase Inhibitor use and reduced mortality in
ruptured abdominal aortic aneurysm. J Amer Coll Surg. 2009;209:41-46.
Goldstein RA, DesLauriers, Burda A, Johnson-Arbor K. Cocaine: history, social
implications, and toxicity: a review. SEMIN DIAGN PATHOL. 2009;26:10-17.
Gross RI, Jacobs LM. Initial assessment and resuscitation, airway management:
what every trauma surgeon should know, from intubation to cricothyroidotomy.
In: Asensio JA, Trunkey DD, editors. Current Therapy of Trauma and Surgical
Critical Care. Philadelphia: WB Saunders/Elsevier; 2008.
Hoffman RS, Kirrane BM, Marcus SM, and the Clenbuterol Study Investigators
(McKay C). A descriptive study of an outbreak of clenbuterol-containing heroin.
Ann Emerg Med. 2008;52:548-553.
Jacobs LM, Burns KJ, Bennett Jacobs B. Trauma death: views of the public and
trauma professionals on death and dying from injuries. Arch Surg.
2008;143:730-735.
Lefberg J, Delgado J. Hyper- and Hypo-natremia. In ToxED Online Reference
based on Haddad & Winchester Clinical Management of Poisoning and Drug
Overdose. Elsevier and Gold Standard. V2, 2008. Available at: http://www.
toxed.com.
Matz, T, Abbott, L. Review article: bilateral acute angle closure glaucoma.
Resident and Staff Physician. 2008;(54)3:10-14.
McKay CA. Chlorine. In ToxED Online Reference based on Haddad &
Winchester Clinical Management of Poisoning and Drug Overdose. Elsevier
and Gold Standard. V2, 2008. Available at: http://www.toxed.com.
McLaughlin S, Fitch M, Deepi G, Hayden E, Kauh C, Laack T, Nowicki T et
al. Simulation in graduate medical education 2008: a review for emergency
medicine. Acad Emerg Med. 2008;15 (11):1117-1129.

Nowicki TA, Suozzi JC, Dziedzic M, Kamin R, Donahue S, Robinson K.
Comparison of the use of the Airtraq with direct laryngoscopy by paramedics in
the simulated airway. Prehosp Emerg Care. 2009;13:75-80.
O’Toole K, Delgado J. Methemoglobinemia. In ToxED Online Reference based
on Haddad & Winchester Clinical Management of Poisoning and Drug Overdose.
Elsevier and Gold Standard. V2, 2008. Available at: http://www.toxed.com.
O’Toole K, Delgado J. Glucose Disturbances. In ToxED Online Reference based
on Haddad & Winchester Clinical Management of Poisoning and Drug Overdose.
Elsevier and Gold Standard. V2, 2008. Available at: http://www.toxed.com.
Phelan HA, Velmahos GC, Jurkovich GJ, et al. (Feeney J.).
An evaluation of multidetector computed tomography in detecting pancreatic
injury: results of a multicenter AAST study. J Trauma. 2009;66:641-647.
Scalora MA, Gross RI, Burns KJ. Management of blunt hepatic trauma at a
Connecticut level I trauma center. Conn Med. 2007;71:529-532.
Smally, AJ. Aging in america, in your own words – emergency physicians discuss
end-of-life care. Emergency Physicians Monthly. 2009;16(6).
Vorih DC, Bolton LD, Marcelynas J, Nowick TA, Jacobs LM, Robinson KJ.
Comparison of Nitrile gloves and Nitrile over Nomex gloves. Air Med J.
2009;28:250-253.
Wu AHB, Smith A, McComb R, Bowers GN, Makowski GS, McKay CA,
Vena J, McDonagh J, Hopfer S, Sena SF, Malkus H, Forte E, Kelly K. Statewide
hospital clinical laboratory plan for measuring cholinesterase activity for
individuals suspected of exposure to nerve agent chemical weapons. Clin Toxicol.
2008;46(2):110-116.
Abstracts and Presentations
Alhelail MA, Hoppe JA, Rhyee SH, Heard KJ, Toxicology Investigator Network
(J. Delgado, et al.) Clinical course of repeated supratherapeutic ingestion of
acetaminophen. Platform presentation. 2008 North American Congress of Clinical
Toxicology, Toronto, Canada, September 13-16, 2008.
Brayton A, Delgado D, Flowers D, Delgado J. Prevalence of intimate partner
violence in an urban ED population. New England Regional Society of Academic
Emergency Medicine, Shrewsbury, MA, March 18, 2009.
Buchanan JA, Phua DH, Mlynarchek SL, Heard K, Toxicology Investigator
Network (J. Delgado, et al.) Serum acetaminophen levels, intravenous
N-acetylcysteine infusion rate and risk of anaphylactoid reactions. Platform
presentation. 2008 North American Congress of Clinical Toxicology, Toronto,
Canada, September 13-16, 2008.
Chartoff S. Critical care in the air - en route care system during recent military
operations. Grand Rounds, Department of Traumatology and Emergency Medicine,
Hartford Hospital, Hartford, CT, July 17, 2008.
Chartoff S. Hartford Hospital Emergency Department mass casualty incident,
a table top disaster drill. Grand Rounds, Department of Traumatology and
Emergency Medicine Hartford Hospital, Hartford, CT, January 15, 2009.
Chartoff S. Critical care in the air – en route care system during recent military
operations. Nursing Critical Care Day, Hartford Hospital, Hartford, CT, March
27, 2009.
Drescher MJ, Spence A, Rockwell D, Smally AJ. Point of care testing for
coagulation studies in an emergency department stroke protocol: a time saving
innovation. Scientific Assembly, American College of Emergency Physicians,
Seattle WA. October, 2007. Ann Emerg Med. 2007; 50(3):S25.
Drescher MJ, Spence A, Rockwell D, Smally AJ. Point of care testing for
coagulation studies in an emergency department stroke protocol: a time saving
innovation. Scientific Assembly, Connecticut College of Emergency Physicians,
Rocky Hill, CT, October 10, 2007.
Drescher MJ. Altered standards of medical care in disasters. Annual meeting,
Israeli Association of Emergency Medicine, Tel Aviv, Israel, March 11, 2008.
Drescher MJ, Spence A, Rockwell D, Staff I, Smally AJ. Point of care testing for
coagulation studies in an emergency department stroke protocol: a time saving
innovation. Poster presentation. New England Regional Society of Academic
Emergency Medicine, Shrewsbury, MA, April 30, 2008.
Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis
in adults presenting to the emergency department. Scientific Assembly,
Connecticut College of Emergency Physicians, Rocky Hill, CT, October 22,
2008.
Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis
in adults presenting to the emergency department. Scientific Assembly,
American Academy of Emergency Medicine, Phoenix, AZ, March 2-4, 2009.
Drescher MJ, Marcotte S, Grant R. Family history is a predictor for appendicitis
in adults presenting to the emergency department. New England Regional
Society of Academic Emergency Medicine, Shrewsbury, MA, March 18, 2009.
Drescher MJ. An evidence based approach to urolithiasis in the emergency
department. Fifth Mediterranean Emergency Medicine Congress, Valencia,
Spain, September 14, 2009.
Drescher MJ. A placebo controlled double blind and randomized trial
of prophylactic etoricoxib given to prevent Yom Kippur headache. Fifth
Mediterranean Emergency Medicine Congress, Valencia, Spain, September 15,
2009.
Drescher MJ. Family history is a predictor of appendicitis in the adult emergency
department patient. Fifth Mediterranean Emergency Medicine Congress,
Valencia, Spain, September 16, 2009.
Dziedzic M, Suozzi J, Nowicki T. Comparison of the Airtraq optical
laryngoscope to direct laryngoscopy in a manikin model for easy and difficult
102.

intubations. Poster presentation. Scientific Assembly, American College of
Emergency Physicians, Seattle, WA, October, 2007.
Frakes M, Delgado J. Bispectral analysis of air transport patients. Poster
presentation. Hartford Hospital Research Day, Hartford, CT, November, 2008.
Frakes M, Thibeault S, Robinson K, McQuay J. Evaluation of a modified sign-out
procedure on hospital documentation of medications administered by critical care
transport teams. Poster presentation. Hartford Hospital Research Day, Hartford,
CT, November, 2008.
Frakes M, Thibeault S, Robinson K, McQuay J. Evaluation of a modified sign-out
procedure on hospital documentation of medications administered by critical care
transport teams. Poster presentation. Society of Academic Emergency Medicine,
New Orleans, LA, May 14-17, 2009.
Jacobs LM. Case Presentations Moderator. UT Southwestern Medical Center.
Dallas, TX, October 17, 2007.
Jacobs LM. Advanced Trauma Operative Management: A new and innovative
method of surgical education. Distinguished Lecturer. Royce Laycock, MD,
Lectureship in Surgery. UT Southwestern Medical Center, Dallas, TX, October
17, 2007.
Jacobs LM. New ways to education physicians in a changing time. Trends in
Medicine and Surgery, Beaver Creek, CO, February 5, 2008.
Jacobs LM. The trauma system in Connecticut and its clinical importance. Stable
spine fractures: when should we be concerned? Multidisciplinary Conference,
Hartford Hospital. Hartford, CT, March 20, 2008.
Jacobs LM. Thoracic trauma: have we made any progress? Moderator. Looking
back… moving forward. Connecticut Trauma Conference, Foxwoods Resort and
Conference Center, Ledyard, CT, April 3, 2008.
Jacobs LM. New ways to educate practitioners in a changing time. Keynote
address. Jacobi Medical Center Trauma/Emergency Medicine Symposium, Bronx,
NY, May 14, 2008.
Jacobs LM. Splenic injuries: should the preference be angiography/embolization
over operative intervention? Point/Counterpoint, American College of Surgeons,
Baltimore, MD, June 10, 2008.
Jacobs LM. Closed head injuries and insertion of intracranial pressure monitors:
should this procedure be strictly done by neurosurgeons only? Point/Counterpoint,
American College of Surgeons, Baltimore, MD, June 10, 2008.
Jacobs LM. New topical hemostatic agents: are they cost effective? Point/
Counterpoint, American College of Surgeons, Baltimore, MD, June 10, 2008.
Jacobs LM. Simulated education in trauma. Grand Rounds. Rush University,
Chicago, IL, October 28, 2008.
Jacobs LM. The Advanced Trauma Operative Management Course: an innovative
response to the technical challenges of trauma surgery. Visiting Professor,
Cedars-Sinai Medical Center, Los Angeles, CA, November 12, 2008.
Jacobs LM. An innovation in surgical education in trauma. Grand Rounds.
University of Iowa, Iowa City, IA, February 25, 2009.
Jacobs LM, Burns KJ. Advanced Trauma Operative Management (ATOM)
Course: an exemplar of simulation education scenario development. Poster
presentation. American College of Surgeons Consortium of Accredited
Education Institutes, Chicago, IL, March, 2009.
Jacobs LM. Pediatric trauma. Moderator. Connecticut Trauma Conference,
Foxwoods Resort, Ledyard, CT, April 2, 2009.
Jacobs LM. Necrotizing soft tissue infections: is hyperbaric oxygen therapy
even an essential adjunct? Point/Counterpoint, American College of Surgeons,
National Harbor, MD, June 8, 2009.
Jacobs LM. Invasive procedures performed by prehospital personnel: the
indications should be broad. Point/Counterpoint, American College of
Surgeons, National Harbor, MD, June 8, 2009.
Jacobs LM. Acute care surgeon: should critical care management be an essential
component? Point/Counterpoint, American College of Surgeons, National
Harbor, MD, June 9, 2009.
Jacobs L M, Burns K J, Luk S, Hull S. Advanced Trauma Operative Management
(ATOM) Course: participant survey. Poster presentation. New England Surgical
Society, Newport, RI, September 12, 2009.
Johnson-Arbor K. Drugs of abuse for EMS providers. LIFE STAR EMS
Conference, Hartford, CT, October 29, 2007.
Johnson-Arbor K. Toxicologic emergencies. LIFE STAR EMS Conference,
Hartford, CT, October 29, 2007.
Johnson-Arbor K. Hyperbaric oxygen therapy: intracranial abscess,
osteomyelitis, acute blood loss anemia, carbon monoxide poisoning. University
of Hartford, Hartford, CT, CT, November 26, 2007.
Johnson-Arbor K. Pressure ulcers: overview and medicolegal issues. PA/NP
Grand Rounds, Hartford Hospital, Hartford, CT, March 4, 2008.
Johnson-Arbor K. Toxins and envenomations for the intensivist. Surgical ICU
Conference, Yale New-Haven Hospital, New Haven, CT , March 18, 2008.
Johnson K. Chemical contamination of food, water, and medication. Toxic
Industrial Chemicals and Materials Conference, American College of Medical
toxicology, Knoxville, TN, May 29, 2008.
Johnson-Arbor K. Pressure ulcers and wounds for ED physicians. Integrated
Residency in Emergency Medicine, University of Connecticut, Hartford, CT,
September 23, 2008.

Judson B, Tilden F, Delgado J, Dean A. Availability of emergency ultrasound: a
statewide survey. Poster presentation. New England Regional Society of Academic
Emergency Medicine, Shrewsbury, MA, April 30, 2008.
Judson B, Tilden F, Delgado J, Dean A. Availability of emergency ultrasound: a
statewide survey. Poster presentation. Scientific Assembly, Connecticut College of
Emergency Physicians, Rocky Hill, CT, October 22, 2008.
Kirton O, Jacobs L, Brautigam R, Hyman N, Kaplan L, Ferguson C.
Rationalization of acute care surgery, Panel Discussion. New England Surgical
Society. Newport, RI, September 12, 2009.
Luk S. Presentation, diagnosis & treatment of major bleeding pelvic vs. other
sources. Orthopedic Multidisciplinary Conference, Hartford Hospital, Hartford,
CT, August 1, 2008.
Luk S. Advanced Trauma Operative Management (ATOM) Course. University of
Alberta, Edmonton, Alberta, Canada, November 9, 2007.
Luk S. Advanced Trauma Operative Management (ATOM) Course. University of
Iowa Hospitals and Clinics, Iowa City, IA, November 19, 2007.
Luk S. Advanced Trauma Operative Management (ATOM) Course. University of
Texas Medical Branch, Galveston, TX, May 20, 2008.
Luk S. Advanced Trauma Operative Management (ATOM) Course. Massachusetts
General Hospital, Boston, MA, June 1, 2008.
Luk S. Pelvic fracture management. Grand Rounds. University of Iowa Hospitals &
Clinics, Iowa City, IA, September 30, 2008.
Luk S. Advanced Trauma Operative Management (ATOM) Course, Course faculty
and site evaluator. King Abdulaziz Medical City & Hamad Medical Corp., Doha,
Qatar, November 27, 2008.
Luk S. Advanced Trauma Operative Management (ATOM) Course, Course faculty
and site evaluator. Jichi Medical University, Jichi, Japan, December 18, 2008.
Luk S. What’s new in the diagnosis and management of pelvic trauma? William
Backus Hospital, Norwich, CT, January, 2009.
Martinelli CJ, Barko IR, O’Toole K, Bayer MJ. “Vitamin” B17 toxicity treated with
hydroxocobalamin. Clin Toxicol. 2008;46: 631.
McKay CA. Interpreting biomonitoring results. Environmental Health Research
Foundation web video, October 2007.
McKay CA. The role of the medical toxicologist in the assessment of moldrelated
complaints. American College of Medical Toxicology Practice Symposium
(moderator), North American Congress of Clinical Toxicology, New Orleans, LA,
October 22, 2007.
McKay CA. Arsenic. Clinical/Analytical Toxicology Case Conference,
Connecticut Department of Public Health Laboratory, Hartford, CT, October 25,
2007.
McKay CA. Introduction/clinical neurotoxicology of chemical terrorism/
delayed toxic syndromes - chemical Agents of Opportunity: Toxic Industrial
Chemicals and Materials Conference, HazMat EXPO 2007, Las Vegas, NV,
November 6, 2007.
McKay CA. Carbon monoxide poisoning in Connecticut: an analysis of three
databases using capture-recapture statistics. Undersea and Hyperbaric Medical
Society Northeast Chapter Annual Scientific Meeting, Newport, RI, November
10, 2007.
McKay CA. Decompression theory and illness. Hyperbaric Medicine Course
(HS490). University of Hartford, Hartford, CT, November 19, 2007.
McKay CA. Cotinine. Clinical/Analytical Toxicology Case Conference,
Connecticut Department of Public Health Laboratory, Hartford, CT, November
29, 2007.
McKay CA. Environmental instrumentation/post-incident medical surveillance
- chemical agents of opportunity. Toxic Industrial Chemicals and Materials
Conference, American College of Medical Toxicology, Oakland, CA, December
18, 2007.
McKay CA. Introduction/post-incident medical surveillance - chemical agents
of opportunity. International Emergency Management Conference. Emergency
Medicine Learning Resource Center, Orlando, FL, January 31, 2008.
McKay CA. Legal (forensic) ethanol. Clinical/Analytical Toxicology Case
Conference, Connecticut Department of Public Health Laboratory, Hartford,
CT, February 28, 2008.
McKay CA. Munchausen by proxy. Clinical/Analytical Toxicology Case
Conference, Connecticut Department of Public Health Laboratory, Hartford,
CT, March 27, 2008.
McKay CA. Introduction and tabletop exercise. Toxic Industrial Chemicals and
Materials Conference, American College of Medical Toxicology, Knoxville, TN,
May 29, 2008.
McKay CA. Cellular toxins. American Association of Poison Control Centers
Webcast, June 13, 2008.
McKay CA. Adulterated heroin. Clinical/Analytical Toxicology Case
Conference, Connecticut Department of Public Health Laboratory, Hartford,
CT, June 19, 2008.
McKay CA. Food, water and medication as vehicles for terrorism and radiation
- chemical agents of opportunity. Toxic Industrial Chemicals and Materials
Conference. 94th Civil Support Team/National Guard, Guam, July 16, 2008.
McKay CA. Chemical terrorism. Connecticut Laboratory Preparedness
Meeting, Connecticut Department of Public Health Laboratory, Hartford, CT,
August 4, 2008.
104.

McKay CA. Toxic warfare: looking beyond conventional chemical weapons.
Force Health Protection Conference, United States Army Center for Health
Promotion and Preventive Medicine (USACHPPM), Louisville, KY, August 5,
2008.
McKay CA. The psychological impact of mass chemical exposures. Force Health
Protection Conference, United States Army Center for Health Promotion and
Preventive Medicine (USACHPPM), Louisville, KY, August 5, 2008.
McKay CA. Introduction. Toxic Industrial Chemicals and Materials Conference,
Force Health Protection Conference, United States Army Center for Health
Promotion and Preventive Medicine; Albuquerque, NM, August 10, 2008.
McKay CA. Melamine-contaminated Chinese food products. Clinical/Analytical
Toxicology Case Conference, Connecticut Agricultural Experiment Station, New
Haven, CT, October 23, 2008 (with MaryJane Mattina PhD).
McKay CA. Introduction/clinical psychological responses to mass exposures.
Chemical agents of opportunity. Toxic Industrial Chemicals & Materials
Conference, Hazmat Expo 2008, Las Vegas, NV, November 5, 2008.
McKay CA. History & epidemiology/table top exercise. Health Consequences of
Clandestine Methamphetamine Laboratories Conference, Hazmat Expo 2008,
Las Vegas, NV, November 5, 2008.
McKay CA. Medical aspects of crucifixion, symposium and banquet. FaithCare,
Bloomfield, CT, November 8, 2008.
McKay CA. Homicidal poisoning. Clinical/Analytical Toxicology Case
Conference. Connecticut Department of Public Health Laboratory, Hartford, CT,
November 20, 2008.
McKay CA. Lethal poisoning. Caribbean Emergency Medicine Congress,
University of the West Indies and the American Academy of Emergency
Medicine, Barbados, West Indies, January 5, 2009.
McKay CA. Chemical terrorism. Caribbean Emergency Medicine Congress,
University of the West Indies and the American Academy of Emergency
Medicine, Barbados, West Indies, January 7, 2009.
McKay CA. Risk communication, neurotoxicology update: advances, challenges,
& future directions. 7th Annual ACMT Spring Conference, American College of
Medical Toxicology, San Juan, Puerto Rico, March 27, 2009.
McKay CA. Mercury exposure & neurotoxicology update: advances, challenges,
& future directions. 7th Annual ACMT Spring Conference, American College of
Medical Toxicology, San Juan, Puerto Rico, March 28, 2009.
McKay CA. Fellows-in-training: roundtable luncheon: assessment of job offers.
7th Annual ACMT Spring Conference, American College of Medical Toxicology,
San Juan, Puerto Rico, March 28, 2009.
McKay CA. Physiologic effects of chemical terrorism. Responding to a chemical
terrorism attack: training for the first responder. Connecticut Department of
Public Health (with FBI, CT State Police, 14th CST, US DHS), Berlin, CT, April
14, 2009.
McKay CA. Use of drug testing in child protection cases. 10th Annual Child
and Youth Law Forum, Cromwell, CT, June 24, 2009 (presentation and panel
discussion w/Attnys. Michael Besso, Scott Sandler, and Carolyn Signorelli).
Mckinney C, Bolton L, Robinson K, Burns K. Characterization of patients
who leave an emergency department without being seen. Scientific Assembly,
American College of Emergency Physicians, Seattle, WA, October 1, 2007.
Mlynarchek SL, Bogdan GM, Heard K, Dart RC, Toxicology Investigator
Network (J. Delgado, et al.). Safety profile of oral versus intravenous
N-acetylcysteine for acute ingestion of acetaminophen. Poster Presentation. 2008
North American Congress of Clinical Toxicology, Toronto, Canada, September
13-16, 2008.
Nowicki TA. Triage of NBC Casualties. Estonian National Medical Conference,
Tartu, Estonia, December, 2007.
Nowicki T. Nuclear and Radiation Emergencies. Estonian Military Physician
Group, Tartu, Estonia, December, 2007.
Nowicki T. Management of the difficult airway, skills laboratory faculty
instructor. 37th Critical Care Congress, Society of Critical Care Medicine,
Honolulu, HI, February 2-6, 2008.
Nowicki T, Dziedzic M, Suazzi J. Comparison of the Airtraq optical laryngoscope
to direct laryngoscopy in a manikin model for easy and difficult intubations. New
England Regional Society of Academic Emergency Medicine, Shrewsbury, MA,
April 30, 2008
Palla K, Jacobs L, Burns K, Luk S, Hull S. Survey of participants attending the
Advanced Trauma Operative Management (ATOM) Course at all sites worldwide
since its inception. Scientific and Annual Meeting, Connecticut Chapter
American College of Surgeons, Waterbury, CT, October 24, 2008.
Robinson K. Developing a three-year marketing plan. Medical Director Forum,
Air Medical Physician Association, Minneapolis, MN, October 1, 2008.
Roche KM, Hart K, Sangalli B, Lefberg J, Bayer M. Kratom: A case of a legal
high. Clin Toxicol. 2008;46:598.
Schnatz PF, Vaidyanathan G, Surette A, Tower M, Price C, Delgado J, Sundaram
K. The medical needs and demographic makeup of menopausal women in a rural
Nigerian village. Poster presentation. 2008 North American Menopause Society
Annual Meeting, Orlando, FL, September 24-27, 2008.
Smally AJ. Management of the difficult airway. Caribbean Emergency Medicine
Congress, University of the West Indies and the American Academy of
Emergency Medicine, Barbados, West Indies, January 7, 2009.
Zosel AE, Varney SM, Heard K, Toxicology Investigator Network
(J. Delgado, et al.). Outcomes of acetaminophen ingestion patients unable to be
classified as acute or repeated supratherapeutic ingestions. Poster Presentation.
2008 North American Congress of Clinical Toxicology, Toronto, Canada,
September 13-16, 2008. UROLOGY

Urology
The Department of Urology continues to expand its research capacity.
Recently the Department welcomed Anoop Meraney, MD. Dr.
Meraney, who completed fellowships at the Cleveland Clinic and at
Memorial Sloane Kettering, will be spending a portion of his time in
the department reviewing its current research efforts and programs and
directing the development of a comprehensive urology database which
will be supported by the hospital.
The Department’s current research includes important work by Drs. Joseph
Wagner and Stuart Kesler comparing the results and complications of
robotic prostatectomy vs traditional prostatectomy. Hartford Hospital
performs more robotic procedures (urologic, gynecologic, and cardiac)
than any hospital in New England. The data obtained through the robotic
prostatectomy studies performed at Hartford Hospital compare favorably
with other high volume centers nationally and verify the excellent clinical
outcomes being obtained at this institution.
New Projects
Unfunded
Wagner, Joseph, MD
Use of Robotic Assistance in Laparoscopic Ureteral Surgery.
Active Projects
Shichman, Steven, MD
Trends in Renal Cancer Surgery: The Hartford Hospital Experience. Analysis
supported by Hartford Hospital Small Grant.
Hartford Hospital Nephrectomy Research Database. Database supported by
Hartford Hospital Small Grant.
Publications and Presentations
Ercole B, Staff I, Champagne A, Tortora J, Kesler SS, Laudone VP, and Wagner
JR. Complications of Robotic Assisted Laparoscopic Prostatectomy: Review and
Assessment of Risk Factors. American Urological Association New England
Section Annual Meeting, Rio Grande, Puerto Rico, 2008. Abstract #28, page 143.
SS, Wagner JR and Laudone VP. Does Prior Abdominal Surgery Influence
Outcomes or Complications of Robotic Assisted Laparoscopic Radical
Prostatectomy? American Urological Association New England Section Annual
Meeting, Rio Grande, Puerto Rico, 2008. Abstract #5, page 59.
Ginzburg S, Staff I, Tortora J, Champagne A, Shichman S, Kesler S, Laudone
VP, Wagner JR. Prostate Cancer Biochemical Recurrence Rates After Robot
Assisted Laparoscopic Radical Prostatectomy. American Urological Association
New England Section Annual Meeting, Washington, DC, 2009. Abstract #13,
pages 83-84.
Ginzburg S, Staff I, Tortora J, Champagne A, Shichman S, Kesler S, Laudone
VP, Wagner JR. Functional Outcomes After Robot Assisted Laparoscopic
Radical Prostatectomy. American Urological Association New England Section
Annual Meeting, Washington, DC, 2009. Abstract #14, pages 85-86.
Irwin BH and Wagner JR. Complications of robotic surgery. In Complications of
Urologic Surgery: Prevention and Diagnosis. Taneja (Ed.). 4th Edition. Elsevier,
2009.
Myer EG and Wagner JR. Robotic-assisted laparoscopic bladder
diverticulectomy. J. Urol., 178 (6): 2406-2410, 2007.
Schimpf M, Gottenger E, and Wagner J. Universal ureteral stent placement at
hysterectomy to identify ureteral injury: A decision analysis. BJOG, 115 (9):
1151 -1158, 2008.
Schimpf MO and Wagner JR. Robotic-assisted laparoscopic boari flap ureteral
reimplantion. J. Endourol., 22(12): 2691-4, 2008.
Schimpf MO and Wagner JR. Robotic-assisted laparoscopic distal ureteral
surgery. JSLS 13(1):44-9, 2009.
Schimpf MO and Wagner JR. Robotic-assisted laparoscopic ureterocalicostomy
with long-term follow-up. J. Endourol. 23(2): 293-5, 2009.
Wagner JR and Schimpf MO. Robot assisted laparoscopic boari flap and ureteral
reimplantation. J. Urol. 181(4): V1547, 553, 2009.
Wagner JR, Schimpf MO, and Cohen JL. Robot-assisted laparoscopic ileal
ureter. JSLS 12 (3): 306-9, 2008.
Ginzburg S, Hu F, Staff I, Tortora, J, Champagne A, Salner A, Shichman S, Kesler
106.

Women’s Health Services Collaborative
Management Team
Joel Sorosky, MD, Janice Cousino RNC, MSN, CNS
and John Greene, MD
Women’s Health
New Projects
Industry
Steinberg, Adam, DO
A Phase 2, 16 Week, Multicenter, Randomized, Double Blind, Placebo Controlled
Parallel Group Proof of Concept Study Evaluating the Efficacy and Safety of PF-
04383119 for the Treatment of Pain Associated with Interstitial Cystitis. Pfizer,
Inc.(MultiCenter), $44,163.
Hartford Hospital Research Endowment Funds
Collins, Sarah, MD
Perioperative Exercise Tolerance and Pain Control in Women Undergoing
Robotic vs Traditional Abdominal Sacral Colpopexy. Small Grant, $8,428.
Patel, Minita, MD
The Use of SennaS for Prevention of Post-operative Constipation After
Urogynecologic Surgery: A Randomized Double Blinded Placebo Controlled
Trial. Small Grant, $9,758.
Unfunded
Borgida, Adam, MD
Determining the Significance of Nuchal Translucency and Pregnancy Associated
Plasma Protein-A in Relation to Adverse Outcomes in the Euploid Fetus.
Outcomes of Fetal Cystic Hygroma Detected at First Trimester Ultrasound.
Predictors of Neonatal Morbidity and Mortality in the Extremely Low Birth
Weight Infant.
Trends in Near-Term Preterm Births at Hartford Hospital.
Brown, Amy, MD
The Impact of a Structured Training Program on Gynecology Residents’ Attitudes
Towards Robotic Assisted Surgery.
Collins, Sarah, MD
Patient Characteristics Associated PISQ-12 Completion. Statistical Analysis
supported through Hartford Hospital Small Grant.
The Impact of Flatal Incontinence on Quality of Life and Sexual Function.
Statistical Analysis supported through Hartford Hospital Small Grant.
Delude, Cassandra
Floor Disorders in Women Under the Age of 65: Quality of Life and
Care-Seeking Behavior.
Feldman, Deborah, MD
Indications for Full-term NICU Admission in a Large Urban Community Hospital.
Risk Factors and Clinical Implications of Cesarean Hysterectomy.
Greene, John, MD
An Institutional Ethnography of the Practice of Male Neonatal Circumcision.
Ingardia, Charles, MD
Effect of Placental Lakes on First Trimester Serum Screening Results.
Johnson, Amy, MD
Is Adenomyosis Associated with Preterm Delivery?
LaSala, Christine, MD
Causes of Overactive Bladder in Women from a Urogynecology Practice.
Statistical Analysis supported through Hartford Hospital Small Grant.
Does Short Interval Pregnancy Increase Risk of Pelvic Floor Disorders?

Patel, Minita, MD
A Cost Minimization Analysis of Three Surgical Procedures for Sacral
Colpopexy. Statistical Analysis supported through Hartford Hospital Small
Grant.
Bother Symptoms and Quality of Life as Related to Prolapse. Statistical Analysis
supported through Hartford Hospital Small Grant.
The Utility of the Beef Tongue Model for Teaching Residents Anatomy and
Repair of a Fourth Degree Laceration. Statistical Analysis supported through
Hartford Hospital Small Grant.
Urinary Incontinence Outcomes After Sacral Colpopexy. Statistical Analysis
supported through Hartford Hospital Small Grant.
Written Survey of How Vaginal Pessaries Affect Body Image in Pelvic Organ
Prolapse. Statistical Analysis supported through Hartford Hospital Small Grant.
Pope, Kisti, MD
Ultrasonographic Evaluation of Post-Partum Endometrial Stripe.
Spencer, Jeffrey, MD
Levels of Cell-Free Fetal DNA in Maternal Plasma in Pregnant Patients with
Euploid and Aneuploid Fetuses.
Natural History of Isolated Fetal Intracardiac Focus and its Relationship to Down
Syndrome.
Active Projects
Beck, Cheryl, DNSc
Docosahexaenoic Acid in Pregnancy: Postpartum Depression.
Borgida, Adam, MD
Effect of Mode of Delivery of 23-28 Week Infants on Infant Morbidity and
Mortality.
Infant Neuronal Maturity and Tobacco Use in Pregnancy: Is There An
Association?
Pregnancy Outcomes After Prenatal Exposure to Antidepressants.
Pregnancy Outcomes of Women Who Report Antepartum Depression.
Trends in Down Syndrome Screening.
Trends in Mode of Delivery for Clinic Versus Private Patients From 1988-2005.
Brown, Susanne, RN
Does Simulation Training Improve Nursing and Resident’s Clinical Performance?
Collins, Sarah, MD
Sexual Activity and Function in Women with Pelvic Floor Disorders.
Currie, John, MD
ChemoFx Registry: An Observational, Longitudinal, Multi-center Study
Examining Outcomes Associated with the Use of the ChemoFx Assay in Solid
Tumor Malignancies. Precision Therapeutics, $30,031.
Feldman, Deborah, MD
A Comparison of Antenatal Betamethasone vs Dexamethasone in Reducing
Neonatal Complications of Prematurity.
Short-term Outcomes of Neonatal Congenital Heart Disease.
Gonci, Mary-Ellen, APRN
Oral Health and its Implications During Pregnancy.
Greene, John, MD
Cigarette Smoking and Effects on Infant/Child Health. UCHC, $37,025.
Resident Education Research Blanket Protocol. Statistical Analysis supported
through Hartford Hospital Small Grant.
Transcatheter Arterial Embolization of Uterine Fibroids.
Johnson, Amy, MD
A Prospective Cohort Study Comparing the Discontinuation Rates Between
Levonorgestrel-Releasing Intrauterine Systems and Etonogestrel Subdermal
Single-Rod Contraceptive Implants in a Residency Clinic Population.
An Institutional Review of Management Outcomes for High Grade Cervical
Dysplasia in Adolescent Women.
Incidence of HPV in an Inner City Population without Dysplasia. Statistical
Analysis supported through Hartford Hospital Small Grant.
Is Breast Arterial Calcification (BAC) Found on Routine Mammography
Associated with an Increased Risk of Cardiovascular Disease? Statistical Analysis
supported through Hartford Hospital Small Grant.
Is Menopause the Same Cross-Culturally? Wyeth Pharmaceuticals, $4,000.
The Role Of The Provider In Racial And Ethnic Disparities In Prenatal Care. CT
Health Foundation, $5,000.
LaSala, Christine, MD
Is Isolated Rectocele Repair Associated with Post-Operative Voiding
Dysfunction? Statistical Analysis supported through Hartford Hospital Small
Grant.
Outcomes of Vaginal Prolapse Surgery on Urinary Continence.
Porcine-Derived Small Intestine Submucosa Graft-Augmented Rectocele Repair -
A Randomized Trial.
Patel, Minita, MD
Anal Incontinence and Impact on Sexual Function. Statistical Analysis supported
through Hartford Hospital Small Grant.
108.

Satherlie-Deasy, Lynn, RN
Food Insecurity, Meal Skipping, Nutrient Intakes and Pregnancy Outcomes
Among Low-Income Latinas.
Schimpf, Megan, MD
Are Mondays and Fridays the Busiest Days for Nursing Phone Triage in a
Urogynecology Office Practice?
Is There a Relationship Between Glomerular Filtration Rate and Detrusor
Overactivity in Women? Statistical Analysis supported through
Hartford Hospital Small Grant.
Using Color, Clarity and Smell to Predict Urinary Tract Infections in
Community-Dwelling Women.
Schnatz, Peter, DO
Comparison of Hormonal Therapy Tapering Regimens for Mediating Hot
Flashes. Hartford Hospital Research Endowment Funds, $56,623.
A Comparison of Skin Closure Techniques after Primary Cesarean Delivery.
Ethicon, Inc., $3,000.
A Retrospective Analysis of Cervical Polyps. Statistical Analysis supported
through Hartford Hospital Small Grant.
Association of Adolescent and Early Adult Pregnancy with Future Development
of Postmenopausal Osteoporosis. Statistical Analysis supported through Hartford
Hospital Small Grant.
Factors Influencing a Third-Year Medical Student’s Decision to Choose
Obstetrics and Gynecology Versus Another Specialty Prior to Beginning Clinical
Rotations. Departmental, $400. Statistical Analysis supported through Hartford
Hospital Small Grant.
Relative Importance of Gender in Patients’ Selection of Obstetrics and
Gynecology Provider. Statistical Analysis supported through Hartford Hospital
Small Grant.
Shaneyfelt, Kristin, DO
Is an ECC Always Necessary During the Colposcopic Evaluation of an Abnormal
Pap Smear?
Sorosky, Joel, MD
GOG 220: Pelvic Mass Study to Develop Serum Proteomic Profiles (Signatures)
for Epithelial Ovarian Cancer Diagnosis and Prognosis. GOG, $8,712.
Women’s Health Clinical Outcomes Protocol. Statistical Analysis supported
through Hartford Hospital Small Grant.
Spencer, Jeffrey, MD
Outcomes of Triplet Gestations Based on Chorionicity.
Screening for Fetal Aneuploidy: A Patient Survey.
Steinberg, Adam, MD
Prolift’s Effect on Post-Operative Hematocrit. Statistical Analysis supported
through Hartford Hospital Small Grant.
Stepnowski, Roxanne, PsyD
Antepartum Depression Inventory: A Comparative Analysis of Performance With
The Beck Depression Inventory. Hartford Hospital Research Endowment Funds,
$9,966.
Taylor, Linda, MD
Patient-Centered Techniques to Enhance Outcomes for Abdominal
Hysterectomy. Hartford Hospital Research Endowment Funds, $10,000.
Tulikangas, Paul, MD
A Comparison of Connective Tissue Remodeling in the Pelvic Floor of Pre and
Postmenopausal Women. NIH / University of Pittsburgh, $4,820.
Late-Pregnancy Fears of Labor and Delivery in Nulliparous Pregnant Women: A
Survey. Hartford Hospital Research Endowment Funds, $8,840.
Watson, James, MD
Recent Trends in VBAC at Hartford Hospital.
Young, Sara, MSN
Breastfeeding Education and Support Trial for Obese Women (BESTOW).
Donaghue Medical Research Foundation/University of Connecticut, $20,590.
Breastfeeding Education and Support Trial for Obese Women: Early Dyad
Dynamics (BESTOW:EDD). University of Connecticut, $16,796.
Publications and Abstracts
Allen GL, Klobocista MM, Sugarman S, Gravel K, Feldman DM,
Schnatz PF. Prevalence of high-risk human papillomavirus in an
inner-city population with atypical squamous cells of undetermined
significance. Journal of Lower Genital Tract Disease, 13(2): 63-65,
April 2009.
Batal I, Domsic RT, Shafer A, Medsger TA Jr, Kiss LP, Randhawa P,
Bastacky S. Renal biopsy findings predicting outcome in scleroderma
renal crisis. Hum Pathol. 2009 Mar;40(3):332-40.
Berzolla CE, Schnatz PF, O’Sullivan DM, Bansal R, Mandavilli
S, Sorosky JI. Dysplasia and malignancy in endocervical polyps.
Journal of Women’s Health. 16(9):1317-21, 2007 Nov.
Boggess JF, Gehrig PA, Cantrell L, Shafer A, Mendivil A, Rossi E,
Hanna R.Perioperative outcomes of robotically assisted hysterectomy
for benign cases with complex pathology. Obstet Gynecol. 2009
Sep;114(3):585-93.
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of

evacizumab in persistent or recurrent epithelial ovarian cancer or
primary peritoneal cancer: a Gynecologic Oncology Group Study.
Journal of Clinical Oncology. 25(33):5165-71, 2007.
Cuzzone D, Allen B, Rowin C, Tulikangas PK, Babigian A.
Development of vaginal erosion and vesicocutaneous fistula
following midurethral transvaginal tape with Pelvilace. International
Wound Journal. 2009;6(1):55-8.
Egan J, Fang YMV, Kaminski L, Smith K, Turner G, Benn P. Changes
in antenatal Down Syndrome risk assessment in the US from 2001 to
2007. Am J Obstet Gynecol 2007;197: 589 (suppl).
Egan J, Fang YMV, Kaminski L, Campbell W, Spencer J, Benn P.
Changes in Down Syndrome screening practices in the US from
2001 to 2007. Am J Obstet Gynecol 2007;197: 149 (suppl)
Fang YM, Benn P, Campbell W, Bolnick J, Prabulos AM, Egan JF.
Down syndrome screening in the United States in 2001 and 2007: a
survey of maternal-fetal medicine specialists. Am J Obstet Gynecol.
2009 Jul; 201(1):97.e1-5.
Fang YMV, Benn P, Egan JF. Use of the genetic sonogram in
the United States in 2001 and 2007. J Ultrasound Med. 2008
Nov;27(11):1543-8.
Fang YMV, Benn P, Tribulato K, Fitzpatrick C, Bolnick J , Egan J.
Down Syndrome screening strategies utilized by United States
Maternal-Fetal Medicine specialists in 2007. Am J Obstet Gynecol;
197: 588 (suppl).
Fang YMV, Egan J, Benn P, Magidina I, Prabulos AM, Sanders M.
Placental pathologic findings associated with intrauterine growth
restriction, preeclampsia and normal pregnancies. Am J Obstet
Gynecol. 2008; 199: S97.
Fang YMV, Egan JFX, Kaminsky L, Bolnick J, Prabulos A, Benn P.
The growing acceptance of second trimester ultrasound to identify
aneuploid fetuses: Markers used in the genetic sonogram by United
States practitioners in 2001 and 2007. J Ultrasound Med 2008;27:
S46 (suppl).
Fang YMV, Egan J, Sanders M, Magidina I, Bolnick J, Benn P.
Placental pathologic findings seen in preterm deliveries, intrauterine
fetal demises, and uncomplicated full term deliveries. Am J Obstet
Gynecol. 2008; 199: S106.
Fang YMV, Egan J, Sanders M, Magidina I, Bolnick J, Mackeen D,
Benn P. Prediction of adverse pregnancy outcome using the results of
the second trimester quadruple maternal serum screening test. Am J
Obstet Gynecol. 2008; 199: S193.
Fang YMV, Mackeen D, Dileo C, Egan J, Zelop C. Insulin glargine
(Lantus) compared with neutral protamine hagedorn insulin in the
treatment of pregnant diabetics. Obstet Gynecol. 2008;111:108S.
Fang YM, MacKeen D, Egan JF, Zelop CM. Insulin glargine compared
with Neutral Protamine Hagedorn insulin in the treatment of pregnant
diabetics. J Matern Fetal Neonatal Med. 2009 Mar;22(3):249-53.
Fang YM, Egan JF, Rombro T, Morris B, Zelop CM. A comparison of
reasons for choosing obstetrician/gynecologist subspecialty training.
Conn Med. 2009 Mar; 73(3):165-70.
Johnson AM, Schnatz PF. Gender preferences in ObGyn clinic vs
private patients.
Connecticut Medicine. 73(4):205-9, 2009 Apr.
Madom LM, Brown AK, Lui F, Moore RG, Granai CO, DiSilvestro
PA. Lower uterine segment involvement as a predictor for lymph node
spread in endometrial cancer Gynecologic Oncology, 107:75-78,
2007.
Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard JW,
Granai CO, Bast RC, Lu K. Utility of a novel serum tumor biomarker
HE4 in patients with endometrioid adenocarcinoma of the uterus.
Gynecologic Oncology, 110: 196-201, 2008.
Moore RG, Brown AK, Miller CM, Skates S, Allard J, Verch T,
Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The
use of multiple novel tumor biomarkers for the detection of ovarian
carcinoma in patients with a pelvic mass. Gynecologic Oncology,
108:404-408, 2008.
Moore RG, McMeekin SD, Brown AK, DiSilvestro PA, Miller CM,
Allard JW, Gajewski W, Kurman RJ, Bast RC, Skates SK. A novel
multiple marker bioassay utilizing HE4 and CA125 for the prediction
of ovarian cancer in patients with a pelvic mass. Gynecologic
Oncology, 112:40-46, 2009.
Moore RG, Robison K, Brown AK, DiSilvestro PA, Steinhoff M, Noto
R, Brard L, Granai, CO. Isolated Sentinel lymph node dissection with
conservative management in patients with squamous cell carcinoma
of the vulva: A Prospective Trial. Gynecologic Oncology, 109:65-70,
2008.
Nieves L, Currie J, Hoffman J Sorosky JI. Ototoxicity after
intraperitoneal chemotherapy: a case report. International Journal of
Gynecological Cancer. 17(5):1133-1135, September/October 2007.
[Letter.][Correspondence and Brief Report]
Nieves L, Hoffman J, Allen G, Currie J, Sorosky JI. Placental-site
trophoblastic tumor with PET scan-detected surgically treated lung
metastasis. International Journal of Clinical Oncology. 13(3):263-5,
2008 Jun.
Patel M, O’Sullivan DM, Steinberg AC. The impact of anal
110.

incontinence on sexual function. Journal of Reproductive Medicine.
2009;54(8):493-499
Patel M, O’Sullivan DM, Tulikangas PK. A comparison of costs
for open, laparoscopic and robot assisted sacral colpopexy. Int J
Urogynecol J Pelvic Floor Dysfunct. 2009(20):223-8.
Rotter MA, Schnatz PF, Currier AA Jr., O’Sullivan DM. Breast
arterial calcifications (BACs) found on screening mammography and
their association with cardiovascular disease. Menopause. 15(2):276-
81, 2008 Mar-Apr.
Saks E, Vakili B, Steinberg AC. Primary Amenorrhea with a
periumbilical abdominal mass. J of Pediatric and Adolescent
Gynecology. 2009: 22 (1): E1-3
Schimpf MO, O’Sullivan DM, Steinberg AC, LaSala CA, Tulikangas
PK. Patterns of phone calls to a nursing triage line in a urogynecology
practice. Urologic Nursing 2008; 28(3):213-216.
Schimpf MO, O’Sullivan DM, Steinberg AC, LaSala CA, Tulikangas
PK. Is there a relationship between glomerular filtration rate and
detrusor overactivity in women? Neurourol. Urodyn. 2009; 28(3):
202-204
Schimpf MO, Patel M, O’Sullivan DM, Tulikangas PK. Differences
in quality of life in women with urge urinary incontinence compared
to women with stress urinary incontinence. Int J Urogynecol J Pelvic
Floor Dysfunct. 2009; 20: 781-786.
Sharpless KE, O’Sullivan DM, Schnatz PF. The utility of human
papillomavirus testing in the management of atypical glandular cells
on cytology. Journal of Lower Genital Tract Disease. 13(2):72-8,
2009 Apr.
Schnatz PF. A unique faith-based medical organization: the Christian
Medical Fellowship. Connecticut Medicine.
72(6):345-50, 2008 Jun-Jul.
Schnatz PF, Guile MW, O’Sullivan DM. Relative importance of
gender in patients’ selection of an obstetrics and gynecology provider.
Connecticut Medicine. 71(9):563, 2007 Oct.
Schnatz PF, Humphrey K. Reasons and principles for starting an
obstetrics and gynecology scholars group. Obstetrics & Gynecology.
111(4):953-8, 2008 Apr.
Schnatz PF, Marakovits K. The next generation of menopause
providers: are medical students being properly prepared? Menopause.
15(5):871-4, 2008 Sep-Oct.
Schnatz PF, Markelova NV, Holmes D, Mandavilli SR, O’Sullivan
DM. The prevalence of cervical HPV and cytological abnormalities
in association with reproductive factors of rural Nigerian women.
Journal of Women’s Health. 17(2):279-85, 2008 Mar.
Schnatz PF, Murphy JL, O’Sullivan DM, Sorosky JI. Patient choice:
comparing criteria for selecting an obstetrician-gynecologist based
on image, gender, and professional attributes. American Journal of
Obstetrics & Gynecology. 197(5):548.e1-7, 2007 Nov.
Schnatz PF, Ricci S, O’Sullivan DM. Cervical polyps in
postmenopausal women: is there a difference in risk? Menopause.
16(3):524-8, 2009 May-Jun.
Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham
D, O’Sullivan DM. The North American Menopause Society: from
abstract to publication. Menopause. 15(5):996-1001, 2008 Sep-Oct.
Schnatz PF, Sharpless KE, O’Sullivan DM. Use of human
papillomavirus testing in the management of atypical glandular cells.
Journal of Lower Genital Tract Disease. 13(2):94-101, 2009 Apr.
Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin
potentiates the effects of paclitaxel in endometrial cancer cells
through inhibition of cell proliferation and induction of apoptosis.
Int J Cancer. 2009 Aug 17.
Sorosky JI. Endometrial cancer. Obstetrics & Gynecology. 111(2,
Part 1):436-447, February 2008.
Sorosky JI. Endometrial cancer. Obstetrics & Gynecology.
112(1):186-187, July 2008. [Letter.][Departments: Letters to the
Editor]
Spencer J, Fang YMV, Borgida A, Benn P, Egan J. Patient’s
understanding of first trimester aneupliody screening based on
counseling time. Obstet Gynecol. 2008;111:38S.
Spencer JV, Ingardia CJ, Nold CJ, Borgida AF, Herson VC, Egan
JFX. Perinatal and neonatal outcomes of triplet gestations based
on placental chorionicity. American Journal of Perinatology.
2009;26:587-90.
Steinberg AC, Collins SA, O’Sullivan, DM. The impact of flatal
incontinence on quality of life. American Journal of Obstetrics and
Gynecology. 2009;201.
Werden J, Schnatz PF, Mandavilli S, Allen G, Murphy J, Greene
JF; Egan JF, Sorosky JI. Prevalence of the human papillomavirus in
an inner-city indigent population with previously normal pap tests.
Journal of Lower Genital Tract Disease. 12(4):287-292, October
2008.
Presentations

Allen GL, Klobocista M, Sugarman S, Gravel K, Schnatz PF.
Prevalence of High Risk Human Papilloma Virus in an Inner
City Population with Atypical Squamous Cells of Undetermined
Significance. Presented March 17th, 2008 at the biennial ASCCP
meeting in Lake Buena Vista, FL.
Borgida AF, Hopkins S, St- Aubin C, Feldman DM, Fang YM,
Ingardia CJ. Trends in near-term preterm birth. Presented at the
Society for Maternal Fetal Medicine, San Diego, February 2009.
Brown AK, Clements A, Robison K, Allard JW, Somers E, Theil R,
Granai CO, Moore R. Use of a novel biomarker HE4 for monitoring
patients with epithelial ovarian cancer. Presented at the 7th Biennial
Ovarian Cancer Research Symposium of the Marcia Rivkin Center,
September 2008.
Brown AK, Currie J, Sorosky, JI. A retrospective comparison of
clinical outcomes between laparotomy and robotic hysterectomy
for endometrial cancer. Presented at the International Gynecologic
Oncology Robotics Symposium, November, 2008.
Brown AK, Raughley M, Robison K, Miller C, Allard JW, Kurman
R, Granai CO, Moore R. Comparison of a novel multiple biomarker
assay to the risk of malignancy index in the prediction of epithelial
ovarian cancer in patients with a pelvic mass. Presented at the 7th
Biennial Ovarian Cancer Research Symposium of the Marcia Rivkin
Center, September, 2008.
Carbone J, Feldman DM, Lazarus S, Borgida AF. Clinical implications
of prenatally diagnosed marginal placental cord insertion. Society for
Maternal Fetal Medicine, San Diego, February 2009.
Carbone J, Feldman DM, Lazarus S, Borgida AF. Clinical implications
of prenatally diagnosed marginal placental cord insertion. American
Institute of Ultrasound in Medicine, New York, April 2009.
Carbone J, Schnatz PF, Werden J. Stump the Professor: Post Partum
Patient with Acute Chest Pain. Presented September 29th, at the
2007 annual ACOG District I meeting in Newport, Rhode Island.
Clements A, Brown AK, Miller C, Robison K, Allard JW, Granai CO,
Moore R. Utility of a Novel Serum Tumor Marker HE4 to Predict
Depth of Myometrial Invasion in Endometrioid Adenocarcinoma of
the Uterus. Presented at the 2008 NEAGO Annual Meeting, June
2008.
Clements A, Brown AK, Robison K, Allard JW, Somers E, Theil R,
Granai CO, Moore R. Use of a novel biomarker HE4 for monitoring
patients with epithelial ovarian cancer. Presented at the 2008
NEAGO Annual Meeting, June 2008.
Collins SA, O’Sullivan DM, LaSala CA. Factors which correlate
with PISQ-12 completion in an academic urogynecology population.
Poster Presentation at the American Urogynecological Society
Meeting, September, 2009.
Currie C, Brown AK, Sorosky JI, Mandavilli S, Joyner A, Currie
J. Endometrial Carcinoma of Fallopian Tube with Metastasis and
Extension to the Obturator Space: A Case Report. Presented at the
2009 NEAGO meeting, June 2009.
Cushman N, Currie J, Romak J, Sorsoky JI, Brown AK. Vulvar Polyps
Secondary to Crohn’s Disease. Presented at the 2008 NEAGO
Annual Meeting, June 2008.
Greene, JF. Uterine Fibroid Embolization: Who, Why, Where and
When. American College of Obstetricians and Gynecologists Annual
Clinical Meeting, New Orleans, LA 2008.
Greene, JF. Uterine Fibroid Embolization: Who, Why, Where and
When. American College of Obstetricians and Gynecologists Annual
Clinical Meeting, Chicago, IL, May 5, 2009.
Greene, JF. A comparison of ACGME Resident Statistics with
Institutional Totals. Association of Professors in Gynecology and
Obstetrics/Coundil on Residency Education in Obstetrics and
Gynecology Annual Meeting, March, 2009, San Diego, CA. Awarded
third best oral presentation.
Joyner A, Sorosky JI, Mandavilli S, Brown AK, Currie, J .
Neuroendocrine Tumor of Uterus and Cervix after Uterine Artery
Embolization for Leiomyomas: A Case Report. Presented at the 2009
NEAGO meeting, June 2009.
Maclaughlan S, Brown AK, Miller C, Robison K, Allard JW, Granai
CO, Bast R, Moore R. Differential expression of CA125 and a novel
serum tumor marker HES in epithelial ovarian cancer. Presented at
the 2008 NEAGO Annual Meeting, June 2008.
McNamara J, Smith K, Feldman DM, Fang YM, Ingardia CJ, Borgida
AF. Predicting survival among neonates born at 24 weeks gestation.
Society for Maternal Fetal Medicine, San Diego, February 2009.
Moore R, McMeekin S, Brown AK, DiSilvestro P, Miller C, Allard J,
Gajewski W, Kurman R, Bast R, Skates S. A Novel Multiple Marker
Bioassay Utilizing HE4 and CA125II for the Prediction of Ovarian
Cancer in Patients with a Pelvic Mass. Presented at the 2008 SGO
Annual Meeting, March 2008.
Nwana C, Johnson A, Egan J, Dumont T. Racial and Ethnic
Disparities in Prenatal Care. Poster presented at the 2009 ACOG.
Patel M, LaSala CA, Tulikangas P, Steinberg AC. Beef tongue
model versus instructional video for teaching residents fourth
degree laceration repair. Poster presentation at 30th annual
American Urogynecologic Society meeting, September 24-26, 2009,
Hollywood, Florida.
112.

Women’s Health
Patel M, Mellen C, O’Sullivan DM, LaSala, CA. Impact of pessary
use on prolapse symptoms, quality of life and body image. Oral
presentation at the American Urogynecological Society Meeting,
September, 24-26, 2009, Hollywood, Florida.
Patel M, O’Sullivan D, LaSala C. Do bowel symptoms change after
pelvic organ prolapse surgery? Poster presentation at 30th annual
American Urogynecologic Society meeting, September 24-26, 2009,
Hollywood, Florida.
Patel M, Schimpf, MO, O’Sullivan DM, LaSala, CA. The use of
SennaS® for post-operative constipation after pelvic reconstructive
surgery: a randomized, double blinded, placebo-controlled trial.
Oral presentation at the 30th annual American Urogynecologic
Society Meeting, September 24-26, 2009, Hollywood, Florida.
Best scientific presentation award.
Patel M, Tulikangas P. Does size matter? A comparison of bother
and quality of life in women with prolapse. Poster presentation at
the 35th annual Society of Gynecologic Surgeons Meeting, March
30-April 1, 2009, New Orleans, Louisiana.
Patel M, Tulikangas P. Evaluation of prolapse type and pelvic floor
symptoms: is every prolapse the same? Poster presentation at 30th
annual American Urogynecologic Society meeting, September 24-26,
2009, Hollywood, Florida.
Platt L, Brown AK, Mandavilli S, Currie J, Sorosky, JI. Complex
Atypical Hyperplasia and the Incidence of Endometrial Cancer at the
Time of Hysterectomy. Presented at the 2009 NEAGO meeting, June
2009.
Platt L, Currie J, Hoffman J, Sorosky JI, Brown AK. Managing
Patients with Pseudomyxoma Peritonei. Presented at the 2008
NEAGO Annual Meeting, June 2008.
Platt L, Sorosky JI, Currie J, Brown AK. An unusual presentation of
metastatic papillary serous ovarian cancer. Presented at the 2008
NEAGO Annual Meeting, June 2008.
Raughley M, Brown AK, Robison K, Miller C, Allard JW, Kurman
R, Granai CO, Moore R. Comparison of a novel multiple biomarker
assay to the risk of malignancy index in the prediction of epithelial
ovarian cancer in patients with a pelvic mass. Presented at the 2008
NEAGO Annual Meeting, June 2008.
Schnatz PF. Medical Missions Provide Education, Experience, and an
Example of Professionalism for Students and Residents. Presented at
the annual APGO Faculty Development Seminar; Women’s Health
Education, Think Globally, Teach Locally, January 13th, 2009.
Schnatz PF. ObGyn Scholars: Developing a Student Interest Group
and Learning from Past Experiences. Presented at the annual APGO
Faculty Development Seminar; The Ob-Gyn Curriculum: The Ideal,
The Practical, The Hidden. Kapalua, Maui, Hawaii. January 22nd,
2008.
Schnatz PF. Preparing the Next Generation of Menopause Providers.
Presented October 4th, 2007 at the NAMS 18th Annual Meeting in
Dallas, Texas.
Schnatz PF, Johnson AM, Hemphill M, Tortora J. Sexual Dysfunction
in Patients of an Inner City Menopause Clinic. Presented September
26th, 2008 at the NAMS 19th Annual Meeting in Orlando, Florida.
Schnatz PF, Kubica L, Murphy J, and O’Sullivan DM. The Risk
of Cardiovascular Disease in Women with a History of Low Birth
Weight. Presented October 5th, 2007 at the NAMS 18th Annual
Meeting in Dallas, Texas.
Schnatz PF, Pattison K, and O’Sullivan DM. The Association of Breast
Disease and Atypical Glandular Cells. Presented at the NAMS 20th
Annual Meeting in San Diego, California, October, 2009.
Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham
D, O’Sullivan DM. The North American Menopause Society: From
Abstract to Publication. Presented September 26th, 2008 at the
NAMS 19th Annual Meeting in Orlando, Florida.
Schnatz PF, Sharpless KE, Bansal R. Use of Human Papillomavirus
Testing in the Management of Atypical Glandular Cells. Presented
March 19th and 20th, 2008 at the biennial ASCCP meeting in Lake
Buena Vista, FL.
Schnatz PF, Vaidyanathan G, Surette A, Tower M, Price C, Delgado
J, Sundaram K. The Medical Needs and Demographic Makeup

of Menopausal Women in a Rural Nigerian Village. Presented
September 26th, 2008 at the NAMS 19th Annual Meeting in
Orlando, Florida.
Sharpless KE, Bansal R, O’Sullivan DM, Schnatz PF. The Utility
of Human Papillomavirus Testing in the Management of Atypical
Glandular Cells on Cytology. Presented March 17th, 2008 at the
biennial ASCCP meeting in Lake Buena Vista, FL and winner of the
best overall resident presentation.
Sorosky JI. Abnormal Cervical Cytology Complicating Pregnancy.
American College of Obstetricians and Gynecologists Annual
Clinical Meeting, New Orleans, LA 2008.
Presented March 20th, 2008 at the biennial ASCCP meeting in Lake
Buena Vista, FL.
Umenyi C, Waszczak W, Schnatz PF, and Mandavilli S. Incidence
of high risk HPV (HR-HPV) and cervical dysplasia in Nigeria.
Presented at the American Society of Cytopathology’s 55th Annual
Scientific Meeting; November 2-6, 2007 in Houston, Texas.
Werden J, Schnatz PF, Mandavilli S, Allen G, Greene JF, Sorosky JI.
Prevalence of the Human Papillomavirus in an Inner City Indigent
Population with Previously Normal Pap Tests. Presented at the
2007 annual ACOG District I meeting in Newport, Rhode Island,
September, 2007.
Sorosky JI. Endometrial Hyperplasia. American College of
Obstetricians and Gynecologists Annual Clinical Meeting, Chicago,
IL, May 4, 2009.
Sorosky JI. Management of Atypical Glandular Cells (AGC) on
Pap Smear Screen Screening. American College of Obstetricians and
Gynecologists Annual Clinical Meeting, New Orleans, LA 2008.
Sorosky JI. Management of Atypical Glandular Cells, (AGC),
the Consensus Guidelines. American College of Obstetricians and
Gynecologists Annual Clinical Meeting, Chicago, IL, May 5, 2009.
Sorosky JI. Techniques in Abdominal Wound Closure. American
College of Obstetricians and Gynecologists, Annual Clinical
Meeting, Chicago, IL, May 4, 2009.
Sorosky JI. Techniques in Abdominal Wound Closure. American
College of Obstetricians and Gynecologists, Annual Clinical
Meeting, New Orleans, LA 2008.
Steinberg AC, Collins SA, O’Sullivan DM. The Impact of Flatal
Incontinence on Quality of Life. Poster Presentation at the Society
for Gynecological Surgeons, New Orleans, LA April, 2009.
St- Aubin C, Hopkins S, Feldman DM, Fang YM, Ingardia CJ,
Borgida AF. Mode of delivery and neonatal respiratory morbidity in
near-term preterm births. Society for Maternal Fetal Medicine, San
Diego, February, 2009.
Surette AM, Schnatz PF, O’Sullivan DM, Sharpless KE. Delayed
Diagnosis Following Atypical Glandular Cells on Cervical Cytology.

Other Departments &
Collaborations
New Projects
Hartford Hospital Research Endowment Funds
Kureshi, Inam, MD, Neurosurgery
Craniotomy for Intraventricular Lesions. Small Grant for Statistics Database
Support.
Mort,Thomas, MD, Anesthesiology
Comparison of Standard Laryngoscopy vs. Video/Optical Laryngoscopy in
Exchanging an ETT in the High Risk Difficult Airway Patient. Supported
through Hartford Hospital Small Grant.
Federal
Baker, William, PharmD, Pharmacy
Epilepsy Medication CERs. AHRQ, $342,651.
Human Growth Hormone in Patients With Cystic Fibrosis. AHRQ, $342,710.
Kureshi, Inam, MD, Neurosurgery
A Randomized Multicenter Clinical Trial of Unruptured Brain Arteriovenous
Malformations (ARUBA). National Institute of Neurological Disorders through
Columbia University, $56,700.
Foundation
Colby, Jennifer, PharmD, Pharmacy
Predictors of Medication Non-Adherence Among Urban Latinos: A Cross-
Sectional Analysis of Patients Enrolled in the Diabetes Among Latinos Best
Practices (DIALBEST) Trial. American Society HealthSystems Pharmacists,
$5,184.
Industry
Baker, William, PharmD, Pharmacy
Biologic and Non-Biologic Systemic Treatments for Moderate to Severe Plaque
Psoriasis: A Systematic Review and Meta-Analysis. Pfizer, $100,000.
Kureshi, Inam, MD, Neurosurgery
S.T.I.C.H. II - Surgical Trial in Lobar Intracerebral Hemorrhage. Newcastle
upon Tyne Hospital NHS Trust, $6,410.
Unfunded
Delgado, Danica, MSW, Social Work
The Domestic Violence Learning Needs of Health Care Social Workers.
Lehmann, William, MD, Otolaryngology
Methods of Education for Patients Undergoing Tonsillectomy.
McLaughlin, Tara, PhD, Research Administration
Utilizing Focus Groups to Support Community Health Collaborations.
Nailor, Michael, PharmD, Pharmacy
Approach to Enhance the Likelihood of Initial Effective Antibacterial Therapy:
Examining Cross-Resistance.
O’Sullivan, David, PhD, Research Administration
Blanket Protocol for Endocrinology/Diabetes Mellitus Outcomes.
Wang, Fei, PharmD, Pharmacy
Health Literacy and Prescription Medication Adherence in Urban Latino Patients
New Collaborations
Herson, Victor, MD, CCMC
Epigenetic Modifications of Human Umbilical Cord Vessel Endothelium.
Clinical Factors Determining the Care Needs For 35 Week Infants.
Kurtz, Matthew, PhD, Wesleyan University
Neurological Soft Signs, Neurocognitive Measures, and Everyday Life Skills.
Wesleyan University, $700.
Lapidus, Garry, PA-C, CCMC
Safe Transportation of Normal Newborns at Hospital Discharge.
The Epidemiology of Trauma Presenting to a Level One Trauma Center.
Nichols, Mary, Wesleyan University
Narrative Coherence and Neurocognition in Schizophrenia: The Effects of Illness
Duration. Wesleyan University, $600.
Oncken, Cheryl, MD, University of Connecticut Health Center
Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy.
UCHC, $1,500.
Wang, Fei, PharmD, University of Connecticut
Establishing Benchmarks for the Medical Office Survey On Patient Safety
(SOPS). The Oregon Health and Science University, $200.
Active Projects
Chhabra, Jyoti, PhD, Research Administration
Examining Behavioral Risk Factors, Chronic Disease and Health Related Polysyndromes
in Hartford CT. DPH subcontract through the City of Hartford,
$80,000.
Gaudio, Paul, MD, Ophthalmology
Detection of Triamcinolone Acetonide in Human Intraocular Fluids. Small Grant,
$9,900.

McIsaac, Joseph, MD, Anesthesiology
• Power Quality in the Operating Room Pilot Study.
• Dental Pressure During Intubation Pilot Study.
• The Brain Temperature Tunnel During General Anesthesia.
• Minimum Training for Successful Cricothyroidotomy: The Effect of an
Adverse Environment.
• High Fidelity Simulation: Assessment of its Role in Resident Education.
• A Multi-Center Survey of Anesthesiologists Attitudes and Abilities in Difficult
Airway Management Using Simulation-Based Performance Evaluation.
McLaughlin, Tara, PhD, Research Administration
• An Assessment of the Homeless of Hartford, 2002. Hartford Health Dept,
$33,750.
• Evaluating the Hartford Continuum of Care’s “Increased Demands for Shelter
Care” Project. Hartford Foundation for Public Giving & City of Hartford,
$18,500.
• A Brief Assessment of the Homeless of Hartford, 2004. City of Hartford,
$1,200.
• Hartford Resident Survey of Environmental Issues.
• 2005 Census of the Homeless of Hartford. Community Renewal Team, $1,700.
• 2006 Census of the Homeless of Hartford. Community Renewal Team, $1,500.
Active Collaborations
Anderson, Elizabeth, PhD
Exploration of the Effect of Nausea, Self-efficacy, and Health Care Relationships
on Medication Adherence in AIDS Patients. Donaghue Medical Research
Foundation, $4300.
Claus, Elizabeth, MD
Genetic Epidemiology of Breast Carcinoma In Situ.
Epperson, Neill, MD
The Role of GABA and Neurosteroids in Postpartum Depression.
The Impact of Fluoxetine Treatment on GABA and Neurosteroid Levels in
Women with Premenstrual Dysphoric Disorder.
Fisher, Jeffrey, PhD
Changing Antiretroviral Therapy (ART) Adherence Behavior. NIH subcontract
through the University of Connecticut (Storrs), $326,482.
Ferris, Ann, PhD
Assessment of the Prevalence of Anemia, and its Correlates and Predictors,
Among Low Income Two Year Olds in Hartford, CT.
Hadler, James, MD
Surveillance of Connecticut for Organisms Causing Neonatal Sepsis.
Horan, Mary, MA
Ethical Force Program’s Organizational Toolkit for Patient-Centered
Communication (Windham).
Jones, Beth. PhD
Glutathione-S-Transferase Polymorphisms, Race, and Survival from Cancer.
Kenny, Anne, MD
Testosterone Effects on Bone Frailty in Men with Osteoporosis.
Lammi-Keefe, Carol, PhD
Can DHA-functional Food in Pregnancy Enhance Infant Neurobehavioral
Development?
Park, Crystal, PhD
Feasibility Study of Gender Differences in Psychosocial Determinants of
Recovery Following MI. UCHC Center for Interdisciplinary Research on
Women’s Health, $2,400.
Predicting and Understanding Positive Life Changes in Young Adult Cancer
Survivors: Types, Trajectories, Predictors, and Relations with Adjustment. Lance
Armstrong Foundation, $500.
Price, Thomas, PhD
Magnetic Resonance Spectroscopy Studies of Statin-Induced Myopathy. Hartford
Hospital Research Endowment Funds, $11,824.
Risch, Harvey, MD
Case Control Study of Ovarian Cancer Hormonal Etiology.
Hartford Hospital Case Control Study of Pancreas Cancer Etiology Factors.
Windham Hospital Case Control Study of Pancreas Cancer Etiology Factors.
Swede, Helen, PhD
Prognostic Value of Intra-Chromosomal Genomic Instability in Colon Cancer.
Wagner, Joseph, MD
Influence of Patient Size and Prostate Weight on Operative and Peri-Operative
Outcomes for Robot-assisted Radical Prostatectomy.
Woods, Scott, MD
Atypical Antipsychotic Medications: Outcomes and Costs.
Yale University, $8,960.
Longitudinal Follow-Up of Patients Undergoing Evaluation for the Schizophrenia
Prodrome. NIMH, Yale University Subcontract, $11,382.
Yu, Herbert, MD
Hartford Hospital Epidemiologic Study of Uterus Cancer.
Heimer, Robert, PhD
Unexplained Deaths Related to Bioterrorism.
Windham Hospital Epidemiologic Study of Uterus Cancer.
Zheng, Tongzhang, MD
The Role of Epstein-Barr Virus in the Etiology of Hodgkin’s Disease.
116.

Hartford Hospital Research Program 80 Seymour St. Hartford, CT
Staff photos by: Kevin Hagan • Design by: Anthony Tropea